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Receptor tyrosine kinase (RTK) signalling is frequently deregulated in cancers, 
developmental syndromes and metabolic diseases. The fibroblast growth factor 
(FGF) receptor (FGFR) family of RTKs have pleiotropic roles in development, 
metabolism and tissue homeostasis. A decade of deep sequencing studies has 
led to the discovery of somatic cancer-associated alterations in FGFRs including 
point mutations, gene fusions and amplifications. Missense substitutions appear 
most frequently in FGFR3 and FGFR2, some of which have been implicated as 
oncogenic drivers. This has led to rapid progress in anti-FGFR therapies. 
 
This work compares and analyses twenty five reported FGFR kinase domain (KD) 
variants using FGFR3 as a model. Kinase activity assays were developed to 
screen missense substitutions in vitro using purified FGFR3 KD proteins. It was 
found that hyperactive mutations did not necessarily occur frequently and 
conversely, frequently occurring mutation 'hotspots' were not necessarily kinase 
hyperactive. Cellular models of FGFR mutations suggested that hyperactive 
mutants activated signalling but did not always transform cells. Investigations into 
the ligand binding characteristics of a subset of activating mutants revealed 
mutation specific signatures of binding properties. However, there appeared to 
be no link between KD activity and stability. These results reinforce the 
importance of screening clinical tumours prior to treatment to provide better data-
driven therapies for patients. 
 
Endocrine FGFR signalling was also explored in this work. Klotho family proteins 
bind to specific FGFs and FGFRs to signal through endocrine signalling 
complexes regulating diverse metabolic activities. This work developed and 
optimised methods to express and purify components of these binary and ternary 
signalling complexes. Preliminary biophysical experiments were then performed 
to begin to understand the protein-protein interactions involved in complex 
formation. This will inform the rational design of therapies already in development 
for targeting deregulated endocrine FGFR signalling in various metabolic 
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Chapter 1: Introduction 
 
1.1 Introduction to receptor tyrosine kinases (RTKs) 
 
The eukaryotic protein kinase (EPK) superfamily makes up one of the largest groups of 
homologous proteins. It constitutes 1.7% of the human genome with 500 members 
related by their function as enzymes that add a phosphoryl moiety to proteins in a 
reversible catalytic process known as the kinase reaction (Manning et al., 2002). In 
humans, the kinase activity of EPKs is mediated by their dynamic and flexible catalytic 
kinase domain (KD). This leads them to mediate most cellular signal transduction, 
regulating diverse cellular and metabolic functions through phosphorylation of specific 
amino acids in 30% of the human proteome. Despite diversity in sequence, structure, 
substrate specificities and regulation kinases share specific structural features of their 
catalytic core (Hanks and Hunter, 1995). Their amino acid-specific activities facilitate 
their grouping into two main subfamilies based on their target phosphorylation site: 
serine/threonine kinases, and tyrosine kinases. The tyrosine kinase family is further 
subdivided into receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases 
based on whether they possess, or lack, a transmembrane domain respectively. 
Fibroblast growth factor receptors (FGFRs) are members of the RTK subfamily that also 
includes other closely related members such as epidermal growth factor receptor 
(EGFR), platelet derived growth factor receptors (PDGFRs), vascular endothelial growth 
factor receptors (VEGFRs) and KIT. 
 
RTKs are cell surface receptors that make up the second largest family of membrane-
spanning proteins in metazoans. They mediate numerous physiological processes 
including cell growth, migration, survival, differentiation, development, metabolism and 
tissue homeostasis. The 58 known RTK members in humans are classified into 20 
subfamilies based on sequence homology and domain organisation of family members 
(Lemmon and Schlessinger, 2010). All RTKs comprise an extracellular ligand binding 
domain linked to the intracellular kinase via a single-helical transmembrane domain 
(Figure 1.1). RTK activation and signalling occurs upon dimerisation and/or 
conformational changes induced by cognate ligand binding to the extracellular domain, 
which leads to trans-autophosphorylation of intracellular tyrosines and activation of the 
catalytic KD. 
 
1.1.1 RTKs in cancer 
More than half a century of RTK research has revealed that deregulated RTK signalling 




Figure 1.1 The human family of receptor tyrosine kinases (RTKs). The 58 members of the 
human family of RTKs are subdivided into 20 RTK subfamilies, each with one to five members 
per subfamily. The domain organisation of members within each subfamily is illustrated in 
schematic representation, showing the diversity of structural folds and domains of the 
extracellular domains within the RTK family. In comparison, the intracellular tyrosine kinase 
domain (the defining feature of the protein family, shown as red rectangles) is better conserved 
across subfamilies. Figure from (Lemmon and Schlessinger, 2010). 
 
 
syndromes and somatic mutations contributing to oncogenesis (McDonell et al., 2015). 
At least ten RTK families have been observed to be mutated in congenital diseases, 
cancers, or both (Robertson et al., 2000). In addition there is substantial crosstalk 
between RTKs such that they are often co-activated in cancers (Xu and Huang, 2010) 
whereby two or more RTKs coordinate their signalling responses to evade regulatory 
cellular mechanisms that normally prevent tumour formation. Although RTKs were 
initially disregarded in drug development because of a lack of causative evidence for 
their carcinogenic roles alongside concerns over inhibitor specificity and on- and off-
target toxicities, RTKs have been considered important targets in cancer for over a 
decade (Krause and Van Etten, 2005). Therefore, efforts to develop RTK targeted 
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therapies as treatments rapidly evolved leading to several RTK inhibitors progressing to 
clinical trials. The first inhibitor to be approved was Imatinib (2001) which specifically 
targets the non-receptor tyrosine kinase Breakpoint Cluster Region-Abelson (BCR-ABL) 
fusion protein found in chronic myeloid leukaemia (Druker et al., 1996). The success of 
this targeted therapy provided the necessary proof-of-concept evidence that fuelled the 
clinical progression of further anti-RTK clinical candidates and to date more than 20 have 
been approved to treat various malignancies (Table 1.1). Several of these therapies 
target relatively well-studied RTKs such as EGFR and VEGFR. Although many approved 
RTK inhibitors also exhibit variable levels of efficacy against other RTKs including 
FGFRs, due to their promiscuous nature and multi-kinase targets, therapies developed 
specifically against FGFRs are lagging behind other RTKs, and to date there are still no 
cancer therapies approved on the basis of FGFR targeting. FGFRs are known 
oncogenes, estimated to be mutated in about 7% of solid tumours of all cancer types 
(Guagnano et al., 2012, Helsten et al., 2016) and in haematological cancers, and remain 
important clinical targets. However, to date the efficacy of FGFR targeting in the clinic 
has been variable despite pre-clinical predictions of FGFRs as good therapeutic targets 
in all types of cancers (Babina and Turner, 2017). Additionally, the multi-kinase 
promiscuity of many approved RTK inhibitors causes on- and off-target toxicities of 
varying levels of seriousness in the clinic (Shah et al., 2013a, Shah et al., 2013b). In 
particular, effects of activating driver mutations on clinical efficacy of chemotherapies 
must not be underestimated. This is less well-studied and might account in part for the 
differences in patient sensitivity and response to targeted therapies observed in the 
clinic. Therefore, there is an urgent need for pre-clinical studies aimed at deepening our 
understanding of the biology, physiology and pathophysiology of oncogenic mutant 
RTKs. This will inform patient selection during clinical trials, accelerate the progression 
of targeted therapies (with fewer side-effects) up the clinical ladder and provide more 
efficacious therapeutic solutions for subsets of cancers, particularly those that warrant 
as yet insufficient clinical attention. 
 
1.1.2 Acquired resistance to RTK inhibitors in the clinic 
Another phenomenon which currently limits the efficacy of RTK inhibitors in the clinic is 
the emergence of resistance mutations in tumours in response to targeted therapies. 
Resistance mutations have been observed across kinases as a tumour relapse 
mechanism in response to ATP-competitive small molecule inhibitors, first observed in 
the clinic in the BCR-ABL kinase following Imatinib treatment (Gorre et al., 2001, Shah 
et al., 2002). Point mutations commonly occur at the ‘gatekeeper’ residue in the ATP 
binding pocket, hindering inhibitor binding through introduction of a sterically and 
chemically distinct residue (T315I in BCR-ABL) to the original gatekeeper residue. 
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Table 1.1 Current small molecule and monoclonal antibody inhibitors approved for the 
treatment of human cancers based on receptor tyrosine kinase (RTK) targeting. 
 
Inhibitor (brand name) Main RTK Targets Cancer type Year of first approval (US) 
Afatinib (Gilotrif) EGFR, HER2 NSCLC 2013 
Alectinib (Alecensa) ALK NSCLC 2015 
Axitinib (Inlyta) VEGFR1-3 RCC 2012 
Cabozantinib (Cometriq, 
Cabometyx) MET, VEGFR2 MTC, RCC 2012 
Ceritinib (Zykadia) ALK NSCLC 2014 
Cetuximab (Erbitux) EGFR EGFR+ CC, NSCLC 2009 
Crizotinib (Xalkori) ALK NSCLC 2011 
Erlotinib (Tarceva) EGFR, HER1 NSCLC, PC 2004 
Gefitinib (Iressa) EGFR NSCLC 2009 
Imatinib (Gleevec) KIT, PDGFR CML, GIST 2001 
Lapatinib (Tykerb) EGFR, HER2 BC, HER2+ 2007 
Lenvatinib (Lenvima) VEGFR2-3 TC, RCC 2015/16 
Osimertinib (Tagrisso) EGFR NSCLC, refractory 2015 
Palbociclib (Ibrance) ER+, HER2 BC, HER2- 2015 
Panitumumab (Vectibix) EGFR EGFR+ CC 2006 
Pazopanib (Votrient) VEGFR1-3 RCC 2009 
Pegaptanib (Macugen)* VEGFR1-3 MD* 2004 
Ponatinib (Iclusig) PDGFR, VEGFR2 CML, ALL 2013 
Regorafenib (Stivarga) VEGFR1-3, PDGFR CC, GIST 2012 
Sorafenib (Nexavar) VEGFR1-3 RCC, HCC 2005 
Sunitinib (Sutent) PDGFR, KIT CML, GIST, RCC 2006 
Trastuzumab (Herceptin) HER2 HER2+ BC, GIST 2010 
Vandetanib (Caprelsa) VEGFR2 MTC 2011 
 
RTK Abbreviations: EGFR [epidermal growth factor receptor]; HER [human epidermal growth 
factor receptor]; ALK [anaplastic lymphoma kinase]; VEGFR [vascular endothelial growth factor 
receptor]; MET [hepatocyte growth factor receptor]; KIT [stem cell growth factor receptor]; ER+ 
[oestrogen receptor positive]; PDGFR [platelet derived growth factor receptor]. 
 
Cancer Abbreviations: NSCLC [non small cell lung cancer]; RCC [renal cell carcinoma]; MTC 
[medullary thyroid cancer]; PC [pancreatic cancer]; CML [chronic myeloid leukaemia]; GIST 
[gastrointestinal stromal tumours]; BC [breast cancer]; TC [thyroid cancer]; ALL [acute 
lymphocytic leukaemia]; CC [colorectal cancer]; HCC [hepatocellular carcinoma]. 
 







Mutations at the corresponding gatekeeper threonine have been observed in relapsed 
tumours in response to inhibitors targeting various RTKs such as PDGFR (Cools et al., 
2003), KIT (Tamborini et al., 2004), EGFR (Kobayashi et al., 2005, Pao et al., 2005) and 
anaplastic lymphoma kinase (ALK) (Choi et al., 2010). Therefore the effects of resistance 
mutations, including at non-gatekeeper residues, on clinical efficacy of RTK inhibitors 
must be anticipated as important limitations of targeted chemotherapy (Azam and Daley, 
2006). More pre-clinical and clinical research is required to elucidate molecular 
mechanisms by which resistance mutations act to hinder inhibitor binding. This will 
facilitate the development of second generation RTK inhibitors to overcome the problem 
of clinical resistance by several distinct mechanisms. 
 
FGFRs are strongly implicated oncogenes, commonly mutated in all types of cancers. 
Despite this, no approved clinical therapies exist, and additionally FGFRs have also been 
shown to acquire resistance mutations in a human tumour cell line in response to FGFR-
targeted therapies (Chell et al., 2013). This pre-clinical study underscores the importance 
of a molecular understanding of therapeutic targeting in addition to in vivo and clinical 
studies in order to pre-empt possible ‘escape’ mechanisms of tumours in response to 
treatment. An understanding of molecular mechanisms by which other mutations might 
also affect inhibitor sensitivity, efficacy and ultimately FGFR pathophysiology in the clinic 
is vital to guide patient selection during clinical trials with the aim of a future personalised 
approach to cancer treatment. It is for these reasons that the biology, cancer mutations 
and signalling of FGFRs have been studied in this work from a molecular perspective, to 
contribute molecular detail to the emerging field of FGFR therapeutics which is still in its 
infancy. In the next section, the FGFR family of RTKs is introduced with respect to FGFR 
biology, physiology and signalling from a structural and biochemical perspective. 
 
1.2 Introduction to FGFRs 
 
The four main FGFR paralogues, FGFR1-4, comprise a modular structure typical of 
RTKs consisting of an extracellular region, a single-pass transmembrane domain and an 
intracellular region which contains the tyrosine KD. In normal physiology, signals are 
transduced through FGFRs in response to the extracellular domain binding to ligand 
fibroblast growth factors (FGFs) in the presence of specific proteoglycan co-factors or 
protein co-receptors. However, due to the involvement of FGFR signalling in numerous 
aspects of physiology, the consequences of pathway malfunction and deregulated FGFR 
signalling lead to the development of several diseases such as cancers, metabolic 
diseases and developmental disorders (Wilkie, 2005, Beenken and Mohammadi, 2009, 
Turner and Grose, 2010, Itoh and Ornitz, 2011, Carter et al., 2015). 
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In the next sections, the features of FGFs, FGFRs and their resultant ternary signalling 
complexes with co-factors or co-receptors that arbitrate successful signal transduction 
will be discussed. There will be a focus on the structural features of FGF and FGFR 
proteins that allow them to perform their specific functions, as well as on the molecular 
mechanisms that intricately activate and regulate FGF-FGFR signalling. The precise 
mechanisms behind deregulated FGFR signalling and the ensuing pathophysiological 
implications will be presented. Finally, the current breadth of therapeutic strategies in 
clinical development for targeting deregulated FGFR signalling will be summarised. 
 
1.3 Overview of FGFR signalling 
 
The FGF family of FGFR ligands comprises 22 members in humans, grouped into seven 
subfamilies based on their phylogeny, sequence homology and structure (Figure 1.2) 
(Itoh and Ornitz, 2004). Five of these subfamilies (comprising 15 FGFs) function as 
paracrine-acting ‘canonical’ ligands, while each of the other subfamilies (comprising 
three and four FGFs respectively) function as either intracellular-acting factors or 
endocrine-acting hormones respectively (Itoh and Ornitz, 2011). Canonical paracrine 
and hormonal endocrine FGFs are secreted proteins that bind to FGFRs at the cell 
surface. Paracrine FGFs form functional signalling complexes with FGFRs in the 
presence of heparan sulphate (HS) proteoglycan moieties at the plasma membrane 
(detailed in section 1.5.6), while endocrine FGFs bind with high affinity to FGFRs only in 
the presence of co-receptor proteins of the Klotho family and in a HS independent 
manner (discussed in detail in Chapter 4). Paracrine FGFs play vital roles in embryonic 
development and tissue homeostasis in adults, reviewed in (Ornitz and Itoh, 2015), while 
endocrine FGFs regulate diverse aspects of metabolism (reported in detail in Chapter 
4). In contrast, although intracellular FGFs share structural homology to canonical FGFs, 
they are not secreted and do not bind to FGFRs (Olsen et al., 2003) and have FGFR-
independent intracrine roles in the regulation of voltage gated sodium channels (Goldfarb 
et al., 2007). For these reasons they will not be discussed further. 
 
The classical FGFR extracellular region comprises three immunoglobulin (Ig) fold-like 
domains (D1, D2 and D3) separated by short linker regions, linked via a single-pass type 
I transmembrane helix to the intracellular region which contains a juxtamembrane region 
and a ‘split’ tyrosine kinase catalytic domain (Figure 1.3). The four FGFR genes (FGFR1-
4) are alternatively spliced to give rise to approximately 50 different FGFR isoforms, of 
which the most important splicing events affect the extracellular D3 domain of FGFR1-3 
giving rise to canonical ‘c’ or alternative ‘b’ isoforms (detailed in section 1.4). FGF ligands 





Figure 1.2 Phylogenetic classification of the human FGF gene family. The 22 FGF genes are 
grouped into seven subfamilies based on sequence and structure-based analyses, with two to 
four members per subfamily. The evolutionary distance between genes is proportionally 
represented by the lengths of the branches. The 15 ‘canonical’ paracrine-acting FGFs make up 
five subfamilies and require heparin or heparan sulphate moieties as co-factors for signalling 
through FGFRs. The endocrine subfamily members act as hormones and require a Klotho family 
co-receptor for signalling. The ‘intracrine’ FGF subfamily do not bind or signal through FGFRs 
and act intracellularly as co-factors for other molecules. Figure from (Ornitz and Itoh, 2015). 
 
 
molecular and physiological outcome of signalling depends on the particular FGF, FGFR 
and co-factor/co-receptor composition of the context-dependent ternary signalling 
complex. In general, paracrine and endocrine FGFs bind to the extracellular domains of 
FGFRs in the presence of HS co-factors or Klotho co-receptors respectively, triggering 
lateral dimerisation and/or activation of FGFRs at the cell surface and trans-
autophosphorylation of the intracellular tyrosine KDs. The phosphorylated tyrosines on 
the activated KDs act as docking sites for the recruitment of substrate adaptor and 
effector proteins which also influence the specific response out of the myriad of possible 
downstream physiological outcomes (Figure 1.4). The two main intracellular FGFR 
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effectors are phospholipase C gamma (PLCγ) and the adaptor FGFR substrate 2 (FRS2) 
which bind to specific phosphorylated tyrosines on activated FGFRs and trigger distinct 
cellular signalling pathways (Figure 1.4). Spatial and temporal expression of FGFs and 
FGFRs (and Klotho co-receptors, discussed in Chapter 4) coupled with inherent 
sequence differences within FGFs and FGFR isoforms serve as key regulators of the 
outcome of FGFR signal transduction (Beenken and Mohammadi, 2009). The pleiotropic 
physiological roles of FGF signal transduction are presented in the next section, followed 







Figure 1.3 Domain organisation and representative structures of FGFRs. (a) Domain 
representation of the four members of the FGFR family of receptor tyrosine kinases (FGFR1-4). 
The extracellular region comprises three immunoglobulin-like domains (D1, D2 and D3) 
separated by short linker regions. The D1-D2 linker region contains a sequence of acidic residues 
termed the acid box (AB) (coloured green). The second half of the D3 domain (shaded purple) 
can be alternatively spliced to produce canonical ‘c’ or alternative ‘b’ splice isoforms. The 
ectodomain links via a single-pass transmembrane (TM) helix to the intracellular region which is 
comprised of a juxtamembrane (JM) segment and a ‘split’ catalytic tyrosine kinase domain (KD). 
(b) Structures of the domains in a are depicted in cartoon representation using representative 
crystal structures of FGFR3, coloured as in a. ‘N’ and ‘C’ label the amino- and carboxy-terminal 
ends of each structure. Shown are the D2-D3 extracellular region (left panel) [PDB: 1RY7] (Olsen 
et al., 2004), TM helix (middle panel) [PDB: 2LZL] (Bocharov et al., 2013) and both parts of the 






Figure 1.4 Overview of canonical paracrine FGFR signalling pathways. FGF ligands bind to 
FGFRs in the presence of heparan sulphate (HS) at the cell surface, inducing dimerisation of 
FGFRs and activation of the intracellular tyrosine kinase domains (KDs) through trans-
autophosphorylation of KD tyrosines. Activated KDs phosphorylate tyrosines on downstream 
adaptor and effector proteins triggering signalling cascades that regulate a myriad of physiological 
outcomes. The two primary intracellular FGFR effectors are PLCγ and the FRS2α adaptor protein. 
Activated PLCγ hydrolyses PIP2 to IP3 and DAG. DAG activates PKC which phosphorylates its 
substrate MARCKS, while IP3 stimulates the release of intracellular calcium, activating calcium-
binding proteins such as calcineurin. Calcium-bound activated calcineurin induces NFAT to 
translocate to the nucleus, and MARCKS and nuclear NFAT activity then modulate cell motility. 
In comparison, FRS2α is constitutively bound to the juxtamembrane region of FGFRs where it 
also binds GRB2, serving as a signalling hub for the activation of distinct downstream pathways. 
In the first, GRB2 recruits the guanine nucleotide exchange factor SOS, which activates the Ras-
RAF-MEK-MAPK cascade. Activated MAPK translocates to the nucleus and promotes cell 
proliferation through activation of immediate early gene transcription factors such as FOS. In the 
second, GRB2 recruits GAB1 which activates the PI3K-PDK-AKT pathway. Activated AKT 
inactivates the pro-apoptotic proteins BAD, BAX, Caspase 9 and the FOX O transcription factor, 
inducing a cell survival response. In a different cellular context for endocrine signalling, FGFRs 
associate with Klotho family proteins (instead of HS) and specific endocrine-acting FGFs to 
modulate aspects of metabolism through activation of the same downstream pathways (detailed 
in Chapter 4). Phospholipase C gamma (PLCγ), FGFR substrate 2α (FRS2α), 
phosphatidylinositol-4,5-bisphosphate (PIP2), inositol-1,4,5-trisphosphate (IP3), diacylglycerol 
(DAG), protein kinase C (PKC), myristoylated alanine-rich C-kinase substrate (MARCKS), nuclear 
factor of activated T cells (NFAT), growth factor receptor bound protein-2 (GRB2), son of 
sevenless (SOS), rat sarcoma GTPase (Ras), rapidly accelerated fibrosarcoma kinase (RAF), 
mitogen-activated protein kinases (MEK and MAPK), GRB2-associated binding protein 1 (GAB1), 
phosphoinositide-3-kinase (PI3K), phosphoinositide-dependent kinase (PDK), protein kinase B 
(PKB or AKT), BCL2-associated death promoter (BAD), BCL2-associated X protein (BAX), 







1.4 Physiological relevance of FGFR signalling 
 
FGFs exert their wide-ranging and non-redundant biological effects in an organised, 
distinct FGFR-isoform, HS-specific and tissue-specific manner. Alternative splicing of 
FGFRs is largely tissue specific, with b and c splice isoforms expressed mostly in 
epithelial or mesenchymal tissues respectively (Miki et al., 1992, Orr-Urtreger et al., 
1993, Goetz and Mohammadi, 2013). A wealth of research has elucidated the FGFR 
isoform specific complexes through which FGFs exert their effects in vitro and in cultured 
cells. It appears that FGFs secreted from mesenchymal tissues preferentially signal 
through epithelial FGFR b splice isoforms, while FGFs secreted from epithelial tissues 
interact predominantly with mesenchymal FGFR c splice isoforms (Finch et al., 1989, 
Ornitz et al., 1996, Zhang et al., 2006b). This results in reciprocal and directional 
paracrine signalling loops that coordinate embryonic development and adult tissue 
homeostasis in vertebrates while preventing illicit, pathophysiological autocrine 
signalling. Reciprocal loops of FGF signalling ubiquitously mediate all kinds of 
organogenesis, as reviewed in (Bottcher and Niehrs, 2005, Pownall and Isaacs, 2010). 
For example, mesenchymal expressed FGF10 signals through epithelial FGFR1b and 
FGFR2b splice isoforms while epithelial expressed FGF8 signals through mesenchymal 
FGFR2c forming reciprocal signalling loops necessary to initiate placenta and limb 
formation (Xu et al., 1998b). In a second example, epithelial FGF9 signalling through 
mesenchymal FGFR1c and FGFR2c causes mesenchymal expression of FGF10 which 
signals through epithelial FGFR2b to regulate caecal development (Zhang et al., 2006c). 
In addition, the formation of FGF7 and FGF10 gradients in the extracellular matrix 
(established by the variable affinities of these FGFs for HS, see section 1.5.1) modulate 
the extent and nature of branching morphogenesis in response to FGF threshold levels 
(Makarenkova et al., 2009). Conversely, endocrine FGF19 subfamily FGFs do not 
mediate this type of reciprocal signalling and organogenesis but control several aspects 
of metabolism in a HS independent and Klotho dependent manner (discussed in detail 
in Chapter 4). 
 
A complete list of FGF-FGFR isoform specificities elucidated to date, summarising 
decades of work, are presented in Table 1.2. This summary demonstrates that members 
within FGF subfamilies mostly function through similar subsets of FGFR isoforms. FGFR 
paracrine signalling in normal physiology is therefore regulated by spatiotemporal and 
tissue specific expression of specific isoforms of FGFs and FGFRs (and HS – see section 
1.5.6). In the next section, the structural and molecular basis for how the signalling 
outcome is determined from all possible physiological effects is described. This will be 
presented with a focus on the current understanding of specific structural features of 
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FGFs and FGFRs that govern FGF-FGFR-HS ternary complex formation, FGFR kinase 
activation and catalysis by the tyrosine KD. 
 
 
Table 1.2 Receptor binding specificities of paracrine and endocrine FGFs for FGFR c 













FGF2 FGFR 1c = 3c > 2c = 1b = 4 
FGF4 
FGF4 



















FGFR 1c = 4 > 2c > 3c 
FGF21 FGFR 1c > 3c > 2c >> 4 
FGF23 αKlotho FGFR 1c = 4 > 3c > 2c 
 
Compiled from: (Ornitz and Leder, 1992, Ornitz et al., 1996, Santos-Ocampo et al., 1996, 
Blunt et al., 1997, Ibrahimi et al., 2004, Itoh and Ornitz, 2004, Kurosu et al., 2006, Olsen 
et al., 2006, Urakawa et al., 2006, Zhang et al., 2006b, Ogawa et al., 2007, Kurosu et 
al., 2007, Suzuki et al., 2008, Harada et al., 2009, Ornitz and Itoh, 2015) 
 
 
1.5 Structural determinants of FGF-FGFR-HS complex activation 
 
Several models of FGFR activation have been proposed based on biochemical and 
structural studies. The two main models are the (1) diffusion based model and the (2) 
pre-formed dimer model (Figure 1.5). The diffusion based model has prevailed since the 
1970s and describes a mechanism whereby RTK monomers move laterally within the 
cell membrane, occasionally stochastically colliding and resulting in basal activation in a 
diffusion dependent rate limiting process (Schlessinger et al., 1978). In this model, 
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dimerisation and FGFR activation is strictly ligand dependent. However, recent studies 
have demonstrated the presence of ligand- and density-independent phosphorylated 
FGFR dimers in cells (Comps-Agrar et al., 2015, Sarabipour and Hristova, 2016). In this 
pre-formed dimer model, inactive FGFR dimers (transmembrane domains and KDs in an 
‘inactive’ configuration, non-permissive of autophosphorylation) are activated upon 
ligand binding by triggering a conformational switch to ‘active’ ligand-specific 
configurations of transmembrane helices, leading to correct juxtaposition of the KDs for 
activation. A similar mechanism has been proposed for other RTKs such as EGFR 
(Sarabipour, 2017). It is likely that a combination of both mechanisms exists in vivo, in 
context dependent situations. In this section, the components of FGFR paracrine 
signalling complexes will be introduced, detailing the specific inter-component binary 
contacts that mediate FGFR dimerisation and activation of the ternary complex. The 
endocrine FGFR signalling complexes (where HS is replaced by a Klotho co-receptor) 





Figure 1.5 Models of FGFR activation. Two proposed working models for FGFR dimerisation 
and activation. (a) Diffusion based model. FGFR monomers can move laterally within the cell 
membrane in a diffusion-limited manner. Occasionally and stochastically they will collide, forming 
inactive dimers or resulting in basal activation, probably at a level too low for meaningful 
downstream signalling. The rate of activation is limited by diffusion (and thus concentration) of 
FGFR molecules within the membrane, and is strictly ligand dependent. (b) Pre-formed dimer 
model. In this model, FGFRs can exist in equilibrium between monomers and dimers at the cell 
surface, in a process not limited by diffusion or concentration of receptors at the cell surface. 
Some dimers are inactive, while some might exhibit low signalling activity depending on whether 
the juxtaposition of the kinase domains (KDs) is conducive for trans-autophosphorylation. In this 
scenario, ligand binding might serve to reorient the KDs to the correct orientation and/or 




1.5.1 Structural features of FGFs impart HS binding affinity and FGFR selectivity 
The human family of FGFs vary in length between 150-300 amino acids (Itoh and Ornitz, 
2004). The domain organisation of all FGFs and representative solved atomic structures 
of one FGF from each subfamily are shown in Figure 1.6. Most paracrine and the 
endocrine FGF subfamilies have an amino- (N-)terminal cleavable secretion signal 
peptide, while the FGF9 subfamily instead has a bipartite uncleaved secretion signal 
sequence (Figure 1.6a). 
 
All FGFs comprise a ‘core’ homology domain which adopts a β-trefoil fold composed of 
approximately 120-125 amino acids. This comprises 12 anti-parallel β-strands (β1-β12) 
in paracrine FGFs. The β10-β12 region (encompassing the β11 strand), as well as other 
residues from regions such as the β1-β2 loop, form the primary site that gives FGFs the 
ability to bind HS (Figures 1.6a and 1.7a), the necessary proteoglycan cofactor for 
paracrine FGFR signalling as first shown for FGF1 and FGF2 (Thornton et al., 1983, 
Shing et al., 1984, Rapraeger et al., 1991, Ornitz and Leder, 1992, Ornitz et al., 1992). 
Indeed, even in this early work, it was shown that FGF1 and FGF2 had distinct binding 
affinities for HS (Lobb and Fett, 1984). Despite having a common structural topology, the 
HS binding site is sequence diverse across FGFs which results in the different binding 
affinities of FGFs for HS (Goetz et al., 2007, Makarenkova et al., 2009, Xu et al., 2012). 
All paracrine FGFs bind HS directly with high or moderate affinity and as a result, HS 
binding can alter FGF signalling capacity by altering conformation, enhancing thermal 
stability and protecting FGFs from proteolysis and inactivation (Gospodarowicz and 
Cheng, 1986, Saksela et al., 1988, Asada et al., 2009, Xu et al., 2012). In addition, the 
length and sulphation pattern of spatiotemporally expressed HS proteoglycans also 
determines the extent of FGF binding and signalling, detailed in section 1.5.6. HS binding 
ultimately controls the extent of diffusion of paracrine FGFs away from their site of 
secretion, allowing them to act locally (Goetz et al., 2007) and to form gradients that 
confer threshold-dependent signalling such as in developmental patterning and 
morphogenesis (Makarenkova et al., 2009). FGF mutations that affect HS binding can 
modulate their diffusion in the extracellular matrix, for example as shown for FGF9 
(Harada et al., 2009, Kalinina et al., 2009). 
 
In endocrine FGFs the β11 strand and its GxxxxGxx(T/S) motif (mostly conserved in 
paracrine FGFs) is missing and replaced by a helix at this position, resulting in loss of 
HS binding affinity for this FGF subfamily (Figure 1.7b). Additionally, endocrine FGF19 
and FGF23 have two and one disulphide bonds respectively (Goetz et al., 2007, Harmer 
et al., 2004) and one of these disulphide linkages appears to be conserved across this 
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FGF subfamily. These key differences between paracrine and endocrine FGFs 





Figure 1.6 Domain organisation and representative structures of FGFs. (a) Domain 
representation of the paracrine and endocrine FGF subfamily proteins. All FGFs comprise an N-
terminus (purple), a conserved ‘core’ (blue) and a C-terminal tail of variable length (light pink). 
They also comprise a cleavable N-terminal secretion signal peptide (SP, yellow) or a bipartite 
uncleaved secretion signal sequence (SP, orange). Paracrine FGFs also contain a heparin 
binding site (HBS, bright pink). (b) Structures of one member from each of the six FGF subfamilies 
depicted in cartoon representation and shown in the same orientation. N- and C-termini and the 
conserved ‘core’ are coloured purple, blue and light pink as in a. The cysteine residues that form 
disulphide bonds are highlighted as green spheres. FGF1 [PDB: 1RG8] (Bernett et al., 2004), 
FGF4 [PDB: 1IJT] (Bellosta et al., 2001), FGF10 [PDB: 1NUN] (Yeh et al., 2003), FGF8 
[PDB:2FDB] (Olsen et al., 2006), FGF9 [PDB: 1IHK] (Plotnikov et al., 2001), FGF19 [PDB: 1PWA] 




The FGF β-trefoil core is flanked by sequence diverse N- and carboxy- (C-)terminal 
regions (highlighted in Figure 1.6b) that confer sequence specific functional properties 
to FGF subfamilies. For example, the N-terminus of FGF8 is alternatively spliced to 
produce several splice isoforms with distinct FGFR binding specificities and biological 
functions (Crossley and Martin, 1995, Gemel et al., 1996, Blunt et al., 1997, Olsen et al., 
2006). The N- and C-termini of FGF9 contribute to its unique ability to reversibly 
homodimerise (unlike other FGFs which only form monomers); part of the FGFR binding 
site is occluded in the homodimer interface and so the FGF9 dimer autoinhibits FGFR 
binding, modulating signalling by controlling the availability of FGFR-binding-competent 
FGF9 monomers (Harada et al., 2009, Kalinina et al., 2009, Plotnikov et al., 2001, Liu et 
al., 2017). Site-specific proteolytic cleavage of the C-terminal tail of FGF23 results in its 
inactivation, implicating the C-terminal tail in activation of FGF23 (Shimada et al., 2002, 
White et al., 2001). In fact, the C-terminal tails of all endocrine FGFs form the Klotho-
FGFR binding sites, conferring the ability to form specific ternary complexes through 






Figure 1.7 Comparison of the heparin binding site (HBS) on paracrine and endocrine FGFs. 
Structures of (a) paracrine FGF1 bound to a heparin hexasaccharide [PDB: 3OJV] (Beenken et 
al., 2012) and (b) endocrine FGF19 [PDB: 2P23] (Goetz et al., 2007) are shown in the same 
orientation in cartoon representation on a surface and coloured blue, with the heparin moiety 
shown as sticks and coloured grey and by atomic element with nitrogen atoms in navy blue, 
oxygen in red and sulphur in yellow. The HBS of each FGF is coloured bright pink, and the 
contributing β1-β2 loop and the β10-β12 regions are labelled. The pink region includes the 
GxxxxGxx(T/S) motif of the β11 strand in a. Note that the β1-β2 loop is extended and that β11 is 
replaced by α11 in b resulting in steric hindrance and partial loss of the HBS in FGF19, reducing 




Structural studies with several FGFs have been useful in identifying specific sequences 
that confer FGFR binding specificity. Structural studies that included HS in the complex 
shed light on the fact that HS and FGFR binding sites on FGFs do not overlap (detailed 
in section 1.5.6). Several atomic structures of FGF-FGFR complexes have now been 
solved by crystallography, clearly demonstrating the diversity, yet similarity, between the 
FGF-FGFR interfaces. In general, the opposite end of the β-trefoil core to the HS binding 
site forms the FGFR binding region on paracrine FGFs (Mohammadi et al., 2005b). 
Visual examples of FGF-FGFR interfaces revealed through these crystal structures are 
shown in Figure 1.8. These highlight the diversity of the FGFR-binding interface of FGFs 
from different subfamilies (including the variable contributions of N- and C-terminal 
elements in determining binding specificity), as well as differences in FGFR-isoform 
specific conformations of key loops and other sequence elements on FGFRs towards 
different FGFs, which cannot be predicted by sequence analyses. 
 
1.5.2 Structural basis by which FGFs bind to the FGFR ectodomain 
Despite only sharing 55-72% sequence identity (Table 1.3a) the four FGFRs share 
overall structural features important for their function. The extracellular domain 
comprises Ig-like domains D1, D2 and D3 connected by flexible inter-domain linkers. A 
sequence of acidic S/D/E residues in the D1-D2 linker constitutes a feature unique to 
FGFRs called the ‘acid box’ (Figure 1.3a). The D1-D2 linker, including the acid box, and 
the terminal D1 domain, impart receptor cis-autoinhibition by competing with HS and 
FGFs for binding to the D2 domain, and exon skipping that excludes the D1 domain 
and/or the acid box in FGFR1-3 gives rise to FGFR isoforms with different affinities for 
FGFs (Wang et al., 1995, Shimizu et al., 2001, Olsen et al., 2004, Roghani and 
Moscatelli, 2007, Kalinina et al., 2012). Subtle sequence differences in the acid box of 
FGFR1-4 might translate to differences in the equilibrium between autoinhibited and non-
autoinhibited conformational states, providing subtly different energy barriers for binding 
of different FGFs to their cognate receptor subtypes. Ultimately, the D1 domain and the 
D1-D2 linker are dispensable for paracrine ligand binding and the membrane proximal 
D2-D3 region on FGFRs is the necessary and sufficient binding site for paracrine FGFs, 
as shown by mutagenesis studies and numerous crystal structures (Johnson et al., 1990, 
Plotnikov et al., 1999, Stauber et al., 2000, Olsen et al., 2004, Mohammadi et al., 2005b). 
Therefore, FGFRs alternatively spliced to include or exclude the D1 domain are referred 
to as canonical ‘α’ (D1-D3) or alternative ‘β’ (D2-D3) splice isoforms respectively and 
have different affinities for paracrine FGFs. Additionally, as mentioned previously, 
alternative splicing of the FGFR1-3 D3 domain gives rise to b and c splice isoforms 
differing in the C-terminal region of the D3 domain that confers FGF binding specificity 
(Miki et al., 1992, Werner et al., 1992, Chellaiah et al., 1994, Yeh et al., 2003). The 
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structural elements that contribute to the FGF-FGFR interface differ slightly between b 
and c splice isoforms, but subtle differences between isoform specific residues are the 
key determinants of FGF binding specificity (Figure 1.8). The conformation and 
sequence of the βC’-βE loop in the D3 domain (the primary alternatively spliced region) 
is considered the key determinant of FGF binding specificity for FGFRs (Olsen et al., 
2004), although FGF8 also interacts with a different region (the βF-βG loop, Figure 1.8c) 
(Olsen et al., 2006). Therefore the D3 domain, its alternative splicing and the relative D2 
and D3 domain orientations together dictate FGF-FGFR binding specificity. 
 
 
Figure 1.8 Structural basis for the variable receptor binding specificities of different FGFs 
and FGFR splice isoforms. Structures of different complexes of FGFs and FGFR D2-D3 
domains of (a) FGF2-FGFR1c [PDB: 1FQ9] (Schlessinger et al., 2000), (b) FGF10-FGFR2b 
[PDB: 1NUN] (Yeh et al., 2003), (c) FGF8-FGFR2c [PDB: 2FDB] (Olsen et al., 2006) and (d) 
FGF9-FGFR1c [PDB: 5W59] (Liu et al., 2017) showing the binary 1:1 FGF-FGFR interfaces in 
cartoon representation and in the same orientation. FGFs and FGFR D2-D3 are coloured light 
blue and salmon respectively, as in Figures 1.3, 1.6 and 1.7. Additionally, the βB’-βC (cyan), βC’-
βE (black) and βF-βG (green) loops that determine receptor binding specificity are highlighted 
and labelled on the FGFRs, and FGF residues at the FGFR interfaces are shown as sticks and 
coloured yellow (but are not labelled for clarity). Note the relatively invariant positions of the βB’-
βC and βF-βG loops at the interface, while the position and/or ordering of the βC’-βE loop, and 
the relative orientation of the D3 domain, depends on differences in the N- and C-termini of the 
binding FGFs coupled with differences between FGFR isoforms. 
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Table 1.3 Percentage sequence (a) identity and (b) similarity between the full length 




FGFR4  79.9 75.8 76.8 
FGFR3c 50.0  84.1 87.6 
FGFR1c 55.7 63.5  87.6 
FGFR2c 57.2 67.2 71.3  




FGFR4  84.5 83.1 82.8 
FGFR3c 64.7  91.0 93.4 
FGFR1c 61.7 69.9  91.0 
FGFR2c 63.6 72.5 77.5  
 FGFR4 FGFR3c FGFR1c FGFR2c 
 
 
1.5.3 The role of transmembrane and intracellular juxtamembrane regions 
C-terminal to the extracellular region is the single helical transmembrane domain which 
links the FGFR ectodomain to the intracellular region comprising a juxtamembrane 
region and the tyrosine KD (Figure 1.3). Apart from putative dimer interfaces based on a 
single solution structure of the dimeric FGFR3 transmembrane helices (Bocharov et al., 
2013), the mechanisms behind transmembrane helix dimerisation are unknown. It is 
hypothesised that residues of the transmembrane helix might not actually regulate 
dimerisation but interact to dimerise upon dimerisation of the ectodomains. A theoretical 
study also suggests a contribution of the C-terminal intracellular juxtamembrane region 
in dimerisation of the transmembrane helices (Peng et al., 2009). This region is a putative 
mediator of FGFR dimerisation because the precise formation of active, asymmetric 
dimers for the closely related EGFR KD is shown to be mediated by its intracellular 
juxtamembrane region through conformational coupling across the cell membrane 
(Zhang et al., 2006a, Jura et al., 2009, Red Brewer et al., 2009, Endres et al., 2013). 
Active asymmetric dimers of the FGFR KD have also been revealed by crystallography; 
in these dimers, one FGFR KD molecule serves as an enzyme, while the other acts as 
a substrate that is trans-phosphorylated by the enzyme-acting KD (Chen et al., 2008, 
Bae et al., 2010, Bae and Schlessinger, 2010). Although not experimentally shown for 
FGFRs, based on the EGFR models it is plausible that the intracellular juxtamembrane 
regions of FGFRs also juxtaposition the KDs upon ligand binding by transmembrane 
conformational coupling, forming active asymmetric dimers aligned for trans-
autophosphorylation (Bocharov et al., 2013). 
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1.5.4 Architecture and activation of the FGFR KD 
The structure of the catalytic tyrosine KD is highly conserved across EPKs. The FGFR 
KD is referred to as a ‘split’ KD, comprising a smaller N-lobe and a larger C-lobe. The 
two lobes behave as semi-rigid bodies in the inactive kinase and are connected by a 
short linker known as the ‘hinge’. The N-lobe consists of five β-strands (β1-β5) forming 
a twisted β-sheet and a single α-helix (αC), while the C-lobe is primarily α-helical (αD-
αE, αEF, αF-αI) with just two β-strands (β7-β8) (Figure 1.9a). The active site, where 
phosphoryl transfer occurs, lies in the cleft between the two lobes. Several other linear 
sequence elements are important for kinase function and activation (Figure 1.9a). These 
are the ATP binding loop (P-loop) and αC-helix in the N-lobe and the catalytic loop (C-
loop), activation loop (A-loop), and kinase insert (KI) in the C-lobe. The triad of catalytic 
residues (‘HRD’ pocket) is located on the P-loop. The A-loop contains the conserved 
‘DFG’ motif, which is involved in nucleotide and Mg2+ co-factor binding, and also contains 
two key tyrosine residues that undergo autophosphorylation during kinase activation 
(Figure 1.9a). 
 
The KD acts as a molecular switch which is rapidly turned ‘on’ and ‘off’ in response to 
biological cues. The switch from active to inactive kinase is a transient, complex and 
highly regulated process resulting from dynamic conformational changes in the listed 
structural elements upon phosphorylation of the A-loop tyrosines (Figure 1.10). In the 
inactive KD the configuration of the A-loop, anchored by the αC-helix, in the ‘closed’ 
conformation autoinhibits activity in cis by hindering protein substrate binding, without 
affecting ATP binding to the active site (Mohammadi et al., 1996b). In addition, a triad of 
residues (non-consecutive in sequence) near the kinase hinge form an autoinhibitory 
network of hydrogen bonds termed the ‘molecular brake’ which maintains the KD in its 
inactive state (Chen et al., 2007b). Extracellular ligand stimulation of FGFRs leads to 
structural rearrangements of the ectodomains (see section 1.5.2) that translate to 
juxtaposition of the KDs in the correct asymmetric conformation required for trans-
autophosphorylation of the essential A-loop tyrosines (Mohammadi et al., 1996a, Bae et 
al., 2010). This activates the KDs through ‘release’ of the molecular brake, rotation of the 
N-lobe towards the C-lobe, stabilisation of the ‘open’ configurations of the αC-helix and 
the A-loop, and reorientation of key catalytic residues (Figure 1.10). This promotes 
autophosphorylation of other intracellular tyrosine residues and permits substrate 
binding (Hubbard, 1999, Belov and Mohammadi, 2013, Chen et al., 2017). 
 
In addition, there are two non-linear hydrophobic ‘motifs’ (composed of residues distant 
in sequence space) that are vital for kinase activation. These are the catalytic (C) and 
regulatory (R) spines, anchored to the N- and C-terminal ends of the αF-helix 
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respectively (Figure 1.9b). Dynamic assembly of the R-spine and its surrounding ‘shell’ 
residues into an ordered structure is dependent on the active A-loop configuration and 
is mandatory for kinase activation, while disassembly leads to kinase inactivation 
(Kornev et al., 2006, Meharena et al., 2013). Assembly of the C-spine during kinase 
activation is completed upon binding of the adenine ring of ATP (Kornev et al., 2008). 
These spines comprise residues vital for catalysis such as the H and F residues from the 
HRD pocket and DFG motif respectively (Figure 1.9b). Assembly of the spines stabilises 
the active KD conformation by connecting residues from the N- and C-lobes and securing 





Figure 1.9 Architecture of the FGFR tyrosine kinase domain (KD). The linear and non-linear 
sequence features that are important for KD function and activation are shown on the structure 
of phosphorylated and active FGFR1 [PDB: 3GQI] (Bae et al., 2009) shown in cartoon 
representation. (a) The FGFR KD is ‘split’ into an N-lobe and a C-lobe connected by a flexible 
linker known as the kinase ‘hinge’ (black) which allows relative movement of the N- and C-lobes. 
The N-lobe comprises five β-strands that form a twisted β-sheet (β1-5, light blue) and a single 
helix (αC, yellow). The C-lobe has two β-strands (β7-8, blue) near the hinge region but is primarily 
α-helical (pale yellow) and comprises a loop unique to FGFRs known and the kinase insert (KI, 
dark blue). The active site lies in the cavity between the N- and C-lobes. The nucleotide binding 
loop (P-loop, green) from the N-lobe and the catalytic loop (C-loop, purple) and activation loop 
(A-loop, red) from the C-lobe contribute to this active site, and specific linear sequence motifs in 
the C-loop and A-loop (HRD and DFG respectively, shown as sticks with a surface on each loop) 
provide the vital residues for ATP and Mg2+ co-factor binding and phosphoryl transfer. Also shown 
in sticks against a surface (and labelled) are the crucial ‘twin’ tyrosines on the A-loop that undergo 
trans-autophosphorylation for full activation of the KD. Three residues (non-linear in sequence) in 
the hinge region which form an autoinhibitory network of interactions in the inactive kinase 
(‘molecular brake’, cyan) are highlighted as sticks against a surface. (b) Residues from both lobes 
of the KD forming two hydrophobic ‘motifs’ (non-linear in sequence) whose conformations are 
crucial for kinase activation, form the regulatory and catalytic R-spine and C-spine (shown as 
sticks against a surface and coloured dark blue and bright pink respectively). Assembly of the 
spines is crucial for kinase activation, as shown on this structure of an active FGFR KD. Full 
assembly of the C-spine is completed with the adenine ring of ATP, which slots into the labelled 
cavity. The spines are ‘anchored’ to the αF-helix in the C-lobe (aquamarine) with the ‘base’ 
residues of each spine contributed by this helix. The R-spine contains two key catalytic residues 
from the HRD and DFG motifs shown in a, and these are labelled. 
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The mechanisms involved in full activation of the KD are partially understood, and key 
questions remain as to the extent, duration and order of autophosphorylation during 
activation. Autophosphorylation of all tyrosines on the FGFR1 KD has been examined 
and appears to follow distinct stages of kinetically driven sequential trans-
autophosphorylation of the key ‘twin’ tyrosine residues in the A-loop and other tyrosines 
in the juxtamembrane, KI and C-terminal tail regions (Furdui et al., 2006, Lew et al., 
2009). The sequential order of autophosphorylation of tyrosines in FGFR2 has also been 
studied and differs from the order of phosphorylation observed for FGFR1 (Chen et al., 
2008). Apart from the A-loop tyrosines, other tyrosines in the FGFR KDs are not all 
conserved, suggesting paralogue specific differences in autophosphorylation between 
FGFR1-4 which remain to be studied. This might translate to differences in the extent of 
kinase activity upregulation and in the effector proteins recruited and subsequent 







Figure 1.10 Switch from inactive to active conformation of the FGFR kinase domain (KD). 
(a) Overlay of FGFR1 KD inactive (light purple) [PDB: 1FGK] (Mohammadi et al., 1996b) and 
active (light pink) [PDB: 3GQI] (Bae et al., 2009) structures shown in cartoon representation, 
showing the global conformational differences between the two KD activation states. The features 
whose conformations are particularly important during the switch are highlighted in dark purple 
(inactive) and bright pink (active) respectively and the positions of key residues are shown as 
sticks. Inward rotation of the αC-helix and movement of the A-loop (and its ‘twin’ tyrosines, 
phosphorylated only in the active kinase) to the ‘open’ and active conformation is clearly visible. 
The autoinhibitory molecular brake residues in the kinase hinge region are boxed. (b) Close-up 
view of the boxed molecular brake residues in a, showing the network of hydrogen bonds (dashed 







1.5.5 Role of the C-terminal tail in regulating kinase activity 
The C-terminal tail region (following the KD) has not been well studied with respect to its 
effect on kinase activity so little is known about any regulatory role this region plays in 
modulating dimerisation and/or kinase activation in vivo. This region contains several 
tyrosines that are phosphorylated during kinase activation and serve as docking sites for 
recruiting downstream effectors (Figure 1.4). None of the structures of the FGFR KDs 
solved to date include the C-terminal tail residues. However, one study has shown that 
the FGFR effector protein growth factor receptor bound protein-2 (GRB2) binds to a 
proline rich region on the C-terminal tail of FGFR2 in cells via its C-terminal SRC 
homology 3 (SH3) domain (Ahmed et al., 2010). A model was subsequently proposed 
whereby GRB2 dimers regulate FGFR2 activity by binding to this region on FGFR2 in 
the absence of ligand, forcing dimerisation of FGFR and ‘basal’ level phosphorylation of 
the A-loop, ‘priming’ the FGFR dimer for rapid activation upon ligand binding (Lin et al., 
2012). However, GRB2 binding sterically inhibited phosphorylation of other tyrosines on 
FGFR and obstructed the recruitment of other downstream effectors, thus regulating 
FGFR signalling. Furthermore, upon stimulation with FGF, GRB2 was phosphorylated 
and released leaving the FGFR free to initiate full activation and signal transduction. This 
model supports the pre-formed dimer model of FGFR activation (Figure 1.5b) (Belov and 
Mohammadi, 2012). 
 
1.5.6 Assembly of the signalling competent FGF-FGFR-HS ternary complex 
The lack of structures of any full length FGFRs means a complete understanding of how 
all the domains are coupled across the membrane to transduce the intracellular signal 
based on extracellular ligand binding is not yet available. However, several crystal 
structures of FGF-FGFR or FGF-FGFR-HS solved using FGFR ectodomains, paired with 
several structures of the KD and biochemical experiments in cells using full length 
FGFRs, have been informative about some of the mechanisms behind complex 
formation. Dimerisation of FGFRs to form signalling competent FGF-FGFR-HS ternary 
complexes requires a combination of direct binary contacts between ligands and receptor 
molecules, namely (1) FGF-FGFR, (2) FGFR-FGFR, (3) FGF-HS and (4) FGFR-HS 
interactions. 
 
Two early crystal structures of a dimer of FGF1:FGFR2 or FGF2:FGFR1 heterodimers 
proposed that FGF-FGFR interactions in the ternary complex had a molecular 
stoichiometry of 2:2 (Plotnikov et al., 1999, Stauber et al., 2000). They showed that 
primary contacts between the D2 domains of the two FGFRs in the complex, contacts 
within 1:1 FGF-FGFR heterodimers (at the D2-D3 domain), and secondary contacts 
between the FGF from one 1:1 heterodimer and FGFR from the other, contributed to 
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assembly of the complex. These studies also mapped a putative HS binding site to a 
region between the two FGFs that contacts both FGFs and the FGFR D2 domains. 
Concurrently, two structures of the FGF2-FGFR1-HS (Schlessinger et al., 2000) or 
FGF1-FGFR2-HS (Pellegrini et al., 2000) ternary complexes were also solved. Both 
structures confirmed the 2:2 stoichiometry of FGF-FGFR in each complex, but differed 
in the stoichiometry of HS. The Pellegrini model proposed an asymmetric 2:2:1 model in 
which a single HS molecule bound to a different positively charged FGF-FGFR interface, 
but this model is thought not to be biologically relevant. The Schlessinger model 
proposed a symmetric 2:2:2 complex of FGF-FGFR-HS with the HS forming several 
hydrogen bonds with the positively charged ‘canyon’ region between FGFs and the 
FGFR D2 domains. HS stabilises the complex by simultaneously interacting with both 
FGF and FGFR in the 1:1 heterodimer prior to homodimerisation of this 1:1:1 trimer to 
the 2:2:2 complex (Figure 1.11). The structure highlights the different contributions of 
FGF-FGFR, FGFR-FGFR, FGF-HS and FGFR-HS interactions cooperating to stabilise 
the FGFR dimer. This model is supported by the majority of experimental evidence to 





Figure 1.11 Structure of the extracellular portion of the ternary signalling complex. The 
crystal structure of the extracellular portion of a signalling competent 2:2:2 ternary complex [PDB: 
1FQ9] (Schlessinger et al., 2000) comprising two molecules of each of FGF2, FGFR1 (D2-D3) 
and a heparin sulphate (HS) octasaccharide is shown. The two orientations are rotated by 90° 
relative to each other, showing the complex from the ‘front’ (left panel) and from ‘above’ (right 
panel). For clarity, only one FGF (light blue) and FGFR (salmon) molecule is shown in cartoon 
representation against the surface. Both HS molecules are shown as sticks and coloured red. 
The HS binds in the positively charged ‘canyon’ between FGF2 and the FGFR1 D2 domain where 
it contacts an FGF and FGFR molecule within each 1:1:1 FGF-FGFR-HS trimer in the 2:2:2 
complex. Contacts between FGF2 and both FGFR molecules in the complex are clearly visible 
from ‘above’ (right panel) while contacts between the D2 domains of the FGFRs can be observed 




Although HS is required for high affinity binding of paracrine FGFs to FGFRs (Yayon et 
al., 1991), the minimal length of HS required for FGFR activation in cells was found to 
be an octasaccharide (Ornitz and Leder, 1992). However, in vitro experiments and the 
crystal structures above suggest that shorter HS chains might be sufficient for binding to 
the FGF-FGFR binary complex (Schlessinger et al., 2000). The observation that 
spatiotemporal differences in HS lengths and sulphation patterns direct signalling 
through different combinations of FGFs and FGFRs suggests that complex assembly 
through FGFs and FGFRs with different affinities for HS will be further fine-tuned by their 
ability to bind to tissue specific HS chains to form signalling complexes (Ostrovsky et al., 
2002, Qu et al., 2011, Qu et al., 2012). Different HS binding affinities establish variable 
FGF diffusion radii within the extracellular matrix, manifesting as (reciprocal) FGF 
gradients that modulate their biological function and the extent of their response 
(Makarenkova et al., 2009). A final level of regulation of extracellular dimer formation 
depends on the extent of autoinhibition by the D1 domain and the acid box region, 
discussed in section 1.5.2. A shift in the equilibrium to more FGFRs in the non-inhibited 
‘open’ D1 conformation will allow greater levels of ligand binding and activation, and vice 
versa. 
 
The current premise is that simple dimerisation of FGFRs is insufficient for activation, 
and that the correct orientation of domains within the dimer is required to fully activate 
the kinase. Subtle FGF specific rotations of D2 and D3 domains of FGFR b and c splice 
isoforms upon FGF-FGFR binding might propagate to differences in the juxtaposition of 
intracellular KDs, modulating the signal (Yeh et al., 2003, Olsen et al., 2006). The 
intracellular FGFR-FGFR contacts are vital for full activation of the complex. As 
discussed in section 1.5.3, it is plausible that this is modulated through conformational 
coupling across the plasma membrane. In the case of the diffusion based model, this will 
be a direct consequence of extracellular ligand binding. In the case of the pre-formed 
dimer model, there might be a switch from an autoinhibitory, symmetric conformation of 
inactive KD dimers (Mohammadi et al., 1996b) to correctly juxtaposed asymmetric KD 
dimers that can trans-phosphorylate (Chen et al., 2008, Bae et al., 2010). The 
asymmetric FGFR1 and FGFR2 homodimers in these structures have very different 
interfaces between enzyme- and substrate-acting KDs, suggesting that sequence 
specific differences between the D3 domains (b and c splice isoforms) and KDs of 
FGFR1-4 will determine the nature of intracellular FGFR-FGFR contacts and tyrosine 






1.6 Activation of downstream FGFR signalling cascades 
 
Upon FGFR activation, the two main downstream effectors that are activated through 
phosphorylation by the activated FGFRs are PLCγ and the adaptor protein FRS2 (Figure 
1.4). PLCγ binds to a phospho-tyrosine residue towards the C-terminus of FGFRs via 
one of its SRC homology 2 (SH2) domains (Mohammadi et al., 1991, Bae et al., 2009). 
Tyrosine phosphorylation of PLCγ by FGFR activates PLCγ causing it to hydrolyse 
phosphatidylinositol-4,5-bisphosphate (PIP2) to inositol-1,4,5-trisphosphate (IP3) and 
diacylglycerol (DAG) at the plasma membrane (Carpenter and Ji, 1999). This activates 
protein kinase C (PKC) and the release of calcium from intracellular stores, affecting cell 
motility. In contrast, FRS2 binds to a phospho-tyrosine on the FGFR juxtamembrane 
region via its phospho-tyrosine binding (PTB) domain and, once activated by 
phosphorylation, serves as a hub for the recruitment of more downstream effectors 
through binding to GRB2 (Kouhara et al., 1997). GRB2 then activates the Ras-RAF-
MEK-MAPK pathway through recruitment of the son of sevenless (SOS) guanine 
nucleotide exchange factor, and activates the PI3K-PDK-AKT pathway through 
recruitment of the GRB2-associated binding protein 1 (GAB1), leading to pro-survival 
signalling and proliferation (Figure 1.4). Other pathways can also be activated by FGFRs 
in different cellular contexts linked to cellular transformation, such as signal transducer 
and activator of transcription (STAT) signalling (Hart et al., 2000, Krejci et al., 2008, Wu 
et al., 2013) and ribosomal S6 kinase 2 (RSK2) signalling (Kang et al., 2009). 
 
1.7 Higher order regulation of FGFR signalling 
 
1.7.1 Cell surface FGFR internalisation by endocytosis 
Ligand-induced internalisation of RTKs  is believed to play an important role in the 
modulation of signalling at the cell surface (Sorkin and von Zastrow, 2009). Several 
reports have shown that ligand bound FGFRs can also be internalised via clathrin- and 
dynamin-dependent or independent routes, based on which receptor isoform is being 
internalised, and FGF-FGFR complexes are then either recycled to the plasma 
membrane or degraded in lysosomes (Haugsten et al., 2005, Sandilands et al., 2007, 
Haugsten et al., 2011). Ubiquitination of the receptor has been shown to be necessary 
for intracellular sorting of internalised FGFRs to lysosomes for degradation but not for 
endocytosis (Haugsten et al., 2008). Additionally, it has been suggested that receptor 
dimerisation might be sufficient, and kinase activity and ligand binding dispensable, for 
internalisation of FGFRs (Opalinski et al., 2017). This leads to the hypothesis that 
receptor internalisation might regulate ligand-independent signalling by removing FGFR 
dimers from the cell surface in the absence of ligand stimulation, dampening basal level 
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signalling. In addition, the duration, and therefore potency, of the transduced signal upon 
ligand binding might depend on the level of FGFR ubiquitination and the rate of FGF-
FGFR complex recycling versus degradation. These open questions will require 
experimental testing to understand the involvement of endocytosis in the regulation of 
FGFR signalling. 
 
1.7.2 Regulation of signalling via extracellular and intracellular docking proteins 
The Klotho family of transmembrane FGFR co-receptor proteins convert the FGFR 
signalling mode from paracrine to endocrine in response to the endocrine FGF19 
subfamily ligands (detailed in Chapter 4). An FGFR-like protein termed FGFR5 that lacks 
a KD, localises to the plasma membrane, is alternatively spliced and can bind FGFs and 
HS through its ectodomain, was first thought to act as a decoy receptor (Wiedemann and 
Trueb, 2000, Sleeman et al., 2001, Trueb et al., 2003). FGFR5 knockout mice (but not 
those lacking only the intracellular domain) are not viable, so it is now thought that the 
ectodomain might mediate most of the activity of FGFR5, although kinase independent 
signalling roles have also been proposed based on the occurrence of a SH2 binding 
motif at its C-terminus (Trueb, 2011, Ornitz and Itoh, 2015, Kilkenny and Rocheleau, 
2016). 
 
It was already described in section 1.5.5 how the FGFR adaptor protein GRB2 might 
regulate signalling through ligand independent binding to the FGFR C-terminal tail. The 
FRS2 isoform FRS2α also constitutively (and ligand independently) binds to the 
intracellular FGFR juxtamembrane region via its PTB domain, from where it regulates 
downstream signalling (Xu et al., 1998a, Ong et al., 2000). Interestingly, GRB2 and FRS2 
also interact with each other following ligand stimulation (Kouhara et al., 1997), and 
ternary complex formation between these two proteins and an E3 ubiquitin ligase in 
response to FGF stimulation leads to FGFR degradation and dampening of the 
transduced signal (Wong et al., 2002). Several other effectors also negatively regulate 
FGFR signalling by inhibiting the functions of signalling proteins downstream of FGFRs, 
as reviewed in (Ornitz and Itoh, 2015). It has even been proposed that extracellular 
ligand binding might be regulated in part by the intracellular FGFR KDs in an ‘inside-out’ 
like negative feedback mechanism (Uematsu et al., 2001). Regulation of FGFR signalling 
is clearly complex and multidimensional and is likely to be modulated in a context 







1.8 Deregulated FGFR signalling in pathology 
Given the pleiotropic physiological roles of FGFR signalling, it is not surprising that 
deregulation of signalling leads to a range of diseases (Carter et al., 2015). First 
implications of deregulated FGFR signalling in pathophysiology came from the 
identification of gain-of-function germline mutations in FGFRs, which constitutively 
activated FGFRs in a ligand independent manner, and which were responsible for 
diverse skeletal dysplasias and craniosynostosis syndromes (Wilkie, 2005). In addition, 
deregulation of endocrine FGFR signalling was found to cause various metabolic 
defects, detailed in Chapter 4. However, it is the compelling evidence implicating 
aberrant FGFR signalling in cancer that has led to an explosion in the field of FGFR 
research in the last two decades. A study of over 1000 somatic mutations from over 200 
different cancers highlighted the importance of FGF signalling in tumour biology 
(Greenman et al., 2007). Abnormal FGFR signalling can directly drive oncogenesis in a 
subset of several types of cancers by promoting cancer cell proliferation and survival and 
tumour angiogenesis (Turner and Grose, 2010, Dieci et al., 2013, Tanner and Grose, 
2016). FGFRs are therefore considered important therapeutic targets in cancer (Brooks 
et al., 2012, Dienstmann et al., 2014, Touat et al., 2015). 
 
1.8.1 Tumour diversity and types of FGFR aberrations 
A recent study used next generation sequencing to comprehensively analyse nearly 
5000 solid tumours from patients for aberrations in FGFRs, providing a representative 
overview of the landscape of FGFR deregulation in cancer (Helsten et al., 2016). This 
work showed that FGFR aberrations are found in 7% of all solid tumours, of which 5% 
and 2% represent gene amplifications and point mutations respectively. FGFR1 was 
found to be the most frequently altered FGFR. In addition, FGFR aberrations were most 
often found in urothelial carcinomas, followed by breast, endometrial and ovarian 
carcinomas. In general, the most commonly occurring FGFR aberrations in cancer are 
gene amplifications, chromosomal fusions and somatic point mutations. 
 
Several studies have shown that amplification and/or overexpression of FGFR genes 
appears to be the most common aberration found across several different cancers, with 
FGFR1 being most frequently amplified (in breast and squamous cell lung cancers) 
followed by FGFR2 (in endometrial cancer) and to a lesser degree FGFR3 and FGFR4 
in a range of cancer types (Carter et al., 2015, Helsten et al., 2016). Chromosomal 
translocations involving FGFR genes are also commonly found in cancers, and in 
general these result in fusion proteins comprising the dimerisation domain of another 
protein fused to either the N- or C-terminus of FGFR, leading to constitutive and ligand 
independent FGFR dimerisation and activation (Turner and Grose, 2010, Gallo et al., 
42 
 
2015). Oncogenic fusions were first found in bladder cancer and gliomas for FGFR3 and 
FGFR1 (Singh et al., 2012, Williams et al., 2013) and were subsequently also identified 
in several other cancers for FGFR1-3 (Wu et al., 2013). FGFR2 is found fused to several 
different partners, whereas FGFR3 is most commonly found fused to transforming acidic 
coiled-coil containing protein (TACC3) and this fusion produces one of the most 
important oncoproteins in bladder cancer (Gallo et al., 2015, di Martino et al., 2016, 
Babina and Turner, 2017). Somatic missense substitutions that result in point mutations 
are also observed very frequently in all FGFRs and in all types of cancer, but are most 
common in FGFR3 and FGFR2 and these occur most often in urothelial (bladder) and 
endometrial carcinomas respectively (Guagnano et al., 2012, Abbosh et al., 2015, Carter 
et al., 2015, Helsten et al., 2016). The most common point mutation in cancers found to 
date is the S249C mutation, in the extracellular D2-D3 linker of FGFR3, which accounts 
for more than 50% of all cancer-associated mutations in FGFR3 (Tomlinson et al., 2007a, 
Babina and Turner, 2017). The breadth of FGFR point mutations in cancer and their 
activating nature and/or roles as oncogenic drivers in cancer will be discussed in detail 
in Chapter 3. Furthermore, the roles of aberrant endocrine FGFR signalling in cancer will 
be discussed in detail in Chapter 4. 
 
1.8.2 Mechanisms of oncogenic FGFR signalling 
There are common themes to the mechanisms by which FGFR aberrations induce 
oncogenic signalling (Figure 1.12). FGFR amplifications can lead to FGFR 
overexpression and accumulation at the plasma membrane, increasing activation of 
FGFRs and downstream signalling (Figure 1.12a). In addition, many FGFs have also 
been found overexpressed by tumour cells, or the adjacent tumour-associated stroma, 
leading to increased angiogenesis and epithelial-mesenchymal transition (EMT) through 
illicit autocrine or paracrine signalling (Figure 1.12b). Oncogenic fusion proteins, and 
certain point mutations, can force constitutive dimerisation of FGFRs leading to ligand 
independent hyperactive signalling (Figure 1.12c). Other types of point mutations can 
lead to allosteric or direct activation of the FGFR KDs leading to increased signalling in 
a ligand dependent or independent fashion, depending on the point mutation 
(Figure1.12d). Altered splicing of the autoinhibitory D1 domain of FGFRs and increased 
tumoural expression of this β splice isoform with a higher affinity for FGFs can lead to 
increased ligand dependent FGFR activation (Figure 1.12e). Similarly, a switch in 
expression from the FGFR b to the c splice isoform can alter the FGFR ligand specificity, 
allowing it to respond to a wider range of FGFs (for example those produced by the 
tumour cells) that it might not normally interact with (Figure 1.12f). It has even been found 
that an alternatively spliced FGFR2 variant lacking its C-terminus results in the loss of 
its ubiquitination site, impairing receptor internalisation and signal attenuation (Figure 
43 
 
1.12g). Finally, gene amplification, overexpression or mutation of intracellular FGFR 







Figure 1.12 Mechanisms of oncogenic FGFR activation and signalling. There are several 
molecular mechanisms through which FGFR signalling can be aberrantly activated in cancer. (a) 
Amplification of the FGFR genes can lead to overexpression of receptors at the cell surface, 
leading to ligand-independent dimerisation by stochastic diffusion-limited activation (see also 
Figure 1.5a). (b) Amplification of FGF genes and/or overexpression of FGFs from surrounding 
(tumour-associated) stromal cells can also dimerise and activate FGFR signalling through illicit 
autocrine or paracrine routes. (c) Oncogenic fusion proteins (from chromosomal translocation or 
gene fusions, dark green) or activating point mutations in the extracellular, juxtamembrane or 
transmembrane domains (purple stars) can constitutively and ligand-independently dimerise and 
activate FGFRs. (d) Activating point mutations (purple stars) in the kinase domain (KD) can 
allosterically or directly activate the KD. (e-g) Alternative splicing of different parts of FGFRs can 
produce splice isoforms with altered ligand dependent or independent signalling properties, and 
relative expression of the more active splice variants is often found to be increased in tumours. 
(e) Alternative splicing of the D1 domain and/or the acid box in the D1-D2 linker relieves receptor 
autoinhibition and can increase affinity for FGFs. (f) Alternative splicing of the D3 domain can 
cause a switch from the alternative ‘b’ to the canonical ‘c’ FGFR splice isoforms. These can 
respond to a larger range of FGFs, such as those produced by tumour-associated stromal cells. 
(g) Alternative splicing of the C-terminal tail can remove crucial regulatory regions such that 
ubiquitination, recycling and/or degradation of activated FGFRs is impaired. (h) Gene 
amplification and/or overexpression of, or activating mutations in, downstream signalling effector 






1.8.3 Therapeutic targeting of aberrant FGFR signalling 
The clear evidence that aberrant FGFR signalling is an important therapeutic target in 
several cancers has led to rapid progression in the field of anti-FGFR targeting. Despite 
these huge efforts, there are currently no approved therapies in the clinic based on FGFR 
targeting (Touat et al., 2015, Babina and Turner, 2017). A variety of therapeutic agents 
are in pre-clinical development, and encouragingly many are also at various stages of 
clinical trials for several cancer types with the aim of specific anti-FGFR targeting. These 
mostly comprise multi-kinase or FGFR-selective small molecule inhibitors which target 
the ATP binding pocket in the KD, but also include other therapeutic agents such as 
monoclonal antibodies (mAbs) and FGF ‘ligand traps’. A list of anti-FGFR agents 
currently undergoing clinical trials is summarised in Table 1.4. 
 
Apart from anti-FGFR therapies, the therapeutic potential of several FGFs has also been 
highlighted (Beenken and Mohammadi, 2009, Tanner and Grose, 2016). Anti-FGF 
therapeutics for various disorders are in pre-clinical development, while FGFs with 
beneficial effects on various aspects of physiology have been engineered to produce 
recombinant FGFs as biologic therapies. One such example is a recombinant form of 
FGF7 (palifermin) which is approved for the treatment of mucositis (Spielberger et al., 
2004). In addition, the endocrine FGFs have been found to exert several beneficial 
metabolic effects and are rapidly being developed as therapeutics for diseases such as 
diabetes and obesity (detailed in Chapter 4). Approval of these candidate anti-FGFR and 
FGF treatments in the near future will help to address subsets of several diseases 









Clinical development (cancer / 
tumour type) 
Multi-kinase (non-selective) small molecules 
Dovitinib 
(Novartis) 
FGFR, KIT, VEGFR, 
PDGFR, RET 
Phase II (gastric, urothelial) 
Phase III (metastatic renal) 
Ponatinib 
(ARIAD Pharmaceuticals) 
FGFR, ABL, VEGFR, 
PDGFR, SRC Phase II (biliary, advanced solid) 
Lenvatinib 
(Eisai) FGFR, VEGFR, PDGFR Phase III (thyroid) 
Lucitanib 
(Clovis Oncology) FGFR, VEGFR, PDGFR 
Phase I (advanced solid) 
Phase II (metastatic breast / lung) 
Nintedanib 
(Boehringer Ingelheim) FGFR, VEGFR, PDGFR Phase III (NSCLC, ovarian) 
Pan-FGFR (FGFR-selective) small molecules 
AZD4547 
(AstraZeneca) FGFR1-3 




Phase I (SCLC, urothelial) 
Phase II (solid, haematological) 
JNJ-42756493 
(Janssen) FGFR1-4 
Phase I (FGF19 amplified HCC*) 
Phase II (urothelial, Asian solid) 
LY2874455 
(Eli Lilly) FGFR1-4 Phase I (advanced solid) 
ARQ-087 
(ArQule) FGFR1-3 Phase III (bile ductal and/or HCC) 
Debio-1347 
(Debiopharm) FGFR1-3 Phase I (advanced solid) 
TAS120 
(Taiho Oncology) FGFR1-4 
Phase I (advanced solid) 
Phase II (myeloma) 
E7090 
(Eisai) FGFR1-3 Phase I (advanced solid) 
ASP5878 
(Astellas Pharma) FGFR1-4 Phase I (advanced solid) 
Anti-FGFR antibodies 
R3Mab 
(Genentech) FGFR3 Phase I (advanced solid) 
FPA144 
(Five Prime Therapeutics) FGFR2b Phase I (advanced solid) 
BAY1179470 
(Bayer) FGFR2 Phase I (advanced solid) 
FGF ligand traps (soluble FGFR ectodomains) 
FP-1039 




Chapter 2: Materials and Methods 
 
2.1 General molecular biology methods 
 
2.1.1 Production of competent E. coli cells 
Escherichia coli (E. coli) cells (specific strains detailed in respective sections) were 
streaked from existing lab competent cell stocks onto lysogeny broth (LB) agar plates 
(10 g/L tryptone, 5 g/L yeast extract, 5 g/L NaCl and 15 g/L agar) containing the 
appropriate antibiotics and incubated overnight at 37°C. A single colony was used to 
inoculate a 25 mL LB medium (10 g/L tryptone, 5 g/L yeast extract and 5 g/L NaCl) starter 
culture for 7 hours at 37°C. The starter culture was used to inoculate 250 mL SOB 
medium (20 g/L tryptone, 5 g/L yeast extract, 0.5 g/L NaCl, 2.5 mM KCl and 10 mM 
MgSO4) supplemented with 10 mM MgCl2 at different cell densities overnight at 18°C. 
When cell density reached an optical density of 0.55 at 600 nm (OD600) the culture was 
transferred to ice for 10 min. Cells were harvested by centrifugation (4,000 x g, 
10 minutes and 4°C) and then resuspended in 80 mL ice-cold Inoue transformation buffer 
(ITB: 10 mM PIPES-KOH pH 6.7, 250 mM KCl, 15 mM CaCl2 and 55 mM MnCl2) by 
swirling gently for 10 minutes at 4°C. Cells were harvested by centrifugation (4,000 x g, 
10 minutes and 4°C) and resuspended in 20 mL ice-cold ITB again by swirling gently for 
10 minutes at 4°C. DMSO was added to the cell suspension to 7% v/v. Cell suspension 
was aliquoted (50 μL and 250 μL), snap frozen in liquid nitrogen and stored at -80°C. 
 
2.1.2 Bacterial transformation 
DNA (50-300 ng in 0.5-2 µL) was mixed with 50 μL competent E. coli cells (specific 
strains detailed in respective sections) for 30 minutes on ice. The mixture was subjected 
to a ‘heat-shock’ (42°C for 45 seconds) before being incubated for a further 2 minutes 
on ice. Transformed cells were then shaken for 1 hour at 37°C after the addition of 250 μL 
SOC medium (SOB medium supplemented with 20 mM MgCl2 and 10 mM D-glucose). 
Cell suspension was then spread on agar plates comprising appropriate growth medium 
and containing the appropriate antibiotics (10 mM D-glucose was also added to the 
plates when necessary to strictly repress basal expression of proteins toxic to the E. coli) 
and incubated overnight at 37°C. 
 
2.1.3 Restriction cloning 
Restriction digests (to prepare vector or insert for cloning) were performed with 1 μg 
template plasmid DNA, 1 x reaction buffer (NEB), 0.1 mg/mL BSA and 1 μL of each 
appropriate restriction enzyme (NEB) per 25 µL digest. Reactions were heat-inactivated 
(65°C for 5 min) and run on 0.9% w/v agarose gels pre-stained with GelRed™ (Biotium). 
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Digested DNA was visualised under a UV-lamp and bands at the correct molecular 
weights were cut and extracted from the gel using the QIAquick Gel Extraction kit 
(Qiagen) as per the manufacturer’s instructions. Vector and insert were then mixed in a 
3:1 molar ratio for ligation with T4 ligase (NEB) and the reaction was incubated overnight 
at 16°C. Competent E. coli XL10 Gold cells were then transformed with 1 μL of ligated 
product and colonies were sequenced to screen for successful cloning. 
 
2.1.4 Ligation-independent cloning (LIC) 
Linearised DNA vectors and inserts were generated using 50 ng template plasmid DNA, 
appropriate primers and PfuUltra™ DNA polymerase (Stratagene) as per the 
manufacturer’s instructions, with reactions performed on a thermal cycler (G storm). 
When required, polymerase chain reactions (PCRs) were performed using temperature 
gradients. Total PCR product was run on 0.9% w/v agarose gels pre-stained with 
GelRed™ dye (Biotium). Linearised DNA was visualised under a UV-lamp and bands at 
the correct molecular weights were cut and extracted from the gel using the QIAquick 
Gel Extraction kit (Qiagen) as per the manufacturer’s instructions. Vector and insert were 
then mixed in variable (optimised) amounts and incubated with In-Fusion® HD 
buffer/enzyme mix (Clontech) for 15 minutes at 37°C followed by 15 minutes at 50°C. 
Competent E. coli XL10 Gold cells were then transformed with 1 μL LIC product and 
colonies were sequenced to screen for successful cloning. 
 
2.1.5 Site-directed mutagenesis (SDM) 
SDM reactions were performed on a thermal cycler (G storm) using 5 ng template 
plasmid DNA, appropriate primers and PfuUltra™ DNA polymerase (Stratagene) as per 
the manufacturer’s instructions. When required, PCR was performed using appropriate 
temperature gradients. Total PCR product was subjected to digestion with DpnI (NEB) 
for 1 hour at 37°C to eliminate remaining template DNA. Competent E. coli XL10 Gold 
cells were then transformed with 2 μL digested PCR product and colonies were 
sequenced to screen for successful incorporation of mutations. 
 
2.1.6 Large scale plasmid purification 
A 3 mL starter culture (inoculated with E. coli XL10 Gold cells transformed with the 
relevant plasmid) was used to inoculate cultures of 500 mL LB medium or terrific broth 
(TB) medium (12 g/L tryptone, 24 g/L yeast extract, 0.4% v/v glycerol, 0.17 M KH2PO4 
and 0.72 M K2HPO4) shaken overnight at 37°C. Cells were harvested by centrifugation 
(4,500 x g, 10 minutes and 4°C) and resuspended in 37 mL alkaline lysis buffer I (50 mM 
D-glucose, 25 mM Tris-HCl pH 8.0 and 10 mM EDTA). Cells were lysed with 50 mL 
alkaline lysis buffer II (0.2 M NaOH and 1% w/v SDS) and genomic DNA precipitated 
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with 37 mL cold alkaline lysis buffer III (3 M potassium acetate and 11.5% v/v glacial 
acetic acid) followed by centrifugation (4,500 x g, 10 minutes and 4°C). Supernatant was 
filtered through 4 layers of cheesecloth and nucleic acid precipitated with 0.7 volumes 
propan-2-ol followed by centrifugation (4,500 x g, 15 minutes and 4°C). The pellet was 
washed in 10 mL 70% ethanol, dried and re-dissolved in 2 mL TE buffer (10 mM Tris-
HCl pH 8.0 and 1 mM EDTA pH 8.0). RNA was precipitated with 2 mL 5 M LiCl followed 
by centrifugation (4,500 x g, 10 minutes and 4°C). All remaining nucleic acid was 
precipitated from the supernatant with 0.7 volumes propan-2-ol followed by 
centrifugation (4,500 x g, 10 minutes and 4°C). Pelleted nucleic acids were re-dissolved 
in 0.5 mL TE buffer and treated with 5 μL of 10 mg/mL RNase A (Qiagen) for 15 minutes 
at 37°C. Undigested nucleic acids were precipitated with 0.5 mL 13% w/v polyethylene 
glycol 8,000 and 1.5 M NaCl for 30 minutes on ice followed by centrifugation (4,500 x g, 
5 minutes and room temperature). Dried pellet was re-dissolved in 200 μL TE buffer and 
added to 200 μL phenol/chloroform (Sigma), vortexed for 30 seconds and centrifuged 
(20,000 x g, 5 minutes and room temperature). The upper phase was transferred to 
0.1 volumes 3 M sodium acetate and 2.5 volumes 100% ethanol added. Following a final 
centrifugation (20,000 x g, 2 minutes and 4°C) the pellet was washed with 0.5 mL 70% 
ethanol, dried completely and re-dissolved in 500 μL TE buffer. DNA concentration was 
quantified on a Nanodrop 2000c and plasmid preparations were adjusted to 1 μg/μL with 
additional TE buffer. 
 
Alternatively, 150 mL cultures were similarly grown up, cells harvested and plasmids 
purified using the ZymoPURE™ Plasmid Maxiprep kit (Zymo Research) as per the 
manufacturer’s instructions. 
 
2.2 Construction of plasmid libraries 
 
2.2.1 FGFR3 and variants 
Native human FGFR3 (455-768) kinase domain (KD) cDNA was obtained from a lab 
stock in the pOPINS vector (OPPF) which contains an N-terminal Ulp1 protease 
cleavable 6His-SUMO tag. Solubilising mutations C482A and C582S (Mohammadi et al., 
1996b) were introduced by sequential SDM by Tom Bunney to produce the ‘2C’ 
mutations C482A and C582S and thus FGFR3-2C (455-768). Native human FGFR3b 
full length cDNA was cloned in the pFB vector (originally pFB-neomycin resistant, 
Stratagene) by the Knowles lab, University of Leeds, modified to be hygromycin B 
resistant (Tomlinson et al., 2005). Missense substitutions were then introduced into both 
pOPINS (kanamycin-resistant) and pFB (ampicillin-resistant) constructs by SDM using 
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the primers in Table 2.1. Some of these mutant plasmids were generated by Sarah Saad 
and Tom Bunney (pOPINS) and Yulia Panina (pFB) respectively. 
 
A codon-optimised human FGFR3-2C (455-768) gene harbouring an additional K650E 
mutation was synthesised in the pJ821 vector (DNA2.0) with an N-terminal cleavable 
6His-SUMO tag to produce a similar construct to the pOPINS construct. The K650E 
mutation was first mutated back to lysine to recreate FGFR3-2C using the primers in 
Table 2.2a. Some of the mutations from Table 2.1, and some mutations selected for 
analysis at a later date, were then introduced into the codon-optimised pJ821 FGFR3-
2C (455-768) backbone (kanamycin-resistant) by SDM using the primers in Table 2.2b. 
 
For pOPINS and pJ821 constructs, individual colonies were picked and used to inoculate 
small volume overnight cultures at 37°C, from which glycerol stocks (containing 25% v/v 
glycerol mixed with cell suspension) were prepared and plasmids were purified using the 
QIAprep Spin Miniprep kit (Qiagen) as per the manufacturer’s instructions. Purified 
plasmids were pre-sequenced using the BigDye3.1 system (ABI Prism) and the DyeEx 
2.0 Spin kit (Qiagen) as per the manufacturer’s instructions, and sequenced (Source 
BioScience) to confirm perfect incorporation of mutations. For pFB constructs, individual 
colonies were picked and subjected to colony PCR using Taq DNA polymerase (Qiagen) 
and PCR product was analysed by 1% w/v agarose gel electrophoresis. Colonies with 
detectable PCR product were used to inoculate small volume overnight cultures at 37°C, 
and glycerol stocks and plasmids were prepared as detailed above. Purified plasmids 
were then pre-sequenced and deep sequenced as described above to retain constructs 




Table 2.1 Site-directed mutagenesis primers used to introduce missense substitutions 
into the native pOPINS FGFR3-2C (455-768) and pFB FGFR3b (full length) backbone 
constructs. Residue numbering is as per the canonical FGFR3c splice isoform. 
FGFR3 mutation Primer 
E466K GAG → AAG Forward 
CCGACCCCAAATGGAAGCTGTCTCGGGCCC 
Reverse GGGCCCGAGACAGCTTCCATTTGGGGTCGG 
A500T GCC → ACC Forward 
GACAAGGACCGGGCCACCAAGCCTGTCACC 
Reverse GGTGACAGGCTTGGTGGCCCGGTCCTTGTC 
N540K AAC → AAG Forward 
CAAAAACATCATCAAGCTGCTGGGCGCCTGC 
Reverse GCAGGCGCCCAGCAGCTTGATGATGTTTTTG 
N540S AAC → AGC Forward 
CAAAAACATCATCAGCCTGCTGGGCGCCTG 
Reverse CAGGCGCCCAGCAGGCTGATGATGTTTTTG 
P572A CCC → GCC Forward 
GCGGGCGCGGCGGGCCCCGGGCCTGGACTAC 
Reverse GTAGTCCAGGCCCGGGGCCCGCCGCGCCCGC 
C582F TGC → TTC Forward 
CTCCTTCGACACCTTCAAGCCGCCCGAGGAG 
Reverse CTCCTCGGGCGGCTTGAAGGTGTCGAAGGAG 
D617G GAC → GGC Forward 
GTGCATCCACAGGGGCCTGGCTGCCCGCAATG 
Reverse CATTGCGGGCAGCCAGGCCCCTGTGGATGCAC 
E627D GAG → GAC Forward 
GTGCTGGTGACCGACGACAACGTGATGAAG 
Reverse CTTCATCACGTTGTCGTCGGTCACCAGCAC 
V630M GTG → ATG Forward 
GACCGAGGACAACATGATGAAGATCGCAGAC 
Reverse GTCTGCGATCTTCATCATGTTGTCCTCGGTC 
D641G GAC → GGC Forward 
GGCTGGCCCGGGGCGTGCACAACCTC 
Reverse GAGGTTGTGCACGCCCCGGGCCAGCC 
D641N GAC → AAC Forward 
CGGGCTGGCCCGGAACGTGCACAACCTCGAC 
Reverse GTCGAGGTTGTGCACGTTCCGGGCCAGCCCG 
H643D CAC → GAC Forward 
GGCCCGGGACGTGGACAACCTCGACTACTAC 
Reverse GTAGTAGTCGAGGTTGTCCACGTCCCGGGCC 
D646Y GAC → TAC Forward 
CGTGCACAACCTCTACTACTACAAGAAGAC 
Reverse GTCTTCTTGTAGTAGTAGAGGTTGTGCACG 
K650E AAG → GAG Forward 
CGACTACTACAAGGAGACAACCAACGGCCG 
Reverse CGGCCGTTGGTTGTCTCCTTGTAGTAGTCG 
K650M AAG → ATG Forward 
GACTACTACAAGATGACAACCAACGGCCGG 
Reverse CCGGCCGTTGGTTGTCATCTTGTAGTAGTC 
K650N AAG → AAC Forward 
GACTACTACAAGAACACAACCAACGGCCGG 
Reverse CCGGCCGTTGGTTGTGTTCTTGTAGTAGTC 
N653H AAC → CAC Forward 
CAAGAAGACAACCCACGGCCGGCTGCCCGTG 
Reverse CACGGGCAGCCGGCCGTGGGTTGTCTTCTTG 
R669G CGA → GGA Forward 
GAGGCCTTGTTTGACGGAGTCTACACTCACC 
Reverse GGTGAGTGTAGACTCCGTCAAACAAGGCCTC 
R669Q CGA → CAA Forward 
GAGGCCTTGTTTGACCAAGTCTACACTCACCAG 
Reverse CTGGTGAGTGTAGACTTGGTCAAACAAGGCCTC 
V677I GTC → ATC Forward 
CTCACCAGAGTGACATCTGGTCCTTTGGGG 
Reverse CCCCAAAGGACCAGATGTCACTCTGGTGAG 
E686K GAG → AAG Forward 
GGTCCTGCTCTGGAAGATCTTCACGCTGGG 
Reverse CCCAGCGTGAAGATCTTCCAGAGCAGGACC 





Table 2.2 Site-directed mutagenesis primers used to (a) reintroduce a native lysine at 
position 650 of the codon-optimised pJ821 FGFR3-2C (455-768) harbouring a K650E 
mutation, and (b) introduce missense substitutions into the pJ821 FGFR3-2C (455-768) 




FGFR3 mutation Primer 






FGFR3 mutation Primer 
I538F ATC → TTC Forward 
CGGCAAGCACAAGAACTTCATCAATCTGCTGGGTGC 
Reverse GCACCCAGCAGATTGATGAAGTTCTTGTGCTTGCCG 
I538V ATC → GTC Forward 
CGGCAAGCACAAGAACGTCATCAATCTGCTGGGTGC 
Reverse GCACCCAGCAGATTGATGACGTTCTTGTGCTTGCCG 
N540K AAT → AAA Forward 
CAAGAACATCATCAAACTGCTGGGTGCTTGTACC 
Reverse GGTACAAGCACCCAGCAGTTTGATGATGTTCTTG 
G637W GGC → TGG Forward 
GAAAATTGCGGACTTCTGGTTGGCACGCGATGTTC 
Reverse GAACATCGCGTGCCAACCAGAAGTCCGCAATTTTC 
D641G GAT → GGT Forward 
CGGCTTGGCACGCGGTGTTCACAACC 
Reverse GGTTGTGAACACCGCGTGCCAAGCCG 
R669G CGT → GGT Forward 
GGAAGCATTGTTTGATGGTGTGTACACCCACC 
Reverse GGTGGGTGTACACACCATCAAACAATGCTTCC 
R669Q CGT → CAG Forward 
GGAAGCATTGTTTGATCAGGTGTACACCCACC 
Reverse GGTGGGTGTACACCTGATCAAACAATGCTTCC 






2.2.2 β-Klotho, FGFR1c, FGF19 and FGF21 
Codon-optimised constructs of human and mouse βKlotho, human FGFR1c and human 
FGF19 and FGF21 were custom designed in the bacterial vector pAZET09 
(AstraZeneca) or mammalian vectors pcDNA3.1 (Invitrogen) and pEBNAZ 
(MedImmune) and cloned by GeneArt™ (Thermo Fisher Scientific). All constructs 
comprised a C-terminal protease cleavable 2StrepII-10His tag. A full length native human 
FGFR1c cDNA construct in the pcDNA3.1 mammalian vector with a C-terminal FLAG 
tag was provided by AstraZeneca. Additionally a full length native mouse βKlotho cDNA 
construct in a pCMV mammalian vector with a C-terminal fusion to eGFP was purchased 
(Addgene). Restriction enzyme cloning, LIC and SDM were used to modify these 
constructs (e.g. introduce or remove fusion tags or sub-clone constructs into different 
expression vectors). Details of all constructs prepared for use in this study are in Tables 
2.3 and 2.4. 
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Table 2.3 Expression constructs prepared for expression testing in E. coli (specific 
strains detailed in respective sections) and for recombinant protein production in this 
work. All constructs have a C-terminal PreScission™ protease-cleavable 2StrepII-10His 
tag. The gene from which the N-terminal secretion signal peptide was derived, where 
applicable, is rendered in italics. Refer to text for full details. 
 
Protein Species Construct Residues Expression vector Source 
FGF19 Human FL 23-216 pAZET09 GeneArt™ 
FGF21 Human FL 29-209 pAZET09 GeneArt™ 
βKlotho Human HSA-ΔKL1 513-1044 pAZET09 GeneArt™ 
βKlotho Human pelB-ΔKL1 513-1044 pAZET09 GeneArt™ 
βKlotho Human pelB-KL1 53-514 pAZET09 GeneArt™ 
βKlotho Human KL1 53-514 pAZET09 GeneArt™ 
βKlotho Human pelB-KL2 513-972 pAZET09 GeneArt™ 
βKlotho Human KL2 513-972 pAZET09 GeneArt™ 
βKlotho Human HSA-FL 53-1044 pAZET09 GeneArt™ 
βKlotho Mouse HSA-FL 53-1043 pAZET09 GeneArt™ 
βKlotho Human pelB-FL 53-1044 pAZET09 GeneArt™ 
βKlotho Human HSA-KL1-KL2 53-995 pAZET09 GeneArt™ 
βKlotho Human pelB-KL1-KL2 53-995 pAZET09 GeneArt™ 
βKlotho Human KL1-KL2 53-995 pAZET09 GeneArt™ 
βKlotho Mouse pelB-FL 53-1043 pAZET09 GeneArt™ 
βKlotho Human HSA-FL 53-1044 pTriEx™4 Subcloned 
βKlotho Human FL 53-1044 pTriEx™4 Subcloned 
βKlotho Human HSA-KL1-KL2 53-995 pTriEx™4 Subcloned 
βKlotho Human KL1-KL2 53-995 pTriEx™4 Subcloned 
FGFR1c Human D1-D3 22-374 pAZET09 Subcloned 
FGFR1c Human D2-D3 142-365 pAZET09 Subcloned 
 
 
2.3 General E. coli recombinant protein expression and purification 
 
2.3.1 Recombinant protein expression 
Cultures of 500 mL TB medium containing the appropriate antibiotics were inoculated 
with transformed E. coli from glycerol stocks (specific strains detailed in respective 
sections) or multiple colonies from freshly transformed E. coli and shaken at 37°C at 200-
250 revolutions per minute (rpm). When cell density reached an OD600 of 1.0, 0.4 mM 
IPTG (or 1 mM L-rhamnose in the case of pJ821 constructs) was added to induce 
expression and cells were incubated overnight at 15°C, 20°C or 37°C as appropriate. 
Cells were harvested by centrifugation (4,500 x g, 20 minutes and 4°C) and pellets were 
frozen at -20°C for at least 1 hour before lysis. 
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Table 2.4 Expression constructs prepared for expression testing in mammalian cell lines 
and for recombinant protein production in this work. The gene from which the N-terminal 
secretion signal peptide was derived, where applicable, is rendered in italics. The alias 
provided for some constructs is used instead of the construct name in some Figures in 
Chapter 4. FL – full length, HSA – human serum albumin. 
 




fusion tag Source 
βKlotho Human βKL-FL [41] 1-1044 pcDNA3.1 2StrepII-10His GeneArt™ 
βKlotho Human βKL-KL1-KL2 [42] 1-995 pcDNA3.1 
2StrepII-
10His GeneArt™ 
βKlotho Human CD33-KL1-KL2 [43] 53-995 pcDNA3.1 
2StrepII-
10His GeneArt™ 
βKlotho Human CD33-KL1-KL2 [K3] 53-995 pEBNAZ 
2StrepII-
10His GeneArt™ 
βKlotho Mouse FL [mβe] 1-1043 pCMV *eGFP Addgene 
βKlotho Mouse FL [mβTe6H] 1-1043 pCMV eGFP-6His Engineered 
βKlotho Human HSA-FL 53-1044 pTriEx™4 2StrepII-10His Subcloned 
βKlotho Human FL 53-1044 pTriEx™4 2StrepII-10His Subcloned 
βKlotho Human HSA-KL1-KL2 53-995 pTriEx™4 
2StrepII-
10His Subcloned 
βKlotho Human KL1-KL2 53-995 pTriEx™4 2StrepII-10His Subcloned 
FGFR1c Human FL 1-822 pcDNA3.1 *FLAG AstraZeneca 
FGFR1c Human D1-D3 22-374 pcDNA3.1 *FLAG Engineered 
FGFR1c Human D2-D3 142-365 pcDNA3.1 *FLAG Engineered 
FGFR1c Human CD33-D1-D3 [45] 22-374 pcDNA3.1 
2StrepII-
10His GeneArt™ 
FGFR1c Human CD33-D1-D3 [F1] 22-374 pEBNAZ 
2StrepII-
10His GeneArt™ 








2.3.2 Chemical lysis 
Harvested frozen E. coli cells (specific strains detailed in respective sections) were 
resuspended by shaking for 1 hour at 4°C in lysis buffer (25 mM Tris-HCl pH 8.0, 250 mM 
NaCl, 40 mM imidazole, 10 mM benzamidine hydrochloride, 1 mM MgCl2, 0.5 mM CaCl2 
and 1 mg/mL lysozyme) and then lysed by the addition of 2% v/v cold Triton X-100 and 
15 mg/L DNase I for another 1 hour at 4°C. Lysate was clarified by centrifugation 
(20,000 x g, 1 hour and 4°C) to separate soluble protein (supernatant) from insoluble 
protein in inclusion bodies (pellet). 
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2.3.3 Small-scale expression tests in E. coli 
Overnight 1 mL cultures were inoculated from glycerol stocks transformed with the 
relevant expression constructs in the relevant E. coli expression strains and were shaken 
at 37°C in LB medium containing the relevant antibiotic. Overnight cultures were used to 
inoculate 50 mL TB medium cultures containing the relevant antibiotic (normally 
100 mg/L kanamycin or 50 mg/L ampicillin) and cultures were shaken at 37°C. 
Alternatively, no overnight starter culture was used and 2-5 mL TB medium cultures 
containing the relevant antibiotics were directly inoculated from glycerol stocks and 
shaken at 37°C. Following induction of expression with 0.5 mM IPTG, cells were shaken 
overnight at the required temperature (15, 20, 25 or 37°C) or for 3-4 hours at 37°C. Cells 
were then harvested and frozen. Harvested frozen cell pellets were then thawed on ice, 
lysed by chemical lysis and separated into soluble (S) and insoluble (IS) fractions. S and 





Protein samples were prepared by mixing 1 volume part 4 x SDS-PAGE sample buffer 
(0.2 M Tris-HCl pH 6.8, 8% w/v SDS, 0.05% w/v bromophenol blue, 40% v/v glycerol 
and 5% 2-mercaptoethanol) with 3 volume parts protein sample. Samples were then 
boiled for 5-10 minutes at 95°C before the denatured samples were loaded onto 7.5%, 
10%, 12% or 15% SDS-PAGE gels (produced in-house) depending on the application. 
Gels were run using Mini-PROTEAN® electrophoresis cells (Bio-Rad) with SDS-PAGE 




Protein samples were resolved by SDS-PAGE. Gels were then soaked in transfer buffer 
(25 mM Tris, 192 mM glycine and 20% v/v methanol) for 2 minutes. Proteins were 
transferred from gel to PVDF or nitrocellulose membranes using either Trans-Blot® SD 
Semi-Dry Transfer Cell or the Mini-PROTEAN® Trans-Blot Cells (Bio-Rad). Membranes 
were blocked in 5% w/v non-fat dried milk (NFDM) or bovine serum albumin (BSA) 
respectively in TBS-T buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl and 0.1% v/v 
Tween® 20) depending on the antibody to be used. Membranes were incubated with 
primary antibodies (details in Table 2.5) in the corresponding blocking solution overnight 
at 4°C. All primary antibodies were used with HRP-conjugated secondary antibodies and 
ECL™ Prime (GE Healthcare) and imaged using the Odyssey® Fc system (Li-Cor 
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Biosciences) or Super RX Fuji medical x-ray film (Kodak). Densitometric analyses were 
performed using Image Studio™ Lite (Li-Cor Biosciences) or ImageJ software. 
 
 
Table 2.5 Primary antibodies and experimental conditions used for immunoblotting. mAb 
(monoclonal antibody), pAb (polyclonal antibody), BSA (bovine serum albumin), NFDM 
(non-fat dried milk), CST (cell signaling technologies). 
 
Primary antibody (clone) Origin Working Dilution 
Blocking 
Conditions Source 
5His Mouse mAb 1:5000 5% BSA Qiagen, #34660 
β-actin Rabbit pAb 1:2000 5% NFDM Abcam, #75186 
FGFR3 (B9) Mouse mAb 1:1000 5% NFDM Santa Cruz, #sc-13121 
ERK1/2 Rabbit pAb 1:2000 5% NFDM Millipore, #06-182 
pERK1/2 
(T202/Y204, T185/Y187) Rabbit mAb 1:2000 5% BSA CST, #4370 
AKT1/2/3 Rabbit pAb 1:1000 5% NFDM CST, #9272 
pAKT1/2/3 
(S473, S474, S472) Rabbit pAb 1:1000 5% BSA CST, #9271 
PLCγ1 Rabbit pAb 1:1000 5% NFDM CST, #2822 








(βKlotho mouse) Goat pAb 1:5000 5% NFDM 
Bio-Techne, 
#AF2619 
GFP Rabbit pAb 1:1000 5% NFDM Santa Cruz, sc-8334 
GFP (B2) Mouse mAb 1:1000 5% NFDM Santa Cruz, #sc-9996 
 




2.6 Expression and purification of recombinant proteins from E. coli 
 
2.6.1 Human FGFR3-2C (455-768) and variant KD proteins 
Competent C41 (DE3) λ37 E. coli cells (pre-transformed with a spectinomycin-resistant 
pCDFDuet-1™ accessory plasmid [Novagen] containing genes for λ-phosphatase and 
CDC37 co-chaperone) were transformed with 6His-SUMO-FGFR3-2C (455-768) and 
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mutant constructs in pOPINS or pJ821 vectors. LB agar plates used for transformations 
of pOPINS constructs contained 10 mM D-glucose to strictly repress basal recombinant 
protein expression during growth on the solid medium, alongside the relevant antibiotics. 
Multiple colonies were used to inoculate cultures of 500 mL TB medium containing 
kanamycin (100 mg/L) and spectinomycin (50 mg/L) and cultures were shaken at 37 °C. 
Following induction of expression with 0.4 mM IPTG (pOPINS constructs) or 1 mM L-
rhamnose (pJ821 constructs) and/or an additional 0.1 mM IPTG (for co-expression of 
accessory plasmid pCDFDuet-1™ with pJ821 constructs) cells were shaken overnight 
at 15°C. Cells were then harvested and frozen. Harvested frozen cell pellets were thawed 
on ice and lysed by chemical lysis. Following lysate clarification, supernatant was loaded 
onto a HisTrap FF Crude 5 mL column (GE Healthcare) pre-equilibrated in His buffer A 
(25 mM Tris-HCl pH 8.0, 500 mM NaCl and 40 mM imidazole). Protein was eluted in an 
imidazole gradient with 0-100% His buffer B (25 mM Tris-HCl pH 8.0, 500 mM NaCl and 
500 mM imidazole) and the proteins eluted at 150-200 mM imidazole. Protein eluate was 
dialysed overnight in dialysis buffer (25 mM Tris-HCl pH 8.0 and 1 mM TCEP) at 4°C in 
10 kDa molecular weight cut-off (MWCO) snakeskin dialysis tubing (Thermo Fisher 
Scientific) in the presence of 50 μg/mL Ulp1 protease (produced in-house) to cleave off 
the N-terminal 6His-SUMO tag. Cleaved protein was loaded onto a HiTrap Chelating HP 
5 mL column (GE Healthcare) pre-equilibrated in dialysis buffer and eluted cleaved and 
tag-free in this buffer. Cleaved eluted protein was then subjected to anion exchange on 
a HiTrap Q HP 5 mL column (GE Healthcare) pre-equilibrated in Q buffer A (25 mM Tris-
HCl, 20 mM NaCl and 1 mM TCEP). Protein was eluted in a NaCl gradient with 0-50% 
Q buffer B (25 mM Tris-HCl, 1 M NaCl and 1 mM TCEP) and protein eluted at 200-250 
mM NaCl. Fractions were analysed by non-reducing 12% SDS-PAGE and relevant peak 
fractions were pooled and concentrated to 3 mL using Vivaspin-20 10 kDa MWCO 
centrifugal concentrators (Sartorius Stedim Biotech). Protein was injected onto a HiLoad 
16/60 Superdex 75 prep grade column (GE Healthcare) for size exclusion 
chromatography (SEC), pre-equilibrated in SEC buffer (25 mM Tris-HCl, 150 mM NaCl 
and 1 mM TCEP). Peak fractions were analysed by non-reducing 12% SDS-PAGE and 
then pooled and concentrated to 100-500 μL, 2-10 mg/mL and over 95% purity in most 
cases (purity estimated by SDS-PAGE analysis) using fresh Vivaspin-6 10 kDa MWCO 
centrifugal concentrators (Sartorius Stedim Biotech). Protein concentrations were 
measured using the Nanodrop 2000c (Thermo Fisher Scientific). Protein was aliquoted 
in 50-100 μL aliquots, snap frozen in liquid nitrogen and stored at -80°C. 
 
2.6.2 Human FGF1 (16-155) protein 
Expression and purification of pOPINS-6His-SUMO-FGF1 (16-155) (DNA construct 
obtained from Tom Bunney) was performed very similarly to methods used to express 
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and purify FGFR3-2C (455-768) and mutant KD proteins, with a few modifications. C41 
(DE3) E. coli cells were used, therefore TB medium was supplemented only with 
kanamycin (100 mg/L). For dialysis steps, 3.5 kDa MWCO snakeskin dialysis tubing 
(Thermo Fisher Scientific) was used. For SEC, a non-reducing (NR) SEC buffer (25 mM 
Tris-HCl and 137 mM NaCl) was used and peak fractions were analysed by reducing 
15% SDS-PAGE. Peak fractions were pooled and concentrated to 1500 μL, 4.3 mg/mL 
and over 95% purity (purity estimated by SDS-PAGE analysis) using fresh Vivaspin-20 
3.5 kDa MWCO centrifugal concentrators (Sartorius Stedim Biotech). 
 
2.6.3 Human βKlotho KL1 (53-514) and KL2 (513-972) proteins 
Competent C41 (DE3) E. coli cells were transformed with a KL1 (53-514) or KL2 (513-
972) construct in the pAZET09 vector. An overnight 10 mL culture inoculated from a 
glycerol stock was used to inoculate 500 mL TB medium cultures containing kanamycin 
(100 mg/L) and cultures were shaken at 37°C. Following induction of expression with 
0.5 mM IPTG cells were shaken overnight at 20°C. Cells were then harvested and 
frozen. Harvested frozen cell pellets were thawed on ice and lysed by chemical lysis. 
Following lysate clarification, supernatant was loaded onto a HisTrap FF Crude 5 mL 
column (GE Healthcare) pre-equilibrated in His buffer A. Protein was eluted in an 
imidazole gradient with 0-100% His buffer B. Protein eluate was dialysed overnight in 
NR dialysis buffer (25 mM Tris-HCl pH 8.0) at 4°C in 10 kDa MWCO snakeskin dialysis 
tubing (Thermo Fisher Scientific) in the presence of 50 μg/mL PreScission™ protease 
(produced in-house) to cleave off the C-terminal 2StrepII-10His tag. Protein was loaded 
onto a HiTrap Chelating HP 5 mL column (GE Healthcare) pre-equilibrated in NR dialysis 
buffer, to separate cleaved protein from the C-terminal tag. Eluted protein was then 
subjected to anion exchange on a HiTrap Q HP 5 mL column (GE Healthcare) pre-
equilibrated in NR Q buffer A (25 mM Tris-HCl and 20 mM NaCl). Protein was eluted in 
a NaCl gradient with 0-75% NR Q buffer B (25 mM Tris-HCl and 1 M NaCl) and protein 
eluted at 500-600 mM NaCl. Fractions were analysed by non-reducing 12% SDS-PAGE 
and relevant peak fractions were pooled and concentrated to 3 mL using Vivaspin-20 
10 kDa MWCO centrifugal concentrators (Sartorius Stedim Biotech). Protein was 
injected onto a HiLoad 16/60 Superdex 75 prep grade column (GE Healthcare) pre-
equilibrated in NR SEC buffer. Peak fractions were analysed by non-reducing 12% SDS-
PAGE and then pooled and concentrated to 100-200 μL and 3-6 mg/mL using Vivaspin-
6 10 kDa MWCO centrifugal concentrators (Sartorius Stedim Biotech). Protein 
concentrations were measured using the Nanodrop 2000c (Thermo Fisher Scientific). 





2.6.4 Refolding recombinant FGF19 and FGF21 proteins from inclusion bodies 
Competent C41 (DE3) E. coli cells were transformed with a FGF19 (23-216) or FGF21 
(29-209) construct in the pAZET09 vector. Glycerol stocks prepared from these were 
used to inoculate cultures of 500 mL TB medium containing ampicillin (50 mg/L) and 
cultures were shaken at 37°C. Following induction of expression with 0.4 mM IPTG cells 
were shaken overnight at 37°C. Cells were then harvested and frozen. Harvested frozen 
cell pellets were thawed on ice, lysed by chemical lysis and the supernatant discarded. 
The pellets contained inclusion bodies of FGF19 or FGF21. Pellets were washed 
sequentially with three solutions buffered with 50 mM Tris-HCl pH 8.0 (centrifuging at 
20,000 x g, 30 minutes and 4°C between washes and discarding the supernatant): 2% 
Triton-X100, 1 M NaCl, and just buffer. The purified inclusion bodies were then reduced 
(25 mM Tris-HCL pH 8.0 and 20 mM TCEP) and denatured (6 M Gdn-HCl pH 8) followed 
by centrifugation (20,000 x g, 30 minutes and 4°C) and the supernatant placed on ice. 
Cold, solubilised inclusion bodies in the supernatant were swiftly poured into 20-30 
volumes of pre-chilled refolding solution (0.5 M L-arginine, 100 mM NaCl, 100 mM Tris-
HCl pH 8.0, 2 mM L-cysteine and 0.2 mM L-cystine) and sealed for 1-2 days at 4°C. 
Refolded protein was dialysed against 25 mM Tris-HCl pH 8.0 and 1 mM NaCl in 3.5 kDa 
MWCO snakeskin dialysis tubing (Thermo Fisher Scientific), sterile filtered (0.22 μM) to 
remove refolding precipitates and loaded onto a HisTrap FF Crude 5 mL column (GE 
Healthcare) pre-equilibrated in His buffer A. Protein was eluted with 100% His buffer B 
and dialysed against 25 mM Tris-HCl pH 8.0 and 1 mM NaCl in 3.5 kDa MWCO 
snakeskin dialysis tubing. Protein was then injected onto a HiLoad 26/60 Superdex 200 
prep grade column (GE Healthcare) pre-equilibrated in NR SEC buffer. Peak fractions 
were analysed by reducing 15% SDS-PAGE, pooled and concentrated to 500-1400 μL, 
1-7 mg/mL and over 95% purity in most cases (purity estimated by SDS-PAGE analysis) 
using fresh Vivaspin-20 3 kDa MWCO centrifugal concentrators (Sartorius Stedim 
Biotech). Protein concentrations were measured using the Nanodrop 2000c (Thermo 
Fisher Scientific) before protein was snap frozen in liquid nitrogen and stored at -80°C. 
 
2.7 Production of phosphorylated recombinant FGFR3 KD protein 
 
Recombinant unphosphorylated FGFR3 KD proteins at 2-10 mg/mL were incubated with 
25 mM MgCl2 and 10 mM ATP at 22°C for 45 minutes for autophosphorylation to occur. 
Kinase reactions were stopped with 50 mM EDTA and desalted on a HiLoad 16/60 
Superdex 75 column (GE Healthcare) using an Akta Purifier (GE Healthcare) with 
desalting buffer (25 mM Tris-HCl pH 8.0, 10 mM NaCl and 1 mM TCEP). Peak fractions 
corresponding to FGFR3 were pooled and loaded on to a 1 mL Resource Q anion-
exchange column (GE Healthcare) equilibrated in Q buffer A. Differently phosphorylated 
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FGFR3 protein was eluted with a very shallow linear gradient over 500 column volumes 
to 40% of Q buffer B. The resulting chromatogram showed five peaks, corresponding to 
the 0p, 1p, 2p, 3p and 4p phosphorylated forms of FGFR3. This was confirmed by native 
PAGE analysis (gels prepared in-house) of pooled fractions from each peak. The 4p 
peak fractions were pooled and concentrated to 1-2 mg/mL using a Vivaspin-20 10 kDa 
MWCO centrifugal concentrator (Sartorius Stedim Biotech). Protein was aliquoted in 
50 μL aliquots, snap frozen in liquid nitrogen and stored at -80°C. 
 
2.8 Top-down native mass spectrometry 
 
Recombinant purified protein samples were diluted to 0.1 mg/mL in UPLC-grade H2O 
containing 0.1% v/v formic acid and 10 μL of each sample was analysed on a Acquity 
UPLC® system (Waters) using a C4 column coupled to a single-quadrupole mass 
spectrometer. Samples were subjected to electrospray ionisation in positive ion mode. 
Absolute molecular masses were determined (to the nearest Dalton) following 
deconvolution of the mass/charge spectra using a maximum entropy method in-built in 
the Waters software. 
 
2.9 Kinase assays 
 
In vitro kinase assays were performed at 21-22°C using the ADP-Glo™ kinase assay 
(Promega). Assay reagents were prepared as per the manufacturer’s instructions, and 
only Ultra Pure ATP (Promega) was used. Kinase reactions were carried out in kinase 
reaction buffer (KRB) (initially buffered with 40 mM Tris-HCl pH 8.0 during optimisations 
with FGFR3-2C, and later with HEPES-HCl pH 7.5 following buffer screening, both 
versions containing 20 mM NaCl, 20 mM MgCl2, 100 μM Na3VO4 and 100 μM TCEP) in 
15 μL triplicate reactions unless otherwise indicated. All assays in which the final kinase 
concentrations were predominantly below 0.5 μM also contained 2 mM MnCl2 and 
0.1 mg/mL BSA. A poly-Glu-Tyr (polyE4Y1) peptide (Sigma) was used as a synthetic 
kinase substrate. All reaction components were serially diluted in KRB. Reactions were 
started by the addition of either ATP or kinase, depending on the type of experiment. 
After the required reaction duration, kinase reactions were stopped by the addition of 
15 μL ADP-Glo™ Reagent for 40 minutes, followed by the addition of 30 μL Kinase 
Detection Reagent for 30-60 minutes (depending on the concentration of ATP used in 
the assay). All 60 μL of each ADP-Glo™ reaction was then transferred to the 
corresponding well of a white opaque shallow 96-well ProxiPlate (Perkin Elmer), unless 
otherwise indicated, and luminescence was measured at 520 nm on a FLUOstar Optima 
microplate reader (BMG Labtech) in arbitrary luminescence units (AU). Data were 
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analysed using Prism software (GraphPad). Different equations, built-in to the Prism 
software, were used for non-linear regression (curve fitting) for analysing data from 
different types of assays. For autophosphorylation and substrate phosphorylation dose 
response experiments, the relevant saturation dose response binding equations 
(equations 1 and 2 respectively) were used to fit the data. For time course experiments, 
a one phase exponential model for pseudo-first order association kinetics (equation 3) 
was used to fit the data, and the equilibrium dissociation constant (KD) concentrations for 
each FGFR3 variant extracted from these fits were then used to set up the ATP titration 
experiments. Data from ATP titration experiments were fit using the Michaelis-Menten 
equation (equation 4), from which the affinity constant for ATP (KM(ATP)) and the maximum 
velocity (Vmax) were extracted and used to calculate the turnover rates and catalytic 
efficiencies for each FGFR3 variant. Error propagation during such calculations was 
performed using the relevant standard product or quotient rules. 
 
Equation 1: ‘Log(agonist) vs. response’ (with variable Hill slope) equation. This was used 
to fit data from autophosphorylation dose response experiments to improve the visual 
clarity of displayed data. It assumes that ligands are in sufficient excess such that 
negligible ligand depletion occurs over the duration of the experiment. Note that although 
the equation analyses the data using logarithmic-transformed values of FGFR3 
concentrations, the data in this work are subsequently displayed in non-logarithmic form. 
 
𝑦 =  𝑌௠௜௡ +  
𝑌௠௔௫ −  𝑌௠௜௡
1 +  10ு(୪୭୥୉େఱబ ି ௫)
 
 
where 𝑦 – phosphorylation (arbitrary units, AU), 𝑥 – FGFR3 concentration (µM), 
𝑌௠௔௫ – maximum phosphorylation (AU), 𝑌௠௜௡ – minimum phosphorylation (AU), 𝐻 – Hill 
slope, ECହ଴ – FGFR3 concentration that produces a response half way between 𝑌௠௔௫ and 
𝑌௠௜௡ (µM). 
 
Equation 2. ‘One site specific binding’ (with variable Hill slope) equation. This was used 
to fit data from polyE4Y1 substrate phosphorylation dose response experiments to 
improve the visual clarity of displayed data. It assumes that enzymes and ligands are 
equally accessible to each other, enzymes are free or ligand bound (no intermediate 
affinity states), ligand binding is reversible and does not alter enzyme or ligands, and all 







where 𝑦 – phosphorylation (arbitrary units, AU), [𝑥] – FGFR3 concentration (µM), 
𝑌௠௔௫ – maximum phosphorylation (AU), Kௗ – equilibrium binding constant (µM). 
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Equation 3. ‘One phase exponential association’ equation. This was used to fit data from 
time course experiments and to calculate the ‘half-time’ (T1/2), the time at which half of 
the ligand binding sites become occupied with ligand. It assumes that all ligands are in 
sufficient excess such that negligible ligand depletion occurs, enzymatic ligand binding 
sites become occupied with ligand over time, fewer ligand binding sites are unoccupied 
over time so fewer ligands bind and the curve levels off. 
 
𝑦 = 𝑌଴ + (𝑌௠௔௫ − 𝑌଴)(1 − 𝑒ି௄௫) 
 
where 𝑦 – phosphorylation (arbitrary units, AU), 𝑥 – time (minutes, min), 𝑌଴ – 𝑦 when 
𝑥 = 0 (min), 𝑌௠௔௫ – 𝑦 when 𝑥 = infinity (min), 𝐾 – rate constant (inverse minutes, min-1). 
Also computed T1/2 = ௟௡ଶ௄  (min). 
 
Equation 4: ‘Michaelis Menten’ equation. This was used to fit data from (ATP or polyE4Y1) 
substrate titration experiments. It assumes that the rate of production of product is linear 
over the chosen time period, all ligands (except the one being titrated) are in sufficient 
excess such that negligible depletion of the secondary ligand occurs, there is negligible 
product formation in the absence of enzyme, and there are no cooperativity or allosteric 







where 𝑣 – phosphorylation (arbitrary units, AU), [S] – ATP or polyE4Y1 peptide ligand 
concentration (µM), 𝑉௠௔௫ – maximum phosphorylation (AU), K୑ – ligand equilibrium 
binding constant (µM). 
 
Analyses using equations 1-4 also assume that ADP produced in kinase reactions is only 
produced by the FGFR3 KD variant being screened (no spontaneous ADP generation), 
that there is no spontaneous degradation or other loss of enzyme over the time course 
of the reaction, and that there are no effects of cooperativity, allostery or inhibition by 
substrates or reaction products. 
 
2.10 General mammalian cell culture materials and methods 
 
2.10.1 Maintenance of adherent mammalian cell lines 
All cells were maintained in T25 and T75 culture flasks (Corning) at 37°C with 5% CO2 
in a humidified incubator unless otherwise specified. NIH 3T3 cells were cultured with 
10% CO2 in high-glucose Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma) 
supplemented with 10% v/v Foetal Bovine Serum (FBS) (Thermo Fisher Scientific) and 
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2 mM GlutaMAX™ (Thermo Fisher Scientific). Stable pFB-FGFR3b NIH 3T3 cell lines 
were cultured similarly with 10% CO2 in this medium supplemented with a maintenance 
dose of 100 μg/mL hygromycin B (Invitrogen). Phoenix™ cell lines were cultured in the 
same medium supplemented with a maintenance dose of 300 μg/mL hygromycin B. HEK 
293T cells were cultured in the same medium without any antibiotics, and were 
transiently transfected when they were 60% confluent. 3T3-L1 pre-adipocytes were 
cultured in the same medium with 1 x penicillin-streptomycin solution (Sigma). For each 
cell line, serum free medium (SFM) refers to medium as specified above, but without 
FBS. 
 
2.10.2 Maintenance of suspension mammalian cell lines 
All cells were maintained in vented Erlenmeyer flasks (Corning) in a humidified incubator 
at 37°C and 8% CO2 with shaking at 130 rpm (FreeStyle™ 293F) or 5% CO2 with shaking 
at 140 rpm (Expi293F™ and CHO-EBNA GS cells, maintained at AstraZeneca by David 
Fisher). FreeStyle™ 293F cells were cultured in FreeStyle™ 293 expression medium 
(Thermo Fisher Scientific) and maintained between 0.1-2.0 x 106 cells/mL. Expi293F™ 
cells were cultured in Expi293F™ expression medium (Thermo Fisher Scientific) and 
maintained between 0.2-2.0 x 106 cells/mL.  Proprietary CHO-EBNA GS cells were 
cultured in CD CHO medium (Thermo Fisher Scientific) supplemented with 25 μM 
methionine sulphoximine and 100 μg/mL hygromycin B (supplements were removed 
from culture medium from two passages prior to transfection to transfection onwards) 
and maintained between 0.2-2.5 x 106 cells/mL. Expi293F™ and CHO-EBNA GS cells 
were maintained at AstraZeneca by David Fisher. 
 
2.10.3 Live Cell Imaging and Counting 
Images of live cells in culture were captured using the Axiovert 25 microscope (Zeiss) 
configured for brightfield phase contrast or green epifluorescence microscopy. Where 
required, cells were counted using the Cellometer® Auto T4 (Nexcelom Bioscience). 
 
2.10.4 Transient Transfections 
Adherent HEK 293T cells were transfected with FuGENE HD (Promega) using (per mL 
medium) 50 μL Opti-MEM™ SFM (Thermo Fisher Scientific), 1 μg purified DNA and 3 μL 
FuGENE® HD incubated together for 15 minutes at room temperature before adding 
these complexes to cells. FreeStyle™ 293F cells were transfected with a branched 10-
25 kDa polyethylenimine (PEI) cationic polymer (Sigma) using (per mL of cell 
suspension) 40 μL Opti-PRO™ SFM (Thermo Fisher Scientific) supplemented with 4 mM 
L-glutamine (Thermo Fisher Scientific), 1.25 μg purified DNA and 1.875 μg PEI incubated 
together for 10 minutes at room temperature before adding these complexes to cells. 
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Expi293F™ cells were transfected with a linear 40 kDa PEI Max cationic polymer 
(Polysciences) using (per mL of cell suspension) 100 μL Expi293F™ expression medium 
(Thermo Fisher Scientific), 1.5 μg purified DNA and 6 μg PEI Max incubated together for 
15 minutes at room temperature before adding these complexes to cells. CHO-EBNA 
GS cells were transfected by the addition of (per mL of cell suspension) 0.5 μg purified 
DNA and 7 μg of the linear 40 kDa PEI Max (Polysciences) directly into the cell 
suspension. Transfection of Expi293F™and CHO-EBNA GS cells was performed at 
AstraZeneca under the supervision of David Fisher. 
 
2.11 Production of stable NIH 3T3 cell lines by retroviral transduction 
 
Purified plasmid preparations (2.5 μg) of the pFB empty vector and the pFB vector 
harbouring human FGFR3b wildtype (WT) and mutants were mixed with TransIT®-293 
transfection reagent (Mirus) as per the manufacturer’s instructions, in the presence of 
SFM for 20 minutes at room temperature. These complexes were transfected into 50-
70% confluent Phoenix™ cells and maintained daily in fresh medium supplemented with 
300 μg/mL hygromycin B. After 72 hours the retroviral supernatant was harvested, sterile 
filtered (0.45 μm) and mixed with 8 μg/mL polybrene (Sigma). NIH 3T3 cells were 
incubated in the retroviral supernatant for 4 hours, and then maintained in fresh medium 
until they were considered ‘stable’ (two passages post-transduction, 72 hours). 
Successfully transduced cells were propagated by antibiotic selection with fresh medium 
supplemented with 200 μg/mL hygromycin B before freezing aliquots of the stable cell 
lines. Upon re-seeding from stocks, cell lines were subjected to selection with fresh 
medium supplemented with 200 μg/mL hygromycin B for a further three passages before 
they were fully selected. Cells were then maintained in fresh medium containing the 
maintenance dose of 100 μg/mL hygromycin B. 
 
2.12 Differentiation of 3T3-L1 pre-adipocytes to adipocytes 
 
3T3-L1 mouse pre-adipocytes were cultured to 80% confluence in a T75 and then 
distributed evenly between 24 wells of 6-well plates (Nunc) with 3 mL per well culture 
medium. Cells were confluent after 48 hours, so differentiation was initiated after a further 
48 hours (96 hours after seeding cells). Differentiation was initiated (Day 0) by treating 
the cells with MDI induction medium (medium supplemented with 0.5 mM 3-isobutyl-1-
methylxanthine, 5 μg/mL insulin, 1 μM dexamethasone and 1 μM rosiglitazone). Three 
days later, MDI induction medium was replaced with insulin medium (medium 
supplemented with 0.2 μg/mL insulin). Three days later, insulin medium was replaced 
with fresh culture medium. Fresh culture medium was replaced twice more every two 
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days, at which point cells were considered sufficiently differentiated to be used for 
experiments (Day 10-13). This method of adipocyte differentiation was modified from a 
published 3T3-L1 differentiation protocol (Zebisch et al., 2012). 
 
2.13 Anchorage independent growth assays 
 
Stable NIH 3T3 WT and mutant cell lines were seeded in triplicate at 5 x 103 cells per 
well of a 6-well plate (TPP) in medium containing 0.4% w/v agarose (diluted from 4% w/v 
agarose, Thermo Fisher Scientific), on a base of medium containing 0.8% w/v agarose. 
Cells were fed weekly with medium containing 0.4% w/v agarose. After two weeks, cells 
were stained for 24 hours with 0.3% w/v p-iodonitrotetrazolium violet (Sigma) and a 
representative area of each well was imaged using a Hamamatsu ORCA-285 camera 
coupled to a Nikon SMZ1000 microscope. Binary masks were applied to the images and 
thresholding parameters for area and perimeter of colonies with a mean diameter greater 
than 100 μm were set on ImageJ. Colonies were counted electronically using ImageJ 
only if they satisfied both the area and perimeter criteria above the threshold values, and 
colony counts were then manually checked and adjusted if necessary. 
 
2.14 Protein extraction from adherent mammalian cells 
 
Cultured cells were either starved in SFM or left ‘unstarved’ (as appropriate), and then 
lysed in situ with 75 μL mammalian-lysis buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 
1 mM EDTA, 1 mM EGTA, 1% v/v Triton X-100, 20 mM sodium pyrophosphate, 25 mM 
sodium fluoride, 1 mM β-glycerophosphate, 3 mM Na3VO4 and 1 µg/ml leupeptin) 
containing cOmplete™ protease inhibitor cocktail (Roche). Lysates were clarified by 
centrifugation (16,000 x g, 5 minutes and 4°C). Total protein concentration was 
determined using the Pierce™ BCA Protein Assay kit (Thermo Fisher Scientific). 
 
NIH 3T3 cells were cultured to 70-80% confluence in 2-3 T75 culture flasks per stable 
cell line. Cultured cells were either starved for 2 hours at 37°C and 10% CO2 in SFM or 
were left ‘unstarved’ in normal medium containing FBS, and then lysed in situ with 75 μL 
(per T75 culture flask) mammalian-lysis buffer. Protein was then extracted and lysates 
clarified. 3T3-L1 cells were differentiated in 6-well plates as described above. 
Differentiated cells were then starved (Day 10-13 differentiated adipocytes) overnight in 
SFM containing 0.2% BSA (Sigma) while partly differentiated cells were left ‘unstarved’ 
(Day 0-10 pre-adipocytes) in normal medium containing FBS. Pre-adipocytes were then 
lysed in situ with 75 μL (per well of 6-well plate) mammalian-lysis buffer and protein 
extracted. Differentiated adipocytes were treated with FGFs at varying concentrations 
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(or no FGF controls) with 0.2% BSA for 10 minutes before being lysed in situ with 75 μL 
(per well of 6-well plate) mammalian-lysis buffer. Protein was then extracted and lysates 
clarified. 
 
2.15 Immunoprecipitation of FGFR3 protein from NIH 3T3 cells 
 
Anti-FGFR3 primary antibody F3922 (Sigma) diluted at 1:25 in mammalian-lysis buffer 
(1 μg antibody per 1 μg of NIH 3T3 lysate) was incubated for 10 minutes at room 
temperature with magnetic Protein A Dynabeads® (Thermo Fisher Scientific) pre-
equilibrated in mammalian-lysis buffer (5 µL Dynabead® suspension per 1 µg F3922 
anti-FGFR3 antibody). Antibody:Dynabead® complexes were washed and incubated 
with clarified NIH 3T3 lysates (prepared as in section 2.14) overnight at 4°C. Target 
protein-bound antibody:Dynabead® complexes were washed and protein was eluted by 
boiling in 4 x SDS-PAGE sample buffer. Eluted supernatant was then analysed by 
immunoblotting. Immunoprecipitation and immunoblots shown in Figure 3.19b were 
performed by the Research and Clinical Pathology Support Unit at the UCL Cancer 
Institute. 
 
2.16 Antibody array 
 
A PathScan® intracellular signalling antibody array kit with chemiluminescent readout 
(Cell Signaling Technologies) was purchased and used as per the manufacturer’s 
instructions, using the array blocking buffer and detection antibody cocktail supplied in 
this kit and using NIH 3T3 lysates prepared as in section 2.14. Arrays were imaged using 
the Odyssey® Fc system (Li-Cor Biosciences). Densitometric analyses were performed 
using Image Studio™ Lite (Li-Cor Biosciences). 
 
2.17 Small-scale expression tests with suspension mammalian cell lines 
 
Cells (10 mL) were seeded in vented 50 mL mini bioreactors (Corning) at densities of 
1.0-1.4 x 106 cells/mL (FreeStyle™ 293F), 3.5-4.2 x 106 cells/mL (Expi293F™) and 1.0-
1.2 x 106 cells/mL (CHO-EBNA GS). Cells were transiently transfected using the PEI 
(FreeStyle™ 293F) or PEI Max (Expi293F™ and CHO-EBNA GS) methods. After 
24 hours post-transfection, Expi293F™ and CHO-EBNA GS cells were fed with 10 mL 
Expi293F™ expression medium (Expi293F™ cells) or 6.7 mL CD CHO medium 
containing a proprietary MedImmune feed ‘M20A’ (CHO-EBNA GS cells) and were 




For FreeStyle™ 293F expression tests, samples of cells and media were taken every 
day for 3-4 days post-transfection for all constructs. For Expi293F™ and CHO-EBNA GS 
transfections samples of cells and media were taken at 3 days (proteins expected to be 
intracellularly expressed) and 7 days (proteins expected to be secreted into the medium) 
post-transfection. Cell samples were lysed in 0.1 volumes PBS-lysis buffer (PBS pH 7.2, 
1% Triton X-100 and 1 x cOmplete™ protease inhibitor cocktail [Roche]). Media and 
whole-cell lysate samples were then denatured with 4 x SDS-PAGE sample buffer and 
analysed for recombinant protein expression by SDS-PAGE and immunoblotting. 
 
2.18 Purification of recombinant FGFR1c proteins from conditioned media 
from mammalian cell lines 
 
Medium harvested from small-scale expression tests of FGFR1c (22-374) constructs in 
FreeStyle™ 293F cells (Day 3, 30 mL), Expi293F™ cells (18 mL, Day 7) and CHO-EBNA 
GS cells (13 mL, Day 7) was loaded onto a HisTrap FF Crude 5 mL column (GE 
Healthcare) pre-equilibrated in His buffer A. Proteins were eluted with 100% His buffer 
B and these eluates were injected onto a HiLoad 26/60 Superdex 200 prep grade column 
(GE Healthcare) pre-equilibrated in NR SEC buffer. Peak fractions were analysed by 
reducing 10% SDS-PAGE, pooled and concentrated to 400-500 μL, 1-5.5 mg/mL and 
over 95% purity in most cases (purity estimated by SDS-PAGE analysis) using fresh 
Vivaspin-20 10 kDa MWCO centrifugal concentrators (Sartorius Stedim Biotech). Protein 
concentrations were measured using the Nanodrop 2000c (Thermo Fisher Scientific) 
before protein was snap frozen in liquid nitrogen and stored at -80°C. 
 
2.19 Homology modelling of human βKlotho KL1 and KL2 domains 
 
Human βKlotho KL1 and KL2 domains share just 28% and 36% sequence identity and 
similarity respectively. Therefore the two KL domains were modelled independently, 
against two different templates, using the SWISS-MODEL web-based protein structure 
modelling workspace (Arnold et al., 2006). Each template was optimally selected from 
searches against the SWISS-MODEL template library (up-to-date as of 24th June 2017). 
Human βKlotho KL1 (53-508) and KL2 (517-967) sequences were used as input queries 
for template searches. SWISS-MODEL was then used to build homology models per 
domain using the top three templates with the ‘best match’ to each KL domain (based on 
sequence identity, SWISS-MODEL GMQE and QMEAN scores for model quality 
evaluation and filtering for resolution of the PDB structure <2.2 Å). Finally, the model with 
the highest GMQE and QMEAN model quality evaluation scores for each KL domain was 
selected for further analysis. 
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2.20 Biophysical techniques for analyses of recombinant proteins 
 
2.20.1 Thermofluor assay 
Recombinant FGFR3 KD protein samples were mixed with Sypro® Orange fluorescent 
dye (Thermo Fisher Scientific) at final concentrations of 1 mg/mL protein and 1:500 dye 
respectively in triplicate reactions. Samples were then subjected to a temperature 
gradient between 10-95°C increasing at 0.5°C intervals (10 seconds each) on a MyiQ™ 
Real-Time PCR detection system (Bio-Rad). Data were analysed using Prism software 
(GraphPad) with a custom Boltzmann sigmoid equation with linear baselines. 
 
2.20.2 Circular Dichroism (CD) spectroscopy 
Purified FGF proteins were diluted to 200 μL in NR SEC buffer to 1 mg/mL and then 
dialysed against 3 x 2 L CD buffer (20 mM sodium phosphate pH 7.5) changed over 
24 hours at 4°C. Final protein concentrations were re-measured using the Nanodrop 
2000c (Thermo Fisher Scientific) before CD experiments were performed on the Jasco 
J-720 instrument using a 0.1 mm path length cuvette. Ten scans were taken for each 
protein (using CD buffer as a reference) between 180-300 nm at 1 nm intervals. Scans 
were averaged, reference subtracted and zeroed using CDtool software (Lees et al., 
2004). Secondary structure analyses of the processed data were performed on the online 
DichroWeb server using the CDSSTR algorithm (Manavalan and Johnson, 1987) with 
reference dataset SP175 (Lees et al., 2006) as well as the online tool BeStSel (Micsonai 
et al., 2015) on the highest quality data between 190-240 nm. 
 
2.20.3 Isothermal Titration Calorimetry (ITC) 
Recombinant purified FGF and FGFR1c proteins were buffer exchanged into the same 
batch of NR SEC buffer using a HiLoad 26/60 Superdex 200 prep grade column (GE 
Healthcare). All proteins were further diluted using this same batch of NR SEC buffer 
where necessary. A MicroCal™ iTC-200 instrument (MicroCal) was used. For all 
experiments, FGF ligands (200 μM) were injected from the syringe into the sample cell 
containing FGFR1c protein (20 μM) purified from FreeStyle™ 293F cells. Experiments 
were all performed at 25°C. Data were analysed using Origin® software (MicroCal) by 
fixing the reaction stoichiometry as 1 (the theoretical stoichiometry for this interaction) 
and attempting to fit the data to a one-site model within the software. 
 
2.20.4 Surface Plasmon Resonance (SPR) spectroscopy 
Experiments were conducted on the Biacore™ T200 instrument (GE Healthcare) using 
NTA sensor chips with four flow cells (Fc) per sensor chip. FGF1, FGF19 and FGF21 
(and ‘no FGF’) were diluted from frozen stocks to 1-2 μg/mL in HBS-EP buffer (10 mM 
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HEPES-NaOH pH 7.4, 150 mM NaCl, 3 mM EDTA and 0.05% v/v Tween® 20). Diluted 
FGFs were immobilised on an NTA sensor chip, using Ni2+-NTA affinity immobilisation 
followed by primary amine coupling and ethanolamine termination, and using a 
30 μL/minute flow rate with a target immobilisation level of 30 response units (RU). A 
two-fold dilution series of purified FGFR1c protein was prepared in HBS-EP buffer and 
kinetics experiments were performed with these analytes using a 30 μL/minute flow rate. 
Analyte was injected for 180 seconds (association) and then HBS-EP buffer was injected 
for 180 seconds (dissociation). The chip surface was washed with 10 mM glycine pH 3.0 
following injection and regenerated with 2 M NaCl. Affinity calculations were performed 








A decade of efforts dedicated to the deep sequencing of patient tumour samples and 
cancer cell lines has resulted in a wealth of mutation data being accumulated for cancer-
associated genes such as FGFRs. As mentioned in Chapter 1, FGFRs are known 
oncogenes and several types of aberrations affect the FGFR genes giving rise to 
deregulated signalling in all types of malignancies. Aberrations in FGFRs are estimated 
to be present in about 7% of solid tumours (Guagnano et al., 2012, Helsten et al., 2016). 
In particular, cancer-associated somatic point mutations make up almost 30% of FGFR 
aberrations and have been reported in all four FGFRs and in all types of cancers (Figures 
3.1 and 3.2). Components of FGFR signalling are in fact thought to be the most enriched 
for non-synonymous point mutations in cancer (Greenman et al., 2007). The highest 
occurrence of point mutations in FGFRs is in FGFR3 followed by FGFR2 and 
subsequently these are found most commonly in urothelial (bladder) and endometrial 
carcinomas respectively (Guagnano et al., 2012, Abbosh et al., 2015, Carter et al., 2015, 
Helsten et al., 2016). Despite the observation that FGFRs (like other RTKs) are 
frequently found mutated in cancers, development of treatments targeting FGFRs in the 
clinic have lagged behind those targeting other RTKs, and currently there are no 
approved agents for the treatment of cancers based on FGFR targeting. Further 
advancement of the molecular understanding of FGFR function and activation, and the 
impact of cancer-associated mutations on these phenomena, will aid the development 
of targeted anti-FGFR agents and will directly inform ongoing clinical trials. 
 
This Chapter will explore the diversity of non-synonymous point mutations in FGFRs in 
cancer. The functional impact and possible activation mechanisms of commonly 
occurring, known activating missense substitutions will be discussed with a focus on 
mutations in FGFR3. Finally, the discovery of acquired mechanisms of resistance in 
FGFRs (including through point mutations) in cancer in response to clinical treatments 
and their mechanisms will be presented. 
 
3.1.1 Identification of somatic missense substitutions in FGFRs in cancer 
The first identification of a somatic mutation in FGFRs in cancer was in FGFR3 in multiple 
myeloma (Chesi et al., 1997). In the two decades that followed, thousands of somatic 
mutations have been identified in FGFR3 and in the other FGFRs through a combination 





Figure 3.1 Landscape of aberrations in FGFRs in all types of cancers. Bar chart showing the 
approximate percentages of FGFR alterations found in diverse tumour types in all four FGFRs, 
including FGFR gene amplifications, point mutations and chromosomal rearrangements leading 
to gene fusions, ranked by the cancer type. The upper bar for each tumour type shows the type 
of mutation, while the lower bar shows the total percentage of aberrations occurring in each FGFR 
isoform. Figure from (Helsten et al., 2016). 
 
 
studies. Two of the largest international consortia (still ongoing) are The Cancer Genome 
Atlas (TCGA) [cancergenome.nih.gov] (Cancer Genome Atlas Research et al., 2013) 
and the International Cancer Genome Consortium (ICGC) [icgc.org] (International 
Cancer Genome et al., 2010) which have currently sequenced more than 11000 and 
17000 cancer genomes respectively from 33 cancer types (October 2017). Other smaller 
studies such as one mentioned in Chapter 1 which analysed nearly 5000 tumour samples 
specifically to assess the mutation status of FGFRs (Helsten et al., 2016) combined with 
data from larger collaborative international projects have fostered efforts to 
comprehensively curate mutation data detected across all studies into central online 
databases. The largest such database, whose entire integrated dataset is also publicly 
available, is the Catalogue of Somatic Mutations in Cancer (COSMIC) 
[cancer.sanger.ac.uk] (Forbes et al., 2015). This database is updated every few months, 
curating new genes and ensuring the dataset is maintained and kept up-to-date by 
including new data from the most recent studies. It has provided invaluable insights into 
patterns of cancer-associated aberrations across different genes and cancer types, 




Figure 3.2 Somatic cancer-associated point mutations span the entire length of FGFRs. 
Total number of observations of somatic point mutations reported in tumours from cancer patients 
in FGFR1-4 from COSMIC, including insertions and deletions (in-frame and frame shift) and 
missense substitutions (upper four panels). The most commonly observed mutations (hotspots) 
in each FGFR are labelled with residue numbering according to the canonical FGFR c splice 
isoforms. The FGFR domain organisation is illustrated below the mutation histograms using 
FGFR3c residue numbering as a reference (lower panel), showing the D1, D2 and D3 
extracellular immunoglobulin-like domains, acid box (AB), transmembrane helix (TM) and the 
‘split’ tyrosine kinase domain (KD). This illustration corresponds to the locations of mutations in 




Rather than being limited only to regions that are important for kinase function (as is the 
case in closely related RTKs) such as the kinase domain (KD), somatic point mutations 
in FGFRs have been found to span the entire length of the receptors (Figure 3.2). 
Notably, several of these mutations are also the same as mutations found in FGFRs in 
germline disorders such as skeletal dysplasias (Wilkie, 2005, Gallo et al., 2015) and 
these mutations were discovered in FGFRs in the context of skeletal disorders in the 
early 1990s, first in FGFR3 (Rousseau et al., 1994, Shiang et al., 1994) and very soon 
after in FGFR1 and FGFR2 (Jabs et al., 1994, Muenke et al., 1994, Reardon et al., 1994). 
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The functional impact and mechanisms of action of several of the most frequently 
occurring point mutations in FGFRs have therefore been investigated over the years in 
the context of both germline disorders and cancer. What is known so far about these is 
presented in the next sections with a focus on point mutations in FGFR3. 
 
3.1.2 Cancer-associated mutation hotspots in FGFR3 
By far the most frequently detected somatic missense substitution in all FGFRs in cancer 
is FGFR3-S249C (Figure 3.2) with over 2000 observations to date. This mutation occurs 
in the D2-D3 linker of the FGFR3 ectodomain, adjacent to another of the ‘top 5’ most 
common FGFR mutations, FGFR3-R248C (over 400 observations). Another very 
frequently detected mutation is FGFR3-Y373C (over 600 observations) which lies in the 
extracellular juxtamembrane region. These three FGFR3 mutations constitute more than 
85% of all cancer-associated mutations detected in FGFR3 to date (di Martino et al., 
2016). The other most frequent mutation ‘hotspots’ in FGFRs (each with 40-500 
observations in cancer) all occur in FGFR3, either in the extracellular juxtamembrane or 
transmembrane region (G370C and A391E) or in the KD (K650E/M and G697C). Similar 
mutations in these regions also occur in the other FGFRs (Figure 3.2), some at the 
precise corresponding residues. It should be noted that some mutations were detected 
in the FGFR b splice isoforms (depending on the tissue of origin which determines which 
splice isoform is expressed, see section 1.4), but in this work all mutations will be referred 
to using the residue numbering of the canonical FGFR c splice isoforms. 
 
3.1.3 Functional impacts of gain-of-function mutations in FGFR3 
FGFR3 mutations are found in 75% of non-muscle invasive (lower grade) urothelial 
carcinomas and in approximately 15% of higher grade muscle invasive urothelial 
carcinomas (Cappellen et al., 1999, Billerey et al., 2001, Kimura et al., 2001, van Rhijn 
et al., 2001, Helsten et al., 2016) as well as in about 5% and 3% of cervical and small 
cell lung carcinomas respectively (Rosty et al., 2005, Helsten et al., 2016). Therefore, 
many of the point mutations listed above have been rigorously studied to assess their 
functional impact in the context of cancers and germline disorders by assessing their 
effects on FGFR dimerisation and activation. Such experiments have helped classify 
mutations into driver mutations that might contribute directly to development and/or 
maintenance of disease, or passenger mutations that might just be passive and not play 
direct roles in pathogenesis. It is thought that many of these ‘drivers’ are gain-of-function 
mutations that constitutively activate FGFRs, allowing illicit ligand-independent 





3.1.4 Oncogenic FGFR3 extracellular and transmembrane region mutations 
Several frequently observed FGFR3 variants in the ectodomain or the transmembrane 
region result in the introduction of a new cysteine residue, particularly R248C, S249C, 
G370C and Y373C. This led to the hypothesis that the mutations may activate FGFRs 
by constitutive dimerisation of the extracellular or transmembrane domains (Figures 3.3 
and 1.12c). Early studies supported this hypothesis by showing (in NIH 3T3, COS or 
BaF3 model cell lines) that these mutations were dominantly acting and activating 
compared to FGFR3 wildtype (WT); they induced ligand independent dimerisation 
through disulphide bonding (abrogated upon chemical reduction), activation and 
constitutive tyrosine autophosphorylation in vitro (Naski et al., 1996, d'Avis et al., 1998, 
Adar et al., 2002, Hafner et al., 2010). Subsequently, studies focusing on S249C and 
Y373C showed that these mutations morphologically transform NIH 3T3 cells, 
hyperactivate several downstream signalling pathways, promote cell proliferation, 
increase cell saturation density and permit anchorage independent growth, and 
additionally these effects could be reversed by targeted gene knockdown or treatment 
with FGFR inhibitors (including in relevant bladder cancer cell lines expressing the 
FGFR3 mutants) (Chesi et al., 2001, Ronchetti et al., 2001, Bernard-Pierrot et al., 2006, 
Tomlinson et al., 2007b, di Martino et al., 2009, Qing et al., 2009, Chell et al., 2013, 
Williams et al., 2013). Furthermore, S249C (Bernard-Pierrot et al., 2006) and Y373C 
(Trudel et al., 2004) also produced tumours in xenograft models in nude mice and tumour 
growth could be inhibited in vivo by FGFR3 inhibitors (Trudel et al., 2004, Xin et al., 2006, 
Miyake et al., 2010), providing further evidence for the drug sensitivity and oncogenicity 
of these mutations. Similar studies performed for R248C and S249C in cellular and 
xenograft lung cancer models showed that these mutations are sensitive to FGFR 
inhibitors and the tumours are oncogene-addicted to mutant FGFR3 (Liao et al., 2013). 
The oncogenic effects and sensitivity of these activating FGFR3 mutants to FGFR 
inhibitors strongly implicates them as oncogenic drivers. 
 
However, despite the notion (supported by evidence from these cellular studies) that 
these cysteine mutants constitutively phosphorylate and activate FGFRs through ligand 
independent dimerisation, many of these studies suggested that this might only be a 
partial effect, with some less activating mutants (e.g. Y373C) becoming fully activated in 
a partially ligand dependent manner. Additionally, Förster Resonance Energy Transfer 
(FRET) experiments suggest that the R248C, S249C and Y373C mutations only partially 
stabilise FGFR3 dimers, but might instead activate FGFRs by inducing conformational 
perturbations (rather than constitutive dimerisation) that juxtapose the dimers in the 
correct orientation for full activation (Del Piccolo et al., 2015) while less activating 
mutations might only achieve correct juxtaposition (for full activation) upon ligand binding 
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(Adar et al., 2002). This mechanism of activation has also been proposed for the 
transmembrane non-cysteine activating hotspot mutation A391E suggesting it traps the 
dimer in the active conformation, mimicking the ligand-bound state (Chen et al., 2013a, 
Sarabipour and Hristova, 2015, Sarabipour and Hristova, 2016). Furthermore, many of 
the studies presented here have suggested that the position of the mutated residue in 
the extracellular or transmembrane region might affect the level of FGFR activation in a 
‘graded’ manner. This might lead to differential activation of the receptors and modulated 
signalling that presents as lower or higher grade tumours. The precise molecular 
activation mechanisms of these mutations remain to be fully elucidated, as is necessary 
for the development of precision targeted therapies against subsets of tumours 




Figure 3.3 Locations of hotspot mutations in the extracellular and transmembrane 
domains of FGFR3. The cysteine mutations are thought to constitutively dimerise, and thus 
activate, FGFR3. (a) Structural location of the two most frequently observed mutation hotpots in 
the FGFR3 extracellular region (R248C and S249C, shown as sticks against a surface and 
coloured green and navy blue respectively) mapped on a cartoon representation of the crystal 
structure of the FGFR3c extracellular region dimer [PDB: 1RY7] (Olsen et al., 2004) (coloured 
salmon), showing that they occur in the D2-D3 linker (left panel). A close-up view of this linker is 
shown in the right panel. (b) Structural location of the three most frequently observed mutation 
hotspots in the FGFR3 transmembrane (TM) region (A391E) and extracellular juxtamembrane 
(JM) region (G370C and Y373C) mapped on a cartoon representation of the structure of the 
FGFR3c TM domain dimer [PDB: 2LZL] (Bocharov et al., 2013) (coloured cyan). All three TM and 
JM hotspot residues are shown as sticks against a surface and coloured green. 
 
 
3.1.5 Mutation hotspots in the FGFR3 tyrosine KD 
Two hotspots in the FGFR3 KD at which mutations are observed most frequently are 
highlighted in Figure 3.4 (middle panel), namely K650 and G697. Mutations to cysteine 
at position G697 (which is in the αF-αG loop in the C-lobe of the KD) were all identified 
in a single study in oral squamous cell carcinomas (OSCC) (Zhang et al., 2005). This 
mutation is unlikely to activate FGFRs through creating disulphide linked dimers because 
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of the reducing nature of the cytoplasmic compartment in which the mutation exists. 
Although this study suggested that G697C is constitutively activating, a follow up study 
could not detect this mutation in any cases of OSCC (Aubertin et al., 2007), and so the 
relevance (and/or activation mechanism) of this hotspot mutation in cancer remains 
unresolved. 
 
In contrast, the activating nature of mutations at position K650 in the A-loop of the KD 
has been comprehensively demonstrated and the probable mechanisms of activation 
deciphered. K650E was initially identified in the context of thanatophoric dysplasia type 
II (Tavormina et al., 1995) where it was shown to be constitutively autophosphorylated, 
to hyperactivate downstream signalling, and (in most cases) increase proliferation in a 
(partially) ligand independent manner compared to WT (Naski et al., 1996, Webster et 
al., 1996, d'Avis et al., 1998, Tavormina et al., 1999, Lievens and Liboi, 2003, Krejci et 
al., 2008). Subsequently, it was shown to exert the same effects in the context of cancer, 
where it also transformed NIH 3T3 cells, promoted anchorage independent growth in soft 
agar, and led to tumour formation in nude mice (Hart et al., 2000, Chesi et al., 2001, 
Ronchetti et al., 2001, Kong et al., 2002, Agazie et al., 2003). However, unlike cysteine 
mutations in the extracellular and transmembrane regions, K650E did not induce 
formation of ligand independent dimers, and appeared to activate FGFR independently 
of dimerisation (Naski et al., 1996, d'Avis et al., 1998, di Martino et al., 2009). It was also 
found that the exact replacement at position K650 was important in determining the level 
of kinase activation, with K650E and K650M being most activating followed by other 
replacements (Webster et al., 1996, Bellus et al., 2000, Chen et al., 2013b). Additionally, 
studies in which the A-loop ‘twin’ tyrosine residues necessary for canonical KD activation 
were mutated to phenylalanine (Y647F and Y648F in FGFR3) showed that K650E was 
still activating in this context (Webster et al., 1996, Chen et al., 2005, Huang et al., 
2013b). It was therefore proposed that K650E might activate the KD by functionally 
mimicking the active kinase conformation independently of ligand binding or 
autophosphorylation. 
 
Recently, the structure of the FGFR3-K650E KD was solved by crystallography, 
providing molecular evidence for this proposed mechanism of KD activation (Huang et 
al., 2013b). This structure showed that mutation of position 650 to glutamic acid 
functionally mimics phosphorylation of the A-loop ‘twin’ tyrosines to stabilise the active 
KD conformation through altering two key networks of hydrogen bonds (Figure 3.4). One 
network is stabilising and is created at the A-loop, between E650 and Y648 and adjacent 
residues from the C-loop (R616 from the HRD motif) and A-loop (R640, T651 and T652), 
rendering the A-loop in an identical active conformation (Figure 3.4, right panel) as seen 
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for phosphorylated, active FGFR1 and FGFR2 KDs (Chen et al., 2007b, Bae et al., 
2009). The second network (the ‘molecular brake’ in the kinase hinge region) stabilises 
the inactive conformation, and E650 allosterically disrupts these autoinhibitory 
interactions (Figure 3.4, left panel). Recently, it was proposed that the assembly of the 
A-loop network upon phosphorylation is ‘sensed’ by the ‘DFG-latch’ and the ‘αC tether’ 
leading them to allosterically and dynamically ‘transmit’ the signal towards the kinase 
hinge to disassemble the ‘molecular brake’ and allow dynamic activation of the kinase 
(Chen et al., 2017). K650E was proposed to act by ‘hijacking’ this allosteric mechanism, 
shifting the equilibrium in favour of the active conformation. In addition, the crystal 
structure shows the presence of the β10/12 strands and ordering of the C- and R-spines, 
characteristic of an active KD (Figure 3.4, middle panel). This evidence for dimerisation- 
and ligand-independent FGFR hyperactivation by K650E strongly implicates it as a 





Figure 3.4 Locations of hotspot mutations in the FGFR3 KD and mechanism of activation 
of pathogenic mutation K650E. Structural locations of the two most frequently observed 
mutation hotspots in the FGFR3 KD (K650E and G697C, shown as sticks against a surface and 
coloured red) mapped on a cartoon representation of the crystal structure of the active FGFR3 
KD harbouring the K650E mutation (coloured grey) and with a non-hydrolysable ATP analogue 
(ACP, shown as sticks and coloured purple) bound in the ATP binding pocket [PDB: 4K33] (Huang 
et al., 2013b), showing that K650E is found in the A-loop and G697C is found in the αF-αG loop 
(middle panel). The mechanism of KD activation by K650E is depicted on this structure in the 
three panels shown in the same orientation. The middle panel shows ordering of the hydrophobic 
regulatory and catalytic (R- and C-) spines (residues shown as sticks against a surface and 
coloured navy blue and bright pink respectively) and presence of the β10/12 strands (coloured 
green). The left panel is a close-up view of the kinase hinge region showing disengagement of 
the hydrogen bonding network formed by the triad of ‘molecular brake’ residues (shown as sticks 
against a surface and coloured cyan and by atomic element with nitrogen atoms in navy blue and 
oxygen in red). The right panel is a close-up view of the A-loop showing an intact hydrogen 
bonding network formed between residues R616 from the C-loop and R640, Y648, E650, T651, 
and T652 from the A-loop (shown as sticks against a surface and coloured purple and by atomic 
element with nitrogen atoms in navy blue and oxygen in red, except for E650 which is coloured 




3.1.6 Acquired resistance through FGFR mutation and/or RTK co-activation 
The phenomenon of acquired resistance mutations in RTKs in response to targeted 
therapies was introduced in section 1.1.2. Resistance mutations arise in response to 
treatment with small molecule inhibitors that bind to the ATP binding site, so resistance 
mutations tend to occur in the ATP binding pocket in the KD. In FGFRs, the crucial 
gatekeeper residue is normally a valine (unlike threonine in most RTKs) and the first 
gatekeeper mutation identified in FGFRs as an acquired resistance mutation was 
FGFR3-V555M in a human cancer cell line resistant to FGFR inhibitors (Chell et al., 
2013). This mutation and mutations at the corresponding gatekeeper residues in FGFR1 
and FGFR2 (V561M and V564I respectively) have been investigated in pre-clinical 
models. They exhibit variable (and currently slightly contradicting) resistance and 
sensitivity to different multi-kinase and FGFR-selective inhibitors in cellular and in vitro 
activity assays (Byron et al., 2013, Nakanishi et al., 2014, Bunney et al., 2015, Sohl et 
al., 2015). However, all these studies demonstrate that gatekeeper mutations exhibit 
elevated kinase activity compared to WT, as also shown for other RTKs (Azam et al., 
2008) and are predicted to shift the equilibrium to the active KD conformation by 
stabilising the R-spine (Figure 3.5a). Gatekeeper mutations therefore seem to function 
by a dual mechanism involving kinase activation as well as steric hindrance of inhibitor 
binding to the ATP binding pocket (Figure 3.5b), imparting resistance to first-generation 
ATP-competitive targeted therapies. Other mutations in the kinase hinge, ‘molecular 
brake’ and A-loop of FGFR2 (some of which are activating) have also been shown to 
exhibit different levels of resistance to kinase inhibitors in cellular studies (Byron et al., 
2013). These include mutations at the corresponding positions to FGFR3 N540 and I538 
(highlighted in Figure 3.5b), although these mutations have not yet been observed as 
acquired resistance mutations in response to clinical targeted inhibition. Recently, 
second-generation inhibitors have been developed that can irreversibly bind to the active 
site, some of which are able to bind and inhibit FGFRs with gatekeeper and other 
activating mutations and inhibit the proliferation of cancer cell lines harbouring FGFR 
aberrations (Tan et al., 2014, Huang et al., 2015). Further development of second-
generation inhibitors might be used in the future in the clinic to overcome inhibitor 
resistance imparted by mutations acquired in response to first-generation targeted 
therapies. 
 
Acquired resistance mutations can also arise in response to therapeutic targeting by an 
entirely different mechanism. As mentioned previously, different RTKs exhibit crosstalk 
between members including FGFRs, and so RTKs are commonly found co-activated in 
cancers (Xu and Huang, 2010). This results in the formation of multimodal signalling 
networks for cancer cells to maintain a robust signal with diverse outcomes using a 
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limited combination of intracellular signalling effectors. Upon inhibition of one RTK with 
a targeted inhibitor, oncogene switching can occur as a compensatory bypass or 
‘escape’ resistance mechanism to reprogram the kinome through activation of other 
RTKs, rendering monotherapy ineffective against cancers in which RTKs are co-
activated. FGFR signalling has been found co-activated with several other RTKs in 
cancers such as gliomas (Stommel et al., 2007, Pillay et al., 2009), cervical carcinoma 
(Pietras et al., 2008), lung cancer (Ware et al., 2010, Cascone et al., 2011) squamous 
carcinoma (Ciaccio et al., 2010), breast cancer (Stuhlmiller et al., 2015), and in FGFR-
addicted urothelial, breast and gastric cancer cell lines (Wilson et al., 2012). Interestingly, 
in one patient that developed resistance in response to treatment with EGFR inhibitors, 
it was found that a mutation at one of the A-loop ‘twin’ tyrosines in the FGFR3 KD 
(Y647C) might be the cause of resistance through oncogene switching to FGFR 
signalling (Crystal et al., 2014). Although not yet experimentally demonstrated, it was 
predicted that this mutation would be likely to be activating due to its location close to 
the FGFR3-K650 mutation hotspot. 
 
Several studies have shown that in cancer cells in which FGFRs are co-activated with 
other RTKs (either as a response to inhibition of the other RTK, or when another RTK is 
co-activated in response to FGFR-targeting), monotherapy is often ineffective and only 
combination therapy with more than one RTK inhibitor can produce the synergistic 
cancer-killing effect to re-sensitise cancer cells to chemotherapy (Ezzat et al., 2005, 
Herrera-Abreu et al., 2013, Singleton et al., 2013, Terai et al., 2013, Holdman et al., 
2015, Kim et al., 2015, Kim et al., 2016, Wong et al., 2016, Hanker et al., 2017). Cancers 
that are addicted to FGFR signalling are more likely to be sensitive to FGFR-targeted 
therapies, making FGFRs important therapeutic targets in such cancers. Therefore 
understanding FGFR aberrations in cancer, their driver or addiction effects on tumours, 
and their effects on the efficacy of targeted therapeutics is crucial before combination 







Figure 3.5 Mechanism of activation by gatekeeper mutations in the FGFR KD. (a) Cartoon 
representation of the crystal structure of the active FGFR1 KD (coloured grey) harbouring the 
V561M gatekeeper mutation (shown as sticks against a surface and coloured orange) [PDB: 
4RWI] (Sohl et al., 2015). The αC-helix (yellow) P-loop (green), kinase hinge (black), C-loop 
(magenta) and A-loop (red) are highlighted and labelled. The A-loop is in the active conformation 
and ordering of the regulatory R-spine is shown, with R-spine residues labelled (shown as sticks 
against a surface and coloured navy blue). The positions of corresponding residues in FGFR3 
are also labelled (bright pink) for the gatekeeper and R-spine residues. (b) Illustration of key 
residues contributing to the ATP binding pocket of FGFR3 shown using a cartoon representation 
of the only available FGFR3 KD crystal structure (FGFR3-K650E) [PDB: 4K33] (Huang et al., 
2013b) in a different orientation to a. Non-hydrolysable ATP analogue (ATP, shown as sticks and 
coloured grey) and magnesium atoms (shown as spheres and coloured green) are shown bound 
in the ATP binding pocket, which ATP-competitive inhibitors also target. Key residues of the 
‘molecular brake (cyan), DFG motif in the C-loop (magenta) and the gatekeeper residue (orange) 
are shown as sticks and coloured by atomic element with nitrogen atoms in navy blue and oxygen 
in red. Hydrogen bonds are shown as dashed lines and coloured black. The position of V555 in 
the pocket suggests why mutation to a bulkier residue at this position might sterically hinder ACP 







A deeper understanding of the functional impact of FGFR cancer-associated mutations 
on kinase activation and inhibitor efficacy is needed for better linking of the mutation data 
to treatment options for patients with the aim of a future personalised approach to FGFR 
targeting in the clinic. Most studies have so far focussed on understanding the functional 
impact and mechanisms of action of hotspot mutations, particularly those in the FGFR3 
and FGFR2 extracellular and transmembrane regions. Few mutations in the FGFR KD 
have been rigorously assessed for their functional impact and oncogenic status, with the 
few studies to date focussing on mutations in the ‘molecular brake’ and A-loop, and a 
few studies have analysed similar mutations in the context of skeletal dysplasias. 
Therefore, there is a need for a direct, comparative, and functional study of cancer-
associated FGFR point mutations to differentiate oncogenic driver mutations from 
passenger mutations in the wealth of genetic mutation data. Additionally, since the 
majority of targeted FGFR inhibitors currently undergoing clinical trials target the ATP 
binding pocket in the FGFR KD, it is important to understand the mechanisms of action 
of mutations in this domain when considering inhibitor binding. Therefore, the diverse, 
mutation-specific mechanisms affecting kinase activation and ligand binding need to be 
elucidated to inform better patient selection and increase the success of personalised 
FGFR targeting in the clinic. 
 
In this work a large panel of representative FGFR mutations from across the KD was 
assembled using the FGFR3 KD as a model. Purified WT and mutant KD proteins were 
directly compared through detailed and quantitative measurements by developing in vitro 
kinase activity assays to assess the impact of mutations on kinase activation, ATP 
binding, turnover and catalytic efficiency. These assays identified potential oncogenic 
driver mutations and assessed possible mechanisms involved in mutation-specific KD 
activation. The impact of mutations on the thermal stability of the FGFR3 KD was then 
assessed using an in vitro biophysical assay to further probe possible contributions to 
KD activation mechanisms. Finally, the functional impact of mutations was compared 
using complementary experiments in a cellular context to attempt to elucidate mutation-
specific impacts on oncogenic FGFR signalling and cellular transformation. These data 
therefore contribute towards an understanding of the molecular mechanisms of FGFR 
activation by cancer-associated point mutations through direct impacts on FGFR activity 
and signalling, and challenge the generalised assumptions of the contributions of hotspot 






3.3.1 Database searching and selection of missense substitutions in FGFR3 
Somatic cancer-associated missense substitutions have been detected in patient 
samples along the entire length of FGFR3 and other FGFRs, as discussed in section 
3.1. Oncogenic driver mutations in the extracellular and transmembrane regions of 
FGFRs have been rigorously studied and mechanisms of action investigated (see 
section 3.1). The focus of this work was to compare and analyse cancer-associated 
FGFR missense substitution mutations that occur in the cytoplasmic region, particularly 
in the KD. FGFR3 was used as the model FGFR for this work because missense 
substitutions occur most frequently in FGFR3, including within this region (Figure 3.2). 
 
As a starting point for this work, cytoplasmic FGFR3 point mutations were sought from 
COSMIC, the most comprehensive and publicly available database of curated cancer-
associated mutations. Of the 63 distinct non-synonymous mutations in the cytoplasmic 
domain of FGFR3 for all cancer types in COSMIC at the start of this work (November 
2013), a comprehensive subset of more than 20 mutations was manually selected for 
this study. Mutations were selected if they were observed with a high frequency in 
FGFR3 or if they occurred in functionally important regions or at conserved residues, for 
example in the A-loop or ‘molecular brake’ in the KD. Some mutations that occur at low 
frequencies, even those with only one observation, were also selected to assess whether 
rare mutations might be relevant in cancer. Since the sequence identity and similarity of 
the four FGFR KDs is over 80% (see Table 1.3), mutations in COSMIC for FGFR1, 
FGFR2 and FGFR4 were also accessed and linked to the corresponding residues in 
FGFR3 based on a multiple sequence alignment of FGFR1-4 and some of these 
mutations were added to the mutation panel for experimental analysis if they occurred 
across more than one FGFR or were frequently observed in the specific FGFR isoform. 
Entries in COSMIC are updated when a new version is released approximately every 
three months, so more mutations were manually selected for analysis (and others 
removed) throughout the project until November 2014 (v71) when no further 
amendments were made to the mutation panel. Mutations present in COSMIC v71 in 
FGFR3 (and corresponding mutations in the other FGFRs) are listed in Table 3.1 
according to their location in the KD. 
 
The compiled data are represented in Figure 3.6a-b as histograms with residue 
numbering according to FGFR3c and the positions of mutations annotated on the 
structure of the FGFR3 KD. Analysis of this dataset revealed an evident conservation of 
mutations across FGFR isoforms, with the corresponding residue in other FGFRs often 
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also found mutated similarly to FGFR3. The analysis also showed that there are two 
hotspot positions in the FGFR3 KD at which the highest numbers of mutations are 
observed (K650 and G697), but revealed a third hotspot in FGFRs (corresponding to 
FGFR3-N540) which only became apparent when mutation frequencies were pooled 
across FGFR1-4. The most frequently mutated hotspot was the position corresponding 
to FGFR3-K650 where mutations to glutamic acid and methionine were much more 
frequently observed than the less common mutations to asparagine, glutamine and 
threonine. At the ‘pooled’ FGFR hotspot corresponding to FGFR3-N540, mutations to 
lysine were most frequent compared to the less common serine, histidine and aspartic 
acid substitutions. The final hotspot mutation, G697C, was only observed in FGFR3, 
although the corresponding mutation to serine was observed rarely in FGFR1 (Table 
3.1). 
 
Interestingly, as mentioned previously, somatic mutations found in FGFRs in cancer 
often correspond to germline mutations observed in developmental syndromes such as 
skeletal dysplasias (Cappellen et al., 1999, Kimura et al., 2001, Wilkie, 2005, Gallo et 
al., 2015, Helsten et al., 2015). The positions at which germline mutations are found most 
commonly in FGFR3 and other FGFRs in skeletal dysplasias were curated from the 
literature and displayed in Figure 3.6c-d with residue numbering according to FGFR3c. 
Mutated positions occurring in both cancer and dysplasias are highlighted and labelled 
and include mutations at the two hotspots N540 (most commonly mutated to lysine) and 
K650 (most commonly mutated to glutamic acid or methionine), similar to the most 
frequently observed mutations in cancer. These two residues are respectively located in 
the FGFR KD in the αC-β4 loop (also in the ‘molecular brake’) and the A-loop. Other 
mutated residues common between cancer and dysplasias occur at I538 (also located 
in the αC-β4 loop adjacent to the ‘molecular brake’) and R669 (located in the αEF-β12 
loop adjacent to the A-loop). The G697 cancer mutation hotspot (located in the αF-αG 








Figure 3.6 Compilation of cytoplasmic FGFR3 cancer-associated and dysplasia mutations 
and corresponding mutations in other FGFRs. (a) Histogram showing the total number of 
observations of somatic missense substitutions in the cytoplasmic region (397-806) of FGFR3 
(upper panel) and corresponding mutations in FGFR1-4 (lower panel) found in cancer, from 
COSMIC v71 (November 2014). Mutation hotspot positions are highlighted in red and labelled 
with the FGFR3 residue number. See Table 3.1 for numbers of observations of mutations at each 
position in each FGFR. (b) Structural locations of the residue positions of missense substitutions 
in a, mapped on a cartoon representation of the only available FGFR3 KD crystal structure 
(FGFR3-K650E) [PDB: 4K33] (Huang et al., 2013b) (coloured grey). Residues at which mutations 
occur are found all over the KD (shown as sticks, coloured blue and labelled). The mutation 
hotspot positions when considering mutations in FGFR1-4 are shown as sticks, highlighted in red 
and labelled (note that K650 is E650 in this crystal structure). (c) Illustration of the positions of 
germline mutations found most commonly in FGFR1-4 in skeletal dysplasias curated from the 
literature and displayed with residue numbering according to FGFR3. Positions at which 
mutations have been observed in both cancer and dysplasias in FGFR3 are highlighted in orange 
and labelled showing five common positions mutated in both types of pathologies. (d) Structural 
locations of the mutations in c, mapped on a cartoon representation of the same crystal structure 
as in b. Residues at which mutations occur (fewer than those found in cancer) are shown as 
sticks, coloured blue and labelled. Positions found mutated in both cancer and dysplasias are 
shown as sticks, coloured orange and labelled. (e) Secondary structure elements and features of 
the FGFR3 cytoplasmic region (including the KD) shown to the same horizontal scale as the 
panels in a and c. The eight α-helices (αC-E, αEF, αF-I) and the eleven β-strands (β1-10, β12) 
are shown as pale yellow and lilac rectangles respectively. The key loop regions are also labelled 
beneath the illustration. 
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Table 3.1 Missense substitutions in the cytoplasmic region (397-806) of FGFR3 (and 
corresponding mutations in FGFR1, FGFR2 and FGFR4) in COSMIC v71 (November 
2014) to complement data in Figure 3.6. The numbers of observations in cancer are 
given in square brackets for the total number of mutations observed at each position. 
 
Structural 
location FGFR3 FGFR1 FGFR2 FGFR4 
Juxta- 
membrane 
R399C/H [2] K400 K401 Q393 
I414V [1] L417 L418 K408 
R421Q [1] R425 R426 R416 
A429V [1] A435 S436 S424 
P449S [1] P455 P458 A444 
E456K [1] E462 E465 S451G [1] 
E466K [1] E472 E475K/G [4] E461 
R469Q [1] R475W/Q [3] R478 R464W [1] 
β2 E490G [1] E496 E499 E485 
β2-β3 loop A500T [1] N506 K509 D495 
β3 V505I [1] V511 V514 V500 V507M [1] V513 V516 V502 
αC-β4 loop I538F [1] I544 I547V/T [3] I533 N540S [1] N546D/S/K [18] N549H/K/S [35] N535 
β5 V555M [1] V561 V564 V550L [1] 
αD A569V [1] A575 A578 A564 
Kinase 
insert 
P572A [1] P578 P581Q [1] P567 
D576N [1] E582 E585 D571 
C582F [1] S588T [1] N591 P577 
αE R603Q [2] R609 R612T [1] R598 L608M [1] L614 L617F [1] L603 
β6 I614N [1] I620 I623 I609 
C-loop 
R616G [1] R622 R625Q [2] R611Q [1] 
D617G [1] D623 D626 D612 
R621H [2] R627 R630 R616G [1] 
β7-β8 loop E627K/G/V/D [4] E633 E636K [1] E622 
A-loop 
V630M/A [2] V636 V639 V625 
F636L [1] F642 F645 F631 
G637W [1] G643 G646 G632 
R640W [1] R646 R649 R635S [2] 
D641N/G [3] D647N [1] D650 G636 
H643D/R [4] H649 N652 H638 
D646N/Y/G [3] D652 D655G [1] D641 
K650E/M/N/Q/T [173] K656E/M [13] K659E/M/N [11] K645E [1] 
N653H/S [2] N659 N662 N648 
αEF-β12 loop R669Q [1] R675Q [1] R678G/S [2] R664L [1] 
αF 
V677I [1] V683 V686 V672 
S679F [1] S685 S688F [1] S674 
E686K [1] E692 E695K [1] E681K [3] 
αF-αG loop 
T689M [1] T695 T698 T684 
P696L [1] P702 P705 P691 
G697C [44] G703S [2] G706 G692 
αG-αH loop K715M [1] K721 K724 R710 P716H [2] P722 P725 P711 
αH M725I [1] M731 M734 G720 
αI R750C [1] R756 R759Q [1] K745 
C-tail 
S779R [1] S785 S788 S773 
S787F [1] S794 S796F [1] S780 
T806M [1] R821 T821 T802 
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The panel of 25 mutations analysed in this work was finally selected using a semi-biased 
selection process. Hotspot mutations (e.g. K650E) and mutations occurring at the same 
residue across more than one FGFR isoform (e.g. R669G) were selected, as it was 
hypothesised that properties of a mutation such as ‘conservation’ and/or frequent 
occurrence across FGFR isoforms in cancer might imply that the mutation plays a role 
in pathogenesis. Variants were also selected in functionally important regions of the 
kinase such as the A-loop (D641N) and active site (D617G) or if they co-occurred in 
dysplasias (e.g. I538V). Two ‘resistance’ mutations were selected from the literature due 
to their occurrence as secondary acquired mutations in pre-clinical models of resistance 
to targeted FGFR therapies (V555M, Y647C) (Chell et al., 2013, Crystal et al., 2014). 
Finally, some rarely observed mutations were selected at random, many of which have 
only been observed in one FGFR isoform (e.g. A500T). The final panel of representative 
mutations taken forward for experimental evaluation included half of all residues found 
to be mutated in the FGFR3 cytoplasmic region in cancer. Details of the mutations in this 
compiled panel are provided in Table 3.2. 
 
3.3.2 Construction of a panel of FGFR3 mutant KD proteins 
A human FGFR3 (455-768) KD construct was cloned by Tom Bunney in the pOPINS 
bacterial expression vector (OPPF) and another was purchased in the pJ821 bacterial 
expression vector (DNA2.0). The pOPINS construct comprised the native FGFR3 cDNA 
sequence while the pJ821 construct was codon optimised for E. coli expression. Both 
constructs were otherwise identical in sequence boundaries and overall design. They 
contained an N-terminal Ulp1 protease-cleavable 6His-SUMO purification tag and 
solubilising ‘2C’ mutations C482A and C582S (Mohammadi et al., 1996b) which also 
increase soluble expression of this construct while maintaining WT kinase activity (data 
not shown). These FGFR3 ‘WT’ constructs will therefore be referred to as FGFR3-2C  or 
2C throughout this work. The modular design of this basic expression construct is shown 
in Figure 3.7a. Point mutations were introduced into this backbone by site-directed 
mutagenesis (SDM) using the primers in Tables 2.1 and 2.2. Constructs were also 
checked by sequencing to confirm the successful incorporation of mutations (for full 













This plasmid library of FGFR3-2C and mutant KDs was used to express and purify 
mutant KD proteins from E. coli C41 (DE3) λ37 cells pre-transformed with an accessory 
plasmid pCDFDuet-1™ (Novagen) containing genes for λ-phosphatase and the CDC37 
co-chaperone. The λ-phosphatase was included to remove traces of phosphorylation 
from the KDs during expression (since the KDs are capable of autophosphorylation) 
while FGFR3 is a client of the CDC37 co-chaperone which aids in folding of FGFR3 and 
improves its solubility (Laederich et al., 2011). Additionally, in the absence of the 
λ-phosphatase, KD yields were lower by several fold (data not shown) so inclusion of the 
λ-phosphatase was crucial for expressing reasonable yields of soluble KD proteins. The 
expression and purification workflow is summarised in Figure 3.7a-b and full methods 
are detailed in section 2.6.1. Yields of different mutants varied greatly, with some being 
much easier to produce and others producing just a few micrograms of purified KD per 
litre of E. coli culture (Table 3.2). Mutations I538F, I538V, V555M and G637W were last 
to be added to the panel and following generation of the mutant plasmid constructs, these 
KD proteins were purified and provided by Tom Bunney. Peak fractions from the final 
step size exclusion chromatography (SEC) that were found to contain monomeric 
proteins (Figure 3.7c) were concentrated and used in further experiments. The final purity 
of FGFR3 mutant KD proteins used in this work was estimated to be over 95% from SDS-
PAGE analysis (Figure 3.7d). Although a lot of care was taken during expression and 
purification (as described above) to ensure the KDs prepared were unphosphorylated, 
all purified KD proteins were checked by native mass spectrometry (see Figure 3.7e for 
example mass spectra) and native PAGE (data not shown) to confirm their zero-
phosphorylation status prior to use in experiments. 
 
3.3.3 Development of an in vitro kinase activity assay 
The first aim of this work was to directly and comparatively screen the comprehensive 
panel of FGFR3 variant KD proteins to differentiate potential oncogenic drivers from 
passenger mutations. This required a robust assay platform to perform screening, activity 
and kinetics assays in a relatively small scale and medium-throughput format. The kinase 
activity assay was developed using FGFR3-2C and using the ADP-Glo™ kinase assay 
(Promega). Figure 3.8 schematically illustrates the rationale of the ADP-Glo™ 
methodology. Briefly, this assay produces a luminescent output signal that is 
representative of and proportional to the amount of ADP produced during an ATPase (or 
kinase) reaction. Assays were performed with and without a poly-Glu-Tyr (polyE4Y1) 
peptide (Sigma) which has been shown to be a suitable substrate in pilot experiments 
where it was phosphorylated by FGFR KDs (data not shown). The assay was designed 
and optimised for a 96-well plate format to allow medium-throughput scale manual 
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Figure 3.7 FGFR3 KD construct design, expression, purification and quality control. (a) 
Construct design, expression and purification workflow used for the production of FGFR3-2C and 
variant KD proteins. The FGFR3 (455-768) construct (in either the pOPINS or pJ821 vector 
backbone) harboured two solubilising cysteine point mutations (C482A and C582S, annotated) 
and the relevant pathogenic point mutations (Table 3.2). It comprised an N-terminal 6His-SUMO 
purification tag cleavable by Ulp1 protease (indicated by scissors). This construct was 
transformed into E. coli and subjected to the depicted expression and purification workflow. SEC 
– size exclusion chromatography, S75 – Superdex 75. (b) Representative Coomassie stained 
SDS-PAGE gels for all FGFR3 variants demonstrating the purification workflow. Protein is shown 
in the clarified E. coli soluble lysate (Lys), elution following Ni2+-NTA chromatography (His), 
flowthrough (RHis) and elution (Tag) following Ulp1 protease cleavage of the 6His-SUMO tag and 
‘reverse’ Ni2+-NTA chromatography, and fractions from ‘Q’ anion exchange chromatography. 
6His-SUMO FGFR3 KD protein is marked by a black asterisk, Ulp1-cleaved FGFR3 KD protein 
(tag-free) is marked by an orange asterisk, and the cleaved 6His-SUMO tag is marked by a purple 
asterisk. Protein from the first three fractions shown from the Q chromatography were pooled and 
concentrated prior to SEC. (c) Representative SEC chromatogram (left panel) and Coomassie 
stained SDS-PAGE gel (right panel) for all FGFR3 variant KD proteins showing that all proteins 
eluted in a single peak comprising monomeric protein in the final chromatographic purification 
step (marked by a single asterisk). All four SEC fractions shown were pooled, concentrated and 
used in further experiments (and similarly for all other variants). (d) Coomassie stained SDS-
PAGE gels for FGFR3 variant KDs produced for this work (I538F, I538V and G637W prepared 
by Tom Bunney are not shown) showing that the purity of the proteins following the final SEC 
purification step was over 95% for all proteins (left panels). Y647C is shown separately (right 
panels) for a sample following the anion exchange purification step (prior to SEC) as an SDS-
PAGE gel is not available for this mutant following SEC. Bands corresponding to FGFR3 KD 
proteins in both panels are marked by a single asterisk. (e) Native LC-MS spectra of purified KD 
proteins following SEC and storage at -80°C. Only spectra for FGFR3-2C (left panel) and FGFR3-
K650E (right panel) are shown as examples, indicating the theoretical calculated masses and LC-
MS measured masses in Daltons (Da). Although the spectra shown do not span the expected 
dimeric mass of the KD proteins, no peaks were observed for the FGFR3 KDs at this mass 








Figure 3.8 Rationale behind the ADP-Glo™ methodology. Illustration of the rationale behind 
the ADP-Glo™ methodology (Promega). Kinase reactions were started at time = 0 seconds by 
the addition of Ultra Pure ATP (Promega) or kinase, depending on the experiment type. During 
the kinase reaction, ATP was converted to ADP by the KDs. Reactions were stopped by the 
addition of ADP-Glo™ reagent into the kinase reaction. This reagent also depleted remaining 
ATP in the reaction over the 40 minute incubation period. Next, Kinase Detection Reagent was 
added to the reactions to convert ADP produced by the kinase reaction into ATP over a 30-60 
minute incubation period, depending on the starting concentration of ATP. This ATP then fuelled 
a luciferase reaction, producing a luminescent signal that was detected using a plate reader 










Assay optimisations were initially performed for constituents of the kinase reaction buffer 
(KRB), reaction time, ATP concentration and polyE4Y1 concentration (Figure 3.9) using 
FGFR3-2C to ensure that signal linearity of all parameters was maintained during the 
course of the assays. The optimal composition of KRB (used for all subsequent 
experiments) was determined to comprise 50 mM HEPES buffer (pH 7.5), 20 mM NaCl 
and 20 mM MgCl2 based on the buffer screening experiment shown in Figure 3.9a. Also 
present in all experiments was 100 μM of both phosphatase inhibitor sodium 
orthovanadate and reducing agent TCEP to prevent dephosphorylation and inhibit 
aggregation respectively during the reactions. The reaction time for further experiments 
was selected to be 10 minutes, below the ‘half-time’ T1/2 (the time at which half of the 
ligand binding sites become occupied with ligand) calculated here for 2C (23 minutes, 
Figure 3.9c) to ensure strict signal linearity while maintaining signal intensity. Similarly 
for concentrations of ATP and polyE4Y1, the affinity constant (KM) for each substrate 
determined here (344 μM and 70.5 μM respectively, Figure 3.9d-e) guided the 
concentrations of each substrate used in further experiments. These concentrations 
varied for different types of assays and the exact concentrations used in specific 





Figure 3.9 Optimisation of the kinase activity assay using FGFR3-2C. (a) Screening of kinase 
reaction buffer (KRB) components including varying the pH (using indicated buffers), NaCl and 
MgCl2 concentrations as indicated. These experiments were uniquely performed using a 
combination of manual and semi-automated liquid dispensing into 384-well plates for kinase 
reactions with a total volume of 4 μL per reaction and subsequently similarly scaled volumes of 
ADP-Glo™ reagents. The results shown are for 1 nM FGFR3-2C, 0-100 mM NaCl and 10-20 mM 
MgCl2, representative of two similar independent experiments performed additionally with other 
variable constituents (which did not alter the trend shown in the graph and so are not shown): 
FGFR3-2C (1, 10, 100 and 1000 nM), bovine serum albumin (0 and 100 μg/mL), four detergent 
conditions (0% or 0.005% Brij-35, CHAPSO and Tween-20), four concentrations of ATP (0,10,100 
and 1000 μM) and polyE4Y1 peptide (0.0286, 0.286, 2.86 and 28.6 μM). All reactions also 
contained 100 μM sodium vanadate (phosphatase inhibitor) and 100 μM TCEP (reducing agent). 
Each condition was tested in at least triplicate reactions per assay, and error bars represent the 
standard deviation of six repeats for each condition. The optimal conditions from this experiment 
(50 mM HEPES pH 7.5, 20 mM NaCl, 20 mM MgCl2, 100 μM sodium vanadate and 100 μM TCEP) 
formed the basic composition of KRB used for experiments in this work. AU – arbitrary units. (b) 
Autophosphorylation experiments performed using increasing concentrations of FGFR3-2C 
between 0-2 μM, 50 μM ATP and 45 minute kinase reactions, displayed as log dose-response 
curves for three independent experiments (green, blue and purple) of at least five independent 
experiments performed under identical conditions and using at least two independent 2C protein 
preparations. Each data point was measured in triplicate and error bars represent the resulting 
standard deviation for each concentration of kinase. The curves connecting the data points are 
not fits to the data and are only shown for visual clarity. (c) Time course experiment performed 
using 0.5 μM FGFR3-2C, 429 μM polyE4Y1, 500 μM ATP, and time points between 0-60 minutes. 
Each data point was measured in triplicate and error bars represent the resulting standard 
deviation at each time point. Data were fitted to a one phase exponential model for pseudo-first 
order association kinetics (equation 3) and used to calculate the ‘half-time’ (T1/2, indicated) for the 
reaction. (d) ATP titration experiment performed using 0.5 µM FGFR3-2C, 429 μM polyE4Y1, 0-
1000 µM ATP and 45 minute reactions. The graph represents results from two independent 
experiments performed under identical conditions. Each data point was measured in triplicate in 
each assay and error bars represent the resulting standard deviation for each concentration of 
ATP. Data were fitted to the Michaelis-Menten equation (equation 4), and used to calculate the 
affinity constant for ATP (KM, indicated) for the reaction. (e) Substrate titration experiment 
performed using 0.5 µM FGFR3-2C, 0-286 μM  polyE4Y1, 500 µM ATP and 45 minute reactions. 
The graph represents results from six independent experiments performed under similar 
conditions. Each data point was measured in triplicate in each assay and error bars represent the 
resulting standard deviation for each concentration of polyE4Y1. Data were fitted to the Michaelis-
Menten equation (equation 4), and used to calculate the affinity constant for polyE4Y1 (KM, 




3.3.4 Autophosphorylation screens reveal potential oncogenic drivers 
The optimised kinase activity assay was then used to screen the panel of twenty six 
purified FGFR3 KD proteins for kinase hyperactivity. Purified FGFR3-2C and variant KDs 
were first incubated at 21-22°C with ATP in the presence of 20 mM Mg2+ in a set of 
experiments designed to assess the impact of FGFR3 KD mutations on 
autophosphorylation compared to FGFR3-2C. Output luminescence was measured at a 
fixed time point over a range of kinase concentrations (Figure 3.10a) or at a single kinase 
concentration (Figure 3.10b). All dose response and single kinase concentration 
experiments were performed in triplicate, with at least two or three independent dose 
response experiments performed with each variant. Subsequently, assays were also 
performed with two independent preparations of protein for several (randomly selected) 
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mutants and with four independent preparations of WT protein, to eliminate any 
possibilities of batch-to-batch variation. No such variation was seen, as demonstrated 
using FGFR3-2C as an example (Figure 3.9b). Both types of autophosphorylation assays 
produced comparable, reproducible results which will be reviewed in parallel. 
 
Eleven of the 25 variants exhibited greater than 3-fold activity compared to FGFR3-2C. 
These are found at eight distinct residue positions on the KD, all of which are conserved 
across the four FGFRs (the only exception is FGFR3-D641 which is a glycine in FGFR4). 
The two hotspot mutations N540K and K650E, which are found most frequently replaced 
at each residue position across FGFRs, caused some of the largest increases in 
autophosphorylation of around 40- and 45-fold respectively. The mutations N540S and 
K650N which are less frequently observed at the same residue positions were also less 
hyperactive, although they were still activating by around 10- and 18-fold respectively. 
Mutations at position K650 have been thoroughly studied in the context of congenital 
diseases and cancer, and shown to be activating in FGFR3 (see section 3.1.5). This 
mutation therefore served as a good positive control for all experiments performed with 
mutations in this work. The mechanism of activation by K650E has also been elucidated 
(see section 3.1.5); briefly, this mutation stabilises the active KD conformation, 
independent of tyrosine phosphorylation and FGF ligand stimulation, by mimicking the 
action of phosphorylated Y647 in the A-loop (Figure 3.4). Mutations at the corresponding 
residues for FGFR3 N540 and K650 in other FGFRs have also been shown to be 
activating in vitro (Chen et al., 2007b, Lew et al., 2009, Byron et al., 2013, Chen et al., 








Figure 3.10 Autophosphorylation experiments. (a) Autophosphorylation experiments 
performed using increasing concentrations of FGFR3 variants between 0-2 μM, 50 μM ATP and 
45 minute kinase reactions, displayed as dose response curves fitted with a saturation dose 
response binding equation for visual clarity (equation 1). Data shown for FGFR3-2C are 
representative of six identical independent experiments (using at least three independent protein 
preparations), while data for other variants are representative of at least two identical independent 
experiments each (using two independent protein preparations for many variants). Each data 
point was measured in triplicate in each assay and error bars represent the resulting standard 
deviation for each concentration of kinase. Eleven mutations found to be more activating than 2C 
are highlighted in different colours (used throughout this work) and labelled. Mutations found to 
not be more activating than 2C are coloured grey and are not labelled. AU – arbitrary units. (b) 
Autophosphorylation screening experiments performed using 1 μM FGFR3 variants, 50 μM ATP 
and 45 minute kinase reactions displayed as a histogram showing fold change compared to 2C 
(normalised 2C = 1). Each data point was measured in triplicate and error bars represent the 
resulting standard deviation for each variant. Some variants were also included in a second 
independent assay under identical conditions. For full experimental details see section 2.9. 
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Interestingly, the mutation displaying the highest activation in both of these assays was 
R669G, a non-hotspot mutation in the αEF-β12 loop displaying an autophosphorylation 
increase of more than 60-fold compared to FGFR3-2C. The other variant found at the 
same residue position (R669Q) was less hyperactive, but still activating by 10-fold. This 
work shows for the first time that pathogenic mutations at this position in FGFR3 activate 
the KD. The corresponding mutation to FGFR3-R669G in FGFR2 (R678G) was once 
assessed for its activation status in the context of skeletal dysplasias and was shown to 
be activating in vitro (Chen et al., 2007b) but was not found to be as activating compared 
to FGFR2-WT as in this work, and the authors made no further comments about this 
mutation. Additionally, replacement of the corresponding residue in FGFR1 to glycine 
(R675G) also results in activation of the KD compared to FGFR1-2C (assessed using a 
construct similar to the FGFR3-2C used in this work) (Patani et al., 2016). The small 
discrepancies between these results might reflect subtle structural and/or local sequence 
differences between the two FGFR KDs which present as small differences in kinase 
activation by the same mutation at the corresponding residue in different FGFR isoforms. 
 
The other five mutations found to moderately activate kinase autophosphorylation were 
I538V adjacent to the ‘molecular brake’ and recently described as part of the ‘DFG-latch’, 
V555M in the ATP binding pocket (the FGFR3 gatekeeper residue) and A-loop mutations 
D641G, D641N and Y647C displaying 6-, 6-, 5.5-, 4.5- and 3-fold activation respectively 
compared to FGFR3-2C (Figure 3.10b). The I538V mutation is also found in 
hypochondroplasia (Helsten et al., 2015) and interestingly, mutation to phenylalanine at 
this residue (I538F) was not found to be activating. The gatekeeper mutation V555M was 
identified as a secondary mutation acquired as a resistance mechanism in response to 
pre-clinical treatment of a human tumour model cell line with an FGFR inhibitor (Chell et 
al., 2013), yet this mutation has been curated into the COSMIC database. Similar to the 
result shown here, previous in vitro activity assays in FGFR3 (Bunney et al., 2015), 
FGFR2 (Byron et al., 2013) and other kinases (Azam et al., 2008) have shown that 
mutations to bulkier residues at the gatekeeper position are activating. The other 
acquired resistance mutation Y647C, observed in response to pre-clinical treatment of a 
model human tumour cell line with an EGFR inhibitor (Crystal et al., 2014) is also 
moderately activating in this assay. Mutations at FGFR3-D641 found in the A-loop or 
corresponding mutations in other FGFRs have not been previously studied, so this assay 
showed for the first time that mutations at this position are also activating in FGFRs. 
Interestingly, mutations occur at the corresponding and conserved position to FGFR3-
D641 in the related RTKs KIT (KIT-D816) and PDGFRα (PDGFRα-D842). They form the 
largest mutation hotspots in COSMIC for both RTKs with approximately 2000 and 600 
observed mutations in cancer at this position in each RTK respectively. This region 
95 
 
(‘DFGLARD’, 635-641 in FGFR3) is 100% conserved in both RTKs and FGFR3. The 
most frequently observed mutations are KIT-D816V and PDGFRα-D842V, almost 
exclusively observed in mastocytosis for KIT-816V (Nagata et al., 1995, Furitsu et al., 
1993), or in soft tissues for PDGFRα-D842V (Heinrich et al., 2003). Both mutations have 
also been shown to be constitutively, ligand-independently activating, as first shown for 
KIT-D816V (Kitayama et al., 1995, Furitsu et al., 1993) and for PDGFRα-D842V 
(Heinrich et al., 2003). Although the corresponding mutation to valine at this position has 
not been observed in FGFRs in cancer, it is interesting that different replacements at 
D641 are also rarely observed in FGFRs (mostly FGFR3) in cancer (Table 3.1) where 
they are also activating (Figure 3.10). 
 
Fourteen of the panel of 25 variants displayed either very little or no effect on activation 
with some variants even being less activating compared to FGFR3-2C (Figure 3.10). 
Most of these variants are only rarely observed in cancers. However, included in these 
non-activating mutations is the hotspot mutation G697C, located in the αF-αG loop, 
whose controversial activation status and relevance in cancer is currently unresolved. In 
this work, the mutation is not activating, supporting the newer study suggesting it is 
irrelevant in cancer (Aubertin et al., 2007). Remarkably, KD activity was completely 
abrogated by mutations D617G and G637W. These mutations occur at catalytically 
essential residues conserved across the kinome; they are part of the HRD and DFG 
motifs located in the C-loop and A-loop respectively. Mutation of the catalytic aspartate 
in the HRD motif (D617G) renders the KD incapable of phosphoryl transfer (Valiev et al., 
2003). Mutations affecting the DFG motif, which coordinates the ATP and Mg2+ co-factors 
during phosphorylation, also render the FGFR3 KD catalytically inactive. This is 
observed across kinases which appear mutated in this motif in cancer more frequently 
than expected (Greenman et al., 2007, McSkimming et al., 2015). This is the first time 
kinase activity has been assessed for the G637W mutation in any kinase. Overall, the 
importance of cancer-associated mutations that reduce or abolish FGFR kinase activity 
is not yet known, but it has been suggested that inactivating mutations may have a 
context-dependent tumour protective role (Gartside et al., 2009, Turner and Grose, 
2010). It is also possible that they are passenger mutations with no oncogenic role and 
are rarely detected in cancers due to the increased genomic instability of tumours. 
 
In summary, from the autophosphorylation experiments, mutations at the three residues 
N540, K650 and R669 (located in the ‘molecular brake’, A-loop and αEF-β12 loop 
respectively) were found to be the most activating, with all six variants at these three 
positions displaying greater than 10-fold activation compared to FGFR3-2C (Figure 
3.10b). Interestingly, all three mutations are also observed in dysplasias in both FGFR3 
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and FGFR2 (Figure 3.6c) where they are responsible for causing the most severe forms 
of skeletal abnormalities (Wilkie, 2005), albeit with less activating mutations at the same 
residues in dysplasias causing less severe pathogenic phenotypes. This work also 
shows that different replacements at the same residue can result in differential levels of 
kinase activation, as has been previously shown for mutations at K650 and N540 
respectively in FGFR3 and other FGFRs (Webster et al., 1996, Bellus et al., 2000, Chen 
et al., 2007b, Chen et al., 2013b). Interestingly, a different replacement at the position 
corresponding to FGFR3-R669 in FGFR1 (R675E) has been shown to reduce kinase 
activity compared to FGFR1-WT (Kobashigawa et al., 2015) and it was suggested that 
this residue is important for trans-autophosphorylation of the first A-loop tyrosine (Y653 
in FGFR1). Therefore, it is likely that different substitutions at any residue might 
differently affect kinase activation. These subtle effects of mutations on kinase activation 
can only be investigated, and the mechanisms deciphered, through experimental testing. 
 
3.3.5 Substrate phosphorylation assays confirm activation status of mutations 
The panel of FGFR3 KD proteins was subsequently screened in two similar and 
complementary experiments to the autophosphorylation screens described above. This 
time (and in all subsequent assays), each reaction also contained the polyE4Y1 peptide 
substrate (also simply referred to as ‘substrate’ in this work) in order to assess the impact 
of FGFR3 KD mutations on substrate phosphorylation compared to FGFR3-2C. As with 
the autophosphorylation experiments, kinase dose response assays and single 
concentration experiments were set up (see section 2.9 for more experimental detail). 
The results were mostly consistent with data from autophosphorylation experiments so 
for clarity, data have been presented grouped according to most activating (including 
moderately activating mutations at the same positions), moderately activating and non-
activating mutations based on the autophosphorylation screens (Figure 3.11). In the 
context of substrate phosphorylation the most activating mutations were still N540K, 
K650E and R669G (Figure 3.11a). Closely following were the other variants at these 
residues (N540S, K650N and R669Q) as well as the moderately activating mutations 
(I538V, V555M, D641G and D641N) (Figure 3.11b). The only moderately activating 
mutation from autophosphorylation experiments that was not activating in the context of 
substrate phosphorylation was Y647C (Figure 3.11b). This is partly consistent with the 
autophosphorylation screen (Figure 3.10b) where this mutation was also the least 
activating of all activating mutations (3-fold activation). Strikingly, the complete 
abolishment of kinase activity could be seen most clearly for the HRD and DFG motif 
mutations D617G and G637W in substrate phosphorylation assays (Figure 3.11c), 





Figure 3.11 Substrate phosphorylation experiments. Substrate phosphorylation experiments 
performed using increasing concentrations of FGFR3 variants between 0-1 μM, 28.6 µM 
polyE4Y1, 500 μM ATP and 10 minute kinase reactions for FGFR3-2C and activating variants at 
positions N540, K650 and R669 (a) and FGFR3-2C and activating variants at positions I538, 
V555, D641 and Y647 (b), displayed as dose response curves fitted with a saturation dose 
response binding equation for visual clarity (equation 2). Data are representative of two 
independent experiments each for most variants under identical conditions. Each data point was 
measured in triplicate in each assay and error bars represent the resulting standard deviation for 
each concentration of kinase. Colouring of variants is the same as in Figure 3.10. AU – arbitrary 
units. (c) Substrate phosphorylation screening experiments performed using 1 μM FGFR3 
variants, 14.3 µM polyE4Y1, 50 μM ATP and 45 minute kinase reactions displayed as a histogram 
showing fold change compared to 2C (normalised 2C = 1). Each data point was measured in 
triplicate and error bars represent the resulting standard deviation for each variant. Some variants 
were included in a second independent assay under identical conditions. For full experimental 
details see section 2.9. 
 
 
These direct quantitative and comparative measurements of kinase activity in vitro 
demonstrate that different pathogenic FGFR mutations are capable of impacting and 
modulating kinase activation (and inactivation) to different degrees. The results suggest 
that while some highly activating mutations are found at genetically-defined hotspots, 
some are not and such non-hotspot activating mutations could be underrepresented in 
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mutation databases (see section 3.4). Their importance in cancer might therefore be 
undermined in studies that tend to focus only on the most commonly occurring mutations 
in cancer mutation databases. Additionally, it has been shown that hotspot mutations 
based solely on genetic information (such as G697C) might not necessarily be activating. 
Therefore, these data reinforce the importance of experimental verification of the 
abundant information in cancer mutation databases. Experimental assessments of the 
functional impact of genetically identified cancer mutations to differentiate potential 
oncogenic drivers from passenger mutations can then improve drug discovery and boost 
the success of candidate drugs in clinical trials. 
 
3.3.6 Highly activating mutations cause partial ligand-independent activation 
Screening the panel of FGFR3 variants showed that mutations impact kinase activation 
to differing degrees. In order to determine which mutations confer kinase activation 
similar to fully- activated WT, a phosphorylated active form of FGFR3-2C was prepared. 
Purified unphosphorylated FGFR3-2C KD was incubated with 25 mM Mg2+ and 10 mM 
ATP for 45 minutes and the resulting mixture of phosphorylated species were separated 
using stringent anion exchange chromatography (see section 2.7 for full experimental 
details). The ultimate-eluting anion exchange peak was found to contain fully 
phosphorylated FGFR3-2C KD (‘4p’, Figure 3.12a). This was concentrated and used in 
subsequent experiments where it is referred to as p2C. Substrate phosphorylation 
experiments were set up exactly as in section 3.3.5 to directly compare kinase activity of 
the FGFR3 KD proteins 2C, p2C and one the most highly activating variants K650E 
(Figure 3.12b-c). Surprisingly, it was found that even such a highly activating mutant only 
partially activated the KD in a ligand independent fashion compared to fully-active ‘WT’ 
p2C under these in vitro conditions. This is similar to the results previously observed for 
activating FGFR2 mutations using a different in vitro activity assay (Chen et al., 2013b). 
 
The structural locations of activating mutations identified in this work through the in vitro 
activity assays are shown mapped on the FGFR3 KD in Figure 3.13a. Analysis of the 
primary sequences of FGFR1-4 in the regions at which the most activating mutations 
occur reveals near perfect sequence conservation of residues in the kinase hinge, 
‘molecular brake’, A-loop and αEF-β12 loop. Therefore, previous mechanistic analyses 
of activation mechanisms for corresponding mutations in FGFR1 and FGFR2 could help 
to explain those in FGFR3. Activation mechanisms involving K650E and other 
replacements at the same residue have been thoroughly elucidated and have already 
been discussed in section 3.1.5 and shown in Figure 3.4. The basis for partial KD 
activation by different FGFR2-K659 mutations has particularly been explained to be a 
result of subtle structural differences that translate to small changes in the two key A-loop 
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and ‘molecular brake’ hydrogen bonding networks that determine the dynamic activation 
of the KD (Chen et al., 2013b). The other FGFR3 A-loop mutations found to be 
moderately activating in this work (D641G, D641N and Y647C) might also follow similar 




Figure 3.12 Mutations only confer partial ligand independent KD activation. (a) Purification 
of fully phosphorylated active FGFR3-2C (p2C). Recombinant unphosphorylated FGFR3-2C KD 
proteins at 2-10 mg/mL were incubated with 25 mM MgCl2 and 10 mM ATP at 22°C for 45 minutes. 
Kinase reactions were stopped with 50 mM EDTA, desalted and loaded on to a 1 mL Resource 
Q anion-exchange column (GE Healthcare). Five peaks eluted, corresponding to 0p, 1p, 2p, 3p 
and 4p phosphorylated forms of FGFR3-2C (the four tyrosines in the KD constructs that undergo 
autophosphorylation are indicated in the top right corner). The 4p peak fractions contained p2C 
KD protein used in subsequent kinase assays. For full experimental details see section 2.7. (b) 
Substrate phosphorylation experiments performed using increasing concentrations of the 
indicated FGFR3 variants between 0-0.2 μM, 28.6 µM polyE4Y1, 50 μM ATP and 45 minute kinase 
reactions, displayed as dose response curves fitted with a saturation dose response binding 
equation for visual clarity (equation 2). Each data point was measured in triplicate and error bars 
represent the resulting standard deviation for each concentration of kinase. AU – arbitrary units. 
(c) Substrate phosphorylation screening experiments performed using 0.1 μM FGFR3 variants, 
28.6 µM polyE4Y1, 50 μM ATP and 45 minute kinase reactions displayed as a histogram showing 
fold change compared to 2C (normalised 2C = 1). Data are representative of two independent 
experiments performed using two different concentrations of kinase. Each data point was 
measured in triplicate in each assay and error bars represent the resulting standard deviation for 
each variant. For full experimental details see section 2.9. 
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In the kinase hinge region, activation mechanisms involving mutation of the gatekeeper 
residue (FGFR3-V555) have already been discussed based on previous studies of the 
corresponding mutation (V561M) in FGFR1 (see section 3.1.6 and Figure 3.5). For 
mutations at N540 in the kinase hinge, activation mechanisms are proposed based on 
previous analyses of the corresponding mutations in FGFR1 and FGFR2 (Chen et al., 
2007b, Lew et al., 2009). The first study shows that FGFR2-N549 mutations cause direct 
disengagement of the molecular brake, to differing degrees depending on the amino acid 
substitution, directly relieving KD autoinhibition. This mechanism is likely to apply to 
FGFR3 as well (Figure 3.13b) due to 100% conservation of the molecular brake residues 
in all FGFR KDs. The second study shows that FGFR1-N546K disrupts the order of 
sequential tyrosine autophosphorylation compared to FGFR1-WT, allowing a higher 
level of basal KD activation without the need for A-loop phosphorylation. It is unclear 
whether this might also apply to FGFR3, which has two fewer tyrosines in its KD than 
FGFR1 and FGFR2, and whose sequential order of autophosphorylation has not yet 
been investigated. One other activating mutation in the kinase hinge (I538V) occurs at a 
position that normally contributes to the ‘molecular brake’ interactions (Figure 3.13b) and 
has also been recently described to form part of the ‘DFG-latch’ which contributes to KD 
activation through forming an allosteric connection that relays information between the 
active A-loop and the ‘molecular brake’ (Chen et al., 2017). Therefore, mutation of this 
isoleucine to valine might activate the KD by abrogating some autoinhibitory interactions 
in the ‘molecular brake’ and through allosteric mechanisms involving local structural 
changes in the ‘DFG-latch’. 
 
The mechanism of activation of the R669G mutation, which resulted in the largest 
increase in kinase activation of all mutations tested in this work, had not been previously 
assessed in any FGFR. Therefore, the crystal structure of FGFR1-R675G (the 
corresponding mutation which is also activating in FGFR1) was solved by Nethaji 
Thiyagarajan, to begin to understand the activation mechanism (Patani et al., 2016). 
Comparison of this structure with those of inactive and active FGFR1-WT confirmed that 
this mutation causes the KD to adopt all aspects of the typical FGFR active conformation 
(Figure 3.13c-e), shifting conformational equilibrium towards the active state by an 
allosteric mechanism similar to that proposed for other activating FGFR mutations (Chen 
et al., 2007b, Huang et al., 2013b). Additionally, while the autoinhibitory interactions at 
the ‘molecular brake’ are lost in this mutation, they are not abrogated to the same degree 
as fully phosphorylated and activated FGFR1-WT (Figure 3.13f). These subtle structural 
differences might partly explain why even this most activating mutation only results in 
partial ligand independent KD activation. Overall, KD activation is a dynamic and graded 
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process and to date, no mutations have been identified that can fully activate the kinase 
as much as fully activated FGFR-WT. 
 
3.3.7 Mutations differently affect KD phosphorylation kinetics and ATP affinity 
To further investigate the impacts of these diverse KD mutations on kinase activity, the 
mutant KDs were next tested in two different experiments using the in vitro kinase activity 
assay to assess the impact of mutations on phosphorylation rates, kinetics and substrate 
binding. 
 
First, a subset of FGFR3 variant KDs was assayed for substrate phosphorylation over a 
60 minute time course. A single concentration of each of the nine FGFR3 mutants, ATP 
and polyE4Y1 substrates was used respectively, similar to the experimental design of the 
phosphorylation screens. Kinase reactions were stopped at different time points between 
0-60 minutes (see section 2.9 for full experiment details) and compared to FGFR3-2C. 
Data were fitted with an exponential model for pseudo-first order association kinetics 
(equation 3) to calculate the KD phosphorylation rates, rate constants and other 
parameters and these values are listed in Table 3.3. The raw time course curves and the 
rate constants for all mutants are displayed in Figure 3.14a-b. The data suggests that 
both mutations at N540 (N540K and N540S) as well as K650E result in the largest 
increases in the initial rate of phosphorylation compared to FGFR3-2C, followed by 
D641G/N and K650N. The R669G mutation only has a slightly elevated initial rate of 
reaction compared to FGFR3-2C but results in the largest total phosphorylation response 
over the course of the 60 minute assay, closely followed by K650E and N540K. The other 
mutation at this position (R669Q) has a much reduced initial rate of reaction, but both 
mutations at R669 are predicted by the kinetic model to cause the largest ultimate 
maximum phosphorylation response by 60 minutes (Table 3.3). In contrast, G697C 
demonstrates a reduced maximum response, has a reduced reaction rate and exhibits 
a similar rate constant to FGFR3-2C. These data are therefore consistent with the results 
from phosphorylation experiments in sections 3.3.4 and 3.3.5 implicating mutations 
N540K, K650E and R669G as the most activating mutations while hotspot G697C still 
does not appear to be activating. 
 
Next, the same subset of activating mutations (as well as moderately activating I538V 
and V555M and non-activating hotspot G697C) was tested to asses for any differences 
in the ability of mutant KDs to bind to ATP. The eleven mutant KDs were assayed in ATP 
dose response experiments and compared to FGFR3-2C. Kinase concentrations were 







assays performed in section 3.3.5 to ensure they fell within the mutant-specific linear 
concentration range (see section 2.9 for full experimental details). Data were then fitted 
with the Michaelis-Menten equation and dose response curves are shown in Figure 
3.14c, presented in two groups for visual clarity (left and right panels). From these 
curves, the affinity constants for ATP binding (KM(ATP)), turnover rates and catalytic 
efficiencies were calculated for each variant and these are presented in Table 3.4 and 
Figure 3.14d-e. These data suggest that mutations impact the FGFR3 KD’s affinity for 
ATP and turnover to differing degrees. The two mutations that caused the largest 
increases in ATP binding affinity were N540K and V555M, a ‘molecular brake’ and 
gatekeeper mutation respectively. These mutations occur in the kinase hinge region, 
where  both  residues  normally  contribute  to  the  ATP  binding  pocket  (Figure  3.5b). 
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Figure 3.13 Possible mechanisms of partial ligand independent activation employed by 
activating mutations. (a) Activating mutations from the kinase activity assays in this work 
mapped on a cartoon representation of the only available FGFR3 KD crystal structure (FGFR3-
K650E) [PDB: 4K33] (Huang et al., 2013b) (coloured grey). Residues at which mutations were 
not found to be activating are shown as blue sticks in both panels, rotated relative to each other 
by 180° around the vertical axis as indicated. Positions at which highly activating mutations occur 
are highlighted in red and labelled (left panel) and remaining positions at which mutations were 
moderately activating are highlighted in orange and labelled (right panel). (b) Close-up view of 
the kinase hinge region of the same FGFR3 structure as in a but in a different orientation, showing 
the six residues of the extended ‘molecular brake’ (shown as sticks and coloured cyan and by 
atomic element with nitrogen atoms in navy blue and oxygen in red), including N540 and I538. 
Activating mutations at these positions directly disengage the ‘molecular brake’ by disrupting 
hydrogen bonds (shown as dashed lines and coloured black). (c) Cartoon representation of the 
crystal structure of active FGFR1-R675G (corresponding to FGFR3-R669G) [PDB: 5FLF] (Patani 
et al., 2016) (coloured pink), showing the αC-helix (yellow) and the A-loop (red) in the active 
conformation. Regulatory and catalytic R- and C- spines are also ordered in this structure (spine 
residues shown as sticks against a surface and coloured navy blue and bright pink for R- and C-
spines respectively). (d) Overlay of the FGFR1-R675G structure in c with inactive (apo) FGFR1 
[PDB: 4UWY] (Patani et al., 2016) and active phosphorylated FGFR1 (3p) [PDB: 3GQI] (Bae et 
al., 2009) coloured pale green and pale orange respectively. The difference in positioning of the 
αC-helix between the apo structure and the 3p and R675G structures is indicated. (e) Close-up 
view of the large inset in d showing the position of the A-loop in the same three structures as in 
d, namely apo (green), 3p (orange) and R675G (bright pink). Key residues are shown as sticks, 
demonstrating that the positions of residues in the R675G structure match more closely to the 
same residues in the 3p than the apo structure. (f) Close-up view of the region corresponding to 
the small inset in d (but in a different orientation) showing the ‘molecular brake’ triad of residues 
in the same three structures as in d and in the same colours. The positions of the three residues 
in the R675G structure are at positions intermediate between the same residues in the apo and 
3p structures, showing a partial disengagement of the ‘molecular brake’. 
 
 
Therefore, it is hypothesised that specific mutations at these positions could alter the 
stereochemistry within this pocket either in favour of ATP binding, or perhaps even in 
favour of ADP release. This might also explain why N540S, a replacement at the same 
position as N540K, differently impacts ATP binding to a lesser extent than N540K. 
Interestingly, the corresponding mutation in FGFR2 (N549K) has also been shown to 
cause a reduction in the binding affinity for ATP-competitive inhibitors (Byron et al., 
2013), while gatekeeper mutations FGFR3-V555M and the corresponding mutation 
FGFR1-V561M also affect the binding of ATP-competitive inhibitors to differing degrees 
(Bunney et al., 2015), in both cases leading to intrinsic resistance to these ligands. These 
effects, as well as the increased and mutation specific ATP binding affinities observed in 
this work, are likely a consequence of the same phenomenon whereby replacement of 
the sidechain of these key residues in the ATP binding pocket improves ATP binding 
while concurrently diminishing the binding of ATP-competitive inhibitors in this site due 
to mutation-induced stereochemical effects. The N540K mutation is additionally unique 
in that, while most mutations only modestly affect the overall catalytic efficiency of the 
FGFR3  KD,  N540K  has  a  large  impact  by  greatly  increasing  catalytic  efficiency 
compared to FGFR3-2C (Figure 3.14e). This is likely the result of the combination of its 







which could improve phosphoryl transfer through improved ATP binding in the active 
site. It is unclear from these experiments how this mutation might affect release of ADP 
from the ATP binding site following phosphoryl transfer, a catalytic step thought to be 
rate limiting for kinase trans-autophosphorylation (Adams, 2001). Further experiments to 
assess mutation specific ADP binding will be required to fully understand this process 
for the FGFR KD. Nonetheless, the mechanism of activation by N540K appears to be 




Figure 3.14 Determination of rates of phosphorylation, affinity constants for ATP and 
catalytic efficiencies of activating mutations. (a) Time course experiments performed using 
0.5 μM FGFR3-2C, 28.6 µM polyE4Y1, 500 μM ATP and time points between 0-60 minutes. Each 
data point was measured in triplicate and error bars represent the resulting standard deviation at 
each time point. Data are representative of four independent experiments performed using 
FGFR3-2C, and of two independent experiments performed for some of the variants. Data for 
G697C is coloured pale orange, and colouring for other variants is the same as in Figures 3.10 
and 3.11. Data were fitted to a one phase exponential model for pseudo-first order association 
kinetics (equation 3) and used to calculate the phosphorylation rate constants (K) for the reactions 
that are displayed as a histogram in b. AU – arbitrary units. (b) Rate constants calculated from 
reactions in a. Error bars represent standard errors calculated from the non-linear fits in a. 
Calculated values for rate constants and other parameters from the fits in a are also presented in 
Table 3.3. (c) ATP titration experiments performed using variable concentrations of FGFR3-2C 
(calculated from the data in Figure 3.11a-b, see section 2.9 for full experimental details), 42.9 µM 
polyE4Y1, 0-750 µM ATP and 10 minute reactions for variants at 2C and positions N540, K650E 
and R669G (left panel) and variants at 2C and positions I538, V555, D641, Y647 and G697 (right 
panel). Colouring for each variant is the same as in a. Each data point was measured in triplicate 
and error bars represent the resulting standard deviation for each concentration of ATP. Data 
were fitted to the Michaelis-Menten equation (equation 4) and this was used to calculate affinity 
constants for ATP (KM(ATP)) and catalytic efficiencies (kcat/KM(ATP)) for the reactions that are 
displayed as scatter plots in d and e. Scatter plots of (d) KM(ATP) and (e) kcat/KM(ATP) calculated from 
reactions in c. Error bars represent standard errors calculated using fitted data in c. Calculated 
values for affinity constants, catalytic efficiency and other parameters from the fits in c are also 








Table 3.3 Maximum response [AU, arbitrary units], initial reaction rate (calculated at 
3 minutes), rate constant (K), time constant (1/K) and ‘half-time’ T1/2 (ln2/K) of variant 
FGFR3 KDs (± standard error where applicable) measured using in vitro kinase activity 















2C 13.18 ± 1.14 0.377 ± 0.013 0.0189 ± 0.0028 53.0 36.7 
N540K 17.27 ± 0.63 1.565 ± 0.129 0.0616 ± 0.0069 16.2 11.3 
N540S 16.55 ± 0.56 1.191 ± 0.161 0.0520 ± 0.0053 19.3 13.3 
D641G 17.89 ± 0.39 0.868 ± 0.015 0.0383 ± 0.0022 26.1 18.1 
D641N 10.98 ± 0.45 0.558 ± 0.034 0.0299 ± 0.0028 33.4 23.2 
K650E 19.75 ± 0.90 2.071 ± 0.078 0.0503 ± 0.0068 19.9 13.8 
K650N 16.83 ± 1.18 1.040 ± 0.078 0.0305 ± 0.0047 32.8 22.7 
R669G 30.11 ± 1.03 0.954 ± 0.071 0.0238 ± 0.0016 42.1 29.2 
R669Q 32.59 ± 7.08 0.022 ± 0.016 0.0083 ± 0.0023 120.6 83.6 





Table 3.4 ATP affinity constants (KM(ATP)), turnover rates (kcat) and catalytic efficiencies 
(kcat/KM) of variant FGFR3 KDs (± standard error where applicable) measured using in 
vitro kinase activity assays, to complement data in Figure 3.14c-e, and calculated using 
equation 4. Concentrations of FGFR3 variants to be used in these assays (column 2) 
were calculated from each saturation binding curve using data in Figure 3.11a-b and 
equation 2. For full experimental details see section 2.9. It should be noted that the KD 
concentrations in column 2 have uniquely been assigned a theoretical error, as it is not 
















2C 600 ± 60.0 187.1 ± 10.7 26.4 ± 0.5 0.141 ± 0.002 
I538V 343 ± 34.3 148 ± 13.2 49.7 ± 1.5 0.335 ± 0.008 
N540K 60 ± 6.0 58.8 ± 3.4 124.1 ± 1.9 2.109 ± 0.039 
N540S 238 ± 23.8 153.2 ± 11.3 71.7 ± 1.9 0.468 ± 0.003 
V555M 377 ± 37.7 86.9 ± 6.7 22.5 ± 0.5 0.259 ± 0.002 
D641G 177 ± 17.7 126.4 ± 8.1 72.7 ± 1.5 0.575 ± 0.005 
D641N 186 ± 18.6 165.7 ± 14.0 60.8 ± 1.8 0.367 ± 0.007 
Y647C 575 ± 57.5 113.7 ± 7.5 19.3 ± 0.4 0.170 ± 0.001 
K650E 183 ± 18.3 115.5 ± 7.2 59.3 ± 1.1 0.514 ± 0.006 
K650N 345 ± 34.5 219.3 ± 12.8 63.8 ± 1.5 0.291 ± 0.003 
R669G 238 ± 23.8 132.8 ± 7.1 39.2 ± 0.7 0.295 ± 0.006 
R669Q 430 ± 43.0 177.8 ± 10.2 32.3 ± 0.7 0.182 ± 0.003 







3.3.8 Kinase activation is not linked to mutation-induced KD instability 
It was hypothesised that variants might impart differing degrees of local and/or global 
structural modifications to the FGFR3 KD which might in turn result in increased 
conformational plasticity of the inactive KDs. This might ‘prime’ individual variants for 
kinase activation to differing extents by shifting the conformational equilibrium from 
inactive to more active states. Therefore, to determine experimentally whether there 
might be a link between thermal stability and activation status of the KD variants, thermal 
melting experiments were performed on the panel of purified variant FGFR3 KD proteins 
using a thermal shift assay with fluorimetric readout. Protein samples in triplicate were 
mixed with a fluorescent hydrophobic dye (SYPRO® Orange) and subjected to a 
temperature gradient from 10-95°C increasing at 0.5°C intervals. Curve fitting was 
performed with an appropriate custom equation (for full experimental details see section 
2.20.1)) and the melting temperatures were extracted from the resulting melting curves 
(Figure 3.15a-b). All curves showed a clear melting transition allowing determination of 
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the melting temperatures calculated at the point of inflection. The melting temperature 
for FGFR3-2C (curve highlighted in green) was determined to be 43.8°C. Most FGFR3 
variants appeared to have similar melting temperatures to FGFR3-2C of 40°C or higher. 
No mutations appeared to cause a large increase in stability. The highly activating 
mutations K650E (located in the A-loop) and R669G and moderately activating R669Q 
(latter two located in the αEF-β12 loop) had the largest standard errors in their calculated 
melting temperatures, suggesting an intrinsic conformational heterogeneity in these 
activating mutant KDs that presents as a wider ‘range’ of melting temperatures. 
 
Variants causing the most striking reductions in melting temperatures of the FGFR3 KD 
to below 37°C (marked by the dashed line on Figure 3.15b) were E466K, I538F and 
N540K with measured melting temperatures of 34.4°C, 32.9°C and 34.9°C. A different 
replacement to V at position I538 also caused a moderate reduction in the melting 
temperature to 39.1°C, however the replacement to S at position N540 does not appear 
to alter melting temperature. Residue E466 is located in the juxtamembrane region while 
I538 and N540 are located in the αC-β4 loop; all in the N-lobe of the split KD (Figure 
3.15c). N540K, I538F and I538V are respectively part of or adjacent to the ‘molecular 
brake’ triad of residues that stabilise the inactive KD in an autoinhibitory state through a 
hydrogen bonding network. The replacement to K at position N540 directly disrupts these 
hydrogen bonds, releasing autoinhibition and destabilising the inactive state as shown 
for corresponding mutations in FGFR2 (Chen et al., 2007b). Mutations at residue I538 
adjacent to the ‘molecular brake’ and part of the ‘DFG-latch’ contribute to destabilisation 
by similar disruptions of ‘molecular brake’ hydrogen bonds, including possible steric 
effects that appear to increase in impact with the size of the replacement side chain such 
as for I538F, possibly affecting the local structure of the ‘DFG-latch’. It is not clear how 
mutation at residue E466 might exert its destabilising effect. It is thought that the FGFR 
juxtamembrane region might mediate dimerisation through a mechanism similar to 
EGFR (see section 1.5.3) by juxtapositioning the KDs to form trans-phosphorylation 
competent asymmetric dimers (Chen et al., 2008, Peng et al., 2009, Bae et al., 2010, 
Bocharov et al., 2013). It is not known whether E466 is involved in FGFR dimerisation, 
but this residue is conserved across all four FGFRs and introduction of a similar mutation 
to the corresponding residue in FGFR1 has also been shown to reduce the thermal 
stability of the FGFR1 KD (unpublished data). In addition, mixing the variant FGFR3 KDs 
with FGFR inhibitors dramatically increases the melting temperature (and therefore 
stability) of all three destabilising variants (unpublished data). The molecular 









Figure 3.15 Thermofluor assay measuring thermal stability of FGFR3 KDs. (a) Thermal shift 
experiments performed using 1 mg/mL FGFR3 variants mixed 1:500 with Sypro® Orange 
fluorescent dye (Thermo Fisher Scientific). A temperature gradient was employed between 
10-95°C increasing at 0.5°C intervals (10 seconds each) for each variant in triplicate reactions. 
Data were analysed using a custom Boltzmann sigmoid equation with linear baselines. Three 
mutations whose melting curves deviated most strongly from 2C are highlighted in different 
colours and labelled (E466K, I538F and N540K). The melting curve for activating mutation K650E 
is also highlighted for comparison. Highlighted curves are coloured as I538F (light red), E466K 
(maroon) and other variants as in Figures 3.10, 3.11 and 3.14. All error bars are omitted for clarity. 
(b) Melting temperatures for FGFR3 KD variants calculated from data fitted in a. Error bars 
represent standard error calculated using fitted data in a. The dashed line at 37°C marks the 
mean human physiological temperature. (c) Positions of all mutations assayed (shown as sticks 
and coloured blue) marked on a cartoon representation of the only available FGFR3 KD crystal 
structure (FGFR3-K650E) [PDB: 4K33] (Huang et al., 2013b) (coloured grey). The positions at 
which the three most destabilising mutations from a and b occur are mapped on this structure 
and highlighted, as is the activating mutation K650E for comparison (shown as sticks against a 






Overall, of these destabilising variants, N540K was the only highly activating mutation, 
I538F and I538V were moderately activating and E466K was not an activating mutation 
in the in vitro kinase activity assays. Therefore there appears to be no link between the 
extent of kinase destabilisation by FGFR3 mutations and activation status. However, 
destabilisation of the inactive KD might play a mechanistic role in activation of some 
mutants such as N540K and mutations at position I538, both of which contribute to the 
‘molecular brake’ network of autoinhibitory hydrogen bonds. 
 
3.3.9 Do activating mutations affect cellular transformation and signalling? 
The kinase activity assays provided a ranked list of variants that could act as potential 
oncogenic drivers. However, it is possible that some mutations do not directly impact 
activity of the KD under the conditions of the in vitro assay design. For example, one 
mutation which has previously been suggested to be highly activating in a cellular setting 
and in the context of the full length receptor is the hotspot mutation G697C (Zhang et al., 
2005) which showed no gain-of-function in any kinase assays using purified and soluble 
KDs in this work. Conversely, it could be that many more mutations were activating in 
the kinase activity assays due to the increased degrees of freedom available to KDs in 
solution to trans-autophosphorylate when not restricted in space by the transmembrane 
and juxtamembrane domains as they would be in cells in the context of full length 
receptors. Therefore, the panel of FGFR KD mutations was next analysed in 
complementary experiments in the context of full length FGFR3 in a cellular setting to 
determine whether the patterns of kinase activation observed in vitro could also be 
detected in cells. 
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3.3.10 Generation of a panel of FGFR3 variant stable cell lines 
A retroviral vector comprising full length FGFR3-WT was generously provided by the 
Knowles group (Tomlinson et al., 2005). The alternatively spliced FGFR3 b splice isoform 
was selected for these experiments (rather than the canonical c splice isoform) because 
FGFR3 mutations occur most frequently in urothelial and other epithelial tissues in which 
the FGFR b splice isoform is more commonly expressed (Figure 3.1 and section 1.4). 
However, to minimise discrepancies of residue numbering between isoforms (which 
differ by two amino acids between b and c splice isoforms), residue numbering of 
mutations in this full length FGFR3b construct follow the canonical numbering of the c 
splice isoform (as in this entire work so far). Point mutations were introduced into this 
pFB-FGFR3b backbone using SDM and the constructs were sequenced to confirm 
successful incorporation of mutations (for full methods, see sections 2.1.5 and 2.2.1). 
This plasmid library of FGFR3-WT and mutant receptors was used to generate stable 
cell lines in NIH 3T3 cells (for full experimental details, see section 2.11). Two 
independent cell lines were made for each FGFR3 variant and WT. Clonal cell lines were 
not made as it was thought this might not accurately represent the genetic heterogeneity 
seen in tumours, for example in urothelial carcinoma (Tomlinson et al., 2007a). 
Additionally, variants I538F, I538V and G637W were not included in cellular analyses 
because these mutations were selected for inclusion in the panel of mutations at a later 
date than when these experiments were performed. 
 
 
3.3.11 Morphological assessment of transformation by FGFR3 variants 
NIH 3T3 cell lines stably expressing each of the panel of FGFR3 constructs were first 
screened for morphological signs of cellular transformation (Figure 3.16). Stable cell lines 
were seeded at low density and imaged at subconfluence after approximately 48 hours. 
An NIH 3T3 cell line stably expressing the known oncogene Ras V12, also known to 
transform NIH 3T3 cells, was generously provided by the Knowles group and used as a 
positive control for transformation. Transformed fibroblasts display a characteristic loss 
of contact-inhibition, their cell morphology becomes more ‘spindle-like’ and the cell edges 
appear ‘raised’ and therefore shiny under the phase contrast microscope compared to 
control fibroblasts which appear ‘flat’ and have a dull appearance (Figure 3.16a). Under 
the conditions of this screen, the only mutations clearly exhibiting these markers of 
transformation were N540K and K650E. In particular, cells containing FGFR3-G697C 
did not appear morphologically transformed in this cell line, and neither did any cell line 
containing moderately activating mutations from the in vitro kinase activity assays. 
Surprisingly, the cell line containing FGFR3-R669G, the mutation which was most 
activating in the kinase activity assays, did not appear to transform NIH 3T3 cells. 
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Interestingly however, all three of these most activating mutations from the kinase activity 
assay displayed increased FGFR3 expression, as did G697C (Figure 3.16b). From this 
initial experiment it was not known whether this was due to heterogeneity of the stable 
cell lines due to different efficiencies of gene integration into the genome during 
generation of the stable cell lines, or whether it might be the result of a feed-forward 
mechanism in response to mutation-induced signal transduction. 
 
In order to eliminate the possibility that the transforming effects of activating mutations 
were due to increased receptor expression, a second FGFR3-WT stable cell line (a gift 
from Sarah Williams) displaying elevated FGFR3 expression similar to the N540K and 
K650E cell lines (Figure 3.17a, left panel) was compared with these two mutant cell lines. 
Increased WT receptor expression in these cells did not morphologically transform them; 
the cells appeared morphologically similar to the WT cell line with lower receptor 
expression (Figure 3.17a, middle panel, and 3.17b). Additionally, two independent 
K650E stable cell lines (the second also a gift from Sarah Williams) with different receptor 
expression levels (Figure 3.17a, right panel) both transformed NIH 3T3 cells (Figure 
3.17b), suggesting that transformation is not a result of increased receptor expression. 
In any case, this type of morphology screen is subjective and qualitative, so further 
quantitative experiments were designed to elucidate whether the elevated receptor 
expression levels were mutation-induced or a transfection artefact, and to further 
characterise the mutations in cells with respect to their effects on cellular transformation 












Figure 3.16 Assessment of mutation-induced morphological transformation of NIH 3T3 
cells. (a) Images of stable NIH 3T3 cell lines generated with full length FGFR3b-WT or variants. 
Mutations that were highly (red) or moderately (orange) activating, and the non-activating hotspot 
mutation G697C (blue) in the in vitro kinase activity assays are highlighted. A stable cell line 
expressing the transforming Ras V12 oncoprotein (a gift from the Knowles group, University of 
Leeds) is also shown (positive control, [+]). A stable cell line generated using the empty vector 
backbone used for generation of all FGFR3 constructs is also shown (negative control, [-]). Stable 
cell lines were seeded at low density and imaged at subconfluence approximately 48 hours later. 
The scale bar represents 100 μM. (b) Relative expression of FGFR3 variants in each cell line in 
a, shown using immunoblots performed with the indicated antibodies. The gaps between panels 
represent the same blot with all panels imaged together, but with samples run on different SDS-
PAGE gels or excluding intervening lanes with mutants no longer included in this work. For full 









Figure 3.17 Transformation of NIH 3T3 cell lines occurs independently of the level of 
FGFR3 expression. (a) Expression of FGFR3 variants in indicated stable cell lines, shown using 
immunoblots performed with the indicated antibodies. Immunoblots in the left, middle and right 
panels are from independent experiments. Stable cell lines WT (2) and K650E (2) were a gift from 
Sarah Williams. (b) Images of stable NIH 3T3 cell lines used for immunoblots in a. Stable cell 
lines were seeded at low density and imaged at subconfluence approximately 48 hours later. The 









3.3.12 Effects of mutations on anchorage independent growth and cell signalling 
A subset of FGFR3 variants was selected for analysis in cellular assays using the stable 
NIH 3T3 cell lines. The three most highly activating mutations from the kinase activity 
assays (N540K, K650E and R669G) were selected alongside the hotspot G697C mutant 
that appeared to be non-activating in the in vitro assays. These four mutant cell lines 
were assayed in parallel and compared with FGFR3-WT. Three types of experiments 
were performed: anchorage independent growth in soft agar, immunoprecipitation (IP) 
of FGFR3 with subsequent immunoblotting and immunoblot experiments performed 
directly on cell lysates. For experiments requiring cell lysates, cells were grown to 
subconfluence and then were either starved overnight in serum-free medium or 
harvested directly without starvation, and cell lysis was performed in situ. Lysates were 
then either used immediately for further experiments (following a total protein 
quantification step) or frozen until next use. Detailed methods can be found in sections 
2.4, 2.5, 2.10, 2.13, 2.14 and 2.15. 
 
The first experiment tested the ability of mutations to induce anchorage independent 
growth of the NIH 3T3 stable cell lines in soft agar to assess whether the mutations were 
transforming. Each stable cell line was seeded in triplicate in freshly prepared soft agar, 
cells were fed weekly and colonies were counted and imaged after two weeks (for full 
experimental details see section 2.13). Cells used for these experiments were also 
imaged for their morphological transformation status during anchorage dependent 
growth (Figure 3.18a). The soft agar assay showed that highly activating and 
morphologically transforming mutations N540K and K650E were also capable of 
inducing anchorage independent growth (Figure 3.18b-c). This has been previously 
shown for the positive control K650E (Chesi et al., 2001, Ronchetti et al., 2001, Agazie 
et al., 2003, di Martino et al., 2009) but was shown for the first time for N540K or any 
mutation at this position in FGFR1-4, although it has recently been shown for the 
corresponding mutation N549K in FGFR2 (Kwak et al., 2015). However, the highly 
activating mutation R669G and the hotspot mutation G697C appeared to be incapable 
of inducing anchorage independent growth in soft agar (Figure 3.18b-c), in agreement 












Figure 3.18 Anchorage independent growth assay. (a) Images of a subset of the same stable 
NIH 3T3 cell lines as in Figure 3.16 prior to their use in anchorage independent growth 
experiments. Stable cell lines were seeded at low density and imaged at subconfluence after 
approximately 48 hours. The scale bar represents 200 μm. These cells were then seeded at 
5 x 103 cells per well of a 6-well plate in medium containing 0.4% w/v agarose on a base of 
medium containing 0.8% w/v agarose. Cells were fed weekly with medium containing 0.4% w/v 
agarose. After two weeks, cells were stained for 24 hours with 0.3% w/v p-iodonitrotetrazolium 
violet and imaged. (b) Representative views of binary masks applied to images of colonies 
growing in the soft agar (black against a white background) during automated colony counting, 
applied using ImageJ. (c) Number of colonies counted for each FGFR3 variant from triplicate 
wells in the soft agar assay. Colonies were counted electronically using ImageJ and were then 
manually checked. Error bars represent the standard deviation for each FGFR3 variant. Colonies 
counted for Ras V12 (positive control) are not shown on this bar chart but can be seen in b. For 










Next, IP and immunoblotting experiments were performed to determine whether these 
mutations elevated the level of FGFR3 phosphorylation in the context of the full length 
receptors, as well as hyperactivation of downstream signalling pathways (for full 
experimental details see section 2.10, 2.14 and 2.15). It was found to be challenging to 
extract similar quantities of FGFR3-WT and each variant by IP, partly due to the variable 
expression levels observed in each cell line. This particularly affected the experiments 
including R669G, as this mutant protein could only be extracted in very small quantities 
(Figure 3.19a). Therefore, following IP of FGFR3-WT and variants from all lysates, 
R669G was compared with FGFR3-WT in separate immunoblots to the other three 
variants using a comparable quantity of IP-extracted FGFR3-WT (Figure 3.19b). These 
experiments showed that all three activating mutations (N540K, K650E and R669G), but 
not G697C, displayed elevated receptor autophosphorylation compared to WT in cells in 
the absence of ligand stimulation, in agreement with the in vitro kinase activity data. 
 
Assessment of the impact of these mutations on downstream signalling using non-IP 
extracted lysates (see sections 2.10 and 2.14 for detailed methods) once again showed 
that all three activating mutations, but not G697C, activated downstream signalling 
pathways compared to FGFR3-WT as evidenced by stronger phosphorylation of ERK 
(pERK) and AKT (pAKT) compared to WT (Figure 3.19c-d). This outcome was observed 
for R669G despite its relatively low expression level compared to N540K and K650E. 
Interestingly, the two different K650E cell lines (with varied expression levels, see Figure 
3.17a, right panel) appeared to differently activate either ERK signalling or AKT 
signalling, but did not fully activate both at the same time. Additionally, in the K650E cell 
line in which pERK was downregulated, the expression of PLCγ1 was also reduced 
compared to all other cell lines. This suggests that K650E might be capable of switching 
between different downstream signalling pathways, possibly to diversify and fine-tune its 
range of signalling outcomes in a context dependent manner. It remains to be tested 
whether this kind of pathway switching might also apply to other activating mutations, as 
in this experiment both N540K and R669G only weakly activated pAKT alongside 
stronger activation of pERK (Figure 3.19c-d). Whether these signalling outcomes depend 











Figure 3.19 Effect of mutations on downstream signalling. (a) Immunoprecipitation (IP) of 
FGFR3 variant proteins from NIH 3T3 stable cell lines. Immunoblots were performed using the 
indicated antibody on lysates prepared from the same stable NIH 3T3 cell lines as in Figure 3.16 
showing the levels of FGFR3 expression (Pre-IP, upper panel) and showing the differences in the 
quantities of immunoprecipitated FGFR3 variants following equal volume IPs of FGFR3 proteins 
from the indicated variant cell lines (IP, lower panel). (b) Immunoblots performed using the 
indicated antibodies on immunoprecipitated FGFR3 variants showing differences in the levels of 
phosphorylated FGFR3 variants for equal quantities of FGFR3. IP and immunoblotting for this 
Figure was performed by the Research and Clinical Pathology Support Unit at the UCL Cancer 
Institute (c) Analysis of ligand-independent downstream signalling pathway activation by indicated 
FGFR3 variants. Stable cell lines (from Figure 3.16) were seeded at low density and at 
subconfluence (approximately 48 hours later) they were starved overnight in serum-free medium 
prior to harvesting the cell lysates. Immunoblots were performed on the lysates using the indicated 
antibodies. Immunoblots shown are representative of two independent experiments. (d) 
Densitometric analyses of data from c, plotted on a bar chart as fold difference compared to WT 
(normalised WT=1). Error bars represent resulting standard deviation of the data from the two 
independent experiments. For full experimental details see sections 2.14 and 2.15. 
 
 
To begin to gain further insights into possible mechanisms of activation via alteration of 
downstream signalling by these mutant FGFR3 receptors, an intracellular signalling 
antibody array experiment was performed using the same subset of FGFR3 variants. 
Cell lysates were added to the wells of an antibody array chip and chemiluminescent 
signals from each antibody ‘spot’ in the array (two per phospho-protein) were captured 
(for full experimental details see section 2.16). Raw data from the arrays is shown in 
Figure 3.20a, and the results of densitometric analyses performed on these data are 
displayed in Figure 3.20b. Since only a single experiment was performed, these are only 
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preliminary data; however, several interesting observations can be made from this 
preliminary dataset. The first is that all three activating mutations appear to activate the 
Ras-RAF-MEK-MAPK and the PI3K-PDK-AKT pathways in this assay, evidenced by 
elevated pERK and pAKT (similar to immunoblot experiments in Figure 3.19c-d) and 
phosphorylated proline-rich AKT substrate of 40 kDa (PRAS40) compared to WT, 
although G697C also appears to activate ERK and AKT in this array. Phosphorylation of 
BCL2-associated agonist of cell death (BAD) by N540K, K650E and G697C is also 
observed, suggesting anti-apoptotic signalling in these mutant cell lines. These 
combined data suggest that mutations increase pro-survival signalling in these cells 
compared to WT. In contrast, STAT3 does not appear to be activated here, despite this 
being previously suggested for K650E in the context of dysplasias (Hart et al., 2000). 
Phosphorylation of AMPKα, the key sensor of cellular energy status (Garcia and Shaw, 
2017) also appears unaffected, suggesting mutations do not appear to greatly impact 
cellular metabolism and/or energy homeostasis. Intriguingly, a strong reduction in active 
p38 is seen for N540K compared to WT, but it is unclear whether this might reflect a 
cause or a consequence of the mutation, and is further complicated by the fact that p38 
can have context-dependent oncogenic or tumour-suppressive roles (Zou and Blank, 
2017). Finally, all four mutations display phosphorylation and therefore inactivation of 
glycogen-synthase kinase-3 beta (GSK-3β), suggesting crosstalk with the Wnt and 
insulin signalling pathways. In fact, several of these potentially activated pathways exhibit 
substantial crosstalk within cells, and rigorous experimental testing is needed to 
elucidate the wider impacts of these mutations and their mechanisms of activation with 
regard to intracellular signalling, pathway co-activation and cellular homeostasis. 
 
It is not known why R669G is not transforming in a cellular context, despite it being clearly 
activating in terms of KD phosphorylation, phosphorylation of the full length receptor and 
even phosphorylation of downstream effectors. Replacement at this position to glycine 
has not been observed in FGFR3 in cancer per se but has been observed in FGFR2 
(Table 3.1) in which it has also been shown to activate the isolated KD in vitro (Chen et 
al., 2007b) similarly to the in vitro assays in this work. FGFR2-R678G was originally 
identified in a lung adenocarcinoma sample by the TCGA project, while a different 
mutation at the same position in FGFR2 (R678S) was identified in an endometrial 
carcinoma sample (Powell et al., 2014). In FGFR3 this position was instead found 
mutated to glutamine (Table 3.1), also by the TCGA project, and this has been similarly 
observed in FGFR1 (Seshagiri et al., 2012); both occurrences to glutamine were 
observed in colon adenocarcinomas. All these cancers are of epithelial origin, and so it 
could be that receptor activation and cellular transformation by mutations at this position 
only become apparent in a strictly cellular context dependent manner, and possibly in an 
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FGFR isoform specific fashion, which might not be detectable by the assays performed 





Figure 3.20 Intracellular signalling antibody array. (a) Images showing raw data from 
intracellular antibody arrays performed using cell lysates from the indicated FGFR3 variant stable 
cell lines as in Figure 3.16. Arrays were performed for each variant in parallel, in different array 
‘wells’ on the same array chip. Two antibody ‘spots’ (duplicates) were present in each array ‘well’ 
for each signalling protein. Three positive control ‘spots’ (top left, top right and bottom right corners 
of each array ‘well’) and three negative control ‘spots’ (bottom left corner and the two spots directly 
above it in each array ‘well’) served as 100% and 0% signal control ‘spots’ respectively for each 
array ‘well’, against which all signalling data within a well were normalised. (b) Densitometric 
analyses of data from a, plotted on a bar chart for phosphorylated intracellular signalling proteins. 
Data are shown for proline-rich AKT substrate of 40 kDa (PRAS40), AMP-activated protein kinase 
alpha (AMPKα), signal transducer and activator of transcription 3 (STAT3), glycogen synthase 
kinase 3 beta (GSK-3β), mitogen-activated kinases 1 and 2 (ERK1/2), BCL-2-associated agonist 
of cell death (BAD), p38 mitogen-activated protein kinase (p38) and protein kinase B (AKT). Data 
from each array ‘well’ for different FGFR3 variants were normalised according to the triplicate 
positive and negative control ‘spots’ within each array ‘well’ as described in a. Error bars represent 
standard deviations of the data from the duplicate ‘spots’ of each signalling protein in each array 




In contrast the FGFR3-G697C was not found more phosphorylated in cells compared to 
WT, similarly to the in vitro kinase assays. It did not enhance signalling via pERK and 
was incapable of anchorage independent growth. The combination of these results 
suggests this FGFR3 hotspot mutation does not appear to be relevant as an oncogenic 
driver, at least from the experimental conditions tested. Crucially, all the observations of 
this cancer mutation were detected in a single study, possibly from a single genetic 
population, in the FGFR3b locus in oral squamous cell carcinomas (OSCC) (Zhang et 
al., 2005). This could have resulted in a biased ‘spike’ appearing in the genetic data, 
creating a potentially misleading mutation hotspot in the COSMIC database (Figures 3.2 
and 3.6a). A second possibility is that activation by this mutation could be tissue specific 
or context dependent; this work has not tested the effects of this mutation in epithelial 
cells similar to the ones in which the G697C mutations were found. However, another 
study that analysed a similar number of OSCC tumours from a different population did 
not detect any G697C mutations in FGFR3 (Aubertin et al., 2007). This supports the first 
interpretation of the data suggesting that population bias has created this mutation hotpot 
in FGFR3, reinforcing the importance of experimental testing during functional 
assessment of genetic data. 
 
In summary, further experimental testing of the effects of these mutations (including in 
more relevant cancer-associated cell lines where available) is needed to understand the 
roles of these mutations in an oncogenic context. Such work can be guided by the 
experimental results shown here which suggest that mutations might impact several 
aspects of downstream signalling compared to WT, in addition to the direct and diverse 







In this chapter a comprehensive panel of cancer-associated mutations in the FGFR KD 
was screened in vitro in search of potential oncogenic drivers. A subset of mutations 
identified as genetic mutation hotspots and/or potential activating mutations from in vitro 
activity assays was further analysed in a cellular setting to assess the mutation-induced 
impacts on cellular transformation and signalling. The importance of two known driver 
mutations in FGFRs (N540K and K650E in FGFR3) has been reinforced, with N540K 
(and N540S) being analysed for the first time in FGFR3 and in the context of cancer. 
This work therefore consolidates previous work that analysed the activation status of 
similar mutations at these positions in FGFRs, specifically N549T/H in FGFR2 (Chen et 
al., 2007b) and K659E/M/N/Q/T and K650E/M/N/Q/T in FGFR2 and FGFR3 (Chen et al., 
2013b, Huang et al., 2013b). This work therefore contributes to the growing recognition 
of highly activating mutations at these two positions as important oncogenic drivers, and 
suggests that while several aspects of the mechanisms of activation at each position are 
similar, other aspects differ (both in terms of direct KD activation as well as cellular 
effects). It was shown that the mechanism of direct KD activation by N540K in particular 
acts by increasing ATP binding affinity, increasing catalytic rate and reducing stability of 
the KD compared to WT. These effects might coincide to increase conformational 
flexibility of the KD, permitting a dynamic shift in the conformational population to more 
activated states. This can occur in a graded manner depending on the replacement as 
suggested for different K659 mutations in FGFR2 (Chen et al., 2013b). Graded activation 
of FGFRs by different replacements at the same residue has been shown even by early 
studies using FGFR3-K650 mutations in the context of dysplasia (Naski et al., 1996, 
Webster et al., 1996), suggesting that different replacements even at the same residue 
determine the extent of kinase activation and severity of the pathogenic phenotype. In 
this work, it has been shown that different mutations at the same residue at several 
different positions in the FGFR3 KD (I538, N540, D641, K650 and R669) display similar 
graded activation, with some of these replacements being more activating than others. 
Specifically, mutations I538V, N540K, D641G, K650E and R669G were more activating 
than I538F, N540S, D641N, K650N and R669Q respectively. In a clinical context, such 
subtle differences might propagate to large impacts on the response of patients to 
targeted treatments (discussed below). This work suggests that the mutation status of a 
therapeutic target must be taken into account during patient selection in the clinic, to help 
in identifying patients with highly activating mutations to which tumours are more likely 




It has also been shown that rare, non-hotspot mutations in terms of the genetic data 
(such as FGFR3-R669G) might be activating and contribute to pathogenesis. 
Conversely, it has been shown that all genetic hotspot mutations (such as FGFR3-
G697C) are not necessarily activating and that intrinsic biases in the compilation of 
genetic data by databases such as COSMIC might lead to the misleading generation of 
mutation hotspots. Additionally, due to the combined use of automated literature mining 
and manual curation of mutations, COSMIC curates all types of cancer-associated 
mutations including de novo cancer mutations (the majority) and acquired resistance 
mutations, with no annotations to distinguish between these other than reading the 
referenced literature sources. One example is the FGFR3 gatekeeper mutation V555M, 
a resistance mutation that was found to be activating in this work and in a recent study 
(Bunney et al., 2015) which might be mistaken as a de novo cancer mutation through 
COSMIC. Genetic data curated in the COSMIC database also has several other 
limitations. Firstly, to date, the mutation dataset is still curated from a relatively small 
number of samples, including both benign and malignant tumours, and is too small to be 
used for accurately inferring functional relevance (although it is constantly growing and 
is still an invaluable resource). Therefore, the absolute number of mutations in cancer is 
likely to be largely underestimated in COSMIC. Secondly, there is an intrinsic bias in that 
several studies from which mutation data is curated have only sequenced part of the 
genome, sometimes even only part of a gene, and sometimes without confirming the 
somatic status of the mutation. A variety of different screening methods are used, tailored 
to the type of mutation being searched for, for example insertions or deletions (such 
methods may miss the identification of missense substitutions, for example). Often these 
sequencing studies are only performed on regions of genes (particular exons) that are 
already known to harbour pathogenic mutations from previous work, from either cancers 
or congenital diseases, or both. In FGFR3, this has led to an explosion in the number of 
genetically identified mutations creating possibly overrepresented hotspots at positions 
such as S249C and K650E due to the relatively early identification of mutations in the 
D2-D3 linker and the A-loop as crucial for pathogenesis in cancer and dysplasia (sections 
3.1.4 and 3.1.5). Conversely, a region such as the αEF-β12 loop in the KD (for example) 
has not been previously associated with cancer, so mutations in this region (for example 
R669G) may be underrepresented in databases such as COSMIC as sequencing studies 
tend to ignore these regions when searching for mutations in new samples. This work 
attempted to compile a comprehensive and representative panel of FGFR mutations 
from all regions of the KD using a semi-biased selection process, incorporating mutations 
irrespective of the number of observations or position in the KD. It was found that both 
hotspot and non-hotspot mutations can be activating and might play roles in oncogenesis 
and importantly, no trend was observed between the number of observations in cancer 
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and activation status. Therefore, this work suggests that functional validation of the 
genetic data in databases like COSMIC must be performed, as both hotspot and non-
hotspot genetically-curated mutations can be important for pathogenesis. An interesting 
observation was that the three most activating mutations in this work (N540K, K650E 
and R669G) are also commonly observed in dysplasias in the syndromes with the worst 
prognoses (Wilkie, 2005). This suggests that mutations that co-occur in both congenital 
diseases and malignancies might aid in the validation of possible cancer-associated 
driver mutations based on their links to the pathogenesis of both types of proliferative 
diseases. The mechanisms of action of such mutations proposed in this work might 
therefore apply to both congenital diseases and cancers. 
 
All pathogenic mutations found in the cytoplasmic region of FGFR in the cancer mutation 
databases (including COSMIC, TCGA and ICGC) were also analysed for their functional 
impacts using a combination of computational algorithms (Patani et al., 2016). This work 
showed that while many predictive algorithms are relatively advanced at identifying 
pathogenic loss-of-function mutations, in silico predictions of activity, stability and 
pathogenicity do not yet accurately represent the experimental reality when it comes to 
gain-of-function mutations in FGFRs, such as those important for the development and 
maintenance of cancers and other congenital disorders. Additionally, the computational 
tools performed better when attempting to link structure and function for FGFR residues 
that have a well-defined function or are found conserved across kinases, but tended to 
inherently overlook infrequently occurring variants or those that are not conserved across 
FGFRs or kinases. Therefore, although in silico predictions of function are an invaluable 
and complementary resource, this work emphasises the importance of experimental 
evaluation in linking genetic data to function. This is also important during selection of 
targets for drug discovery, to ensure critical selection based on pre-clinical data-driven 
predictions of the oncogene addiction status of a kinase or its mutant. In general, the use 
of a combination of complementary techniques to biochemically determine the roles of 
pathogenic mutations in cancer in this work presents a combinatorial platform for similar 
studies in other RTKs and EPKs involved in cancer. The data generated from such 
studies can then be used to better train predictive algorithms to improve the quality of 
future in silico predictions of the effects of mutations on function, particularly gain-of-
function. 
 
Useful functional information can be gained from assessing the direct impacts of 
mutations on the activity of isolated KDs in solution, as shown in this study and by others 
(discussed above). In particular, this work used several variations of in vitro kinase 
activity assays to comprehensively assess the impact of mutations on the activation 
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status and kinetics of catalysis by KDs in solution, something which is much more difficult 
to investigate in the context of the full length receptor in cells. However, such minimalist 
experiments also have some limitations. For example, due to the reductionist nature of 
the in vitro experimental system used in this work, it might not be possible to accurately 
assess the functional impact of mutations that affect kinase activity by mechanisms other 
than direct activation of isolated KDs. For example, mutations such as E466K that lie 
within the intracellular juxtamembrane region (a region implicated as vital for activation 
of full length RTKs such as EGFRs and perhaps FGFRs, see section 1.5.3) which has 
been shown to greatly reduce the thermal stability of the isolated FGFR3 KD (Figure 
3.15), might only exhibit elevated kinase activity in the context of the full length receptor 
comprising an intact, anchored juxtamembrane segment. This mode of kinase activation 
might be missed by the experimental design used in this work. Although efforts were 
made to assess the impact of a subset of mutations in the context of full length FGFR3 
in cells using a simple cellular model (Figures 3.16-3.20) more work needs to be done to 
elucidate their functional roles in cells. In this work, the focus was on assessing the 
mechanistic impacts of highly activating mutations identified from the in vitro activity 
assays. In particular, the effects of mutations in the correct cellular context need to be 
addressed, guided by the cancer cell types in which the mutations were originally 
identified (see Table 3.2 for examples). The addiction status of cancers to these 
mutations also needs to be determined to validate specific variants as individual 
therapeutic targets. Combining in silico molecular dynamics simulations with structural 
studies using full length mutant FGFRs will provide clarification of the modes of FGFR 
activation adopted by different mutations. Newly identified gain-of-function mutations 
from such studies can then be rigorously tested in cells and in vivo, including detailed 
analyses of changes in downstream signalling. Experiments to test these hypotheses 
are currently in progress in the lab for activating mutations and also for the three most 
destabilising mutations identified in this work, namely E466K, I538F and N540K. 
 
The correct cellular context might be vital for some mutations to exert their cell-
transforming effects, as was proposed for the R669G and G697C mutations investigated 
in this work in cells. This work showed that highly activating mutations K650E and N540K 
were activating both in vitro and in cells, and transformed NIH 3T3 cells morphologically 
as well as by promoting anchorage independent growth. However, despite R669G being 
highly activating in in vitro assays and even showing activation in cells, this mutation did 
not morphologically transform NIH 3T3 cells or enable anchorage independent growth. 
Similarly, G697C was not activating in vitro or in cells despite a previous study 
suggesting it is an activating mutation when expressed in an insect cell line (Zhang et 
al., 2005). In addition, Y647C which was reported to act as a mechanism of acquired 
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resistance to EGFR targeting by activating FGFR signalling in a pre-clinical human 
tumour model (Crystal et al., 2014) was not found to be activating in this work and did 
not morphologically transform NIH 3T3 cells. Although very useful for providing a direct 
and comparative readout of cellular transformation between mutants, there are several 
limitations of NIH 3T3 cells used to generate the model stable cell lines in this work. 
Firstly, the cells are of mouse origin and therefore have subtle overall differences 
compared to human cells. Secondly, the cells are not of epithelial origin, as are the 
majority of tumours in which FGFR cancer mutations are detected. Finally, generation of 
stable cell lines and subsequent overexpression of FGFRs might not accurately 
represent the situation in cancer and so may result in slight differences in cell 
morphology, signalling and anchorage independent growth compared with a real 
tumoural context. Therefore, the mutations need to be assessed for their functional 
impact in cell lines of epithelial origin as well, similar to the cancer cells in which the 
mutations were identified. In addition, this could be done using three-dimensional tissue 
culture models in which the tumour microenvironment can be better represented. These 
combinations of experiments will help to ascertain whether the cell transforming and/or 
oncogenic effects of mutations will present in the correct cellular context or tumour 
microenvironment. 
 
Interestingly, it has recently been proposed that FGFR3 mutations such as S249C and 
K650E might only impart highly oncogenic effects in vivo when found in combination with 
other deregulated genes (such as loss of the tumour suppressors p53 or pRB) in specific 
cellular contexts in urothelial cells (Zhou et al., 2016). This can be further complicated 
by the fact that tumours often comprise heterogeneous clonal populations of cells that 
arise from different aberrations and propagate to different tumour grades within the same 
cancer, including urothelial tumours harbouring FGFR3 aberrations (Tomlinson et al., 
2007a). This work has also shown preliminary data suggesting FGFR mutations increase 
crosstalk with different intracellular signalling pathways compared to WT (Figure 3.20). 
It was also noticed that two independent K650E cell lines differently activated 
downstream signalling pathways via either pERK or pAKT (Figure 3.19c-d). Although 
experimental validation of these initial findings is required, these data suggest that 
oncogenic signalling networks induced by FGFR mutations can be multifaceted. They 
might even include co-activation of other RTKs as both de novo mechanisms of 
activation by aberrant FGFRs and/or in response to targeted inhibition of other RTKs or 
FGFRs (as discussed in section 3.1.6). Therefore, the cellular context, including the 
mutation and co-activation status of other genes, might be a crucial determinant for 
FGFR mutations to act as oncogenic drivers in cancer. This remains to be rigorously 
investigated for the majority of FGFR cancer-associated mutations. 
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This work performed the first kinetic analysis of a large panel of FGFR variants including 
calculations of ATP affinity constants and rates of reaction. It was shown that N540K 
directly impacted KD activity by increasing its rate of phosphorylation, at least partly due 
to its increased affinity for ATP (Figure 3.14) and possibly partly due to reduced KD 
stability, as discussed above. However, in many of these assays, the initial ATP 
concentrations used were below the KM(ATP) of the KDs being investigated, and reaction 
time was longer than that required for maintaining linearity. In autophosphorylation and 
some substrate phosphorylation experiments (Figures 3.9b, 3.10a-b, 3.11c and 3.12b-c) 
which were assays to compare variant activity, this helped to maximise the observed 
differences in activity between variants to clearly rank them in order of activation status 
compared to FGFR3-2C. Here, the relatively low 50 µM ATP and longer 45 minute 
reaction time used were of less importance than the fact that these values were identical 
for each variant in the same assay; however they may have contributed to the ‘levelling 
off’ of curves, particularly by more activating variants, as the reactions slowed down due 
to consumption of large proportions of substrates. An exception is the substrate 
phosphorylation experiment (Figure 3.11a-b) which was more than just a comparative 
screening experiment as KD values were also extracted from the fitted curves, but this 
assay was performed with at least a 2-3 fold excess of ATP (compared to the KM(ATP) of 
variants being assayed, Figure 3.14d) and with a 10 minute reaction time, so that it 
sufficiently conformed to the laws of steady-state enzyme kinetics. Time course and 
substrate (ATP or polyE4Y1 peptide) titration experiments (Figure 3.9c-e and 3.14) were 
also performed with at least a 2-3 fold excess of ATP and with a 10 minute reaction time 
to ensure signal linearity. In addition, the non-linear regression analyses of these data 
performed using equations built-in to the Prism software (equations 1-4, section 2.9) are 
designed for assays with these types of experimental set-up. The assumptions involved 
in these analyses are already listed in section 2.9. 
 
Interestingly, despite the general trends observed in this work from the in vitro kinase 
assays (phosphorylation responses and reaction rates increasing with more activating 
variants), there are a few key instances when these trends do not hold true. For example, 
the maximum extents of phosphorylation observed in Figure 3.14a and 3.14c do not 
appear to mimic the ranked activation status of the variants, and in addition the reactions 
differently slow down over time. In particular, reactions involving N540K have a very high 
initial rate but then appear to ‘level off’ very rapidly compared to all other variants, while 
reactions involving R669G/Q (Figure 3.14a) and K650N (Figure 3.14c, left panel) appear 
to barely decelerate within the tested duration or ATP concentration range respectively. 
These reaction properties are likely to emerge as a consequence of combinations of 
possible phenomena including (but not limited to) concentration threshold dependent 
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product and/or substrate inhibition, and degradation of KD proteins over the course of 
reactions (the N540K KD is a particularly unstable activating variant, see Figure 3.15). 
These will probably result from (small) mutation induced differences in KD structure and 
chemical microenvironments that affect substrate binding (and release), allosteric sites, 
and overall KD function. This presents as a range of mutation specific in vitro properties 
as described. However, in the context of a cell where substrates and products are in 
constant flux, different permissive kinetic properties might allow distinct extents and rates 
of reactions to those observed in the in vitro assays in this work. 
 
Another limitation of the in vitro kinase assay arises because nanomolar concentrations 
of kinases are required to ensure strict signal linearity and to overcome ‘assay wall’ 
(phenomenon by which the lowest IC50 value that can be measured by the assay is half 
the initial kinase concentration) when developing the assay for the determination of 
catalytic and inhibitory binding constants for potent inhibitors (Yli-Kauhaluoma and 
Tuominen, 2011), as was a future aim of this assay. Such low concentrations cannot be 
measured by standard laboratory instrumentation and therefore for kinetic calculations 
involving absolute kinase concentrations (such as determination of kcat and kcat/KM(ATP)) a 
theoretical error (10%) was applied to the calculated kinase concentrations. This was 
based on the expected errors involved in measurement of the concentrated protein stock 
solutions and subsequent dilution for assays. Calculations of affinity and rate constants 
were then performed both with and without this theoretical error, and resulted in only 
small differences in the propagated errors. Subsequently, Figure 3.14e and Table 3.4 
were created using the resulting calculated errors for kcat and kcat/KM(ATP). Although these 
analyses were used to define several kinetic parameters and rate constants using a very 
robust activity assay, all parameters should ideally be calculated using measurements 
from at least two different types of assays to ensure the absolute values measured are 
accurate. However, it should be noted that within a cell, kinase activity probably does not 
actually follow Michaelis-Menten kinetics as protein substrates are unlikely to be in 
excess in the crowded intracellular environment. Therefore, the values measured in this 
work in direct and comparable assays in parallel provide valuable insights into the 
relative catalytic rates and substrate binding affinities compared to WT, which are useful 
for informing future FGFR-targeted drug discovery. However, these data provide little 
information about the kinetics of catalysis by different mutations within the cell; single-
molecule FRET experiments (for example) can be useful for investigating such properties 
further, including in a cellular context or using saturating ATP concentrations to provide 




Highly activating mutations were found to activate downstream signalling compared to 
WT. It was also noticed that N540K and K650E resulted in higher receptor expression 
levels compared to WT and compared to other less activating mutations (and even 
compared to highly activating R669G). It was not known whether this was a feed-forward 
mutation-induced mechanism that is involved in oncogenesis, or whether it is a 
consequence of artefacts incurred during the production of (non-clonal) stable cell lines. 
Increased receptor expression compared to WT has previously also been observed for 
stable cell lines harbouring activating FGFR2 mutations (Byron et al., 2013). Additionally, 
a similar association has been previously observed in a study using urothelial cancer 
samples which showed that 85% of tumour samples harbouring FGFR3 mutations also 
overexpressed the receptor (Tomlinson et al., 2007a). This was observed across 
urothelial tumours of all grades and stages, albeit in a greater proportion of lower grade 
tumours. In this work, it was suggested that transformation of NIH 3T3 cells is 
independent of the expression level of the WT or mutant receptors. However, it remains 
to be investigated whether threshold levels of mutant FGFRs are required for the 
alterations in downstream signalling observed in this work. Additionally, it is currently 
less clear how mutations found to be moderately activating (such as I538V, N540S, 
V555M, D641G/N, K650N and R669Q from this work) might be involved in oncogenesis, 
as none of these variants caused transformation of NIH 3T3 cells. In particular, FGFR3-
D641 mutations did not transform NIH 3T3 cells in this work, despite the activating 
hotspot mutation D816V at the corresponding position in the KIT receptor having been 
shown to transform the mast cells in which it exerts its oncogenic effects (Hashimoto et 
al., 1996) and KIT-D816V also confers resistance to the inhibitor imatinib (Frost et al., 
2002). The V555M gatekeeper mutation has been previously shown to provide acquired 
resistance to several ATP-competitive inhibitors (section 3.1.6) and this work suggests 
that this might occur through steric hindrance of these inhibitors binding in the ATP (and 
thus inhibitor) binding pocket as suggested by the increase in ATP binding affinity of the 
FGFR3-V555M KD. Several of these moderately activating mutations increased the 
catalytic efficiency and ATP binding affinity of the FGFR3 KD by varying degrees (Figure 
3.14d-e). This might ‘prime’ the mutant FGFRs by increasing basal ligand-independent 
activation so that they may present as oncogenic drivers in the optimal cellular context 
(discussed above). In addition, the effects of double mutations in FGFRs have not been 
analysed in this work, but double mutations have been previously observed in cancer 
including in FGFR3 in urothelial carcinoma (Tomlinson et al., 2007a). Their effects have 
only recently begun to be studied in FGFRs, such as in a recent structural analysis of 
double KD mutations in FGFR2 showing that double mutations in different parts of the 
KD confer enhanced, additive activation compared to their single-mutant counterparts 
(Chen et al., 2017). Although the occurrence of double mutations in the same allele is 
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predicted to be extremely rare in cancer, a double FGFR3 mutation including N540K and 
another KD mutation on the same allele has been observed in a dysplasia where it 
increase the severity of the disease phenotype (Pannier et al., 2009). Further analysis of 
these mutations, including in cells (using the relevant cancer cell lines where available) 
will provide information such that even malignancies and congenital disorders with rare 
mutations can be treated in a patient-personalised manner in the future. 
 
The clinical efficacy of FGFR targeted therapies has so far fallen short of the expected 
success of these drug candidates despite their success in pre-clinical testing (Babina 
and Turner, 2017). This could be due to the fact that patients have so far not been 
selected for clinical trials based on mutation, and importantly addiction, status of their 
tumours to aberrant FGFR signalling, possibly resulting in suboptimal clinical success of 
several pre-clinically potent FGFR inhibitors. Additionally, the efficacy of pre-clinical drug 
candidates is normally only experimentally verified using WT protein targets, with only 
rare functional assessment of the impact of mutations on inhibitor efficacy. In the case 
of kinases, this can be particularly relevant for mutations in the KD which can directly 
affect the activity and conformation of the KD and/or inhibitor binding site. To test this, 
the in vitro kinase assay developed here was used to assess the impact of several FGFR 
activating mutations identified in this work on the efficacy of a panel of FGFR inhibitors 
currently in clinical trials (Patani et al., 2016). This work clearly demonstrated that 
different mutations affect drug efficacy to differing degrees. Rarely, mutations increased 
the efficacy of specific inhibitors, while others (more commonly) reduced efficacy. 
Impacts on potency differed for different binary combinations of mutations and inhibitors, 
with no trend that could be predicted without experimental testing. For example, the 
V555M gatekeeper mutation and N540S (also in the ATP binding pocket) conferred 
particular resistance to the FGFR-selective inhibitor JNJ-42756493 while a different 
replacement at the same ‘molecular brake’ residue to N540K provided most resistance 
to another FGFR-selective inhibitor, AZD4547, with less impact on JNJ-42756493 
binding. Other mutations in the vicinity of the ATP binding pocket such as moderately 
activating I538V also conferred resistance to these two inhibitors as well as the multi-
kinase inhibitor Dovitinib. In contrast, activating mutations distant from the ATP (and 
inhibitor) binding site (K650E and R669G) did not greatly impact inhibitor binding. None 
of the mutations tested conferred a change in the sensitivity to the multi-kinase inhibitor 
Ponatinib. This agrees with a recent study which showed that the corresponding N549K 
mutation in FGFR2 exhibited increased resistance to the inhibitors Dovitinib and 
PD173074, but not Ponatinib, compared to FGFR2-WT in an endometrial carcinoma cell 
line (Byron et al., 2013). Such subtle differences in the primary sequence leading to 
conformational changes in the KD and alteration of the chemical environment in the 
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inhibitor binding site can therefore lead to large impacts on the success of targeted 
inhibition, including in the clinic. Resistance to targeted therapies is one of the key 
challenges still to be anticipated and overcome in the clinic. Therefore, a combination of 
functional studies such as those performed in this work, combined with a pre-clinical 
assessment of the impact of mutations on inhibitor potency, should be a crucial step in 
data-driven targeted therapeutics in the future and similar principles can be applied 
across RTK and EPK targets in cancer. The true success of clinical targeted therapies, 
particularly ATP-competitive inhibitors, might depend on such multifaceted information. 
Specifically, the impacts of subtle point mutations on the efficacy of clinical candidate 
drugs have not always been taken into account during clinical trials (although this is 
rapidly changing). This might have led to sub-optimal patient selection which could be at 
least partly responsible for the unexpectedly low clinical response rates observed to date. 
Pre-clinical studies that take into account the effects of mutations should help to boost 
the clinical success of targeted therapies which are currently less successful at targeting 
FGFRs harbouring point mutations compared to their relative success against cancers 
with FGFR amplifications and fusions which contain receptors with a WT sequence 
(Babina and Turner, 2017). This should help to combat clinical resistance to FGFR and 
other RTK inhibitors through knowledge of the mechanisms of action of different 
pathogenic mutations against them. In addition to resistance through specific point 
mutations in FGFRs, other mechanisms of resistance can develop in tumour cells 
through co-activation of other RTKs or other downstream signalling pathways, bypassing 
the need for FGFRs to maintain a robust oncogenic signal. As previously mentioned, this 
work showed preliminary results demonstrating crosstalk between FGFR signalling and 
other downstream signalling networks such as the Wnt signalling pathway (Figure 3.20). 
This pilot experiment also showed that pathogenic mutations might affect these signalling 
patterns, possibly by altering the networks in favour of maintaining the robust oncogenic 
signal and/or to diversify the oncogenic outcomes. Treating tumours with FGFR inhibitors 
can therefore also lead to oncogene switching such that the tumour becomes addicted 
to signalling via another kinase, simultaneously becoming resistant to FGFR inhibition 
through loss of oncogene-addiction to FGFR signalling due to the targeted therapy. 
Therefore, knowledge of the combined mechanisms of resistance through FGFR 
mutation, oncogene switching and/or co-activation of oncoproteins is required to target 
cancers with appropriate combination therapies to robustly eliminate them. Further 
signalling level data combined with studies as in this work are therefore required to inform 








The endocrine sub-axes of FGFR signalling refer to the more recently discovered, and 
less well-researched, modes of signalling that have key regulatory differences compared 
to ‘canonical’ paracrine FGFR signalling. Endocrine signal transduction requires the 
constitutive recruitment of a member of the Klotho family of FGFR co-receptors into the 
ternary signalling complex instead of the HS co-factors required for paracrine signalling. 
Inclusion of Klotho proteins, exclusion of HS and switching of FGF ligands in the ternary 
signalling complexes from paracrine to endocrine sub-family members (FGF19, FGF21 
and FGF23 in humans) all serve to alter the mode of FGFR signal transduction from 
paracrine to endocrine (Belov and Mohammadi, 2013, Goetz and Mohammadi, 2013). 
This leads to changes in the physiological outcomes of signalling from controlling 
development, growth, migration and tissue homeostasis to hormonally regulating diverse 
metabolic processes including glucose uptake, bile acid synthesis and phosphate and 
vitamin D homeostasis. Strong tissue specific expression of the Klotho family proteins 
coupled with selective inclusion of specific endocrine FGFs and FGFR isoforms in the 
ternary complexes dictate the metabolic outcome of the transduced signal (Kurosu and 
Kuro, 2009). 
 
The important discovery that endocrine FGFR signalling mediates several aspects of 
normal metabolism coincided with the growing observations that the most common side-
effects in response to targeted FGFR therapeutics (Table 1.4) in pre-clinical tumour 
models were due to on-target inhibition of specific endocrine FGFR signalling pathways, 
most commonly involving FGF23 (Dieci et al., 2013, Brooks et al., 2012). Additionally, in 
contrast to FGFR point mutations involved in cancer discussed in Chapter 3, an aspect 
of aberrant endocrine FGFR signalling such as amplification of FGF19 has also been 
identified as a de novo driver of oncogenesis in specific cancers (Sawey et al., 2011). 
The same FGF19 aberration has also been shown to confer sensitivity to targeted FGFR 
inhibitors in specific subsets of cancer cell lines, but only when the cognate Klotho family 
co-receptor required for FGF19 signalling is concurrently expressed (Guagnano et al., 
2012). Finally, FGF21 has been identified as an important modulator in several clinically 
important metabolic diseases such as diabetes and obesity. These involvements of 
components of endocrine signalling in oncogenesis, modulation of toxicity profiles in 
response to targeted FGFR therapies and in widespread metabolic diseases provides a 




In this Chapter, the three components of the endocrine ternary signalling complexes will 
be introduced from a structural and biochemical perspective, with a focus on the Klotho 
family of co-receptors and the endocrine FGF19 sub-family proteins (the FGFR family of 
RTKs has already been described in detail in Chapter 1). In particular, the focus will be 
on βKlotho, FGF19 and FGF21 and the roles of their resultant ternary FGFR complexes 
in endocrine signalling. The importance of composition of the signalling complexes and 
tissue specificity of expression on context-dependent metabolic effects will be presented. 
The roles of deregulated endocrine signalling on various pathologies, including cancer, 
will be discussed. Finally, the development of components of the ternary complexes and 
related biomolecules as therapeutics for several diseases, including cancer, will be 
reported. 
 
4.1.1 The Klotho family of FGFR co-receptors 
The three members of the Klotho family of proteins are αKlotho (alias KLA), βKlotho 
(alias KLB) and γKlotho (alias lactase-like protein, LCTL). The Klotho gene (for the 
αKlotho protein) was first discovered as an anti-ageing gene in a knockout mouse model 
that displayed signs of human-like ageing and reduced lifespan (Kuro-o et al., 1997). 
Later, the mouse βKlotho gene was also identified based on sequence identity of the 
protein to Klotho of 44% (Ito et al., 2000). This was followed by discovery of γKlotho, the 
third Klotho family member identified to date (Ito et al., 2002). The three proteins make 
up a sub-family within the superfamily of type I β-glucosidases based on their sequence 
similarities to glycosyl hydrolases (Henrissat and Bairoch, 1993). Most research has so 
far focussed on the anti-ageing αKlotho, with emerging interest in the βKlotho branch of 
signalling. Very little is known about γKlotho and its functions so this Klotho family 
member will not be discussed in much detail in this work except for the rare cases where 
data is available. 
 
4.1.2 The endocrine sub-family of FGF ligands 
Members of the FGF19 sub-family of FGF ligands comprise FGF19 (mouse orthologue 
is FGF15), FGF21 and FGF23 (see section 1.5.1 and Figure 4.1). Each FGF forms 
complexes with specific Klotho family members and FGFRs and this dictates the 
outcomes of endocrine signal transduction. The first endocrine FGF to be identified was 
FGF19, which was discovered to bear the least sequence homology to all human FGFs 
known at the time (Xie et al., 1999, Nishimura et al., 1999). It was found to be the 
orthologue of mouse FGF15 discovered previously due to 53% sequence identity 
between the two proteins (McWhirter et al., 1997). FGF21 was discovered next in mouse 
embryos (Nishimura et al., 2000), followed soon after by FGF23 (ADHR Consortium, 
2000, Yamashita et al., 2000). All were predicted to be secreted proteins and were 
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grouped into their own sub-family of endocrine FGFs (Itoh and Ornitz, 2008, Itoh and 
Ornitz, 2011). Compared to paracrine FGFs, they were all found to require specific Klotho 
co-receptors for high affinity binding to and signalling through FGFRs in a HS 
independent manner. They comprise unique structural features that facilitate their 
signalling capabilities as hormones compared to other FGF sub-families, as mentioned 








Figure 4.1 Domain organisation of the human FGF19 subfamily of endocrine FGF ligands. 
Schematic representation of the domain structures of endocrine FGFs (to relative scale). All three 
FGFs comprise a short N-terminal secretion signal peptide (SP), a ‘core’ N-terminal domain (NTD) 
which is highly conserved among all FGFs and a C-terminal domain (CTD) referred to as the C-
terminal tail, which confers Klotho protein binding specificity. The amino acid length of each 





4.1.3 FGFR isoforms 
FGFRs have already been introduced in Chapter 1. All FGFR isoforms (FGFR1-4) can 
form endocrine signalling complexes, but several studies have shown that it is 
particularly the canonical c, and not the alternative b, splice isoforms of FGFR1-3 that 
bind and transduce signals in complexes with Klotho proteins and endocrine FGFs (Xie 
et al., 1999, Urakawa et al., 2006, Kurosu et al., 2007, Ogawa et al., 2007). Some ternary 
complex combinations can form in vitro and in cellular models but cannot transduce a 
signal; therefore few specific ternary complexes appear to be functionally relevant in vivo 




4.1.4 Domain organisation and possible functions of Klotho proteins 
The Klotho proteins are transmembrane glycoproteins with a very short cytoplasmic 
domain, a single-pass type I transmembrane helix and a large ectodomain with variable 
numbers of putative N-glycosylation sites (Table 4.1). The ectodomain of αKlotho and 
βKlotho comprises two β-glucosidase-like tandem repeat domains termed KL1 and KL2 
separated by a short linker, while γKlotho has only one KL domain (Figure 4.2). To date, 
no atomic structural information exists for any Klotho proteins or any of their individual 
domains, with or without FGF or FGFR binding partners. This information is eagerly 
sought in order to understand the molecular basis for the crucial roles of Klotho co-
receptors in the switch from paracrine to endocrine signalling. Additionally, structural 
information will help to decipher the stoichiometry of signalling complexes and will aid in 
designing therapeutics targeting these ternary complexes for the treatment of a range of 
metabolic pathologies and specific malignancies in which Klotho-dependent signalling is 
deregulated (reported below), as well as in combating the adverse effects observed in 




Figure 4.2 Domain organisation of the human Klotho family of transmembrane co-receptor 
proteins. The three Klotho family members known to date (αKlotho, βKlotho and γKlotho), based 
on sequence homology, are schematically illustrated (to relative scale). They all comprise an 
extracellular region, a single pass type I transmembrane helix and a very short C-terminal 
cytoplasmic region. The large ectodomains of αKlotho and βKlotho (almost 1000 amino acids in 
length) comprise two β-glucosidase-like tandem repeat domains termed KL1 and KL2 (labelled) 
separated by a short linker, while the ectodomain of γKlotho comprises only one KL domain. The 
entire extracellular region comprising KL1-KL2 (αKlotho and βKlotho) or just the individual KL 
domains for all three Klotho proteins are also shed into the circulation where they are referred to 
as soluble Klotho. At least one of the essential catalytic aspartate (D) residues required for β-
glucosidase activity is missing in all the KL domains, and the replacement residues (N, A, S or E) 
have been labelled on each KL domain. For this reason, the KL domains are predicted to be 
catalytically inactive. Putative N-glycosylation sites on the ectodomains of all three Klotho proteins 




Table 4.1 Human Klotho family members predicted protein and domain lengths, protein 
molecular masses and numbers of putative glycosylation sites. 
 
 αKlotho βKlotho γKlotho 
Protein length (amino acids) 1012 1014 567 
Extracellular domain (amino acids) 948 996 519 
TM domain (amino acids) 21 21 21 
Intracellular domain (amino acids) 10 27 5 
Non-glycosylated molecular mass (kDa) 116 120 65 
Glycosyl hydrolase (KL) domains KL1 (57-506) KL2 (515-953) 
KL1 (509-516) 
KL2 (517-967) KL (33-503) 





4.1.5 Possible enzymatic functions of KL domains 
Despite their sequence similarity to β-glucosidases, all KL domains appear to lack an 
essential catalytic aspartate residue required for glucosidase activity (Figure 4.2) and are 
therefore predicted to be catalytically inactive (Ito et al., 2002). A few studies have 
suggested that αKlotho might exhibit weak β-glucuronidase activity (Tohyama et al., 
2004, Chang et al., 2005) while others have suggested that sialidase activity of αKlotho 
might regulate ion channel activation by specifically acting on α2,6-linked sialic acids 
(Cha et al., 2008). To date, no such studies have implicated βKlotho or either of its 
individual KL domains to perform any glucosidase, glucuronidase or sialidase activities. 
Additionally, whether or not either of the KL domains in any Klotho family member retains 
any of these enzymatic activities is still an open, unresolved question. However, it is 
hypothesised that the KL domains may have retained the ability to bind to sugars such 
as galactosides (Kilkenny and Rocheleau, 2016). This might have important implications 
for cell surface signalling with Klotho proteins possibly retaining the ability to bind, but 
not metabolise, cell-surface glycan moieties (discussed further below). 
 
4.1.6 Roles of Klotho ectodomains as secreted humoral factors 
The ectodomain of αKlotho is also shed into the circulation as a hormone, particularly in 
humans and to a lesser extent in mice (Matsumura et al., 1998, Shiraki-Iida et al., 1998). 
In humans it is thought to originate predominantly from the kidney, the organ where full 
length membrane-bound αKlotho is most highly expressed (Olauson et al., 2017), as 
described in section 4.1.7 below. The secreted ectodomain has been named soluble 
Klotho (sKlotho) and refers to the entire ectodomain comprising both KL domains (Figure 
4.2), although secretion of individual KL domains has also been observed (Chen et al., 
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2007a). However, the human αKlotho KL1 domain, compared to the entire ectodomain, 
could not efficiently induce FGF23 signalling in cells or hypophosphatemia in mice 
(Abramovitz et al., 2011) suggesting that the ectodomain is needed in its entirety for the 
hormonal functions of αKlotho. sKlotho has been detected in bodily fluids such as sera 
and cerebrospinal fluid where it is released post-translationally through enzymatic 
cleavage from membrane-bound full length αKlotho, rather than being directly 
transcribed (Imura et al., 2004). Cleavage is catalysed at least in part in an insulin 
dependent manner by A Disintegrin and Metalloproteinase (ADAM) family sheddases 
ADAM10 and ADAM17 (Chen et al., 2007a) and possibly by other secretase proteins 
(Bloch et al., 2009) in vivo, although sKlotho might also result as a product of alternative 
mRNA splicing (Hu et al., 2010, Mizuno et al., 2001). Physiological levels of sKlotho 
appear to vary between distinct genetic populations (Schmid et al., 2013) and have been 
shown to decline with age (Yamazaki et al., 2010). The levels of protein are important in 
regulating a range of pathologies, and can serve as useful biomarkers in disease (see 
section 4.1.19). 
 
4.1.7 Expression profiles of Klotho, FGFs and FGFRs: implications for signalling 
It has been shown that the Klotho proteins are expressed in a limited range of tissues 
with discrete and specific expression for each family member. In adult mice, αKlotho is 
expressed predominantly in the kidney and in the brain (Kuro-o et al., 1997, Chang et 
al., 2005, Fon Tacer et al., 2010), with lower levels of expression in other organs such 
as the thyroid and arterial vasculature, and similar expression patterns are observed in 
humans (Lim et al., 2015). The γKlotho protein is expressed highly in the eye, brown 
adipose tissue (BAT), skin and kidney (Ito et al., 2002, Fon Tacer et al., 2010, Zhang et 
al., 2017b). Expression of βKlotho is more widespread that the other Klotho family 
members, with highest levels of expression observed in the liver, pancreas, gall bladder 
and BAT and white adipose tissues (WAT) with lower levels in the gut, skin, arterial 
vasculature, reproductive tissues, skeletal muscle and hypothalamus (Ito et al., 2000, 
Lin et al., 2007, Fon Tacer et al., 2010, Adams et al., 2012, Bookout et al., 2013, Ding et 
al., 2012). It has emerged that the specificity of endocrine signalling depends on these 
tissue specific expression profiles of Klotho family members. In contrast, FGFRs are 
much more ubiquitously expressed across tissues compared to the Klotho proteins (Fon 
Tacer et al., 2010), and impart a much lower influence on the tissue specificity of 
signalling. Specific examples are discussed in sections 4.1.9 and 4.1.10. 
 
The endocrine FGFs also exhibit discrete tissue specific expression profiles, however as 
mentioned previously, they are secreted hormones that exert their physiological effects 
mostly away from their sites of production. FGF19 (or FGF15 in mice) is expressed 
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mainly in the small intestine (Inagaki et al., 2005, Fon Tacer et al., 2010) but exerts its 
effects primarily on the liver and gall bladder where it dampens bile acid synthesis and 
gluconeogenesis, promotes post-prandial protein and glycogen synthesis and stimulates 
filling of the gall bladder (Inagaki et al., 2005, Choi et al., 2006, Lin et al., 2007, Kir et al., 
2011, Potthoff et al., 2012). It has also been implicated to exert anti-diabetic and anti-
obesity effects in mice (Tomlinson et al., 2002, Fu et al., 2004). FGF21 appears to have 
a broader tissue expression profile than FGF19 with sites of production including the 
liver, pancreas, testes, gut, thymus, and BAT (Nishimura et al., 2000, Fon Tacer et al., 
2010) but circulating FGF21 is thought to be mostly liver derived and its expression is 
induced in response to fasted states in mice (Nishimura et al., 2000, Badman et al., 2007, 
Inagaki et al., 2007, Lundasen et al., 2007, Lee et al., 2011, Markan et al., 2014). In other 
tissues such as WAT, BAT and skeletal muscle FGF21 expression is induced in 
response to various other transcription factors involved in nutrient-sensing, reviewed in 
(Owen et al., 2015, Kilkenny and Rocheleau, 2016). The primary sites of action of FGF21 
are the liver, pancreas and adipose tissues where it regulates a range of metabolic 
outcomes such as nutritional stress-induced energy homeostasis in liver and glucose 
uptake, insulin and leptin sensitisation, ketogenesis, lipolysis and thermogenesis in WAT 
and BAT, reviewed in (Owen et al., 2015, Itoh et al., 2015). Its primary role is thought to 
be stimulation of glucose uptake, first shown in 3T3-L1 adipocytes (Kharitonenkov et al., 
2005). The potential anti-diabetic, anti-obesity and life extending effects of FGF21 have 
fostered great therapeutic interest in the hormone, as presented in section 4.1.19 below. 
The final endocrine FGF, FGF23, is expressed in bone, heart, thyroid, brain, lung, 
thymus, spleen, muscle and liver (ADHR Consortium, 2000, Liu et al., 2003, Fon Tacer 
et al., 2010). It targets the kidney and heart to exert its roles in phosphate and vitamin D 
homeostasis (Shimada et al., 2004). The predominant sites of endocrine FGF expression 
and metabolic action are summarised in Figure 4.3. Of the three endocrine FGFs, 
multiple studies have revealed that FGF19 and FGF23 also affect proliferation and have 
mitogenic activities in addition to their metabolic roles, while FGF21 uniquely has only 
metabolic activities without any proliferative or oncogenic effects (discussed further 
below). 
 
It was noticed that there were similarities between phenotypes of multiple knockout 
mouse models for different combinations of αKlotho, βKlotho, FGF19, FGF21, FGF23 
and various FGFRs. This led to the hypothesis that specific Klotho co-receptors were 
required for binding to specific combinations of FGFs and FGFRs for signal transduction. 
A wealth of further experimentation in mice and in vitro biochemical experiments were 
employed to decipher the roles of the proteins in relation to each other, leading to the 
discovery of the FGF-FGFR-Klotho ternary complexes and the requirements for Klotho 
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co-receptors for endocrine signalling. The biochemical evidence supporting the 
functional relevance of the specific complexes thought to be important to date is 






Figure 4.3 Summary of predominant sites of endocrine FGF expression and metabolic 
action in response to stimuli. Physiological activities of (a) FGF19, (b) FGF21 and (c) FGF23 
acting through their respective FGF-FGFR-Klotho ternary complexes (predominantly FGF19-
FGFR4-βKlotho, FGF21-FGFR1c-βKlotho and FGF23-FGFR1c-αKlotho). The summary is of 
literature including aspects of signalling not discussed in detail in the text. FXR – farnesoid X 
receptor, CYP7A1 – cholesterol 7 α-hydroxylase 1, ACC2 – acetyl-Co-A carboxylase 2, SCD1 – 
stearoyl-CoA desaturase 1, PPARα/γ – peroxisome proliferator-activated receptor, PTH – 







4.1.8 The ternary complexes and intra-complex protein-protein interactions 
The ternary endocrine FGFR signalling complexes comprise specific combinations of 
FGF, FGFR and Klotho proteins. Endocrine FGFs themselves exhibit lower affinities for 
FGFRs and HS compared to paracrine FGFs (Harmer et al., 2004, Goetz et al., 2007, 
Asada et al., 2009, Goetz et al., 2012b), and require Klotho co-receptors for high affinity 
binding to and signalling via FGFRs (Kurosu et al., 2006, Urakawa et al., 2006, Ogawa 
et al., 2007, Kurosu et al., 2007, Kharitonenkov et al., 2008, Suzuki et al., 2008). These 
studies and others have slowly characterised physiologically relevant ternary signalling 
complexes over a decade of biochemical and cellular research. In general, it was found 
that αKlotho and βKlotho form mutually exclusive complexes exclusively with their 
cognate combinations of FGFRs and FGFs, namely FGF23 for αKlotho and FGF19 and 
FGF21 for βKlotho. Additionally, endocrine FGFs bind with lower affinities to FGFRs or 
Klotho co-receptors on their own, and bind more effectively to FGFR-Klotho binary 
complexes. The specific ternary complexes formed regulate distinct physiological 
outcomes, in a tissue specific manner. They will therefore be presented separately, with 
a focus on binary and ternary complexes involved in the sub-axes of βKlotho endocrine 
signalling which is the experimental focus of this work. 
 
4.1.9 FGF23-αKlotho ternary complexes 
Direct binding of FGF23 to each of the FGFR isoforms was shown to be weak, with a 
preference for signalling via the canonical c compared to the alternative b FGFR splice 
isoforms, and with some dependence on heparin (Yu et al., 2005, Zhang et al., 2006b). 
The binary interactions between FGF23 and αKlotho, and αKlotho and various FGFRs, 
and the possible ternary complexes were first demonstrated in HEK 293 cells (Kurosu et 
al., 2006). This study demonstrated direct binding of αKlotho to various FGFRs, again 
highlighting a preference for the c compared to the b splice isoforms. FGF23 
preferentially bound to binary complexes of αKlotho with either FGFR1c, 3c or 4 (but not 
2c) but did not bind to any individual receptor on its own. Additionally, FGF23 signalling 
could only be activated in the presence of αKlotho, highlighting the Klotho-dependence 
of FGF23 in receptor binding and signal transduction. Another study similarly 
demonstrated that αKlotho directly binds FGF23 and the FGFR1c isoform in a HS-
independent manner (Urakawa et al., 2006). This study also showed that αKlotho binds 
to FGFR1c, converting it into a specific HS-independent receptor to which FGF23 can 
bind and can signal through in a αKlotho-dependent fashion. However, although receptor 
interaction with FGF23 was strongly αKlotho-dependent and HS-independent, it was 
suggested that HS might enhance binding and signalling. Two more studies 
demonstrated that FGF23 could directly bind αKlotho-FGFR1c, but not βKlotho-FGFR1c, 
to transduce a signal (Suzuki et al., 2008, Kharitonenkov et al., 2008). One study which 
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demonstrated direct binding of FGF23 to αKlotho (but not βKlotho) in vitro also provided 
evidence that the C-terminal tail residues of FGF23 might be sufficient for binding to 
αKlotho (Wu et al., 2008). Another study showed that wildtype, but not the N-terminal 
‘core’ of FGF23 without the C-terminal tail, could activate signalling, suggesting the C-
terminal tail was necessary and sufficient for signalling (Goetz et al., 2007). Direct in vitro 
competition experiments comprehensively demonstrated that the C-terminal tail of 
FGF23 does indeed mediate the high affinity interaction of FGF23 with the full length 
ectodomain complex of αKlotho-FGFR1c, but not with FGFR1c or αKlotho alone, and 
this occurs in the absence of HS (Goetz et al., 2010). This study also showed that the C-
terminal tail of FGF23 can compete with the full length protein for binding to the αKlotho-
FGFR1c binary complex and can therefore inhibit signalling. Finally, the binding affinities 
for the binary interactions between αKlotho and each FGFR isoform were measured in 
vitro by surface plasmon resonance (SPR) (Table 4.2a), confirming that αKlotho binds 
with highest affinity to FGFR1c, 3c and 4, but not 2c or any of the b splice isoforms 
(Goetz et al., 2012a). The binding affinities for the interactions between FGF23 and 
FGFR1c or FGF23 and the αKlotho-FGFR1c binary complex were also measured in 
comparable experiments using SPR in a second study (Table 4.2b) (Goetz et al., 2012b). 
 
 
Table 4.2 Equilibrium dissociation constants (KD, nM) for (a) FGFR-Klotho interactions 
and (b) for known FGF-FGFR and FGF-FGFR-Klotho interactions with endocrine FGFs 
from comparative studies (Goetz et al., 2010, Goetz et al., 2012a, Goetz et al., 2012b). 
 
(a) 
 FGFR1c FGFR2c FGFR3c FGFR4 
αKlotho 72 – 82 123 
βKlotho 124 170 – 84 
 
(b) 
 FGF2 FGF19 FGF21 FGF23 
FGFR1c 58 1910 2520 648 




Resolution of the crystal structure of the N-terminal ‘core’ of FGF23 demonstrated that a 
large HS-binding region present in paracrine FGFs is missing in FGF23, explaining its 
reduced affinity for HS and therefore its ability to exert its physiological actions away 
from its tissue of production by being secreted into the circulation to function as a 
hormone (Goetz et al., 2007). Mutagenesis experiments performed in this study and a 
later study (Goetz et al., 2012b) confirmed FGF23 residues involved in HS binding as 
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the mutations abrogated HS binding of FGF23 further (Figure 4.4c). These mutations to 
FGF23, which rendered it completely unable to bind HS, did not affect its signalling 
activity. The latter study also showed that it was possible to engineer FGF2, a paracrine 
FGF, to act in an endocrine FGF23-like manner by mutating the HS binding residues of 
FGF2 to abrogate its HS-binding affinity, and adding to it the C-terminal tail of FGF23 
enabled the chimeric FGF2 to bind to the αKlotho-FGFR1c complex. So the role of the 
FGF23 C-terminal tail as the binding site for αKlotho-FGFR1c is emphasised and there 
is confirmation that this endocrine signalling complex is HS-independent. These studies 
also confirm that αKlotho (and not βKlotho) is required for FGF23 signalling, and that 
signalling occurs predominantly via FGFR1c. 
 
4.1.10 FGF19-βKlotho and FGF21-βKlotho ternary complexes 
The first reports demonstrating the involvement of βKlotho in FGFR signalling showed 
that the activities of FGF19 and FGF21 were dependent on the βKlotho co-receptor (Lin 
et al., 2007, Ogawa et al., 2007). The first study suggested that βKlotho-FGFR4 was the 
primary receptor for FGF19. Similar to experiments performed for FGF23, the latter study 
demonstrated binding of βKlotho to FGFR1c and 4, and weakly to FGFR2c. It also 
showed that FGF21 bound and signalled preferentially through βKlotho-FGFR binary 
complexes compared to direct signalling through just FGFRs, showing for the first time 
the βKlotho-dependence of FGF21 signalling. A very similar study by the same group 
showed that FGF19 also depends on βKlotho, and not αKlotho, for signalling through 
FGFRs, once again emphasising the importance of FGFR1c and 4, and to a lesser extent 
FGFR2c and 3c (Kurosu et al., 2007). This study began to address the tissue specificity 
of signalling through βKlotho-FGFR complexes, showing that both FGF19 and FGF21 
can signal in 3T3-L1 adipocytes, which express FGFR1c, but not the other FGFR 
isoforms. They also showed that only FGF19 could transduce a signal in hepatocytes, 
which express predominantly FGFR4, although FGF21 was capable of binding to 
βKlotho-FGFR complexes in these cells. This pattern of signalling in adipocytes and 
hepatocytes was confirmed in vitro and in vivo by another study (Adams et al., 2012). 
The βKlotho-dependence of FGF19 (Wu et al., 2007) and FGF21 (Kharitonenkov et al., 
2008) signal transduction respectively were further emphasised by two further studies. 
One final study demonstrated that both FGF19 and FGF21 could directly bind and signal 
via the βKlotho-FGFR1c or βKlotho-FGFR3c complexes, and again demonstrated that 
signalling could not occur through any of the FGFR b splice isoforms (Suzuki et al., 
2008). The proposed βKlotho dependent specificity of FGF21 for FGFR1c and dual 
specificity of FGF19 for FGFR1c and FGFR4 was further evaluated with dose response 
assays (Gupte et al., 2011) and using dose dependent competition assays (Yang et al., 
2012). Tissue- and FGFR-specificity of signalling was further shown using FGFR1c 
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knockout mouse tissues, where FGF21 signalling was abrogated in adipose tissues 
(which predominantly express FGFR1c) but FGF19 signalling in hepatocytes (which 
predominantly express FGFR4) was maintained (Foltz et al., 2012). Direct binding 
affinities for βKlotho binding to FGFR isoforms were later determined by SPR and 
confirmed the importance of FGFR1c, 2c and 4, but not 3c or any of the b splice isoforms, 
in binding to βKlotho (Yie et al., 2009, Goetz et al., 2012a). These studies also observed 
direct binding of βKlotho respectively to FGF19 and FGF21 (in the absence of FGFRs), 
a phenomenon which does not occur for FGF23 and αKlotho. The importance of the C-
terminal tails of FGF19 and FGF21 in directly binding to βKlotho, but not αKlotho, was 
first demonstrated by direct binding experiments similar to those performed for FGF23-
αKlotho (Wu et al., 2008). Further studies confirmed this, as well as the importance of 
the C-terminal tails for signalling through βKlotho-FGFR complexes in vitro and in cells 
(Yie et al., 2009, Micanovic et al., 2009, Goetz et al., 2012a). The C-terminal tails of 
FGF19 and FGF21 were demonstrated to be the βKlotho binding site for these FGFs in 
similar experiments to those performed for FGF23 by engineering a chimeric FGF, 
consisting of paracrine FGF2 fused with the C-terminal tail of FGF21, to enable the 
chimeric FGF2 to bind to βKlotho (Goetz et al., 2012b). Lastly, these studies also 
suggested that the C-terminal tails of FGF19 and FGF21 compete for the same binding 
site on βKlotho and bind with variable affinities, implicating the importance of specific 
sequences of the C-terminal tails in determining ternary complex formation. This also 
suggests that FGF19 and FGF21 signalling might compete in vivo in cells in which other 
common components of their cognate signalling complexes are expressed, for example 
in adipocytes. 
 
The role of HS in complexes particularly involving FGF19 has provided substantial 
controversy. Early work suggested that the FGFR4-HS binary complex might be the 
unique, HS-dependent and Klotho-independent receptor for FGF19 (Xie et al., 1999). 
Although a second report suggested that despite FGF19 possibly uniquely binding 
FGFR4, it was unlikely to bind HS based on the analysis of features of the first crystal 
structure of FGF19, discussed further below (Harmer et al., 2004). Several reports have 
shown that although FGF19 signalling is indeed HS-independent, HS might enhance the 
signal (Zhang et al., 2006b, Lin et al., 2007, Wu et al., 2008, Kharitonenkov et al., 2008) 
and some reports have also suggested this for signalling via FGF21 and/or FGF23 
(Zhang et al., 2006b, Suzuki et al., 2008, Wu et al., 2008). However, some of these 
studies were performed in cells in which the FGFRs (and some FGFs) are ubiquitously 
expressed and have used different readouts of activity. Therefore, it could be that HS is 
enhancing a non-endocrine FGF signalling pathway in these experiments, since 
paracrine and endocrine signalling can and do occur in parallel in vivo. Direct binding of 
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FGF19, FGF21 and FGF23 to HS in vitro has clearly demonstrated the low binding 
affinity of these FGFs for HS (Goetz et al., 2007, Asada et al., 2009). It is likely that the 
incorporation of HS in the endocrine signalling complexes could be context dependent, 
and so far its involvement in endocrine signalling has been reported most frequently for 
the FGF19-FGFR4-βKlotho complex. Direct binding and activation experiments 
combined with structural studies with purified ternary complexes are needed to clarify 






Figure 4.4 Structural basis for the reduced HS binding affinity of endocrine FGFs compared 
with canonical paracrine FGFs. Comparison of HS binding sites on the crystal structures of 
human endocrine FGFs (FGF19 and FGF23) with a canonical paracrine FGF (FGF2). (a) Crystal 
structure of paracrine FGF2 (pink cartoon) bound to a heparin decasaccharide (shown as sticks 
and coloured grey and by atomic element with nitrogen atoms in navy blue, oxygen in red and 
sulphur in yellow) [PDB: 1FQ9] (Schlessinger et al., 2000). The side chains of HS binding residues 
are shown as sticks and coloured white and the side chains that form most of the hydrogen bonds 
with the heparin decasaccharide are coloured red. Crystal structures of endocrine (b) FGF19 
(blue cartoon) [PDB: 2P23] (Goetz et al., 2007) and (c) FGF23 (orange cartoon) [PDB: 2P39] 
(Goetz et al., 2007) shown in the same orientation as FGF2 in a. Side chains of residues that 
provide residual HS binding affinity are shown as sticks and coloured white, while side chains that 
abrogate residual HS binding affinity when mutated are shown as sticks and coloured red. 
Disulphide bonded cysteines in FGF19 (C58-C70 and C102-C120) and FGF23 (C95-C113) are 
shown in sticks and coloured green. Only one of these disulphide linkages is conserved between 












As mentioned above, the crystal structure of human FGF19 has been solved, and by two 
independent groups, yielding two very similar structures (Harmer et al., 2004, Goetz et 
al., 2007). The structures reveal two disulphide bonds (C58-C70 and C102-C120) in 
FGF19, compared to none present in all solved structures of paracrine FGFs (with the 
exception of FGF8, see Figure 1.6b) and only one disulphide bond (C95-C113) in FGF23 
(Figure 4.4c). Additionally, mutagenesis experiments similar to those performed for 
FGF23 (Goetz et al., 2012b) confirmed the residues conferring residual HS binding ability 
in FGF19 compared to paracrine FGFs (Figure 4.4a-b). The implications of the stabilising 
disulphide bonds coupled with the reduced HS binding affinities of FGF19 family 
members have led to the proposal that these two features of endocrine FGFs allow them 
to diffuse away from their sites of production into the circulation to participate in longer 
range signalling as hormones. 
 
4.1.11 γKlotho might also form endocrine signalling complexes 
Very little is known about the roles of γKlotho in FGFR signalling. A single study has 
shown that γKlotho might interact specifically with FGFR1b, 1c, 2c, 3c and 4 (Fon Tacer 
et al., 2010). This study also showed that γKlotho could transduce a signal in the 
presence of FGF19, but not FGF21 or FGF23, and transduction of this signal was 
γKlotho-dependent. More evidence will be needed to elucidate the functional roles of this 
member of the Klotho family in FGF signalling. 
 
4.1.12 Specific interactions between FGFs, FGFRs and Klotho co-receptors 
The FGF23 C-terminal tail was shown to confer high affinity binding to αKlotho-FGFR 
binary complexes, and the C-terminal tails of FGF19 and FGF21 were shown to directly 
bind with high affinity to βKlotho and βKlotho-FGFR binary complexes, discussed in 
detail in sections 4.1.9 and 4.1.10. However, so far there is no information about specific 
FGF or FGFR binding sites on αKlotho and βKlotho. Additionally, limited molecular detail 
has been elucidated regarding the Klotho-FGFR and endocrine FGF-FGFR interfaces 
and the specific sequences involved in their binding interactions. The binding affinities 
for the interactions between FGFR isoforms and Klotho co-receptors have been 
measured in vitro using the ectodomains of each receptor (Table 4.2a). These support 
the possibility of heterodimerisation of these receptors, and thus binary complex 
formation, prior to the addition of ligand to form ternary complexes. 
 
The first structural information to date regarding specific binding interfaces comes from 
a few main studies (Gupte et al., 2011, Wu et al., 2011, Goetz et al., 2012a). The first 
study created chimeric FGFR1c and FGFR4 receptors by exchanging either their D2 or 
D3 domains, demonstrating that the D3 domain provided the specific determination of 
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binding and activation by FGF21 in the presence of βKlotho, while FGF19 activation was 
less affected by swapping of the D3 domains but was slightly affected when the D2 
domain of FGFR4 was removed in exchange for the FGFR1c D2 domain. They went 
further to propose a potential six amino acid sequence in the βC’-βE loop of the D3 
domain of FGFR1c as a potential FGF21 interaction site (residues 318-323, ‘TTDKEM’). 
The second study implicated the N-terminus of FGF19 in binding to FGFR4. The third 
study also mapped a partial Klotho-binding site to residues of the hydrophobic ‘groove’ 
in the D3 domain of FGFR1c (Figure 4.5). This was achieved by demonstrating that 
αKlotho, βKlotho and the paracrine FGF8b could all bind to an FGFR1c ectodomain 
protein comprising the D2-D3 domains, but specific site-directed mutagenesis of 
hydrophobic residues in the D3 domain ‘groove’ (conserved across FGFR1-3 c splice 
isoforms and FGFR4) diminished binding of all three proteins to the FGFR1c protein. 
Furthermore, FGF8b signalling was inhibited in cells in the presence of βKlotho, 
suggesting overlap between the FGF8b and Klotho binding sites on FGFR. This has 
important tissue specific implications is suggesting that paracrine and endocrine 
signalling must complete with each other in tissues in which multiple FGFs, FGFRs and 
Klotho proteins are present. Endocrine signalling might ‘win’ in tissues in which the 
correct combinations of FGFRs and Klotho proteins are expressed, or perhaps highly 
regulated thresholding of levels of expression of the Klotho proteins might play a role in 
modulating signalling. Additionally, a recent study monitoring the effects of excess levels 
of FGF19 and FGF21 in mice suggested the two hormones might compete for binding to 
the βKlotho-FGFR4 complex to exert opposite effects on inhibiting and stimulating bile 
acid synthesis respectively (Zhang et al., 2017a). This study proposed that FGF21 
achieves this through direct inhibition of FGF19 by binding to, but not signalling through, 
the βKlotho-FGFR4 binary complex. This suggests a role for crosstalk between 
endocrine FGFs in regulating metabolism, similar to that observed for FGF8b and 
βKlotho in modulating crosstalk between paracrine and endocrine signalling (Goetz et 
al., 2012a). These studies suggest an additional method of functional regulation of 
endocrine signalling through competition between FGFs for Klotho-FGFR complexes 
and between FGFs and Klotho co-receptors for binding to FGFRs, ultimately mediating 
the output effect on metabolism. However, spatiotemporal expression of different factors 
cannot be ruled out as a possible contributor to the outcome of signalling via these factors 









Figure 4.5 Location of a potential Klotho binding region in a hydrophobic ‘groove’ in the 
D3 domain of FGFR1c. Crystal structure of the ligand binding region of FGFR1c (D2-D3) shown 
as a surface and coloured red with the hydrophobic ‘groove’ coloured yellow (left panel) [PDB: 
1CVS] (Plotnikov et al., 1999). A close-up view of the D3 domain is shown as a cartoon against 
a surface and coloured red (right panel). The residues that make up the hydrophobic ‘groove’ in 
FGFR1c are shown as sticks against a surface and coloured yellow. Mutations at three residues 
shown to most strongly abrogate binding to αKlotho, βKlotho and FGF8b (Goetz et al., 2012a) 
are labelled in black. Mutations at other residues also shown to perturb binding to αKlotho and 




A therapeutic antibody has been found to compete with FGF21 for binding to βKlotho, 
and the discontinuous region on the KL1 domain of βKlotho implicated in binding 
encompasses residues 1-80 and 303-522, proposing that the FGF21 binding region on 
βKlotho might be (at least in part) on the KL1 domain (Foltz et al., 2012). It has also been 
proposed that the intracellular C-termini of βKlotho and FGFR1c might provide part of 
their binding interfaces (Ming et al., 2012), however this has not been directly 
demonstrated experimentally and is unlikely due to the very short intracellular domains 
of the Klotho proteins (Figure 4.2 and Table 4.1). Another study has proposed the D1 
domain of FGFR1c as an inherent inhibitor of formation of the FGF21-FGFR1c-βKlotho 
complex, while implicating the N-terminus of FGF21 in binding to the FGFR1c D2-D3 
region (Yie et al., 2012). Further work is needed to define the true and specific interfaces 







4.1.13 Stoichiometry of components of the ternary complexes 
So far, almost no experimental evidence exists defining the composition of the ternary 
signalling complexes with respect to the stoichiometry of proteins within the complexes. 
Three main working models for the functional ternary complexes were proposed, namely 
a 2:2:2, 1:2:1 and a 2:2:1 model of FGF-FGFR-Klotho components (Goetz and 
Mohammadi, 2013, Kilkenny and Rocheleau, 2016). Various studies have proposed 
similar models and some evidence has emerged supporting either the 2:2:2 complex 
(Yie et al., 2012, Comps-Agrar et al., 2015) or the 2:2:1 complex (Ming et al., 2012). It 
has also been suggested that the galectin lattice might play a role in mediating Klotho 
protein availability at the cell surface, particularly for βKlotho which has the most 
glycosylation sites of all Klotho family members (Figure 4.2 and Table 4.1), thus 
modulating complex formation as reviewed in (Kilkenny and Rocheleau, 2016). 
Additionally, the fact that Klotho proteins can bind to FGFRs in the absence of FGF 
ligands suggests that pre-formed Klotho-FGFR heterocomplexes might exist (if only 
transiently) prior to ligand binding, but the possible stoichiometries of such pre-formed 
heterocomplexes has only been partially and indirectly evaluated so far (Figure 4.6a). It 
is likely that all proposed stoichiometric models might exist in different contexts. 
Structural information at the molecular level is therefore much needed to resolve the true 
nature of the stoichiometry of components of the ternary complexes. 
 
4.1.14 Summary of endocrine signalling complexes and interactions 
Several studies have begun to elucidate the compositions and functional significance of 
Klotho-dependent endocrine signalling complexes. These studies have shown that 
signalling via FGF19 and FGF21 is βKlotho-dependent, in combination with different 
possible FGFR isoforms, while FGF23 signalling is αKlotho-dependent and occurs 
mostly through FGFR1c. The importance of FGFR1c and 4 has been rigorously 
confirmed, while the roles of FGFR2c and 3c in endocrine signalling remain to be 
deciphered and are likely context dependent. The predominant modes of action of the 
endocrine signalling complexes believed to be functionally important to date are 
summarised in Figure 4.3. Working models for proposed stoichiometries of the ternary 
complexes are summarised in Figure 4.6b In general, the tissue specific expression of 
Klotho family members and FGFR isoforms in vivo dictates the tissue selectivity and 










Figure 4.6 Current working models for receptor stoichiometries of endocrine ternary 
signalling complexes, before and after FGF ligand binding. (a) Possible receptor 
stoichiometries at the cell surface for FGFRs and α/βKlotho prior to FGF conjugation. Both FGFRs 
and Klotho co-receptors might exist in equilibrium between monomeric, homodimeric and 
heterodimeric inactive states. Dimeric states might represent ‘primed’ conformations for binding 
to FGFs. (b) Stoichiometries of proposed functional endocrine ternary signalling complexes, 
demonstrating the components of 1:2:1, 2:2:1 and 2:2:2 FGF:FGFR:Klotho complex 









4.1.15 Age related pathologies predominantly involving αKlotho 
Overexpression of the αKlotho ectodomain has been shown to suppress ageing and 
extend the lifespan of mice by specifically inhibiting insulin and insulin growth factor 1 
(IGF1) signalling, with no effects on EGFR or PDGFR (Kurosu et al., 2005). αKlotho 
overexpression in breast cancer cell lines first revealed its potential tumour suppressive 
properties (Wolf et al., 2008). It has since been implicated as a tumour suppressor in a 
range of cancers (Zhou and Wang, 2015). αKlotho is often depleted in early stage 
cancers due to epigenetic silencing of the Klotho gene by promoter hypermethylation as 
first shown in cervical carcinoma (Lee et al., 2010) and subsequently in a range of other 
cancers, reviewed in (Mencke et al., 2017). The protective and tumour suppressive roles 
of αKlotho in cancer are increasingly being evaluated (Xie et al., 2013) alongside its 
possible benefits as a biomarker for several diseases (Zhou and Wang, 2015). Similarly, 
βKlotho has independently been suggested to act as a tumour suppressor through 
FGF19-induced apoptosis of hepatoma cells (Luo et al., 2010), although this is in 
contrary to a much larger pool of evidence implicating FGF19 as a mitogen in 
hepatocellular carcinomas (discussed in section 4.1.19). The consequences of αKlotho 
deficiency have been implicated in a range of pathologies including acute kidney injury 
(Hu and Moe, 2012), chronic kidney diseases (Hu et al., 2013, Hu et al., 2012) and 
cancer and fibrosis (Mencke et al., 2017). FGF23 has also been found to be associated 
with chronic kidney disease and cardiovascular diseases (Kovesdy and Quarles, 2016), 
and all this evidence alludes to the FGF23-FGFR1c-αKlotho complex as a therapeutic 
target for several important age-related pathologies. 
 
4.1.16 Germline diseases caused by mutated FGF23 
Congenital gain-of-function mutations in FGF23 lead to the development of autosomal 
dominant hypophosphatemic rickets through stabilisation of the active form of FGF23 
(ADHR Consortium, 2000, White et al., 2001) while loss-of-function mutations lead to 
hyperphosphatemic familial tumoural calcinosis (Benet-Pages et al., 2005, Chefetz et 
al., 2005, Garringer et al., 2008). FGF23 also causes tumour-induced osteomalacia in 
humans (Shimada et al., 2001) and has once been implicated to possibly stimulate the 
progression of prostate cancer (Feng et al., 2015). 
 
4.1.17 Autocrine FGF19 signalling is an oncogenic driver in liver cancers 
It was found that FGF19, but not FGF21, could induce the proliferation of hepatocytes in 
an FGFR4-dependent manner (Wu et al., 2010, Wu et al., 2011). The importance of 
FGF19 in liver regeneration has also been confirmed in mice (Uriarte et al., 2013, Kong 
et al., 2014). The chromosomal locus harbouring the FGF19 gene has more recently 
been found amplified in hepatocellular carcinoma (and relevant liver cancer cell lines) by 
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several studies (Sawey et al., 2011, Guagnano et al., 2012, Kaibori et al., 2016). FGF19 
has also been found to act as a paracrine or autocrine stimulator of proliferation in 
hepatocellular carcinoma (Nicholes et al., 2002, Uriarte et al., 2015), as well as in other 
tumours such as in prostate cancer (Feng et al., 2013), ovarian cancer (Hu and Cong, 
2015) and hepatoblastoma (Elzi et al., 2016). A recent study demonstrated that 
amplification of FGF19 is the oncogenic driver for a subset of hepatocellular carcinoma 
which is dependent on FGF19 signalling via FGFR4 (Sawey et al., 2011). Amplification 
of FGF19 has also been shown to confer sensitivity to targeted FGFR inhibitors in 
specific subsets of liver cancer cell lines, but only when the βKlotho co-receptor and 
FGFR4 are co-expressed (Guagnano et al., 2012, Futami et al., 2017). Another study 
showed that chronic exposure to FGF19 for a year in mice can lead to hepatocellular 
carcinoma formation, but not if the N-terminal residues 23-42 and 50-57 are substituted 
by the corresponding residues of FGF21 (Ge et al., 2012). Together, this work strongly 
implicates the FGF19-FGFR4-βKlotho complex as an oncogenic driver and therapeutic 
target in hepatocellular (and possibly other) carcinomas, particularly for a subset of 
nearly a third of hepatocellular carcinomas which express FGF19, FGFR4 and βKlotho. 
 
4.1.18 Clinical adverse effects involving endocrine FGFR signalling 
Anti-FGFR targeting in the clinic, involving both multi-kinase and FGFR-specific 
inhibitors, has slowly progressed over recent years, as discussed in Chapter 1. Large 
advances have been made to develop potent and specific pan-FGFR inhibitors that 
predominantly target FGFR1-3 (Table 1.4). However, in contrast to multi-kinase inhibitors 
for which clinical toxicity normally involves off-target adverse effects via co-inhibition of 
other RTKs (Dieci et al., 2013, Shah et al., 2013b, Dienstmann et al., 2014, Soria et al., 
2014), it has been widely observed that the adverse side-effects in response to potent 
and specific pan-FGFR inhibitors in pre-clinical tumour models are most commonly due 
to on-target inhibition of endocrine FGFR signalling (Herbert et al., 2014). 
Hyperphosphatemia-mediated tissue calcification is the most common adverse outcome 
in pre-clinical in vivo models due to inhibition of FGF23 signalling (Brown et al., 2005, 
Dieci et al., 2013, Wohrle et al., 2013). It is expected that this and other side-effects will 
present in the clinic in response to FGFR-targeting with the most potent inhibitors, but 
early clinical data suggests that the adverse effects might be manageable and reversible 
by careful management (Nogova et al., 2017, Dienstmann et al., 2014). Better 
understanding of endocrine FGF23 signalling will help to create targeted agents to re-
activate signalling via this crucial pathway during inhibition of oncogenic FGFR signalling 
in the clinic, since adverse side-effects have so far prevented optimal anti-cancer 
targeting due to premature termination or dose reduction of the targeted therapy in the 
case of severe adverse effects (di Martino et al., 2016). 
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4.1.19 Endocrine FGFs as biologic therapeutics and biomarkers 
Involvement of endocrine signalling (predominantly through FGF19 and FGF23) in a 
range of cancers and inherited and metabolic diseases has led to interests in these 
molecules and their ternary signalling complexes as therapeutic targets. However, 
potential safety concerns of targeting FGF19-FGFR4 signalling in hepatocellular 
carcinoma have been emphasised due to possible adverse on-target effects such as on 
bile acid synthesis (Mellor, 2014). Moreover, the potential anti-diabetic, anti-obesity and 
life extending effects of FGF21 (which additionally does not exhibit the mitogenic 
activities seen with FGF19) have arguably fostered the most therapeutic interest in 
developing this hormone as a biologic therapeutic compared to the other two endocrine 
FGFs. One therapeutic antibody for X-linked hypophosphatemia (caused by elevated 
FGF23 levels) is the only endocrine FGF related therapy to date to reach Phase III clinical 
trials. A plethora of patents has been filed covering a multitude of variants and fusions of 
endocrine FGFs, therapeutic antibodies and various other agonists and antagonists as 
context dependent therapeutics. A current selected list of endocrine FGF related 
therapies at various stages of pre-clinical or clinical development is summarised in Table 
4.3. Additionally, the levels of endocrine FGFs have been found to be altered in the blood 
circulation of patients with various metabolic, cardiovascular and oncogenic diseases, 
reviewed in (Itoh and Ornitz, 2011, Itoh et al., 2015). Endocrine FGF levels in patients 
are therefore thought to serve as useful biomarkers for several metabolic, cardiovascular 




















Table 4.3 Selected endocrine FGF related therapeutics currently in pre-clinical or clinical 
development. mAb – monoclonal antibody, HSA – human serum albumin, PEG – 
polyethylene glycol, NYU – New York University, WMC – Wenzhou Medical College 
 
Name Description Company Reference 
1A6 Anti-FGF19 mAb Genentech (Desnoyers et al., 2008) 
LD1 Anti-FGFR4 mAb Genentech (French et al., 2012) 
U3-1784 Anti-FGFR4 mAb Daiichi Sankyo 
Clinical Trial 
NCT02690350 
sFGFR4 Soluble FGFR4 mimic, dominant negative – (Ezzat et al., 2001) 
BLU9931 
FGFR-paralogue specific 
irreversible anti-FGFR4 small 
molecule  inhibitor 
Blueprint 
Medicines (Hagel et al., 2015) 
NVP-FGF401 Anti-FGFR4 small molecule inhibitor Novartis 
Clinical Trial 
NCT02325739 










FGF21 Native FGF21 – – 
LY2405319 
Aggregation-resistant, improved 
stability FGF21 analogue 
(ΔHPIP, L118C, A134C, 
S167A) 
Eli Lilly (Kharitonenkov et al., 2013) 
FGF21/19 FGF21/19 chimera NYU (Goetz et al., 2012a) 
FGF211-171-WD22 FGF211-171-WD22 avimer Amgen (Smith et al., 2013b) 
Fc-FGF21 
Aggregation-resistant, improved 
stability, long acting FGF21 
analogue (FcIgG1, L98R, P171G) 
Amgen (Hecht et al., 2012) 
PEG-FGF21 PEGylated FGF21 analogues Amgen (Xu et al., 2013) 
PEG-FGF21 PEGylated FGF21 analogue WMC (Huang et al., 2011) 
ARX-618 PEGylated FGF21 analogue Merck (Mu et al., 2012) 
CVX-343 
FGF21 (ΔH1, A129C) 
covalently linked to IgG1κ mAb 
CVX200 
Pfizer (Huang et al., 2013a) 
FGF2/21 FGF2/21 chimera NYU (Goetz et al., 2012a) 
mimAb1 Anti-βKlotho / anti-FGFR1c-βKlotho mAb (FGF21 mimetic) Amgen (Foltz et al., 2012) 
C3201-HSA HSA-coupled FGFR1c-βKlotho bispecific avimer Amgen (Smith et al., 2013a) 
bFKB1 Anti-FGFR1c-βKlotho bispecific agonist mAb Genentech (Kolumam et al., 2015) 
KRN23 Anti-FGF23 neutralising mAb Ultragenyx (Yamazaki et al., 2008) 
FGF23 C-tail FGF23 C-terminal tail peptides NYU (Goetz et al., 2010) 
Klotho-FGF Klotho-FGF fusion peptides Novartis – 
sKlotho variants sKlotho variant polypeptides Novartis – 





Deregulated FGFR signalling is implicated in diverse aspects of tumourigenesis (section 
4.1.17 and Chapter 3) and in mediating on-target toxic side effects observed in response 
to treatment with potent and specific FGFR inhibitors in the clinic (section 4.1.18). 
However, despite their importance in modulating these effects, the endocrine sub-axes 
of FGFR signalling have so far been less well-studied than the ‘canonical’ paracrine 
modes of FGFR signalling presented in Chapter 1. Although considerable advances 
have been made in understanding the physiological roles of endocrine FGFR signalling 
in biology and pathophysiology, less is known about the molecular details in terms of 
structures, stoichiometry and protein-protein interactions of the ternary endocrine 
signalling complexes, and there are in fact no atomic structures for any of the Klotho 
proteins. Together, this provides a strong rationale to further study endocrine FGFR 
signalling proteins and complexes from a structural, biophysical and biochemical 
perspective. 
 
This work sought to characterise endocrine FGFR signalling complexes involving 
βKlotho, its cognate ligands FGF19 and FGF21 and FGFR1c from a structural and 
biophysical perspective.  To this end, bioinformatics analyses, homology modelling and 
analyses of existing crystal structures and the literature were used to design constructs 
for protein expression. Methods were then developed and optimised to express and 
purify protein components of the binary and ternary endocrine signalling complexes, and 
to assess the ‘foldedness’ and bioactivity of refolded recombinant proteins. Finally, 
preliminary biophysical experiments were performed to begin to understand the protein-
protein interactions involved in complex formation. This work will inform the rational 
design of therapies already in development for targeting deregulated endocrine FGFR 






4.3.1 Structural bioinformatics analyses of human βKlotho 
As discussed in section 4.1, there is a wealth of existing structural and biochemical 
information available for FGFR1 and little information about some endocrine FGFs. 
However, there is limited biochemical and no structural information available in the public 
domain for any of the full length Klotho proteins or their individual KL domains. Therefore 
to determine potential N- and C-terminal boundaries for βKlotho protein constructs to be 
recombinantly expressed in this work, there was a requirement for some in silico 
predictive structural bioinformatics analyses prior to construct design. A combination of 
tools including multiple sequence alignment, secondary structure prediction and 
homology modelling were utilised for this purpose. This analysis was then compared with 
constructs available commercially and from the literature. 
 
Sequence alignments of the predicted βKlotho KL1 and KL2 domains, as well as several 
other sequence alignments of human, mouse and rat αKlotho and βKlotho protein 
sequences were performed using the online multiple sequence alignment tool Clustal 
Omega (Sievers et al., 2011). It was found that human and mouse βKlotho share 79% 
sequence identity, with their individual KL domains sharing over 80% sequence identity. 
Human αKlotho and βKlotho share just 45% sequence identity, and human βKlotho KL1 
and KL2 domains only share 28% sequence identity (30% for the orthologous mouse 
domains). A Basic Local Alignment Search Tool (BLAST) search (Altschul et al., 1990) 
combined with assessment of the human KLB UniProtKB entry with accession #Q86Z14 
(The UniProt, 2017), and secondary structure predictions including predictions of 
secretion signal peptide and transmembrane regions using online tools SignalP 
(Petersen et al., 2011) and TMHMM (Krogh et al., 2001) helped in defining potential 
domain lengths and boundaries for the individual and combined KL domains. Construct 
boundaries used previously in commercially available recombinant proteins (R&D 
Systems, #5889-KB) and in the literature (Goetz et al., 2012a) were also considered. 
These sequence analyses are summarised in Figure 4.7 and Table 4.4. 
 
Homology models of human βKlotho KL1 and KL2 domains were generated separately 
using different templates due to the low sequence identity and similarity (28% and 36% 
respectively) between these two domains. A cyanogenic β-glucosidase (PDB: 1CBG, 
resolution 2.15 Å) (Barrett et al., 1995) was found to share 40% sequence identity with 
residues 66-505 of the KL1 domain. A cytosolic β-glucosidase, also called Klotho related 
protein (KLrP) (PDB: 2E9M, resolution 1.80 Å) (Hayashi et al., 2007) was found to share 





Figure 4.7 Summary of secondary structure prediction for human βKlotho. A compilation of 
several secondary structure prediction analyses performed in this work for full length human 
βKlotho (accession #Q86Z14)). Annotations have been displayed on the predicted sequence-
structure output from the Sequence Annotated by Structure (SAS) online tool (Milburn et al., 
1998). A putative signal peptide and transmembrane region are labelled, as predicted using online 
tools SignalP (Petersen et al., 2011) and TMHMM (Krogh et al., 2001). The short cytoplasmic 
domain (see Table 4.1) is also labelled. The predicted KL1 domain is coloured red based on 
sequence homology to β-glucosidases. Putative boundaries of KL1 and KL2 domains predicted 
by a combination of methods (Table 4.4) are marked with black triangles and labelled. Accession 
numbers for entries from the UniProtKB database for other αKlotho and βKlotho sequences used 
for multiple sequence alignments include human αKlotho (#Q9UEF7), mouse αKlotho (#O35082), 









Table 4.4 Extracellular βKlotho domain boundary annotations curated using in silico 
bioinformatics tools BLASTP (Altschul et al., 1990), UniProtKB (The UniProt, 2017) using 
accession #Q86Z14 (human KLB), Clustal Omega (Sievers et al., 2011), SAS (Milburn 
et al., 1998), SignalP (Petersen et al., 2011) and TMHMM (Krogh et al., 2001) or from 
expression constructs supplied from a commercial source (R&D Systems) or used in the 
literature (Goetz et al., 2012a). 
 





BLASTP + UniProtKB Human Predicted 77-508 517-967 
Clustal Omega (multiple 
sequence alignments) 
Human, 
mouse, rat Predicted 73-513 512-972 
SAS (secondary 
structure prediction) Human Predicted 73-508 513-962 
SignalP + TMHMM Human Predicted 53-996 
Commercial (R&D 
Systems, #5889-KB) Human 
Expressed (mouse 
myeloma cell line) 53-997 





generated the best-scoring homology models of KL1 and KL2 domains respectively (see 
section 2.19 for more details). The model structures are overlaid and compared in Figure 
4.8a. The KL1 and KL2 domain models appear structurally similar, despite their 
sequence diversity. They adopt a TIM-barrel fold predominantly consisting of eight 
parallel β-strands surrounded by eight stabilising α-helices forming a central core (Figure 
4.8c), similar to the structures of cyanogenic β-glucosidase and KLrP proteins from which 
the structures were modelled. The α-helices and β-strands alternate along the amino 
acid sequence and are occasionally interrupted by other small α-helix or β-strand 
insertions (Figure 4.8c). From these models, the spatial distribution of the two (KL1) and 
five (KL2) cysteine residues in each KL domain relative to each other (Figure 4.8b) 
suggests that intra-domain disulphide bonding is unlikely to occur. It is difficult to predict 
from these models of individual KL domains whether any of the cysteines might be 
involved in inter-domain or inter-molecular disulphide bonding. Only one cysteine is 
conserved between the KL1 and KL2 domains (C225 in KL1 and C677 in KL2) both in 
sequence alignment and in the structural model, but it is buried in the core structure and 
is not solvent exposed (Figure 4.8b). It is therefore unclear whether it might have any 







Figure 4.8 Homology models of human βKlotho KL1 and KL2 domains. (a) Model of human 
βKlotho KL1 (pink) overlaid with a model of human βKlotho KL2 (cyan) generated using the 
SWISS-MODEL web-based protein structure modelling workspace (Arnold et al., 2006). Two 
different templates were used for each KL domain, each with the highest sequence identity to 
each individual KL domain, selected from searches performed against the template library within 
the SWISS-MODEL workspace. Despite low (28%) sequence identity between the two KL 
domains, the homology models are very similar with an RMSD of 1.153. For full experimental 
details refer to text and see methods section 2.19. (b) Overlay of the same KL1 and KL2 models 
with all cysteine resides depicted as spheres for KL1 (pink) and KL2 (cyan), demonstrating that 
only one cysteine is conserved between the KL1 and KL2 domains (boxed and labelled) whose 
function is unknown. All cysteines within each KL domain are further apart than 2.05 Å (the length 
of a disulphide bond) so intra-domain disulphide bonding is unlikely to occur. However, it is difficult 
to infer putative intermolecular (between βKlotho monomers) or KL1-KL2 inter-domain (within the 
same βKlotho monomer) disulphide bonds from these models. (c) Overlay of the same KL1 and 
KL2 models highlighting their TIM-barrel structural fold. Eight parallel β-strands (blue) are 
surrounded by eight stabilising α-helices (green) forming a central core, with several insertions in 
between. Left and right panels show the same overlay from two different perspectives rotated 






Based on these combined analyses, it seemed most probable that βKlotho KL domains 
could reasonably be defined by boundaries 73-508 and 513-967 for the KL1 and KL2 
domains respectively, separated by a short KL1-KL2 linker. However, the N-terminal KL1 
boundary appears to be very close to a region of predicted secondary structure (Figure 
4.7). Additionally, the signal peptide is predicted to terminate between residues 52-53, 
therefore it is likely that the true N-terminus of the mature βKlotho protein exists at 
residue 53, supported by the constructs used in the literature (Table 4.4). The C-terminus 
of the extracellular region is predicted to terminate at residue 996. Therefore, based on 
all this information, the construct boundaries for the βKlotho KL1 and KL2 protein 
constructs for bacterial expression in this work were defined as 53-514 and 513-972 
respectively, and as 53-995 for the entire extracellular KL1-KL2 construct. These 
incorporate each entire KL domain surrounded by a few extra linker residues and are 
comparable to constructs produced by commercial sources and used in the existing 
literature. 
 
4.3.2 Bacterial expression constructs: design and expression testing in E. coli 
In order to reconstitute FGFR endocrine signalling complexes in vitro, purification of the 
three components of the ternary protein complexes (FGF, FGFR and Klotho) were 
required. Previous efforts by predominantly one research group have shown that human 
and mouse FGF19, FGF21 and extracellular FGFR1 proteins can be expressed and 
refolded from inclusion bodies produced in E. coli, for example (Plotnikov et al., 1999, 
Harmer et al., 2004, Kharitonenkov et al., 2005, Ryu et al., 2006, Wu et al., 2008, Asada 
et al., 2009, Xu et al., 2009, Yie et al., 2009, Beenken et al., 2012) while other groups 
have chosen to express the endocrine FGF proteins in diverse cellular systems including 
in mammalian, insect and yeast cell lines (Xie et al., 1999, Inagaki et al., 2005, Micanovic 
et al., 2009, Wu et al., 2011, Song et al., 2016). Some attempts have also been made to 
express and/or purify the ectodomains of the human βKlotho (Yie et al., 2009), mouse 
αKlotho (Kurosu et al., 2005, Goetz et al., 2010, Goetz et al., 2012b) and mouse βKlotho 
(Goetz et al., 2012a) proteins from insect or mammalian cells, while others have resorted 
to protein fusions to potentially solubilising modules such as human IgG1 Fc, expressed 
and purified from the conditioned media of CHO cells (Tohyama et al., 2004). 
Extracellular and full length FGFRs have also been previously expressed and purified 
from insect and mammalian cells by some commercial labs. 
 
In order to produce the large amounts of each recombinant protein required for this work, 
a panel of constructs was initially designed for expression testing in E. coli (Table 2.3). 
The basic design of these constructs is shown in Figure 4.9. Each endocrine FGF and 
βKlotho construct was synthetically codon-optimised for expression in E. coli and 
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comprised a PreScission™ protease-cleavable C-terminal 2StrepII-10His tag. Construct 
boundaries for FGFs were defined as the full length mature protein sequences without 
the N-terminal secretion signal peptide, whereas construct boundaries for βKlotho 
domains were determined based on the analyses in section 4.3.1. All constructs were 
also generated with and without a non-native N-terminal secretion signal peptide from E. 
caratovora pectate lyase B (pelB) or human serum albumin (HSA) proteins to test for 
periplasmic expression. The two extracellular FGFR1c constructs were generated using 
standard molecular biology subcloning techniques from a native human full length 
FGFR1c mammalian cDNA construct which was a gift (AstraZeneca). This construct 
comprised a C-terminal FLAG tag, but both subcloned extracellular FGFR1c constructs 
were engineered with the PreScission™ protease-cleavable C-terminal 2StrepII-10His 
tag. Construct boundaries were defined as either the full length extracellular region D1-
D3 without the N-terminal signal peptide, or the previously characterised D2-D3 domain 
construct (Plotnikov et al., 1999). Attempts were also made to subclone some of these 
FGFR1c and βKlotho constructs into the pTriEx™4 vector (Novagen) using a variety of 
different molecular biology techniques but this proved to be challenging and only a few 
constructs could be successfully generated (Table 2.3). For full methods see sections 
2.1 and 2.2.2. 
 
These constructs were then subjected to a series of small scale (2-5 mL) expression 
tests in E. coli C41 (DE3) cells. Additionally, E. coli XL10 Gold cells were employed to 
test for periplasmic expression based on a previously published protocol (Hage et al., 
2015). A variety of expression conditions were tested including different temperatures 
and durations of expression. Harvested cell samples were lysed and separated into 
soluble and insoluble fractions and analysed by SDS-PAGE and immunoblotting. Only a 
few constructs expressed reproducibly and these successful protein expressions are 
shown in Figure 4.10. The human βKlotho KL1 domain expressed well, both in the 
soluble and insoluble fractions, with increasing soluble expression upon lowering of the 
expression temperature down to 15°C (Figure 4.10a, left panels). The KL2 domain 
expressed best at 37°C and in inclusion bodies, with only weak soluble expression at 
lower temperatures (Figure 4.10a, right panels). The longer KL1-KL2 protein only 
expressed at 37°C and in inclusion bodies (Figure 4.10c). FGF19 and FGF21 and both 
lengths of extracellular FGFR1c expressed in inclusion bodies (Figure 4.10b and 4.10d), 
as expected from the literature (mentioned above in section 4.3.2). Expression of FGF19 
was reproducibly lower than FGF21 expression, similar to the expression pattern seen 
for the longer FGFR1c D1-D3 (22-374) compared to the shorter D2-D3 (142-365) 
construct. No periplasmic expression was observed for any of the FGF, FGFR or βKlotho 
constructs in either of the two E. coli strains tested (data not shown). Additionally, some 
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other βKlotho constructs expressed in one expression trial but could not be reproduced 








Figure 4.9 Bacterial expression constructs: design and nomenclature. Fundamental design 
of human endocrine FGF, FGFR1c and βKlotho constructs designed for E. coli expression. All 
constructs were codon optimised for expression in E. coli and comprised a PreScission™ 
protease-cleavable C-terminal 2StrepII-10His tag (light purple). All βKlotho constructs were also 
generated with and without a non-native N-terminal secretion signal peptide (light grey) from E. 
caratovora pectate lyase B (pelB) or human serum albumin (HSA) to test for periplasmic 
expression. (a) FGF19 (23-216) and FGF21 (29-209) construct boundaries were defined as the 
full length mature protein sequences without the N-terminal secretion signal peptide. (b) FGFR1c 
extracellular domain constructs were prepared as either the full length extracellular region 22-374 
(D1-D3) without the N-terminal signal peptide or the shorter length 142-365 (D2-D3) construct 
which has been used in the literature by several groups since its first use (Plotnikov et al., 1999) 
and comprises the minimal paracrine FGF ligand binding region of FGFRs. (c) βKlotho construct 
boundaries were defined based on the bioinformatics and manual literature mining analyses 










Figure 4.10 Successful recombinant protein expression from bacterial expression tests in 
E. coli. From the panel of bacterial expression constructs generated (Table 2.3 and Figure 4.9) 
those that expressed in E. coli reproducibly in either the soluble (S) or insoluble (IS) fractions from 
overnight expressions at different temperatures are shown here as identified by immunoblotting 
with the indicated anti-5His antibody. The corresponding Coomassie stained SDS-PAGE gels of 
IS fractions for which the recombinant proteins could be easily identified on the gels (proteins 
were normally indistinguishable on gels of S fractions due to the presence of too many proteins 
at the same molecular weights in crude lysates) are also shown for all constructs (upper panels). 
The correct bands on the SDS-PAGE gels corresponding to bands of recombinant proteins 
identified by immunoblotting are marked by asterisks in a and b. Gels and immunoblots shown 
are representative of at least three expression trials for each construct. For full experimental 
details see section 2.3.3. (a) Soluble expression of the βKlotho KL1 domain decreased when the 
expression temperature was increased. Very low levels of soluble KL2 domain could be detected 
at lower expression temperatures, but expression increased at higher temperatures with protein 
instead expressing in inclusion bodies in the IS fraction. (b) Both endocrine FGFs expressed only 
in the IS fraction, as expected from the literature (see section 4.3.2). (c) Expression of the entire 
extracellular region of βKlotho (comprising KL1-KL2 domains, also known as soluble Klotho) 
could only be detected in the IS fraction. (d) The longer length FGFR1c protein (D1-D3) expressed 
less well than the shorter length (D2-D3) construct, and both expressed only in inclusion bodies 





The KL1 and KL2 domain protein expressions were scaled up to test purification from 
the soluble fractions (using optimal expression temperatures as determined from the 
expression tests, Figure 4.10a) and in parallel to attempt refolding of the inclusion bodies. 
Soluble lysate was purified by affinity and ion exchange chromatography followed by 
analytical SEC. Representative chromatograms and gels are shown in Figure 4.11. Both 
KL1 and KL2 eluted in the void volume as soluble aggregates as a minor species 
alongside various contaminating proteins (Figure 4.11a, upper panel, and 4.11b, two left 
panels). It was not possible to dissociate these aggregates in the presence of high salt 
or reducing agent (Figure 4.11a, lower panel and 4.11b, two right panels). It was decided 








Figure 4.11 Purification of individual βKlotho KL1 and KL2 domain proteins from soluble 
expressions in E. coli. (a) Size exclusion chromatography (SEC) chromatograms for the final 
stage chromatographic purification of recombinant KL1 and KL2 domain proteins under normal 
salt (137 mM) and non-reducing buffer conditions (upper panel), and in the presence of high salt 
(1 M NaCl) or reducing agent (1 mM TCEP) for KL1 from a single experiment (lower panel). The 
asterisks label specific peaks and highlight KL protein eluting in the void volume under all buffer 
conditions tested. (b) SDS-PAGE analysis of proteins eluting in the peaks marked by asterisks in 
a, demonstrating the (lack of) purity of KL proteins. On the Coomassie stained gels, bands 
corresponding to KL proteins (based on similar results from pilot experiments, see Figure 4.10a) 
are indicated by matching asterisks to those in a. Chromatograms and gels shown are 
representative of five and four independent large scale purifications performed with soluble E. coli 






All inclusion body samples were washed sequentially with three different wash buffers 
prior to denaturation and refolding via several different workflows (Figure 4.12a-b). 
Inclusion body denaturation using 8 M urea was initially attempted but subsequently 6 M 
guanidine hydrochloride was used as the denaturant for all experiments due to its ease 
of use compared to urea, the latter of which is prone to crystallisation, particularly at high 
concentrations. Attempts to refold inclusion bodies for each KL domain protein led to 
precipitation of all protein during various stages of the refolding procedures (data not 
shown). A similar outcome emerged from scaling up and attempting to refold the KL1-
KL2 protein from inclusion bodes (Figure 4.12c). In the case of the FGFR1c proteins, 
refolding of the inclusion bodies appeared to be initially successful up to the stage of the 
Ni2+-NTA affinity chromatography step but all protein degraded during dialysis prior to 
the final SEC step (Figure 4.12d). The refolding conditions tested for all FGFR1c and 
βKlotho constructs in each case are detailed in Table 4.5. Due to the challenging and 
empirical nature of purifying proteins via inclusion body refolding, further experiments 
were not continued via such methods for these relatively large (for refolding) extracellular 
domain proteins following these unsuccessful refolding trials. 
 
 
Table 4.5 Specific refolding conditions tested for βKlotho and FGFR1c inclusion body 
(IB) preparations in this work. All refolding solutions also contained 2 mM L-cysteine and 
0.2 mM L-cystine (disulphide shuffling agents). It should be noted that dilute, low 
denaturing concentrations of guanidine hydrochloride and/or urea (from previous steps 
of IB denaturation and solubilisation) were also present in the final refolding solutions. 
CHAPS: 3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulphonate, PPS: 3-(1-
pyridinio)-1-propanesulphonate. 
 





KL1 Tris/ethanolamine [50] 8.0 0 PPS [1 M] 0.1 0 
KL2 
Tris/ethanolamine [50] 8.0 0 PPS [1 M] 0.1 0 
Tris [50] 8.5 100 L-arginine [0.5 M] 0 0 
KL1-KL2 
Tris [100] 8.0 100 PPS [1 M] 0.1 0 
Tris [100] 8.0 100 L-arginine [0.5 M] 0.1 0 
Tris [100] 8.0 100 CHAPS [80 mM] 0.1 0 
FGFR1c 
D1-D3 
HEPES [25] 7.5 150 Glycerol [10%] 0.25 1 
Tris [100] 8.5 100 L-arginine [0.5 M] 0.25 1 
Tris/ethanolamine [50] 8.0 0 PPS [1 M] 0.25 1 
Tris/ethanolamine [50] 7.0 0 PPS [1 M] 0.25 1 
FGFR1c 
D2-D3 
HEPES [25] 7.5 150 Glycerol [10%] 0.25 1 
Tris [100] 8.5 100 L-arginine [0.5 M] 0.25 1 
Tris/ethanolamine [50] 8.0 0 PPS [1 M] 0.25 1 







Figure 4.12 Inclusion body (IB) preparation, general refolding workflow and preliminary 
refolding trials for βKlotho and FGFR1c. All IBs expressed in E. coli were treated in the same 
way prior to denaturation and refolding. (a) The insoluble (IS) fraction (dark brown) containing IBs 
was sequentially washed with three different buffers to remove different protein and nucleic acid 
contaminants. Washed IBs (light brown) were then solubilised and denatured using guanidine 
hydrochloride (Gdn-HCl) prior to refolding. (b) Schematic representation of the general refolding 
workflow used for all protein IBs. All parameters were empirically determined based on 
observations made during refolding trials. Flexibility in the workflow was crucial for customising 
the method for individual proteins based on variables such as temperature, pH, ionicity and 
viscosity of the refolding solution while trying to minimise protein aggregation and precipitation. 
For full details of refolding conditions tested for βKlotho and FGFR1c, see Table 4.4, and for 
refolding and purification of FGF19 and FGF21 see Figures 4.13 and 4.14. (c) Immunoblots with 
the indicated anti-5His antibody showing the progression of the KL1-KL2 protein through the 
refolding workflow in a (left panel) and following refolding, dialysis, filtration and Ni2+-NTA affinity 
chromatography (right panel) as marked by the single asterisk. All KL1-KL2 protein precipitated 
during the refolding step prior to Ni2+-NTA affinity chromatography, under all three (1-3) refolding 
conditions tested (refolding condition details in Table 4.5). IS – insoluble fraction following E. coli 
lysate clarification, S – soluble lysate following E. coli lysate clarification, W1, W2, W3 – washes 1-
3 as in a, IB – washed IBs prior to solubilisation/denaturation with Gdn-HCl, PPT – refolding 
precipitate removed by filtration following dialysis and prior to Ni2+-NTA affinity chromatography, 
Elu – elution fractions following Ni2+-NTA affinity chromatography. (d) Coomassie stained gels 
representative of at least two independent refolding trials performed for FGFR1c D2-D3 (142-
365) under four (1-4) refolding conditions (details in Table 4.5) demonstrating partially successful 
purification of these proteins (marked by a single asterisk) following the Ni2+-NTA affinity 
chromatography step. All protein then degraded during dialysis prior to the size exclusion 
chromatography (SEC) step. A similar result was obtained with FGFR1c D1-D3 (22-374) which 
expressed more poorly than the D2-D3 construct, so this data is not shown. i – refolded protein 
prior to filtration, ii – refolded and filtered protein prior to Ni2+-NTA affinity chromatography, iii – 
elution fractions following Ni2+-NTA affinity chromatography, iv – dialysed Ni2+-NTA elution 
fractions prior to SEC (not filtered to remove precipitate), v – dialysed and filtered Ni2+-NTA elution 




4.3.3 Refolding of endocrine FGFs from inclusion bodies and quality control 
Of all the proteins expressed in inclusion bodies, two which were successfully refolded 
to produce soluble protein were FGF19 and FGF21. A refolding method adapted from 
one used previously to refold FGF19 (Harmer et al., 2004) was employed for both FGF19 
and FGF21. Inclusion bodies were first washed as described above (Figure 4.12a) and 
then subjected to several different refolding trials in parallel (Figure 4.13a). Optimal yields 
of the FGFs required one day under refolding conditions with L-cysteine/L-cystine as the 
disulphide shuffling agents, and overall FGF21 yielded larger amounts of protein than 
FGF19 (Figure 4.13b). The immunoblot in Figure 4.13b also suggested that extra days 
under refolding conditions did not appear to provide any advantage or disadvantage on 
final yields of FGF21, however FGF19 appeared to be less stable and more was lost 
through degradation when longer refolding durations were used. The affinity purification 
step also clearly provided the most efficient separation of FGFs from all other proteins in 
the refolding solution (Figure 4.13c). In contrast, ion exchange chromatography did not 
add any chromatographic benefit to the purification and was therefore eliminated from 
the optimised protocol (data not shown). 
 
From all the various purification ‘routes’ tested in the refolding workflow, the best method 
for both FGFs (that which ultimately produced the largest quantities of refolded, soluble 
protein) is highlighted in Figure 4.13a and detailed in Figure 4.14b. Expression of each 
FGF was then scaled up (Figure 4.14a) and the protein refolded and purified using this 
method. Representative SEC chromatograms and Coomassie stained SDS-PAGE gels 
demonstrating protein purity are shown in Figure 4.14c. Peaks on the chromatograms 
marked with a single asterisk comprised monomeric, soluble FGFs. Peaks marked with 
double asterisks comprised FGFs in soluble dimers or aggregates as well as various 
other protein contaminants. Protein in fractions from both monomer and aggregate peaks 
was separately retained, concentrated and stored until it was required for experiments. 
Figure 4.14c (upper and lower right panels) and 4.14f show the resulting purity of the 
concentrated proteins. 
 
In addition to the two endocrine FGFs, a full length human FGF1 wildtype protein was 
also produced as a control paracrine FGF for further experiments in which FGF19 and 
FGF21 were used. This protein was expressed in E. coli where it expressed abundantly 
in the soluble fraction (unlike FGF19 and FGF21 which only expressed in inclusion 
bodies in the insoluble fraction) and so it was purified from the soluble lysate. The FGF1 
construct design is shown in Figure 4.14d. A single peak was observed on the SEC 
chromatogram and this contained pure, monomeric FGF1 protein, demonstrated using 






Figure 4.13 Refolding trials for FGF19 and FGF21 expressed in inclusion bodies (IBs) in 
E. coli. (a) Schematic representation of the workflow used to test refolding conditions for 
recombinant FGF19 and FGF21 IBs based on a published protocol (Harmer et al., 2004). GSH 
and GSSG (reduced and oxidised glutathione) or L-cysteine and L-cystine (reduced and oxidised 
L-cysteine) were tested as disulphide shuffling agents. Refolding samples were taken after 1 day 
or 7 days under the different refolding conditions (condition ‘routes’ numbered 1-4). Various 
chromatographic steps were tested for the purification, in different orders post-refolding. The 
method found to be optimal for both FGFs is highlighted in the flow diagram (condition 3). (b) 
Immunoblot with the indicated anti-5His antibody showing relative soluble yields of FGF19 and 
FGF21 under various refolding conditions tested (numbered as in a), representative for two 
independent refolding trials performed for all ‘routes’ in the workflow shown. (c) Coomassie 
stained SDS-PAGE gel (upper panel) and corresponding immunoblot with the indicated anti-5His 
antibody (lower panel) showing the efficient separation of His-tagged recombinant FGF19 and 
FGF21 from the refolding solution using affinity (Ni2+-NTA) chromatography. FT and Elu refer to 
the flowthrough and eluate fractions after proteins from the indicated refolding ‘routes’ (numbered 









In order to assess the bioactivity of the refolded recombinant FGFs, a series of cell-based 
activity assays were set up. First, assays were set up to observe the effects of FGFs on 
downstream signalling in 3T3-L1 mouse adipocytes. The adipocytes can be generated 
in vitro from 3T3-L1 pre-adipocyte precursor cells using an established differentiation 
protocol (Zebisch et al., 2012). These adipocytes are known to express both FGFR1 and 
βKlotho upon differentiation, and have been shown to respond to both FGF19 and 
FGF21 in a dose dependent manner (Kurosu et al., 2007, Ogawa et al., 2007, Yang et 
al., 2012). For full experimental details see section 2.12. In a first experiment, cells were 
treated with a single low concentration of each recombinant endocrine FGF and FGF1 
(control). In a second experiment, mini dose response assays were set up whereby cells 
were treated with higher concentrations of each recombinant FGF or additionally with 
commercially available FGF19 and FGF21 (R&D Systems) as further controls. Cellular 
responses to FGFs were recorded in each case by monitoring the level of ERK 
phosphorylation (Figure 4.15a and 4.15c). Concurrently, the differentiation process of 
3T3-L1 pre-adipocytes to mature adipocytes was also followed by observing increased 
ERK phosphorylation over the course of the differentiation process (Figure 4.15b). In 
both the first and second assays the cells responded to FGF1 as depicted by elevated 
ERK phosphorylation, although the dose response was not very apparent at the highest 
concentration of FGF1 tested. In both experiments, there was a small increase in ERK 
phosphorylation for both FGF19 and FGF21 but the responses were not very clear and 
there was no obvious dose response for both the refolded FGFs and surprisingly also for 
the control commercially acquired endocrine FGFs. This assay was also repeated with 
lower concentrations of FGFs but produced similarly disappointing results (data not 
shown). 
 
It was therefore decided to apply circular dichroism (CD) spectroscopy to determine 
whether the recombinant FGFs were correctly folded. This useful biophysical technique 
can provide information about the secondary structural content (and therefore the 
‘foldedness’) of proteins, but cannot report on oligomerisation status or bioactivity. 
Despite this, validation of the ‘foldedness’ of the FGFs following in vitro refolding was 
considered the minimal requirement to proceed with the FGFs in further experiments. 
Based on the analysis of existing atomic structures of human FGF1 (more than 70 
structures in the RCSB PDB, e.g. PDB: 1RG8 and 2ERM) and FGF19 (PDB: 1PWA and 
2P23), these FGFs are expected to be composed of predominantly β-strands and 
unstructured loop regions, with little 310 and α-helical content (Figure 4.16). Therefore, if 
the recombinant FGFs were correctly folded, the resulting CD spectra would be expected 
to display a strong negative peak between the wavelengths at which the primary negative 
















Figure 4.14 Purification of refolded FGF19, FGF21 and FGF1 proteins. (a) Immunoblot using 
the indicated anti-5His antibody showing the relative expression of FGF19 and FGF21 in bacterial 
inclusion bodies. (b) Details of the final conditions and method developed for refolding of 
recombinant FGF19 and FGF21 based on refolding trials in Figure 4.13. (c) SEC chromatograms 
from the final stage of purification of FGF19 (upper left panel) and FGF21 (lower left panel) 
representative for one and three independent completed protein preparations of FGF19 and 
FGF21 respectively. The single asterisk highlights peaks containing monomeric, soluble FGFs, 
and adjacent Coomassie stained SDS-PAGE gels (upper and lower right panels) show the purity 
of the monomeric proteins. Double asterisks highlight peaks containing FGF protein aggregates 
as well as various other contaminants. Only monomeric protein preparations were used in further 
experiments in this work. (d) Schematic diagram showing construct design for the full length 
recombinant human FGF1 (16-155) protein expressed in this work. The plasmid construct was 
provided by Tom Bunney. Recombinant FGF1 protein expressed in E. coli using this construct 
was found in the soluble fraction (data not shown). (e) SEC chromatogram for the final stage of 
purification of FGF1 (left panel). The protein eluted in a single peak (marked by a single asterisk) 
which contained monomeric protein. SDS-PAGE analysis (right panel) shows the purity of the 
monomeric FGF1 used in further experiments in this work. (f) Coomassie stained SDS-PAGE gel 
(left panel) and corresponding immunoblot with the indicated anti-5His antibody (right panel) 
demonstrating the level of protein purity and degradation observed in purified preparations of 
recombinant FGF1, refolded FGF19 and two independently refolded FGF21 preparations (1 and 
2). Monomer (single asterisk) and aggregate (double asterisks) fractions are shown following 
variable durations of storage of concentrated purified proteins at -80°C. Bands corresponding to 
FGF19 and FGF21 (black asterisk) and FGF1 (red asterisk) are indicated adjacent to the SDS-





CD scans were measured for each recombinant FGF monomeric protein (protein from 
gels and SEC chromatogram peaks marked with a single asterisk in Figure 4.14c and 
4.14e-f) between 180-300 nm wavelengths. Two refolded and purified samples of 
independently prepared FGF21 proteins were included in the experiment, where they 
are referred to as ‘FGF21’ and ‘FGF21 (2)’. Data were processed and analysed using 
standard CD spectral analysis software and two independent online analysis algorithms 
(for full methods see section 2.20.2). Both analysis methods produced very similar final 
results, so the best quality data between 190-240 nm wavelengths from the better of the 
two analyses are displayed in Figure 4.17a. All four samples of FGFs displayed a strong 
negative peak between 203-206 nm, characteristic of proteins comprising largely a 
mixture of parallel and anti-parallel β-sheet and loop, turn or unstructured regions. The 
small differences in the nature of the negative peak for the two independently prepared 
FGF21 samples suggest an inherent susceptibility to conformational instability over 
different durations of long-term storage of the two protein preparations at -80°C. Overall, 
the CD traces compared well with secondary structural predictions from the published 
FGF atomic structures (Figure 4.16) and with previously published CD traces measured 
for FGF1 and FGF21 (Xu et al., 2012). Based on these results, the recombinant FGFs 








Figure 4.15 Bioactivity assays for refolded FGF proteins. (a) All FGFs activate ERK1/2 
signalling in 3T3-L1 adipocytes, to differing degrees. Differentiated 3T3-L1 adipocytes were 
stimulated with recombinant FGF1, FGF19 and FGF21 (80 ng/mL) for 10 minutes before the cells 
were harvested, lysed and analysed for activation of downstream signalling pathways. 
Immunoblots with the indicated antibodies representative of two repeats from a single experiment 
are shown in the left panel. The results from densitometric analyses performed on these data are 
displayed in the right panel. (b) Increases in ERK1/2 signalling upon differentiation of 3T3-L1 pre-
adipocytes to adipocytes. Differentiation was induced on Day 0, and cells were harvested and 
lysed on the indicated day post-induction of differentiation. Lysates were then analysed for 
activation of downstream signalling pathways using the indicated antibodies and the resulting 
immunoblots are shown. (c) An experiment similar to that in a was performed using higher 
concentrations of all recombinant FGFs as well as commercially obtained FGF19 and FGF21 
(R&D Systems, indicated by single asterisks). Resulting immunoblots are shown (left panel) and 
results from the densitometric analyses performed on these data are presented (right panel). For 
















Figure 4.16 Comparison of secondary structural composition of FGF1 and FGF19. Overlays 
of two crystal structures from the RCSB PDB for each of (a) human FGF1 [PDB: 1RG8 and 2ERM] 
(Bernett et al., 2004, Canales et al., 2006) and (b) human FGF19 [PDB: 1PWA and 2P23] (Harmer 
et al., 2004, Goetz et al., 2007) shown in cartoon representation and in the same orientation. The 
atomic models are coloured by secondary structure with α-helices (orange), 310 helices (yellow), 
β-strands (blue), turns (green) and loops (purple). The FGFs are composed of predominantly β-
strands and unstructured loop regions, with little 310 and α-helical content. The structures of 







Figure 4.17 Recombinant FGFs are folded and comprise primarily β-strands and 
unstructured / loop regions. Circular dichroism (CD) spectroscopy was employed to assess the 
foldedness of the recombinant FGFs. In each experiment, ten scans for each protein between 
180-300 nm wavelengths, were measured, averaged, reference subtracted and normalised using 
CDtool spectral analysis software (Lees et al., 2004). Some proteins were also scanned in two 
duplicate experiments. Processed data were analysed by multiple algorithms and the highest 
quality results from CDSSTR (Manavalan and Johnson, 1987) with reference dataset SP175 
(Lees et al., 2006) between 190-240 nm wavelengths are displayed. (a) Processed CD scans for 
each recombinant FGF showing experimentally measured values (open red circles) and non-
linear fits (continuous black lines) between 190-240 nm wavelengths. NRMSD values (Mao et al., 
1982) for the fits are displayed in square brackets, showing that data fits for all CD scans are 
robust. (b) Proportional secondary structure assignment for each FGF performed using the same 
algorithm as in a. Specific secondary structure content percentages are annotated around each 
pie chart. For full experimental details, see section 2.20.2. 
 
 
4.3.4 Redesigning FGFR1c and βKlotho constructs for mammalian expression 
As described in section 4.3.2, it was not possible to successfully purify extracellular 
domain constructs of any length tested of FGFR1c or βKlotho from expression in E. coli. 
Extracellular FGFR1c and βKlotho proteins have, however, been overexpressed and 
purified previously from mammalian cells by some commercial labs and academic 
groups, such as FGFR1 from Sf9 insect and HEK 293 cells (OriGene), human βKlotho 
from CHO cells (Yie et al., 2009) and mouse βKlotho from HEK 293 cells (Goetz et al., 
2012a). Therefore the FGFR1 and βKlotho expression constructs were next redesigned 
to test for overexpression in mammalian cell lines. All existing constructs were first 
codon-optimised for expression in mammalian cell systems. Non-membrane bound 
extracellular constructs were designed as fused to either the native (βKlotho) or a non-
native (human CD33) N-terminal secretion signal peptide. The construct boundaries 
were maintained for all FGFR1c and βKlotho constructs generated but this time the focus 
was on the longer βKlotho constructs (KL1-KL2 and full length) rather than the shorter 
length individual KL domain constructs. In addition, a full length native mouse βKlotho 
cDNA construct with a C-terminal fusion to eGFP (mβe) was obtained (Addgene) to add 
to the expression panel. This mouse construct was modified by the addition of an 
engineered protease cleavable C-terminal 6His tag to aid purification (mβTe6H). The 
designs of all mammalian expression constructs generated for this work are listed in 






Figure 4.18 Mammalian expression constructs: design and nomenclature. Fundamental 
design of FGFR1c and βKlotho constructs designed for mammalian expression. All human 
constructs (a-b) were codon optimised for expression in mammalian cells and comprised a TEV 
protease-cleavable C-terminal 2StrepII-10His tag (pink). Non-membrane bound extracellular 
constructs were also generated with the native (βKlotho, green) or a non-native (human CD33, 
orange) N-terminal secretion signal peptide. (a) Human FGFR1c extracellular domain constructs 
boundaries were the same as those used for bacterial expression. (b) Human βKlotho construct 
boundaries were the same as those used for the bacterial expression but with a focus on the 
longer KL1-KL2 constructs and the full length protein. (c) A full length mouse βKlotho cDNA 
construct with a C-terminal fusion to eGFP (mβe) was obtained (Addgene). A TEV-protease 
cleavable C-terminal 6His tag (bright red) was added to aid purification (mβTe6H). For full 
experimental details, see section 2.2.2 and refer to Table 2.4 for further construct information. 
 
 
These constructs were then put through a series of small scale (10 mL) expression tests, 
by transiently expressing the proteins first in FreeStyle™ 293F cells and later in 
Expi293F™ and CHO-EBNA GS cells. Samples of whole cells and media were analysed 
for each expression. Samples were taken every day for 3-4 days post-transfection for 
FreeStyle™ 293F expression tests. Samples were taken at 3 days (for proteins expected 
to be intracellularly expressed) and 7 days (for proteins expected to be secreted into the 
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medium) post-transfection for Expi293F™ and CHO-EBNA GS expression tests. 
Representative results for all constructs with observable expression are summarised in 
Figure 4.19. In FreeStyle™ 293F cells, the longer length FGFR1c D1-D3 protein was 
reproducibly secreted in large quantities into the medium, while the shorter length 
FGFR1c D2-D3 protein was also secreted into the medium but in lower quantities and 
less reproducibly (Figure 4.19a). In Expi293F™ and CHO-EBNA GS cells a similar 
pattern of secretion and reproducibility was observed for these two proteins, one of which 
could be expressed in both cell types and from two different expression vector 
backbones (Figure 4.19b). Disappointingly, none of the human βKlotho proteins could 
be detected in either cells or media in any expression tests performed in FreeStyle™ 
293F cells (data not shown). Very little mβTe6H expression could be detected in these 
cells (Figure 4.19d). Some of the human and mouse βKlotho proteins were detected in 
expression tests in Expi293F™ and CHO-EBNA GS cells, however those expected to 
be secreted into the medium were detected intracellularly (Figure 4.19d and 4.19f). 
Additionally, an experiment performed in Expi293F™ cells co-transfected with the 
FGFR1c D1-D3 construct and one of the βKlotho KL1-KL2 constructs revealed that while 
co-expression appeared to reduce the production of secreted FGFR1c, larger quantities 
of βKlotho KL1-KL2 could be detected in the co-transfected cells, albeit still not secreted 
into the medium as should be expected (Figure 4.19e). Preliminary attempts were made 
to extract and purify all these visibly expressing extracellular KL1-KL2 and FL βKlotho 
proteins from cell lysates but this proved to be challenging and none of the proteins could 
be extracted into the soluble fraction from these samples (Figure 4.19g). Purification of 
the abundant extracellular FGFR1c proteins was successful, and is detailed in section 
4.3.5. 
 
Little expression of the full length human and mouse βKlotho proteins could also be 
detected in both Expi293F™ and CHO-EBNA GS cells (Figure 4.19f). However, it was 
not possible to extract these proteins into the soluble fraction for purification using 
standard extraction methods (Figure 4.19g). It was hypothesised that suspension cells 
might not provide an optimal environment to express these membrane proteins. To 
determine whether this might be the case, expression of both the mβe and the mβTe6H 
constructs was tested in HEK 293T cells and followed by monitoring the green 
epifluorescence of the C-terminal GFP fusion tag. In these cells, both mouse βKlotho 
constructs were expressed and the proteins appeared to localise to the plasma 
membrane as expected (Figure 4.20a-b). This promising result led to a medium-scale 
expression trial of mβTe6H in these cells, followed by a detergent extraction of the 






















Figure 4.19 Successful recombinant protein expression from mammalian expression tests 
in HEK 293F and CHO cells. From the panel of mammalian expression constructs generated 
(Table 2.4 and Figure 4.18) those that expressed from FreeStyle™ 293F (F293F), Expi293F™ 
(E293F) or CHO-EBNA GS (CHO-EG) suspension cells are depicted here by immunoblotting 
using the indicated antibodies. Cells were transiently transfected on Day 0 and samples were 
taken 1-7 days post-transfection. Transfection of E293F and CHO-EG cells was performed at 
AstraZeneca using their cell lines under the supervision of David Fisher. Secreted protein 
expression was analysed in conditioned media (Med) while intracellular protein expression was 
analysed in whole cell lysates (Lys) comprising both soluble (S) and insoluble (IS) fractions. 
Numbering of constructs is as in Table 2.4 and Figure 4.18. In all anti-KLB immunoblots, the lower 
molecular weight band detected in E293F samples (at approximately 100 kDa) corresponds to a 
non-specific band (validated by probing a non-specific lysate with the anti-KLB antibody, data not 
shown). (a) Secreted expression for FGFR1c constructs from F293F cells with samples taken 1-
4 days post-transfection. Immunoblots show results from two out of three independent expression 
tests for each construct, demonstrating the reproducibility of expression of the D1-D3 construct 
(45) while the D2-D3 construct (46) only expressed in two out of three expression tests. (b) 
Expression of all FGFR1c constructs from E293F and CHO-EG cells with samples taken 7 days 
post-transfection. (c) Expression of all human βKlotho extracellular constructs from E293F and 
CHO-EG cells with samples taken 7 days post-transfection. (d) Expression of mouse full length 
βKlotho constructs from F293F cells with samples taken 1-2 days post-transfection. (e) Co-
expression of human FGFR1c and βKlotho constructs F1 and K3 (this transfection was performed 
at AstraZeneca by David Fisher) from E293F cells with samples taken 3 days post-transfection. 
(f) Expression of human and mouse full length βKlotho constructs from E293F and CHO-EG cells 
with samples taken 3 days post-transfection. (g) The mβe, 41 and K3 Lys samples from E293F 
and CHO-EG cells were further separated into S and IS fractions to test extraction and purification 
for each protein. The non-specific band was found in the S fraction while the Klotho bands were 
found in the IS fraction. The immunoblots show results for mβe, representative for S/IS 
separations of all three proteins. For full experimental details, see section 2.17 and refer to Table 







other proteins in this work. The protein was only partially extracted into the soluble  
fraction by this method and the resulting solubilised protein proved challenging to purify 
further (Figure 4.20b, right panel). To further optimise the purification procedure, a 
detergent screen was performed to determine if the protein could be better extracted 
using a different detergent (Figure 4.20c). Promising preliminary data emerged from this 
screen, as all the detergents screened performed better at mβTe6H extraction than 
Triton X-100, with the non-ionic detergent n-decyl-β-D-maltopyranoside (DM) providing 
the best extraction. Further experiments using these detergents, and possibly their 
combinations, to extract βKlotho proteins might eventually lead to success in purifying 








Figure 4.20 Extraction of GFP-tagged mouse βKlotho expressed in HEK 293T cells. HEK 
293T cells were transiently transfected with each GFP-tagged mouse βKlotho construct and 
expression was monitored visually by green epifluorescence microscopy and biochemically by 
immunoblotting using the indicated antibodies over a 48 hour time period. Scale bars represent 
62.5 μm. BF – brightfield, GFP – green fluorescence protein (green epifluorescence). (a) Cells 
transiently transfected with the mβe construct (or a non-transfected control) for 24 or 48 hours 
showed mβe expression through green epifluorescence (left panel) and immunoblotting of whole 
cell lysates (WCL) with the indicated antibodies (right panel). (b) Cells transiently transfected with 
the mβTe6H construct (or a non-transfected control) for 24 or 48 hours showed mβTe6H 
expression through green epifluorescence (left panel) and immunoblotting of WCL, S and IS 
fractions with the indicated antibodies (right panel). Results are representative of four 
independent experiments. (c) Detergent screen for solubilisation of mβTe6H expressed in the 
insoluble (IS) fraction. Solubilised mβTe6H was detected by immunoblotting using the indicated 
antibodies. CHAPS – (3-((3-cholamidopropyl)-dimethylammonio)-1-propanesulfonate), Cymal-5 
– 5-cyclohexyl-1-pentyl-β-D-maltoside, DM – n-decyl-β-D-maltopyranoside, DDM – n-dodecyl-β-
D-maltoside, OG – octyl glucoside, SDS – sodium dodecyl sulphate. For full experimental details, 




4.3.5 Purification of FGFR1c proteins 
As demonstrated in section 4.3.4, extracellular FGFR1c proteins can be recombinantly 
expressed in suspension mammalian cells (Figure 4.19a-b). The longer length FGFR1c 
D1-D3 protein was abundantly secreted from all three cell types tested, whereas the 
shorter length D2-D3 protein was less robustly expressed. Attempts to purify the D2-D3 
protein proved challenging and due to the lower yield of this protein further purification 
was not attempted from the small-scale expression tests (data not shown). However, the 
more-physiologically relevant FGFR1c D1-D3 proteins were all successfully purified from 
all expression test media samples using a combination of affinity chromatography and 
SEC (detailed methods in section 2.18). SEC chromatograms, Coomassie stained SDS-
PAGE gels and immunoblots used to demonstrate protein purity are shown in Figure 
4.21. Protein purified from CHO compared to 293F cells ran at a slightly higher molecular 
weight on the gels, possibly revealing different glycosylation states of protein produced 
by the two cell types. Expression in the Expi293F™ cell line yielded the largest quantities 
of FGFR1c protein at 60 and 130 mg/L (respectively from pcDNA3.1 and pEBNAZ 
expression  vector backbones), while the FreeStyle™ 293F cells yielded 30 mg/L and 
CHO-EBNA GS cells yielded  45 mg/L. The sheer abundance of these proteins facilitated 
their successful purification from just 10 mL expression cultures. All four FGFR1c D1-D3 
protein preparations were estimated from SDS-PAGE analysis to be more than 95% pure 
(Figure 4.21b) and suitable for use in further experiments. 
 
4.3.6 Preliminary characterisations of endocrine FGF-FGFR1c binary complexes 
To begin to understand the protein-protein binding interactions involved in endocrine 
FGFR signalling complexes, initial characterisations of the endocrine FGF-FGFR1c 
binary complexes were performed using biophysical methods. As it was not possible to 
purify any βKlotho proteins to completion, no in vitro binding experiments could be 
performed in this work to characterise the FGF-FGFR1c-βKlotho ternary signalling 
complexes. The binary heteromeric complexes formed between FGF19-FGFR1c and 
FGF21-FGFR1c, prepared with recombinant proteins purified in this work, were analysed 







Figure 4.21 Purification of FGFR1c proteins. (a) Overlay of size exclusion chromatography 
(SEC chromatograms for the final stage of purification of all four recombinant FGFR1c D1-D3 
proteins expressed in mammalian suspension cell lines. A single asterisk highlights the peak 
containing monomeric, soluble FGFR1c protein for each preparation. (b) Purified FGFR1c 
proteins from the SEC peaks marked by a single asterisk in a from expression in all four 
mammalian cell lines visualised by Coomassie stained SDS-PAGE analysis. From this analysis, 
protein was estimated to be more than 95% pure. (c) Immunoblotting using the indicated 




One of the best methods to study such biophysical properties is isothermal titration 
calorimetry (ITC). This technique can report on all parameters of binding interactions 
concurrently and in a single experiment, such as affinity, enthalpy, entropy and 
stoichiometry of binding of biomolecules in their native label-free state in solution. ITC 
measures the heat transfer during binding by gradually titrating one binding partner into 
the other in solution, providing a thermodynamic profile of the binding interaction. For 
these reasons, ITC was employed as a starting point for quantitatively characterising 
these protein-protein interactions. The MicroCal™ iTC-200 instrument (Malvern) was 
used for these experiments. FGF1 and FGF21 ligands were independently titrated into 
FGFR1c in the sample cell in two independent experiments each. Unfortunately, it was 
not possible to measure heats of interaction for either of the FGF ligands in the single 
buffer and at the single temperature (25°C) tested, despite a contrived fit attempted for 
FGF1 (Figure 4.22). It was thought that optimising these experiments further might 
consume too much protein sample, of which the FGFs were particularly challenging to 





Figure 4.22 Isothermal titration calorimetry (ITC) experiments were unsuccessful for the 
interrogation of FGF-FGFR binary complex interactions. Pilot ITC experiments performed 
using FGFR1c and a ten-fold molar excess of recombinant FGF ligands (a) FGF1 or (b) FGF21 
were largely unsuccessful for probing the binding interactions between these proteins using the 




Previous attempts have been made to characterise FGF-FGFR1c-βKlotho interactions 
using surface plasmon resonance (SPR) experiments (Goetz et al., 2012b), albeit using 
the shorter FGFR1c D2-D3 protein rather than the longer and more physiologically 
relevant FGFR1c D1-D3 protein prepared in this work. In order to determine whether it 
was possible to reproduce these data, preliminary SPR experiments were performed 
with FGFR1c D1-D3, FGF19 and the two independent preparations of FGF21 prepared 
in this work. The Biacore™ T200 system (GE Healthcare) was used for the experiments. 
Each FGF was immobilised (using the C-terminal 10His tag) on three out of four flow 
cells of an NTA sensor chip, leaving the first flow cell empty as a reference cell to record 
background response including non-specific binding of FGFR1c D1-D3 (the analyte) to 
the chip surface. Different concentrations of analyte were then flowed simultaneously 
over each flow cell using a flow rate of 30 μL/min. Representative sensorgrams and 
equilibrium dissociation constant (KD) values for each interaction are shown in Figure 
4.23. The maximum response (Rmax) for all active flow cells was lower than expected 
based on the levels of FGFs immobilised (Table 4.6) suggesting that the FGFs were only 
partially or heterogeneously active. A decrease in response was observed at the end of 




due to analyte protein sticking to the microfluidics. To minimise inaccuracy, the steady 
state response values used to calculate KD values were taken at 90 seconds post-
injection of analyte. Although it was possible to determine preliminary KD values for the 
FGF-FGFR interactions from these pilot data, it was not possible to fit the data to any 
kinetic model within the Biacore™ T200 evaluation software. This might be due to FGF 
ligand heterogeneity or possibly due to transient homodimerisation of FGF and/or 
FGFR1c analyte proteins in addition to FGF-FGFR heterodimerisation. The KD values 
measured here were two orders of magnitude lower than those determined previously 
(Figure 4.23 and Table 4.6), although the FGFR1c construct used to assess binding in 
this work is longer by an entire Ig-like domain than the FGFR1c protein used in the 
previous study which lacks the D1 domain (Goetz et al., 2012b). Although early evidence 
proposed roles for the D2 and D3 domains in binding to the endocrine FGFs, this was 
proposed following experiments performed using FGFR proteins lacking the D1 domain, 
and therefore the potential importance of the D1 domain in binding to endocrine FGFs 
cannot be ruled out. Perhaps the preliminary KD values measured here (Figure 4.23 and 
Table 4.6) do indeed suggest a putative role for the FGFR D1 domain in conjugation of 
FGFs within the endocrine ternary complexes, but need to be directly compared with KD 
values measured with the D2-D3 protein as well to confirm this. These pilot data provide 
a useful starting point to further probe these interactions. Further optimisations of these 
experiments will provide more accurate information about the true binding affinities and 
kinetics involved in binding of the endocrine FGFs to FGFR1c. This will help to begin 
characterisation of the protein-protein interactions involved in the binary and ternary 





Table 4.6 Comparison between preliminary equilibrium dissociation constants (KD) for 
endocrine FGF-FGFR binary interactions measured by surface plasmon resonance 
(SPR) in this work (± standard error) and by a similar study. Other SPR parameters from 
the preliminary experiments in this work are also reported. RU – response units. 







KD FGF19-hFGFR1c 1.91 µM 68.1 ± 2.1 nM 12.6 6.4 
KD FGF21-hFGFR1c 2.52 µM 
53.8 ± 2.2 nM 13.9 13.7 






Figure 4.23 Surface plasmon resonance (SPR) experiments provide preliminary binding 
affinities for the endocrine FGF-FGFR binary interactions. Preliminary SPR experiments were 
performed by immobilising recombinant (a) FGF19, (b) FGF21 and (c) FGF21 (2) on three flow 
cells of an NTA sensor chip (Table 4.6) using their C-terminal 10His tags, leaving the first flow 
cell empty to serve as a reference flow cell. Recombinant FGFR1c (from F293F cells, Figure 4.21) 
at increasing concentrations between 0-250 nM (purple – red traces) was then flowed over the 
flow cells and responses recorded. Sensorgrams (left panels) and steady-state responses used 
to calculate the equilibrium dissociation constants (KD) (right panels) are shown and are 
representative of two independent experiments performed under slightly different buffer 
conditions (0.05% and 0.005% Tween® 20). The KD values ± standard error calculated from the 
non-linear fits are indicated. Data were analysed using the Biacore™ T200 software (Biacore). 





A wealth of research into the canonical modes of paracrine FGFR signalling has shed 
light on its importance in all aspects of developmental and metabolic homeostasis. 
However, the endocrine sub-axes of FGFR signalling have been much less well 
researched, particularly from a biochemical and structural perspective. Therefore, 
despite the importance of these signalling complexes in regulating a number of vital 
metabolic processes and malignant outcomes, a lot of molecular-level information linking 
structure to function is currently lacking. This information is required to elucidate the 
molecular mechanisms by which the Klotho co-receptor family play a role in both normal 
and deregulated FGFR signalling. This will inform the design of endocrine FGF biologic 
drug candidates and anti-endocrine FGF therapeutics currently in pre-clinical and clinical 
development for the treatment of metabolic diseases and cancer. 
 
In this chapter the foundations have been laid to investigate endocrine FGFR signalling 
complexes from a structural, biophysical and biochemical perspective. There was a focus 
on investigating the sub-axes of signalling complexes involving the most important 
FGFR, FGFR1c, with its co-receptor βKlotho and the cognate ligands to their binary 
complexes, FGF19 and FGF21. Combinations of bioinformatics and literature searching 
methods were used to determine construct lengths for the production of expression 
competent constructs for all three protein components of the ternary complexes. In vitro 
experiments were employed to begin to establish analytical routes to study these protein 
complexes further. The experimental part of this work proved to be very challenging, 
involving a lot of method development as well as optimisation of previously published 
protocols which often omit the detailed experimental methods needed to reproduce them. 
This work progressed from the difficult molecular biology stages to preliminary 
biophysical characterisations of binary complexes with two out of three purified 
components of the ternary signalling complexes. Robust methods to express and purify 
these two components have been presented, and progress was made in recombinantly 
producing human βKlotho proteins from E. coli and mammalian cells. The most 
encouraging results for production of the larger extracellular proteins came from 
expression tests in mammalian cells, which have been less commonly used in the 
literature to produce these recombinant proteins for in vitro studies. Several methods 
and experiments that proved unsuccessful with these materials can be ruled out for 
future research involving these complexes. In this section, both the technical and 





4.4.1 Bioinformatic analyses used to guide experimentation and drug discovery 
There is a complete lack of structural information available for all Klotho proteins and any 
of the individual KL domains. This could be because, as in this work, the Klotho KL 
domains and longer Klotho proteins proved challenging to produce recombinantly in 
terms of cDNA manipulation, molecular biology and stages of protein overexpression 
and purification. Structural information of the extracellular Klotho domains would aid in 
the rational design of endocrine FGF related therapeutics for the treatment of several 
diseases including diabetes, obesity, cancers and genetic diseases (see section 4.1). To 
alleviate some of the structural challenges, a combination of sequence analyses, in silico 
modelling approaches and comprehensive literature searching were undertaken for 
βKlotho and its individual KL domains in order to inform experimental planning. Multiple 
sequence alignments, secondary structure prediction tools and homology modelling 
based on the most closely related protein structures available in the RCSB PDB provided 
a useful starting point to determine probable KL domain boundaries and therefore protein 
construct boundaries for recombinant expression. The low degree of sequence 
conservation between KL1 and KL2 domains, despite a high degree of apparent 
structural similarity, made boundary selection challenging. Evaluation of βKlotho proteins 
expressed and purified by others (Table 4.4) coupled with multiple bioinformatics 
analyses proved most useful in helping to define the lengths of KL domain proteins 
expressed in this work. Further fine-tuning of the construct boundaries might help to 
improve soluble yields of the individual KL domain proteins; this remains to be tested 
experimentally. Nevertheless, the fact that some degree of expression and purification 
was possible for both KL1 and KL2 domain proteins might suggest that more stringent 
chromatographic purification will eventually lead to the production of purer protein 
preparations. This might also facilitate resolution of the protein aggregation problem or 
alternatively, detergent screening during protein extraction (similar to that performed for 
the full length mouse βKlotho) might help identify different routes to purify these proteins 
to a final soluble and non-aggregated state. 
 
The homology models of the βKlotho KL1 and KL2 domains generated in this work 
provided valuable information about expected secondary and tertiary structure of these 
experimentally structurally uncharacterised domains. This was useful in developing 
protein purification methods and will complement future experimental structural studies. 
The models can be used to aid the design of site-directed mutagenesis experiments to 
elucidate KL domain function and probe inter-protein binding interfaces. The models are 
also very similar to models created recently for the αKlotho KL1 domain (Wright et al., 
2017) and part of the βKlotho KL1 domain (Ming et al., 2012) adding a level of validity in 
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using these models to inform structure-based design of βKlotho related therapeutics in 
a case where atomic structures might be challenging to obtain. 
 
Sequence divergence of the two βKlotho KL domains might suggest that each KL domain 
has sequence specific roles, for example in ligand binding or dimerisation. Therefore 
although the primary aims of this work were to reconstitute the entire extracellular (or full 
length) endocrine signalling complexes, it was interesting to additionally prepare proteins 
of each individual KL1 and KL2 domain with the aims of elucidating their potential roles. 
Although optimisations are still required to purify soluble monomeric versions of these 
recombinant proteins (discussed above), the basis for expression and purification from 
E. coli has been established in this work. Additionally, secretion of these KL domains 
from mammalian cell systems should be considered to produce sufficient protein as 
required for structural and biophysical experiments. This was done recently to 
recombinantly produce a secreted splice variant of the αKlotho KL1 domain (Wright et 
al., 2017), although the authors gave no indication of the final protein yields from 
expression in HEK 293 cells. With sufficient protein, further work might then try to define 
the roles of each KL domain in binding to FGFs, FGFRs and possibly in βKlotho 
homodimerisation, if this occurs (currently unknown). Paired with in silico protein-protein 
docking, site-directed mutagenesis and solvent exclusion studies (such as using 
hydrogen-deuterium mass spectrometry or nuclear magnetic resonance experiments), it 
should soon be possible to define the specific sequences involved in the interactions of 
the ternary complexes. Simple native PAGE or analytical SEC experiments could also 
be used to assess the ability of each KL domain to dimerise with other KL domains and/or 
FGFs and/or FGFRs. 
 
Another debate that remains unresolved concerns the implied β-glucuronidase and α2,6-
sialidase enzymatic activities of the KL domains (Chang et al., 2005, Tohyama et al., 
2004, Cha et al., 2008) despite these domains lacking crucial catalytic aspartates needed 
for glycosyl hydrolase activity (Figure 4.2). A recent study suggested that a secreted 
version of the αKlotho KL1 domain may be sufficient for binding to α2-3-sialyllactose 
(Wright et al., 2017). This adds to the range of substrates implicated in being bound 
and/or metabolised by Klotho proteins. It might also exemplify the possibility of sequence 
specific roles for the different KL domains. Indeed, KL domains from different Klotho 
family members might target diverse and context-dependent substrates depending on, 
for example, tissue specific expression. An example from within the β-glucosidase type 
I family comes from the S. alba myrosinase. This enzyme is a β-glucosinolase but one 
of the two essential glutamate residues conserved across the rest of the β-glucosidase 
type I family has been replaced by glutamine in the myrosinase (Burmeister et al., 1997). 
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Instead, this enzyme has a modified function as an S-glycosidase (instead of an O-
glycosidase) and catalyses its substrate with the help of an ascorbate co-factor that 
replaces its need for the ‘missing’ catalytic aspartate (Burmeister et al., 2000). Similarly 
for the KL domains, sequence variation of the catalytic aspartates may indeed have 
altered putative enzymatic activities of the KL domains. Alternatively, combined with the 
existence of multiple putative glycosylation sites on the Klotho proteins (Figure 4.2 and 
Table 4.1), the deviation of catalytic residues from consensus sequences could have 
important implications for cell surface signalling whereby binding to various carbohydrate 
moieties might play vital roles in determining the tissue specificity of Klotho related 
signalling, without the necessity for carbohydrate catabolic activities. High-throughput 
screening of carbohydrates for their ability to bind Klotho proteins or individual KL 
domains, coupled with in silico docking studies using different carbohydrate moieties and 
the homology models produced in this work, should help to narrow down possible 
candidates for further testing in quantitative in vitro enzyme-substrate metabolic activity 
assays. This, combined with future structural information, should help to resolve this 
currently open question. 
 
4.4.2 Refolding inclusion bodies: an empirical method of ‘last resort’? 
Attempts were made to refold both endocrine FGFs and FGFR1c proteins expressed in 
inclusion bodies in E. coli in this work. Despite closely following what was available of 
published protocols (see section 4.3.2), it proved to be challenging to produce sufficient 
amounts of folded FGFR1c protein via such methods. Refolding proteins from inclusion 
bodies might be an empirical method of ‘last-resort’ which can be employed successfully 
for proteins such as relatively small growth factors and even FGFs, as reported above, 
but has proved difficult with larger proteins. In this work, the problems incurred with trying 
to refold FGFR1c proteins led to attempts to express them using secretion from 
mammalian expression systems. All suspension mammalian expression systems tested 
in this work yielded large quantities of soluble, non-aggregated FGFR1c protein. In fact, 
superior expression was observed for the longer length extracellular FGFR1c protein via 
these methods in terms of both yield and quality of the protein; this is the more 
physiologically relevant construct compared to the shorter length D2-D3 protein used in 
the majority of previous structural studies and binding experiments in the literature 
(section 4.3.2). Mammalian systems are rapidly gaining popularity for protein 
overexpression, even for structural studies, perhaps because the relative length of time 
and costs involved compared to bacterial expression systems might be worthwhile if the 
ultimate rates of success in robust protein production are higher. These potential benefits 
remain to be evaluated including for the proteins produced in this work. Additionally, for 
biochemical and biophysical experiments using human proteins, recombinant proteins 
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produced in mammalian cells are more likely to be natively or near-natively post-
translationally modified, including glycosylation or smaller chemical modifications such 
as phosphorylation or acetylation. Modifications such as glycosylation can be crucial for 
protein function and intra- and inter-complex interactions of the ternary signalling 
complexes being investigated in this work, as both FGFRs and Klotho proteins have 
several glycosylation sites on their extracellular domains (see Figure 4.2 and Table 4.1 
for Klotho glycosylation information) with mostly uncharacterised specific functions. 
Glycosylations might be crucial players in mediating tissue-specific functions of FGFR 
endocrine signalling complexes, including in metabolic tissues and in specific cancers. 
 
4.4.3 Evaluation of quality control of refolded proteins 
When refolding proteins from denatured inclusion bodies, it is vital to demonstrate that 
the final purified protein is correctly folded, homogeneous, and bioactive. Successfully 
demonstrating bioactivity would imply that protein is also correctly folded. Therefore cell-
based assays were developed to test the bioactivity and indirectly the ‘foldedness’ of the 
FGFs produced in this work. The 3T3-L1 adipocytes used were cultured and 
differentiated using an established protocol with slight modifications (Zebisch et al., 
2012) and all experimental parameters were similar to those used previously (Kurosu et 
al., 2007, Ogawa et al., 2007, Yang et al., 2012). Despite successful differentiation of the 
pre-adipocytes to adipocytes as visually confirmed by phase contrast microscopy (data 
not available), problems were encountered with both bacterial and fungal infections in 
this cell type, which worsened throughout the differentiation process. Although only cells 
with no visible infection were used in these experiments, underlying infections could not 
be ruled out, and might explain the unexpected responses of the cells to the different 
FGFs including lack of dose response with high concentrations of FGF1 and a general 
lack of response with commercially obtained control endocrine FGFs (Figure 4.15). In 
this case, being able to assess secondary structural fold of the recombinant FGFs using 
biophysical methods was very useful in validation of the refolding methods used here, 
despite only providing little and indirect information about bioactivity of the refolded 
FGFs. The SPR experiments revealed that the endocrine FGFs were probably only 
partially active or conformationally heterogeneous (section 4.3.6). This might reflect the 
intrinsic problem with in vitro protein refolding leading to the creation of a 
heterogeneously folded mixture of proteins. The homogeneity of this mixture could be 
improved by adding orthogonal chromatographic techniques to the purification such as 
ion exchange and reverse phase chromatography, although these were unsuccessful in 
this study and dramatically reduced the final purified protein yields (data not shown). 
Alternatively, it might reflect the fact that both refolded FGFs demonstrated instability as 
they visibly degraded over time with FGF19 degrading faster than FGF21 (Figures 4.13 
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and 4.14), and in fact this was also observed for recombinant FGF19 and FGF21 proteins 
produced by others, for example (Asada et al., 2009). Protein degradation over time 
might therefore be a more plausible explanation since all FGFs appeared to be correctly 
folded when assessed by CD spectroscopy (Figure 4.17) but then appeared to be 
heterogeneous during SPR experiments performed a few weeks later. Interestingly, 
other groups have used mammalian, insect and yeast cell systems to express 
recombinant endocrine FGFs (Xie et al., 1999, Inagaki et al., 2005, Micanovic et al., 
2009, Wu et al., 2011). It could be worth pursuing this experimental course considering 
the success of mammalian expression systems in this work in producing large quantities 
of the extracellular FGFR1c protein as discussed above. Stabilising mutations could be 
introduced to the FGFs such as those used to engineer long-acting FGF21 therapeutic 
biologic molecules (Table 4.3), however this would result in non-native protein and is a 
less favoured option. Finally, only freshly prepared FGF19 and FGF21 proteins should 
be used to ensure minimal degradation and maximal activity are maintained during 
experiments. 
 
4.4.4 Recombinant βKlotho protein production – an experimental bottleneck? 
In this work, the primary limitation was the lack of sufficient quantities of βKlotho protein 
expression for purification. This impeded experimental analyses of ternary signalling 
complexes in vitro including the much sought βKlotho and binary and ternary complex 
structural information. Although small quantities of extracellular and full length βKlotho 
could eventually be expressed (Figures 4.19 and 4.20), further optimisation of the 
detergent extraction and purification methods and large scale-ups will be needed before 
sufficient quantities of this protein can be robustly extracted from mammalian cells. In 
previous work, human βKlotho (1-992) was expressed and purified from HEK 293F cells 
(Yie et al., 2009). Mouse orthologues of αKlotho (35-982) and βKlotho (53-995) were 
also expressed and purified from HEK 293F cells in three studies performed by the same 
group (Goetz et al., 2012a, Goetz et al., 2012b, Goetz et al., 2010). A chimeric mouse 
αKlotho ectodomain with a C-terminal fusion to human IgG1 Fc (Tohyama et al., 2004) 
and the corresponding human αKlotho orthologue (Yamazaki et al., 2010) were also 
previously expressed and purified from the conditioned medium of CHO cells. In this 
study, it was not possible to detect similar secretion of βKlotho into the conditioned 
medium from CHO cells or HEK 293F cells, despite small amounts of intracellular 
expression being observed (Figure 4.19c and 4.19f). The constructs used in this work 
have slightly different N- and C-terminal boundaries (by a few amino acids) compared to 
some of the constructs used in the previous studies (Yie et al., 2009). Optimisation of 
the construct boundaries, secretion signal peptides and expression conditions in the 
mammalian systems used in this work should eventually lead to the successful secretion 
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of βKlotho ectodomain for purification. Much of the eagerly awaited molecular 
information required for a complete understanding of these complexes and their 
pathophysiological roles will continue to rely on the ability to produce sufficient quantities 
(and of a high purity) of the Klotho proteins. 
 
4.4.5 Preliminary characterisation of binary endocrine FGF-FGFR complexes 
With the protein components that were possible to produce recombinantly in this work, 
preliminary protein-protein binding experiments were performed using FGF19, FGF21 
and the ectodomain of FGFR1c. It was initially attempted to analyse these interactions 
between FGF19-FGFR1c and FGF21-FGFR1c using ITC to probe the energetics, 
kinetics and stoichiometries of the binary ligand-receptor interactions. However, it was 
found to be challenging to use this technique to characterise FGF-FGFR interactions, 
partly due to the very small released heats of interaction (Figure 4.22). This led to 
attempts to reproduce the binary interaction data generated previously for FGF19-
FGFR1c and FGF21-FGFR1c (Goetz et al., 2012b), albeit using a longer length and 
more physiologically relevant FGFR1c construct (D1-D3) than the published version (D2-
D3, lacking the D1 domain). Preliminary SPR experiments yielded KD values two orders 
of magnitude lower than those published in the above study (Table 4.6). These 
discrepancies between the two datasets could reflect several possibilities. Firstly, in this 
work, the FGFR1c construct used comprised the additional D1 domain whose role in 
binding to endocrine FGFs and/or Klotho-co-receptors has not been fully elucidated, as 
most biochemical and biophysical analyses have utilised the shorter length FGFR1c D2-
D3 construct (discussed above). Additionally, the FGFR1c protein produced in this work 
was glycosylated due to production from mammalian cells (Figure 4.21), whereas the 
D2-D3 protein in the published study was refolded from bacterial inclusion bodies and 
so was not glycosylated. Since stronger binding between endocrine FGFs and FGFR1c 
was observed in this work using the glycosylated D1-D3 construct compared to the 
published study using the non-glycosylated D2-D3 construct (Table 4.6), this works 
tentatively suggests that the D1 domain and/or specific glycosyl moieties might play a 
role in the endocrine FGF-FGFR interaction, although previous studies have proposed 
roles for the D2 and D3 domains in the FGF-FGFR interaction (Goetz et al., 2012a, Gupte 
et al., 2011, Wu et al., 2011). Additionally, no studies have methodically investigated the 
importance of glycosylation in the binary and/or ternary complexes. Further experiments, 
including using a control paracrine FGF such as FGF1, and both glycosylated and non-
glycosylated proteins, are needed to verify these data. Secondly, the likely heterogeneity 
of the refolded FGFs and analyte protein sticking to the SPR microfluidics added 
complexity to the analysis of these data, as evidenced by the shape of the steady-state 
binding curves (Figure 4.23). More robust preparations of protein and optimisation of the 
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SPR buffer conditions are required to improve the SPR data quality to extract reliable 
information about binding affinity and kinetics. In this work, it was not possible to fit the 
data to any kinetic model, and in fact little kinetic data has been reported for any 
endocrine FGF-FGFR interactions, with one study attempting to perform kinetic 
experiments with these complexes in cells (Yang et al., 2012). This could reflect the 
inherent complexity of the interactions, which might involve transient or constitutive 
homodimerisation of FGF ligands and/or FGFRs in solution in addition to the FGF-FGFR 
heterodimerisation that these experiments attempt to report on. Such biological 
complexity cannot be modelled by the ‘simple’ 1:1 or 2:1 kinetic models inbuilt into the 
SPR analytical software. In any case, these preliminary binding experiments provide a 
useful starting point to further probe these interactions. Further optimisations of these 
experiments will provide more accurate information about the true affinities and kinetics 
involved in binding of the endocrine FGFs to FGFR1c, and can eventually be extended 
to similar analyses of the ternary complexes involving Klotho proteins. This information 
will then eventually inform the clinical development of FGF21 and its biologic drug 





In summary, this work laid the foundations for future experiments to study the protein-
protein interactions within endocrine FGFR signalling complexes from a structural, 
biophysical and biochemical perspective. Homology models of the βKlotho KL domains 
were generated to aid in experimental planning and these will also aid structure-based 
drug design in the future in the absence of any Klotho atomic structures. Progress was 
made in recombinant protein production and quality control, with the indication that 
mammalian expression systems might perform better when attempting to produce large 
quantities of extracellular proteins for biophysical studies. Preliminary characterisations 
of protein-protein interactions involved in βKlotho endocrine signalling complexes were 
performed similarly to those performed by others with a slightly different construct, and 
possible explanations for deviations from the published study in the early results were 
suggested based on the slightly different experimental conditions used in this work. 
Methods and experiments tested and found to be unproductive will guide future studies 
based on progress established in this work. Overall, the priority for the future is 
production of βKlotho protein in sufficient quantities to allow determination of the much-
awaited molecular information of ternary endocrine FGFR signalling complexes. This is 
needed to inform the rational development of therapeutics for targeting deregulated 
endocrine FGFR signalling involved in metabolic pathologies and cancer. 
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Chapter 5: Conclusions and Perspectives 
 
In this thesis, two aspects of the diverse modes of FGFR signalling involved in cancer 
and several other adverse pathologies were investigated. In Chapter 3, a comprehensive 
panel of 25 missense substitutions identified in the FGFR KD was assembled and the 
variant KD proteins produced. The impacts of these cancer-associated variants on 
activation, catalysis, substrate binding affinity and stability of the FGFR KD were 
assessed using biochemical and biophysical in vitro assays. The most interesting 
mutations identified from in vitro assays were further investigated in model stable cell 
lines in the context of the full length receptor, and their effects on downstream signalling 
and transformation were assessed. In Chapter 4, several protein components of 
endocrine FGFR signalling complexes involving endocrine ligands FGF19 and FGF21, 
FGFR1c and the FGFR co-receptor β-Klotho were produced and preliminarily 
characterised. The early stages of a project aiming to investigate the protein-protein 
interactions in the ternary endocrine signalling complexes from structural, biophysical 
and biochemical perspectives was therefore established. In this Chapter, the key findings 
from this thesis will be summarised and discussed, including a synoptic discussion 
linking common concepts between the two subject areas and cancer. The importance of 
this study will be linked to the current status of cancer-related FGFR and RTK therapies 
undergoing clinical trials, stressing the importance of a progression towards a patient-
personalised approach to targeted therapeutics in combating cancer. 
  
5.1 Why study cancer-associated point mutations? 
 
In Chapter 3, the importance of both genetic hotspot and non-hotspot mutations as 
oncogenic drivers in FGFRs was highlighted, with a focus on missense substitutions in 
cancer, although oncogenic fusion proteins and FGFR gene amplifications also play 
important roles in oncogenesis (Turner and Grose, 2010, Gallo et al., 2015). A similar 
phenomenon could apply to other kinases (and even other oncogenes and tumour 
suppressor genes) in cancer. In this work, known and new potential driver mutations in 
the FGFR KD were identified using a combination of in vitro and cell-based assays while 
several mutations were classified as probable passenger mutations, and some were 
hypothesised to be oncogenic in the optimal cellular environment. This work therefore 
contributes to the growing understanding of the oncogenic mechanisms and functions of 
oncogenic driver mutations in FGFRs, adding to knowledge for those previously 
identified as drivers in FGFR3 (section 3.1). Defining specific FGFR aberrations that are 
most likely to benefit from specific targeted therapies in the clinic will hopefully help to 
boost the success of candidate drugs currently in clinical trials. Studies using a 
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combination of complementary assays similar to those in this work could be employed 
for other kinases, to better link the currently biased genetic data in mutation databases 
to function. Particularly, this will be useful for kinases that are also drug targets for various 
diseases. Such interdisciplinary studies will help to validate new oncogenic driver 
mutations which can then be tested in vivo to confirm their oncogenicity and assess the 
oncogene dependency of tumours on individual aberrations. In addition, experimental 
datasets such as that generated in this work using large panels of mutations can help to 
improve the ability of computational algorithms to predict the pathogenicity of new gain-
of-function mutations that are constantly being identified from the ongoing international 
cancer genome sequencing projects. This will ultimately accelerate the process by which 
new driver mutations can be pre-clinically experimentally validated as therapeutic targets 
to inform specific targeting in clinical trials. 
 
5.2 Why study Klotho-dependent endocrine signalling complexes? 
 
In Chapter 4, less-well researched endocrine FGFR signalling complexes involving the 
βKlotho FGFR co-receptor were preliminarily characterised from a biochemical and 
biophysical perspective. This study was performed due to endocrine signalling being 
deregulated in various metabolic disorders and cancer. In the case of metabolic 
diseases, the focus has so far been on developing FGF21 and related analogues as 
agonist treatments for a range of metabolic diseases including diabetes, obesity and 
ageing (Table 4.3). In cancer, FGF19 amplification has been identified as the driver 
mutation for a subset of liver cancers for which it also confers sensitivity to FGFR-specific 
inhibition (Sawey et al., 2011, Guagnano et al., 2012), making this branch of endocrine 
signalling a relatively new therapeutic target. 
 
Additionally, endocrine signalling is also found deregulated in response to targeted 
inhibition of oncogenic FGFR signalling in the clinic, due to inhibition of FGF23-αKlotho 
signalling (Brown et al., 2005, Nogova et al., 2017). Currently, anti-FGFR targeting using 
pan-FGFR inhibitors results in side-effects due to these on-target toxicities. These 
FGF23 signalling-related on-target toxicities arise because FGFR signalling regulates a 
plethora of cellular functions, so potent inhibition of oncogenic FGFR signalling also has 
knock-on adverse effects on normal ‘beneficial’ FGFR signalling (such as through 
FGF23) in vivo. Targeting these on-target adverse effects of potent pan-FGFR inhibitors 
therefore requires a molecular understanding of the mechanisms giving rise to these 
toxicities, which occur due to the co-occurrence of paracrine and endocrine signalling in 
vivo. Molecular studies of endocrine Klotho-dependent signalling complexes are 
therefore urgently needed to complement the existing wealth of information about 
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paracrine signalling, so that appropriate data-driven dosing regimens can be 
implemented in current clinical trials with potent pan-FGFR inhibitors. Molecular 
information will also aid the rational design of agonists to target and activate specific 
‘beneficial’ signalling complexes alongside inhibition of canonical ‘oncogenic’ FGFR 
signalling, to help to alleviate the on-target toxicities caused by clinical pan-FGFR 
inhibition. One example of an agonist (effective against the FGFR1c-βKlotho complex, 
Table 4.3) has recently entered pre-clinical development (Sakamoto et al., 2016). 
However, in general, the Klotho-dependent sub-axes of FGFR signalling need to be 
better studied from a molecular perspective to rationally address several of these clinical 
problems. 
 
5.3 Challenges and opportunities of targeting aberrant FGFR signalling 
 
There are several challenges associated with targeting aberrant FGFR signalling in the 
clinic. As previously mentioned, the field of specific FGFR-targeting in the clinic has so 
far lagged behind other RTKs despite pre-clinical evidence implicating several aspects 
of FGFR signalling in oncogenesis. The importance of patient selection through 
identifying subsets of patients with specific FGFR aberrations for a personalised 
approach to treatment in the clinic has already been stressed in this work. In addition, 
the success of anti-FGFR targeting in the clinic has so far been variable despite pre-
clinical models validating FGFRs as promising therapeutic targets. This is probably due 
to a combination of variable addiction of tumours to aberrant FGFR signalling and tumour 
heterogeneity (including heterogeneity of FGFR aberrations within a cancer) which might 
limit the efficacy of single-agent targeted therapies. Toxic effects of targeted therapies in 
the clinic currently result in withdrawal of treatments (including early termination of 
clinical trials) and/or dose reductions which limit the potential to eliminate a tumour. 
Finally, it is widely known that cancers evolve and respond to therapeutic inhibition by 
acquiring mechanisms of resistance to targeted therapies. These challenges associated 
with clinical FGFR targeting are discussed further below, emphasising the importance of 
this work, and highlighting aspects where further efforts should focus to improve the 
outcomes of personalised anti-FGFR therapy. These concepts are summarised in Figure 
5.1. 
 
5.3.1 Importance of patient selection based on specific FGFR aberrations 
The first challenge of patient selection has already been discussed in this work. It is clear 
from both pre-clinical and clinical evidence that the importance of considering specific 
aberrations in FGFRs (and other oncogenes) is crucial for distinguishing between 
oncogenic driver and passenger mutations (Greenman et al., 2007, Guagnano et al., 
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2012, Patani et al., 2016). In this work, it was shown that of the hundreds of mutations 
found in FGFRs, only a subset are activating and an even smaller subset are strongly 
transforming. An additional complication arises because distinct aberrations are only 
observed infrequently in the clinic, making it difficult to define stratified populations of 
patients that will benefit most from specific targeted therapies. Studies that functionally 
characterise large panels of cancer-associated mutations as in this work to distinguish 
between oncogenic driver and passenger mutations will help towards defining patient 
subsets that are most likely to present opportunities to respond to specific FGFR 
inhibitors in the clinic. This strategy must be undertaken alongside patient screening prior 
to treatment to identify the specific genetic aberrations within each tumour. This will help 
to provide treatment options with the best monotherapy or combinations of anti-FGFR 
therapies to boost the translation of the pre-clinical efficacy of candidate drugs to the 
clinic. Furthermore, an understanding of the mechanisms by which different mutations 
affect sensitivity to therapeutics can help to define different treatment options for patients 
based on their aberrations. For example, more specific inhibition of FGFR2 or FGFR3 
using therapeutic antibodies which target the extracellular domains might be useful for 
tumours in which mutations in the KD alter conformation of the intracellular region and 
so reduce sensitivity to small molecule inhibitors targeting the KD, without affecting the 
ectodomains. These and more molecular selection approaches are recently beginning 
to be applied in the clinic (Andre et al., 2011). 
 
5.3.2 Validating oncogene addiction status of a tumour to an FGFR aberration 
Often pre-clinical identification of oncogenic driver mutations is insufficient to translate to 
clinical responses to targeted inhibition. An additional complication comes from growing 
evidence that only subsets of cancers harbouring FGFR aberrations are oncogene-
addicted to the altered FGFR signalling, and it is currently difficult to predict which 
subsets these might be without in vivo data. Tumours that are not dependent on the 
aberrant FGFR signalling for proliferation and survival are less likely to respond to anti-
FGFR treatments. Therefore, alongside identifying driver FGFR aberrations as in this 
work, the next important step should include validation of the oncogene addiction status 
of a tumour to its aberration(s). For example, despite FGFR1 amplification being the 
most frequent aberration in FGFRs across tumours (Carter et al., 2015, Helsten et al., 
2016) and demonstrating sensitivity to targeted therapies that is associated with 
amplification status in pre-clinical models (Shiang et al., 2010, Weiss et al., 2010, 
Guagnano et al., 2012), in vivo evidence suggests that FGFR1 is not a dominant 
oncogene (Babina and Turner, 2017). It has been suggested that higher FGFR copy-
number amplification (and therefore overexpression), the downstream signalling 
pathways activated and co-aberrant genes present in the same tumour all affect 
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oncogene dependency, defining small subsets of patients likely to benefit from FGFR1 





Figure 5.1 The challenges of clinical FGFR-targeting. A summary of the current 
challenges that need to be addressed for a future personalised approach to successful 
anti-FGFR targeting in the clinic. Addressing these areas should lead to therapies 
eventually being approved on the basis of anti-FGFR targeting. This thesis makes a 




Conversely, FGF19 amplification has been demonstrated to be an inhibitor-sensitive 
oncogenic driver aberration in pre-clinical hepatocellular carcinoma models, but not in 
other cancers (Sawey et al., 2011, Guagnano et al., 2012, Futami et al., 2017). This is 
dependent on the co-expression of βKlotho, and together these observations correlate 
with in vivo evidence showing that FGF19 overexpression is tumourigenic in mice (Ge et 
al., 2012). This provides a stronger case for the context dependency and oncogenicity 
of FGF19 amplification in cancer. Although no clinical evidence is yet available, this early 
pre-clinical evidence suggests that tumours overexpressing FGF19 in the presence of 
βKlotho and FGFR4 are likely to define a subset of hepatocellular carcinomas likely to 
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benefit from specific targeting of the FGF19-FGFR4-βKlotho signalling complex. In 
contrast, complexes with FGFR1c-βKlotho are thought to regulate the metabolic roles of 
FGF19. Therefore, specific targeting of FGFR4 might produce less adverse side-effects 
than the current strategy of pan-FGFR targeting, by inhibiting only oncogenic effects of 
FGF19 signalling without affecting its ‘beneficial’ metabolic roles. Anti-FGFR4 inhibitors 
currently in pre-clinical development or in clinical trials are listed in Table 4.3. Two new 
clinical trials against hepatocellular carcinomas in patients specifically harbouring FGF19 
amplification (using the pan-FGFR inhibitor JNJ-42756493) or expressing FGFR4 and 
βKlotho (using a new FGFR4 inhibitor NVP-FGF401) are currently underway (Table 4.3). 
However, validation of the oncogene addiction status of FGF19-βKlotho signalling in the 
clinic is still required from these ongoing clinical trials to confirm the hypothesised roles 
of FGFR1c/FGFR4 in mediating the different FGF19 dependent signalling outcomes, 
which are currently controversial (section 4.1). Progress made towards the molecular 
characterisation of FGF19 endocrine signalling complexes as in this work with FGFR1c 
and in future studies with FGFR4 will aid the rational design of targeted agonists or 
antagonists against FGF19-βKlotho complexes in the different contexts of hepatocellular 
carcinomas and in metabolic diseases. 
 
As a final example, despite the diversity of point mutations and oncogenic fusions found 
in FGFRs in cancer (particularly in FGFR3 and FGFR2), many of which are transforming 
and inhibitor-sensitive in pre-clinical models as shown in this work and by others 
(Tomlinson et al., 2007b, di Martino et al., 2009, Singh et al., 2012, Byron et al., 2013, 
Liao et al., 2013, Williams et al., 2013, Wu et al., 2013, Patani et al., 2016), not much is 
known about the specific effects of each mutation on oncogene addiction to FGFR 
signalling in tumours. Observations from several of the above studies suggest that 
tumours harbouring oncogenic fusions might confer greater inhibitor sensitivity than 
those harbouring individual point mutations, but individual point mutations also confer 
differing degrees of inhibitor sensitivity (as discussed in section 3.4). It is not known 
whether this is due to greater oncogene dependence of the tumour models on fusion-
dependent signalling, or whether point mutations alter inhibitor efficacy compared to the 
fusion proteins which tend to have a ‘WT’ protein sequence (against which most drug 
candidates are validated), reducing inhibitor potency. Direct comparisons between the 
impacts of oncogenic fusions and point mutations on inhibitor sensitivity have rarely been 
made, and should be prioritised in the future. In this work, a large panel of FGFR3 KD 
mutations was ranked by their activation status and ability to transform cells, forming a 
pre-clinical basis for the identification of potential oncogenic driver point mutations. The 
addiction status of tumours to these point mutations and to all types of FGFR aberrations 
(including FGFR fusions) will need to be validated by data from the ongoing clinical trials. 
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5.3.3 The problem of on-target toxicities due to clinical pan-FGFR targeting 
To date, there are still no approved therapies based on FGFR-targeting, but both multi-
kinase and FGFR-specific (pan-FGFR) inhibitors are undergoing clinical trials on this 
basis. The results from these clinical studies revealed that inhibitors with different target 
specificities ultimately displayed varied toxicity profiles. Multi-kinase inhibitors that co-
target other closely related RTKs such as VEGFRs, PDGFRs and KIT with nanomolar 
efficacy tended to exhibit off-target adverse effects due to co-inhibition of these other 
RTKs (Dieci et al., 2013, Shah et al., 2013b, Dienstmann et al., 2014, Soria et al., 2014). 
This led to rapid development of specific anti-FGFR targeted agents, of which many 
small molecule inhibitors target several FGFRs (most commonly FGFR1-3 which have 
the most similar KDs) (Table 1.4). However, due to the pleiotropism of FGFR signalling 
in all types of tissues and organs, potent FGFR-specific therapies were found to exhibit 
adverse on-target toxicities in vivo. Predominantly, these include hyperphosphatemia-
mediated tissue calcification and bone mineralisation due to inhibition of FGF23-αKlotho 
endocrine signalling which regulates vitamin D and phosphate homeostasis (Brown et 
al., 2005, Nogova et al., 2017). Nevertheless, it is believed that these toxicities are 
manageable (Herbert et al., 2014) and that the more favourable toxicity profiles of pan-
FGFR inhibitors suggest they are still overall better clinical candidates than multi-kinase 
inhibitors for FGFR targeting (Dieci et al., 2013, Dienstmann et al., 2014). However, 
studying oncogenic mutations will ultimately be required to define which inhibitors should 
be used for the most efficacious targeting of different subsets of FGFR aberrations. In 
order to limit knock-on inhibition of FGF23 signalling inhibitors, doses of potent FGFR 
inhibitors and inclusion of co-treatments for expected toxicities in treatment regimens 
should be carefully controlled. Alternatively, FGF-ligand traps such as the clinical 
candidate FP-1039 can be used, since early clinical data suggest that this molecule does 
not cause endocrine FGF-related toxicities (Herbert et al., 2014). Additionally, using 
FGFR2- or FGFR3-specific therapeutic antibodies (that have just entered early Phase I 
clinical trials, Table 1.4) for tumours harbouring aberrations of these genes might 
alleviate toxicities that potentially occur through FGF23-αKlotho-FGFR1 complexes 
(although this is yet to be validated clinically). Characterisation of FGF23-αKlotho 
signalling complexes to determine the FGFR isoform specificity of its phosphate 
homeostatic effects, and to aid in the design of new agonists targeting these complexes, 
will greatly help in management of the FGF23-dependent clinical toxicities, and will allow 
higher doses of FGFR inhibitors to be used in cancer targeting. Together, this will 






5.3.4 Tumour mechanisms of acquired resistance to targeted therapies 
Currently, dosing limitations or even treatment withdrawal of potent FGFR inhibitors due 
to on-target toxicities contribute to the next challenge of clinical FGFR inhibition: the 
development of acquired resistance mutations by tumours. The observation of acquired 
gatekeeper mutations in FGFRs and other RTKs in response to targeted ATP-
competitive inhibitors has already been discussed in detail in sections 1.1.2 and 3.1.6 as 
a major limitation of optimal efficacy for this class of FGFR inhibitors. The acquisition of 
resistance point mutations by tumours should continue to be anticipated as clinical trials 
progress, however it should be noted that gatekeeper FGFR mutations (and other 
mutations associated with inhibitor resistance) confer resistance to different degrees 
against individual inhibitors (Bunney et al., 2015, Byron et al., 2013, Patani et al., 2016, 
Chell et al., 2013). This work also suggests that FGFR3-N540K, the gatekeeper FGFR3-
V555M and several other activating FGFR3 mutations likely impart different degrees of 
resistance to ATP-competitive inhibitors due to their increased affinities for ATP (Figure 
3.14d). Those inhibitors that retain efficacy (based on pre-clinical testing in the above 
studies) could still be tested clinically in the event of resistance mutations in a tumour. 
Additionally, the recent development of second-generation irreversible inhibitors that 
bind covalently in the ATP-binding pocket through a P-loop cysteine residue conserved 
in FGFRs (Tan et al., 2014, Huang et al., 2015) are capable of maintaining their efficacy 
against gatekeeper and other resistance mutations in the ATP-binding pocket. Further 
clinical development of these molecules might help to provide second-line treatments 
against tumours refractory to currently used FGFR targeted therapies due to acquired 
resistance. In vitro assays as developed in this work can be used to identify mutations 
likely to confer resistance to ATP-competitive inhibitors and to screen new second-
generation inhibitors against large panels of FGFR variants to validate their efficacies 
prior to clinical development of lead compounds. 
 
Another recently observed mechanism of resistance in pre-clinical hepatocellular 
carcinoma models was to the multi-kinase inhibitor Sorafenib through activation of 
FGF19-FGFR4-βKlotho signalling, although these cells could be effectively targeted 
using a novel pan-FGFR inhibitor ASP5878 (Futami et al., 2017, Gao et al., 2017). 
Similar ‘escape’ mechanisms of resistance through targeting of another RTK, such as 
EGFR, have been shown to lead to resistance to the targeted therapy via activation of 
FGFR signalling (Crystal et al., 2014). Conversely, the opposite effect, whereby 
resistance to FGFR inhibitors occurs through activation of signalling via another RTK 
such as EGFR, has also been observed (Herrera-Abreu et al., 2013). Both mechanisms 
also occur with several other RTKs, already detailed in section 3.1.6, and this defines a 
different subset of clinical resistance mechanisms involving FGFRs and co-activation of 
200 
 
other oncogenes. These clear indications of crosstalk between RTKs that are co-
activated in cancer and their observed strategies to co-operatively develop and maintain 
oncogenic signalling networks in the event of monotherapy against a single RTK highlight 
the emerging importance of dual- or multi-targeted inhibition in such cancers. In this 
work, preliminary data suggested there was indeed crosstalk between different signalling 
pathways activated in model FGFR3 point mutated cell lines. In these contexts, 
monotherapies will ultimately be ineffective and might even facilitate the development of 
acquired resistance through oncogene switching. This will be particularly dependent on 
whether the tumour is addicted to signalling via the RTK being targeted. Similarly, other 
non-RTK oncogenes and downstream signalling proteins have also been observed to be 
co-activated with FGFRs in specific cancers (di Martino et al., 2016). Therefore, as 
discussed in this Chapter, understanding the oncogenic status of specific FGFR 
aberrations, those of other oncogenes, and the addiction status of the tumour to each of 
these and whether they activate common downstream signalling pathways will pave the 
way to administration of optimal multi-kinase inhibitors or combinations of monotherapies 




In summary, this work studied the impacts of 25 cancer-associated FGFR KD mutations 
on kinase activation, kinetics, catalysis and stability of the KD in vitro, as well as on 
transformation and downstream signalling in a cellular model. It was shown that all 
hotspot mutations are not necessarily activating, while non-hotspot mutations might in 
fact be highly activating (such as the newly identified R669G). The context-dependency 
of the oncogenic nature of activating mutations was also hypothesised based on these 
studies. In parallel, early progress was made towards the expression and purification of 
proteins and the analysis of βKlotho dependent endocrine FGFR signalling complexes 
which are involved in oncogenesis of specific subsets of cancers and in the manifestation 
of adverse responses to targeted clinical FGFR inhibition. Finally, the importance of 
identifying specific molecular determinants driving cancers, in order to inform targeted 
clinical therapeutics, was discussed. Together, this work summarises and contributes to 
the current status of progress made towards personalised approaches to FGFR targeting 





ABBOSH, P. H., MCCONKEY, D. J. & PLIMACK, E. R. 2015. Targeting Signaling Transduction 
Pathways in Bladder Cancer. Curr Oncol Rep, 17, 58. 
ABRAMOVITZ, L., RUBINEK, T., LIGUMSKY, H., BOSE, S., BARSHACK, I., AVIVI, C., 
KAUFMAN, B. & WOLF, I. 2011. KL1 internal repeat mediates klotho tumor suppressor 
activities and inhibits bFGF and IGF-I signaling in pancreatic cancer. Clin Cancer Res, 
17, 4254-66. 
ADAMS, A. C., CHENG, C. C., COSKUN, T. & KHARITONENKOV, A. 2012. FGF21 requires 
betaklotho to act in vivo. PLoS One, 7, e49977. 
ADAMS, J. A. 2001. Kinetic and catalytic mechanisms of protein kinases. Chem Rev, 101, 
2271-90. 
ADAR, R., MONSONEGO-ORNAN, E., DAVID, P. & YAYON, A. 2002. Differential activation of 
cysteine-substitution mutants of fibroblast growth factor receptor 3 is determined by 
cysteine localization. J Bone Miner Res, 17, 860-8. 
ADHR CONSORTIUM, T. 2000. Autosomal dominant hypophosphataemic rickets is associated 
with mutations in FGF23. Nat Genet, 26, 345-8. 
AGAZIE, Y. M., MOVILLA, N., ISCHENKO, I. & HAYMAN, M. J. 2003. The phosphotyrosine 
phosphatase SHP2 is a critical mediator of transformation induced by the oncogenic 
fibroblast growth factor receptor 3. Oncogene, 22, 6909-18. 
AHMED, Z., GEORGE, R., LIN, C. C., SUEN, K. M., LEVITT, J. A., SUHLING, K. & LADBURY, 
J. E. 2010. Direct binding of Grb2 SH3 domain to FGFR2 regulates SHP2 function. Cell 
Signal, 22, 23-33. 
ALTSCHUL, S. F., GISH, W., MILLER, W., MYERS, E. W. & LIPMAN, D. J. 1990. Basic local 
alignment search tool. J Mol Biol, 215, 403-10. 
ANDRE, F., DELALOGE, S. & SORIA, J. C. 2011. Biology-driven phase II trials: what is the 
optimal model for molecular selection? J Clin Oncol, 29, 1236-8. 
ARNOLD, K., BORDOLI, L., KOPP, J. & SCHWEDE, T. 2006. The SWISS-MODEL workspace: 
a web-based environment for protein structure homology modelling. Bioinformatics, 22, 
195-201. 
ASADA, M., SHINOMIYA, M., SUZUKI, M., HONDA, E., SUGIMOTO, R., IKEKITA, M. & 
IMAMURA, T. 2009. Glycosaminoglycan affinity of the complete fibroblast growth factor 
family. Biochim Biophys Acta, 1790, 40-8. 
AUBERTIN, J., TOURPIN, S., JANOT, F., AHOMADEGBE, J. C. & RADVANYI, F. 2007. 
Analysis of fibroblast growth factor receptor 3 G697C mutation in oral squamous cell 
carcinomas. Int J Cancer, 120, 2058-9; author reply 2060. 
AZAM, M. & DALEY, G. Q. 2006. Anticipating clinical resistance to target-directed agents : the 
BCR-ABL paradigm. Mol Diagn Ther, 10, 67-76. 
AZAM, M., SEELIGER, M. A., GRAY, N. S., KURIYAN, J. & DALEY, G. Q. 2008. Activation of 
tyrosine kinases by mutation of the gatekeeper threonine. Nat Struct Mol Biol, 15, 1109-
18. 
BABINA, I. S. & TURNER, N. C. 2017. Advances and challenges in targeting FGFR signalling in 
cancer. Nat Rev Cancer, 17, 318-332. 
BADMAN, M. K., PISSIOS, P., KENNEDY, A. R., KOUKOS, G., FLIER, J. S. & MARATOS-
FLIER, E. 2007. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a 
key mediator of hepatic lipid metabolism in ketotic states. Cell Metab, 5, 426-37. 
BAE, J. H., BOGGON, T. J., TOME, F., MANDIYAN, V., LAX, I. & SCHLESSINGER, J. 2010. 
Asymmetric receptor contact is required for tyrosine autophosphorylation of fibroblast 
growth factor receptor in living cells. Proc Natl Acad Sci U S A, 107, 2866-71. 
BAE, J. H., LEW, E. D., YUZAWA, S., TOME, F., LAX, I. & SCHLESSINGER, J. 2009. The 
selectivity of receptor tyrosine kinase signaling is controlled by a secondary SH2 
domain binding site. Cell, 138, 514-24. 
BAE, J. H. & SCHLESSINGER, J. 2010. Asymmetric tyrosine kinase arrangements in activation 
or autophosphorylation of receptor tyrosine kinases. Mol Cells, 29, 443-8. 
BARRETT, T., SURESH, C. G., TOLLEY, S. P., DODSON, E. J. & HUGHES, M. A. 1995. The 
crystal structure of a cyanogenic beta-glucosidase from white clover, a family 1 glycosyl 
hydrolase. Structure, 3, 951-60. 
BEDUSSI, F., BOTTINI, A., MEMO, M., FOX, S. B., SIGALA, S. & GENERALI, D. 2014. 
Targeting fibroblast growth factor receptor in breast cancer: a promise or a pitfall? 
Expert Opin Ther Targets, 18, 665-78. 
202 
 
BEENKEN, A., ELISEENKOVA, A. V., IBRAHIMI, O. A., OLSEN, S. K. & MOHAMMADI, M. 
2012. Plasticity in interactions of fibroblast growth factor 1 (FGF1) N terminus with FGF 
receptors underlies promiscuity of FGF1. J Biol Chem, 287, 3067-78. 
BEENKEN, A. & MOHAMMADI, M. 2009. The FGF family: biology, pathophysiology and 
therapy. Nat Rev Drug Discov, 8, 235-53. 
BELLOSTA, P., IWAHORI, A., PLOTNIKOV, A. N., ELISEENKOVA, A. V., BASILICO, C. & 
MOHAMMADI, M. 2001. Identification of receptor and heparin binding sites in fibroblast 
growth factor 4 by structure-based mutagenesis. Mol Cell Biol, 21, 5946-57. 
BELLUS, G. A., SPECTOR, E. B., SPEISER, P. W., WEAVER, C. A., GARBER, A. T., BRYKE, 
C. R., ISRAEL, J., ROSENGREN, S. S., WEBSTER, M. K., DONOGHUE, D. J. & 
FRANCOMANO, C. A. 2000. Distinct missense mutations of the FGFR3 lys650 codon 
modulate receptor kinase activation and the severity of the skeletal dysplasia 
phenotype. Am J Hum Genet, 67, 1411-21. 
BELOV, A. A. & MOHAMMADI, M. 2012. Grb2, a double-edged sword of receptor tyrosine 
kinase signaling. Sci Signal, 5, pe49. 
BELOV, A. A. & MOHAMMADI, M. 2013. Molecular mechanisms of fibroblast growth factor 
signaling in physiology and pathology. Cold Spring Harb Perspect Biol, 5. 
BENET-PAGES, A., ORLIK, P., STROM, T. M. & LORENZ-DEPIEREUX, B. 2005. An FGF23 
missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum 
Mol Genet, 14, 385-90. 
BERNARD-PIERROT, I., BRAMS, A., DUNOIS-LARDE, C., CAILLAULT, A., DIEZ DE MEDINA, 
S. G., CAPPELLEN, D., GRAFF, G., THIERY, J. P., CHOPIN, D., RICOL, D. & 
RADVANYI, F. 2006. Oncogenic properties of the mutated forms of fibroblast growth 
factor receptor 3b. Carcinogenesis, 27, 740-7. 
BERNETT, M. J., SOMASUNDARAM, T. & BLABER, M. 2004. An atomic resolution structure 
for human fibroblast growth factor 1. Proteins, 57, 626-34. 
BILLEREY, C., CHOPIN, D., AUBRIOT-LORTON, M. H., RICOL, D., GIL DIEZ DE MEDINA, S., 
VAN RHIJN, B., BRALET, M. P., LEFRERE-BELDA, M. A., LAHAYE, J. B., ABBOU, C. 
C., BONAVENTURE, J., ZAFRANI, E. S., VAN DER KWAST, T., THIERY, J. P. & 
RADVANYI, F. 2001. Frequent FGFR3 mutations in papillary non-invasive bladder 
(pTa) tumors. Am J Pathol, 158, 1955-9. 
BLOCH, L., SINESHCHEKOVA, O., REICHENBACH, D., REISS, K., SAFTIG, P., KURO-O, M. 
& KAETHER, C. 2009. Klotho is a substrate for alpha-, beta- and gamma-secretase. 
FEBS Lett, 583, 3221-4. 
BLUNT, A. G., LAWSHE, A., CUNNINGHAM, M. L., SETO, M. L., ORNITZ, D. M. & 
MACARTHUR, C. A. 1997. Overlapping expression and redundant activation of 
mesenchymal fibroblast growth factor (FGF) receptors by alternatively spliced FGF-8 
ligands. J Biol Chem, 272, 3733-8. 
BOCHAROV, E. V., LESOVOY, D. M., GONCHARUK, S. A., GONCHARUK, M. V., HRISTOVA, 
K. & ARSENIEV, A. S. 2013. Structure of FGFR3 transmembrane domain dimer: 
implications for signaling and human pathologies. Structure, 21, 2087-93. 
BOOKOUT, A. L., DE GROOT, M. H., OWEN, B. M., LEE, S., GAUTRON, L., LAWRENCE, H. 
L., DING, X., ELMQUIST, J. K., TAKAHASHI, J. S., MANGELSDORF, D. J. & 
KLIEWER, S. A. 2013. FGF21 regulates metabolism and circadian behavior by acting 
on the nervous system. Nat Med, 19, 1147-52. 
BOTTCHER, R. T. & NIEHRS, C. 2005. Fibroblast growth factor signaling during early 
vertebrate development. Endocr Rev, 26, 63-77. 
BROOKS, A. N., KILGOUR, E. & SMITH, P. D. 2012. Molecular pathways: fibroblast growth 
factor signaling: a new therapeutic opportunity in cancer. Clin Cancer Res, 18, 1855-62. 
BROWN, A. P., COURTNEY, C. L., KING, L. M., GROOM, S. C. & GRAZIANO, M. J. 2005. 
Cartilage dysplasia and tissue mineralization in the rat following administration of a FGF 
receptor tyrosine kinase inhibitor. Toxicol Pathol, 33, 449-55. 
BUNNEY, T. D., WAN, S., THIYAGARAJAN, N., SUTTO, L., WILLIAMS, S. V., ASHFORD, P., 
KOSS, H., KNOWLES, M. A., GERVASIO, F. L., COVENEY, P. V. & KATAN, M. 2015. 
The Effect of Mutations on Drug Sensitivity and Kinase Activity of Fibroblast Growth 
Factor Receptors: A Combined Experimental and Theoretical Study. EBioMedicine, 2, 
194-204. 
BURMEISTER, W. P., COTTAZ, S., DRIGUEZ, H., IORI, R., PALMIERI, S. & HENRISSAT, B. 
1997. The crystal structures of Sinapis alba myrosinase and a covalent glycosyl-
enzyme intermediate provide insights into the substrate recognition and active-site 
machinery of an S-glycosidase. Structure, 5, 663-75. 
203 
 
BURMEISTER, W. P., COTTAZ, S., ROLLIN, P., VASELLA, A. & HENRISSAT, B. 2000. High 
resolution X-ray crystallography shows that ascorbate is a cofactor for myrosinase and 
substitutes for the function of the catalytic base. J Biol Chem, 275, 39385-93. 
BYRON, S. A., CHEN, H., WORTMANN, A., LOCH, D., GARTSIDE, M. G., DEHKHODA, F., 
BLAIS, S. P., NEUBERT, T. A., MOHAMMADI, M. & POLLOCK, P. M. 2013. The 
N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and 
ponatinib ATP-competitive inhibitors. Neoplasia, 15, 975-88. 
CANALES, A., LOZANO, R., LOPEZ-MENDEZ, B., ANGULO, J., OJEDA, R., NIETO, P. M., 
MARTIN-LOMAS, M., GIMENEZ-GALLEGO, G. & JIMENEZ-BARBERO, J. 2006. 
Solution NMR structure of a human FGF-1 monomer, activated by a hexasaccharide 
heparin-analogue. FEBS J, 273, 4716-27. 
CANCER GENOME ATLAS RESEARCH, N., WEINSTEIN, J. N., COLLISSON, E. A., MILLS, 
G. B., SHAW, K. R., OZENBERGER, B. A., ELLROTT, K., SHMULEVICH, I., SANDER, 
C. & STUART, J. M. 2013. The Cancer Genome Atlas Pan-Cancer analysis project. Nat 
Genet, 45, 1113-20. 
CAPPELLEN, D., DE OLIVEIRA, C., RICOL, D., DE MEDINA, S., BOURDIN, J., SASTRE-
GARAU, X., CHOPIN, D., THIERY, J. P. & RADVANYI, F. 1999. Frequent activating 
mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet, 23, 18-20. 
CARPENTER, G. & JI, Q. 1999. Phospholipase C-gamma as a signal-transducing element. Exp 
Cell Res, 253, 15-24. 
CARTER, E. P., FEARON, A. E. & GROSE, R. P. 2015. Careless talk costs lives: fibroblast 
growth factor receptor signalling and the consequences of pathway malfunction. Trends 
Cell Biol, 25, 221-33. 
CASCONE, T., HERYNK, M. H., XU, L., DU, Z., KADARA, H., NILSSON, M. B., OBORN, C. J., 
PARK, Y. Y., EREZ, B., JACOBY, J. J., LEE, J. S., LIN, H. Y., CIARDIELLO, F., 
HERBST, R. S., LANGLEY, R. R. & HEYMACH, J. V. 2011. Upregulated stromal EGFR 
and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant 
human lung adenocarcinoma. J Clin Invest, 121, 1313-28. 
CHA, S. K., ORTEGA, B., KUROSU, H., ROSENBLATT, K. P., KURO, O. M. & HUANG, C. L. 
2008. Removal of sialic acid involving Klotho causes cell-surface retention of TRPV5 
channel via binding to galectin-1. Proc Natl Acad Sci U S A, 105, 9805-10. 
CHANG, Q., HOEFS, S., VAN DER KEMP, A. W., TOPALA, C. N., BINDELS, R. J. & 
HOENDEROP, J. G. 2005. The beta-glucuronidase klotho hydrolyzes and activates the 
TRPV5 channel. Science, 310, 490-3. 
CHEFETZ, I., HELLER, R., GALLI-TSINOPOULOU, A., RICHARD, G., WOLLNIK, B., 
INDELMAN, M., KOERBER, F., TOPAZ, O., BERGMAN, R., SPRECHER, E. & 
SCHOENAU, E. 2005. A novel homozygous missense mutation in FGF23 causes 
Familial Tumoral Calcinosis associated with disseminated visceral calcification. Hum 
Genet, 118, 261-6. 
CHELL, V., BALMANNO, K., LITTLE, A. S., WILSON, M., ANDREWS, S., BLOCKLEY, L., 
HAMPSON, M., GAVINE, P. R. & COOK, S. J. 2013. Tumour cell responses to new 
fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a 
gatekeeper mutation in FGFR3 as a mechanism of acquired resistance. Oncogene, 32, 
3059-70. 
CHELLAIAH, A. T., MCEWEN, D. G., WERNER, S., XU, J. & ORNITZ, D. M. 1994. Fibroblast 
growth factor receptor (FGFR) 3. Alternative splicing in immunoglobulin-like domain III 
creates a receptor highly specific for acidic FGF/FGF-1. J Biol Chem, 269, 11620-7. 
CHEN, C. D., PODVIN, S., GILLESPIE, E., LEEMAN, S. E. & ABRAHAM, C. R. 2007a. Insulin 
stimulates the cleavage and release of the extracellular domain of Klotho by ADAM10 
and ADAM17. Proc Natl Acad Sci U S A, 104, 19796-801. 
CHEN, F., SARABIPOUR, S. & HRISTOVA, K. 2013a. Multiple consequences of a single amino 
acid pathogenic RTK mutation: the A391E mutation in FGFR3. PLoS One, 8, e56521. 
CHEN, H., HUANG, Z., DUTTA, K., BLAIS, S., NEUBERT, T. A., LI, X., COWBURN, D., 
TRAASETH, N. J. & MOHAMMADI, M. 2013b. Cracking the molecular origin of intrinsic 
tyrosine kinase activity through analysis of pathogenic gain-of-function mutations. Cell 
Rep, 4, 376-84. 
CHEN, H., MA, J., LI, W., ELISEENKOVA, A. V., XU, C., NEUBERT, T. A., MILLER, W. T. & 
MOHAMMADI, M. 2007b. A molecular brake in the kinase hinge region regulates the 
activity of receptor tyrosine kinases. Mol Cell, 27, 717-30. 
CHEN, H., MARSIGLIA, W. M., CHO, M. K., HUANG, Z., DENG, J., BLAIS, S. P., GAI, W., 
BHATTACHARYA, S., NEUBERT, T. A., TRAASETH, N. J. & MOHAMMADI, M. 2017. 
204 
 
Elucidation of a four-site allosteric network in fibroblast growth factor receptor tyrosine 
kinases. Elife, 6. 
CHEN, H., XU, C. F., MA, J., ELISEENKOVA, A. V., LI, W., POLLOCK, P. M., PITTELOUD, N., 
MILLER, W. T., NEUBERT, T. A. & MOHAMMADI, M. 2008. A crystallographic 
snapshot of tyrosine trans-phosphorylation in action. Proc Natl Acad Sci U S A, 105, 
19660-5. 
CHEN, J., WILLIAMS, I. R., LEE, B. H., DUCLOS, N., HUNTLY, B. J., DONOGHUE, D. J. & 
GILLILAND, D. G. 2005. Constitutively activated FGFR3 mutants signal through 
PLCgamma-dependent and -independent pathways for hematopoietic transformation. 
Blood, 106, 328-37. 
CHESI, M., BRENTS, L. A., ELY, S. A., BAIS, C., ROBBIANI, D. F., MESRI, E. A., KUEHL, W. 
M. & BERGSAGEL, P. L. 2001. Activated fibroblast growth factor receptor 3 is an 
oncogene that contributes to tumor progression in multiple myeloma. Blood, 97, 729-36. 
CHESI, M., NARDINI, E., BRENTS, L. A., SCHROCK, E., RIED, T., KUEHL, W. M. & 
BERGSAGEL, P. L. 1997. Frequent translocation t(4;14)(p16.3;q32.3) in multiple 
myeloma is associated with increased expression and activating mutations of fibroblast 
growth factor receptor 3. Nat Genet, 16, 260-4. 
CHOI, M., MOSCHETTA, A., BOOKOUT, A. L., PENG, L., UMETANI, M., HOLMSTROM, S. R., 
SUINO-POWELL, K., XU, H. E., RICHARDSON, J. A., GERARD, R. D., 
MANGELSDORF, D. J. & KLIEWER, S. A. 2006. Identification of a hormonal basis for 
gallbladder filling. Nat Med, 12, 1253-5. 
CHOI, Y. L., SODA, M., YAMASHITA, Y., UENO, T., TAKASHIMA, J., NAKAJIMA, T., YATABE, 
Y., TAKEUCHI, K., HAMADA, T., HARUTA, H., ISHIKAWA, Y., KIMURA, H., 
MITSUDOMI, T., TANIO, Y., MANO, H. & GROUP, A. L. K. L. C. S. 2010. EML4-ALK 
mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med, 363, 
1734-9. 
CIACCIO, M. F., WAGNER, J. P., CHUU, C. P., LAUFFENBURGER, D. A. & JONES, R. B. 
2010. Systems analysis of EGF receptor signaling dynamics with microwestern arrays. 
Nat Methods, 7, 148-55. 
COMPS-AGRAR, L., DUNSHEE, D. R., EATON, D. L. & SONODA, J. 2015. Unliganded 
fibroblast growth factor receptor 1 forms density-independent dimers. J Biol Chem, 290, 
24166-77. 
COOLS, J., DEANGELO, D. J., GOTLIB, J., STOVER, E. H., LEGARE, R. D., CORTES, J., 
KUTOK, J., CLARK, J., GALINSKY, I., GRIFFIN, J. D., CROSS, N. C., TEFFERI, A., 
MALONE, J., ALAM, R., SCHRIER, S. L., SCHMID, J., ROSE, M., VANDENBERGHE, 
P., VERHOEF, G., BOOGAERTS, M., WLODARSKA, I., KANTARJIAN, H., MARYNEN, 
P., COUTRE, S. E., STONE, R. & GILLILAND, D. G. 2003. A tyrosine kinase created by 
fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in 
idiopathic hypereosinophilic syndrome. N Engl J Med, 348, 1201-14. 
CROSSLEY, P. H. & MARTIN, G. R. 1995. The mouse Fgf8 gene encodes a family of 
polypeptides and is expressed in regions that direct outgrowth and patterning in the 
developing embryo. Development, 121, 439-51. 
CRYSTAL, A. S., SHAW, A. T., SEQUIST, L. V., FRIBOULET, L., NIEDERST, M. J., 
LOCKERMAN, E. L., FRIAS, R. L., GAINOR, J. F., AMZALLAG, A., GRENINGER, P., 
LEE, D., KALSY, A., GOMEZ-CARABALLO, M., ELAMINE, L., HOWE, E., HUR, W., 
LIFSHITS, E., ROBINSON, H. E., KATAYAMA, R., FABER, A. C., AWAD, M. M., 
RAMASWAMY, S., MINO-KENUDSON, M., IAFRATE, A. J., BENES, C. H. & 
ENGELMAN, J. A. 2014. Patient-derived models of acquired resistance can identify 
effective drug combinations for cancer. Science, 346, 1480-6. 
D'AVIS, P. Y., ROBERTSON, S. C., MEYER, A. N., BARDWELL, W. M., WEBSTER, M. K. & 
DONOGHUE, D. J. 1998. Constitutive activation of fibroblast growth factor receptor 3 by 
mutations responsible for the lethal skeletal dysplasia thanatophoric dysplasia type I. 
Cell Growth Differ, 9, 71-8. 
DEL PICCOLO, N., PLACONE, J. & HRISTOVA, K. 2015. Effect of thanatophoric dysplasia type 
I mutations on FGFR3 dimerization. Biophys J, 108, 272-8. 
DESNOYERS, L. R., PAI, R., FERRANDO, R. E., HOTZEL, K., LE, T., ROSS, J., CARANO, R., 
D'SOUZA, A., QING, J., MOHTASHEMI, I., ASHKENAZI, A. & FRENCH, D. M. 2008. 
Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic 
hepatocellular carcinoma models. Oncogene, 27, 85-97. 
DI MARTINO, E., L'HOTE, C. G., KENNEDY, W., TOMLINSON, D. C. & KNOWLES, M. A. 
2009. Mutant fibroblast growth factor receptor 3 induces intracellular signaling and 
205 
 
cellular transformation in a cell type- and mutation-specific manner. Oncogene, 28, 
4306-16. 
DI MARTINO, E., TOMLINSON, D. C., WILLIAMS, S. V. & KNOWLES, M. A. 2016. A place for 
precision medicine in bladder cancer: targeting the FGFRs. Future Oncol, 12, 2243-63. 
DIECI, M. V., ARNEDOS, M., ANDRE, F. & SORIA, J. C. 2013. Fibroblast growth factor 
receptor inhibitors as a cancer treatment: from a biologic rationale to medical 
perspectives. Cancer Discov, 3, 264-79. 
DIENSTMANN, R., RODON, J., PRAT, A., PEREZ-GARCIA, J., ADAMO, B., FELIP, E., 
CORTES, J., IAFRATE, A. J., NUCIFORO, P. & TABERNERO, J. 2014. Genomic 
aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. 
Ann Oncol, 25, 552-63. 
DING, X., BONEY-MONTOYA, J., OWEN, B. M., BOOKOUT, A. L., COATE, K. C., 
MANGELSDORF, D. J. & KLIEWER, S. A. 2012. betaKlotho is required for fibroblast 
growth factor 21 effects on growth and metabolism. Cell Metab, 16, 387-93. 
DRUKER, B. J., TAMURA, S., BUCHDUNGER, E., OHNO, S., SEGAL, G. M., FANNING, S., 
ZIMMERMANN, J. & LYDON, N. B. 1996. Effects of a selective inhibitor of the Abl 
tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med, 2, 561-6. 
ELZI, D. J., SONG, M., BLACKMAN, B., WEINTRAUB, S. T., LOPEZ-TERRADA, D., CHEN, Y., 
TOMLINSON, G. E. & SHIIO, Y. 2016. FGF19 functions as autocrine growth factor for 
hepatoblastoma. Genes Cancer, 7, 125-35. 
ENDRES, N. F., DAS, R., SMITH, A. W., ARKHIPOV, A., KOVACS, E., HUANG, Y., PELTON, 
J. G., SHAN, Y., SHAW, D. E., WEMMER, D. E., GROVES, J. T. & KURIYAN, J. 2013. 
Conformational coupling across the plasma membrane in activation of the EGF 
receptor. Cell, 152, 543-56. 
EZZAT, S., HUANG, P., DACKIW, A. & ASA, S. L. 2005. Dual inhibition of RET and FGFR4 
restrains medullary thyroid cancer cell growth. Clin Cancer Res, 11, 1336-41. 
EZZAT, S., ZHENG, L., YU, S. & ASA, S. L. 2001. A soluble dominant negative fibroblast 
growth factor receptor 4 isoform in human MCF-7 breast cancer cells. Biochem Biophys 
Res Commun, 287, 60-5. 
FENG, S., DAKHOVA, O., CREIGHTON, C. J. & ITTMANN, M. 2013. Endocrine fibroblast 
growth factor FGF19 promotes prostate cancer progression. Cancer Res, 73, 2551-62. 
FENG, S., WANG, J., ZHANG, Y., CREIGHTON, C. J. & ITTMANN, M. 2015. FGF23 promotes 
prostate cancer progression. Oncotarget, 6, 17291-301. 
FINCH, P. W., RUBIN, J. S., MIKI, T., RON, D. & AARONSON, S. A. 1989. Human KGF is 
FGF-related with properties of a paracrine effector of epithelial cell growth. Science, 
245, 752-5. 
FOLTZ, I. N., HU, S., KING, C., WU, X., YANG, C., WANG, W., WEISZMANN, J., STEVENS, 
J., CHEN, J. S., NUANMANEE, N., GUPTE, J., KOMOROWSKI, R., SEKIROV, L., 
HAGER, T., ARORA, T., GE, H., BARIBAULT, H., WANG, F., SHENG, J., KAROW, M., 
WANG, M., LUO, Y., MCKEEHAN, W., WANG, Z., VENIANT, M. M. & LI, Y. 2012. 
Treating diabetes and obesity with an FGF21-mimetic antibody activating the 
betaKlotho/FGFR1c receptor complex. Sci Transl Med, 4, 162ra153. 
FON TACER, K., BOOKOUT, A. L., DING, X., KUROSU, H., JOHN, G. B., WANG, L., GOETZ, 
R., MOHAMMADI, M., KURO-O, M., MANGELSDORF, D. J. & KLIEWER, S. A. 2010. 
Research resource: Comprehensive expression atlas of the fibroblast growth factor 
system in adult mouse. Mol Endocrinol, 24, 2050-64. 
FORBES, S. A., BEARE, D., GUNASEKARAN, P., LEUNG, K., BINDAL, N., BOUTSELAKIS, 
H., DING, M., BAMFORD, S., COLE, C., WARD, S., KOK, C. Y., JIA, M., DE, T., 
TEAGUE, J. W., STRATTON, M. R., MCDERMOTT, U. & CAMPBELL, P. J. 2015. 
COSMIC: exploring the world's knowledge of somatic mutations in human cancer. 
Nucleic Acids Res, 43, D805-11. 
FRENCH, D. M., LIN, B. C., WANG, M., ADAMS, C., SHEK, T., HOTZEL, K., BOLON, B., 
FERRANDO, R., BLACKMORE, C., SCHROEDER, K., RODRIGUEZ, L. A., 
HRISTOPOULOS, M., VENOOK, R., ASHKENAZI, A. & DESNOYERS, L. R. 2012. 
Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models. PLoS 
One, 7, e36713. 
FROST, M. J., FERRAO, P. T., HUGHES, T. P. & ASHMAN, L. K. 2002. Juxtamembrane 
mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit 
whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther, 1, 1115-24. 
FU, L., JOHN, L. M., ADAMS, S. H., YU, X. X., TOMLINSON, E., RENZ, M., WILLIAMS, P. M., 
SORIANO, R., CORPUZ, R., MOFFAT, B., VANDLEN, R., SIMMONS, L., FOSTER, J., 
STEPHAN, J. P., TSAI, S. P. & STEWART, T. A. 2004. Fibroblast growth factor 19 
206 
 
increases metabolic rate and reverses dietary and leptin-deficient diabetes. 
Endocrinology, 145, 2594-603. 
FURDUI, C. M., LEW, E. D., SCHLESSINGER, J. & ANDERSON, K. S. 2006. 
Autophosphorylation of FGFR1 kinase is mediated by a sequential and precisely 
ordered reaction. Mol Cell, 21, 711-7. 
FURITSU, T., TSUJIMURA, T., TONO, T., IKEDA, H., KITAYAMA, H., KOSHIMIZU, U., 
SUGAHARA, H., BUTTERFIELD, J. H., ASHMAN, L. K., KANAYAMA, Y. & ET AL. 
1993. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a 
human mast cell leukemia cell line causing ligand-independent activation of c-kit 
product. J Clin Invest, 92, 1736-44. 
FUTAMI, T., OKADA, H., KIHARA, R., KAWASE, T., NAKAYAMA, A., SUZUKI, T., KAMEDA, 
M., SHINDOH, N., TERASAKA, T., HIRANO, M. & KUROMITSU, S. 2017. ASP5878, a 
Novel Inhibitor of FGFR1, 2, 3, and 4, Inhibits the Growth of FGF19-Expressing 
Hepatocellular Carcinoma. Mol Cancer Ther, 16, 68-75. 
GALLO, L. H., NELSON, K. N., MEYER, A. N. & DONOGHUE, D. J. 2015. Functions of 
Fibroblast Growth Factor Receptors in cancer defined by novel translocations and 
mutations. Cytokine Growth Factor Rev, 26, 425-49. 
GAO, L., WANG, X., TANG, Y., HUANG, S., HU, C. A. & TENG, Y. 2017. FGF19/FGFR4 
signaling contributes to the resistance of hepatocellular carcinoma to sorafenib. J Exp 
Clin Cancer Res, 36, 8. 
GARCIA, D. & SHAW, R. J. 2017. AMPK: Mechanisms of Cellular Energy Sensing and 
Restoration of Metabolic Balance. Mol Cell, 66, 789-800. 
GARRINGER, H. J., MALEKPOUR, M., ESTEGHAMAT, F., MORTAZAVI, S. M., DAVIS, S. I., 
FARROW, E. G., YU, X., ARKING, D. E., DIETZ, H. C. & WHITE, K. E. 2008. Molecular 
genetic and biochemical analyses of FGF23 mutations in familial tumoral calcinosis. Am 
J Physiol Endocrinol Metab, 295, E929-37. 
GARTSIDE, M. G., CHEN, H., IBRAHIMI, O. A., BYRON, S. A., CURTIS, A. V., WELLENS, C. 
L., BENGSTON, A., YUDT, L. M., ELISEENKOVA, A. V., MA, J., CURTIN, J. A., 
HYDER, P., HARPER, U. L., RIEDESEL, E., MANN, G. J., TRENT, J. M., BASTIAN, B. 
C., MELTZER, P. S., MOHAMMADI, M. & POLLOCK, P. M. 2009. Loss-of-function 
fibroblast growth factor receptor-2 mutations in melanoma. Mol Cancer Res, 7, 41-54. 
GE, H., BARIBAULT, H., VONDERFECHT, S., LEMON, B., WEISZMANN, J., GARDNER, J., 
LEE, K. J., GUPTE, J., MOOKHERJEE, P., WANG, M., SHENG, J., WU, X. & LI, Y. 
2012. Characterization of a FGF19 variant with altered receptor specificity revealed a 
central role for FGFR1c in the regulation of glucose metabolism. PLoS One, 7, e33603. 
GEMEL, J., GORRY, M., EHRLICH, G. D. & MACARTHUR, C. A. 1996. Structure and 
sequence of human FGF8. Genomics, 35, 253-7. 
GOETZ, R., BEENKEN, A., IBRAHIMI, O. A., KALININA, J., OLSEN, S. K., ELISEENKOVA, A. 
V., XU, C., NEUBERT, T. A., ZHANG, F., LINHARDT, R. J., YU, X., WHITE, K. E., 
INAGAKI, T., KLIEWER, S. A., YAMAMOTO, M., KUROSU, H., OGAWA, Y., KURO-O, 
M., LANSKE, B., RAZZAQUE, M. S. & MOHAMMADI, M. 2007. Molecular insights into 
the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily 
members. Mol Cell Biol, 27, 3417-28. 
GOETZ, R. & MOHAMMADI, M. 2013. Exploring mechanisms of FGF signalling through the 
lens of structural biology. Nat Rev Mol Cell Biol, 14, 166-80. 
GOETZ, R., NAKADA, Y., HU, M. C., KUROSU, H., WANG, L., NAKATANI, T., SHI, M., 
ELISEENKOVA, A. V., RAZZAQUE, M. S., MOE, O. W., KURO-O, M. & MOHAMMADI, 
M. 2010. Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting 
FGF23-FGFR-Klotho complex formation. Proc Natl Acad Sci U S A, 107, 407-12. 
GOETZ, R., OHNISHI, M., DING, X., KUROSU, H., WANG, L., AKIYOSHI, J., MA, J., GAI, W., 
SIDIS, Y., PITTELOUD, N., KURO, O. M., RAZZAQUE, M. S. & MOHAMMADI, M. 
2012a. Klotho coreceptors inhibit signaling by paracrine fibroblast growth factor 8 
subfamily ligands. Mol Cell Biol, 32, 1944-54. 
GOETZ, R., OHNISHI, M., KIR, S., KUROSU, H., WANG, L., PASTOR, J., MA, J., GAI, W., 
KURO-O, M., RAZZAQUE, M. S. & MOHAMMADI, M. 2012b. Conversion of a paracrine 
fibroblast growth factor into an endocrine fibroblast growth factor. J Biol Chem, 287, 
29134-46. 
GOLDFARB, M., SCHOORLEMMER, J., WILLIAMS, A., DIWAKAR, S., WANG, Q., HUANG, X., 
GIZA, J., TCHETCHIK, D., KELLEY, K., VEGA, A., MATTHEWS, G., ROSSI, P., 
ORNITZ, D. M. & D'ANGELO, E. 2007. Fibroblast growth factor homologous factors 
control neuronal excitability through modulation of voltage-gated sodium channels. 
Neuron, 55, 449-63. 
207 
 
GORRE, M. E., MOHAMMED, M., ELLWOOD, K., HSU, N., PAQUETTE, R., RAO, P. N. & 
SAWYERS, C. L. 2001. Clinical resistance to STI-571 cancer therapy caused by BCR-
ABL gene mutation or amplification. Science, 293, 876-80. 
GOSPODAROWICZ, D. & CHENG, J. 1986. Heparin protects basic and acidic FGF from 
inactivation. J Cell Physiol, 128, 475-84. 
GREENMAN, C., STEPHENS, P., SMITH, R., DALGLIESH, G. L., HUNTER, C., BIGNELL, G., 
DAVIES, H., TEAGUE, J., BUTLER, A., STEVENS, C., EDKINS, S., O'MEARA, S., 
VASTRIK, I., SCHMIDT, E. E., AVIS, T., BARTHORPE, S., BHAMRA, G., BUCK, G., 
CHOUDHURY, B., CLEMENTS, J., COLE, J., DICKS, E., FORBES, S., GRAY, K., 
HALLIDAY, K., HARRISON, R., HILLS, K., HINTON, J., JENKINSON, A., JONES, D., 
MENZIES, A., MIRONENKO, T., PERRY, J., RAINE, K., RICHARDSON, D., 
SHEPHERD, R., SMALL, A., TOFTS, C., VARIAN, J., WEBB, T., WEST, S., WIDAA, 
S., YATES, A., CAHILL, D. P., LOUIS, D. N., GOLDSTRAW, P., NICHOLSON, A. G., 
BRASSEUR, F., LOOIJENGA, L., WEBER, B. L., CHIEW, Y. E., DEFAZIO, A., 
GREAVES, M. F., GREEN, A. R., CAMPBELL, P., BIRNEY, E., EASTON, D. F., 
CHENEVIX-TRENCH, G., TAN, M. H., KHOO, S. K., TEH, B. T., YUEN, S. T., LEUNG, 
S. Y., WOOSTER, R., FUTREAL, P. A. & STRATTON, M. R. 2007. Patterns of somatic 
mutation in human cancer genomes. Nature, 446, 153-8. 
GUAGNANO, V., KAUFFMANN, A., WOHRLE, S., STAMM, C., ITO, M., BARYS, L., PORNON, 
A., YAO, Y., LI, F., ZHANG, Y., CHEN, Z., WILSON, C. J., BORDAS, V., LE DOUGET, 
M., GAITHER, L. A., BORAWSKI, J., MONAHAN, J. E., VENKATESAN, K., 
BRUMMENDORF, T., THOMAS, D. M., GARCIA-ECHEVERRIA, C., HOFMANN, F., 
SELLERS, W. R. & GRAUS-PORTA, D. 2012. FGFR genetic alterations predict for 
sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov, 2, 1118-33. 
GUPTE, J., YANG, L., WU, X., WEISZMANN, J., HECHT, R., LEMON, B., LINDBERG, R., 
WANG, Z. & LI, Y. 2011. The FGFR D3 domain determines receptor selectivity for 
fibroblast growth factor 21. J Mol Biol, 408, 491-502. 
HAFNER, C., DI MARTINO, E., PITT, E., STEMPFL, T., TOMLINSON, D., HARTMANN, A., 
LANDTHALER, M., KNOWLES, M. & VOGT, T. 2010. FGFR3 mutation affects cell 
growth, apoptosis and attachment in keratinocytes. Exp Cell Res, 316, 2008-16. 
HAGE, N., RENSHAW, J. G., WINKLER, G. S., GELLERT, P., STOLNIK, S. & FALCONE, F. H. 
2015. Improved expression and purification of the Helicobacter pylori adhesin BabA 
through the incorporation of a hexa-lysine tag. Protein Expr Purif, 106, 25-30. 
HAGEL, M., MIDUTURU, C., SHEETS, M., RUBIN, N., WENG, W., STRANSKY, N., BIFULCO, 
N., KIM, J. L., HODOUS, B., BROOIJMANS, N., SHUTES, A., WINTER, C., 
LENGAUER, C., KOHL, N. E. & GUZI, T. 2015. First Selective Small Molecule Inhibitor 
of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 
Signaling Pathway. Cancer Discov, 5, 424-37. 
HANKER, A. B., GARRETT, J. T., ESTRADA, M. V., MOORE, P. D., ERICSSON, P. G., KOCH, 
J. P., LANGLEY, E., SINGH, S., KIM, P. S., FRAMPTON, G. M., SANFORD, E., 
OWENS, P., BECKER, J., GROSECLOSE, M. R., CASTELLINO, S., JOENSUU, H., 
HUOBER, J., BRASE, J. C., MAJJAJ, S., BROHEE, S., VENET, D., BROWN, D., 
BASELGA, J., PICCART, M., SOTIRIOU, C. & ARTEAGA, C. L. 2017. HER2-
Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of 
Resistance to Dual Therapeutic Blockade of HER2. Clin Cancer Res, 23, 4323-4334. 
HANKS, S. K. & HUNTER, T. 1995. Protein kinases 6. The eukaryotic protein kinase 
superfamily: kinase (catalytic) domain structure and classification. FASEB J, 9, 576-96. 
HARADA, M., MURAKAMI, H., OKAWA, A., OKIMOTO, N., HIRAOKA, S., NAKAHARA, T., 
AKASAKA, R., SHIRAISHI, Y., FUTATSUGI, N., MIZUTANI-KOSEKI, Y., KUROIWA, 
A., SHIROUZU, M., YOKOYAMA, S., TAIJI, M., ISEKI, S., ORNITZ, D. M. & KOSEKI, 
H. 2009. FGF9 monomer-dimer equilibrium regulates extracellular matrix affinity and 
tissue diffusion. Nat Genet, 41, 289-98. 
HARMER, N. J., PELLEGRINI, L., CHIRGADZE, D., FERNANDEZ-RECIO, J. & BLUNDELL, T. 
L. 2004. The crystal structure of fibroblast growth factor (FGF) 19 reveals novel features 
of the FGF family and offers a structural basis for its unusual receptor affinity. 
Biochemistry, 43, 629-40. 
HART, K. C., ROBERTSON, S. C., KANEMITSU, M. Y., MEYER, A. N., TYNAN, J. A. & 
DONOGHUE, D. J. 2000. Transformation and Stat activation by derivatives of FGFR1, 
FGFR3, and FGFR4. Oncogene, 19, 3309-20. 
HASHIMOTO, K., TSUJIMURA, T., MORIYAMA, Y., YAMATODANI, A., KIMURA, M., TOHYA, 
K., MORIMOTO, M., KITAYAMA, H., KANAKURA, Y. & KITAMURA, Y. 1996. 
Transforming and differentiation-inducing potential of constitutively activated c-kit 
208 
 
mutant genes in the IC-2 murine interleukin-3-dependent mast cell line. Am J Pathol, 
148, 189-200. 
HAUGSTEN, E. M., MALECKI, J., BJORKLUND, S. M., OLSNES, S. & WESCHE, J. 2008. 
Ubiquitination of fibroblast growth factor receptor 1 is required for its intracellular sorting 
but not for its endocytosis. Mol Biol Cell, 19, 3390-403. 
HAUGSTEN, E. M., SORENSEN, V., BRECH, A., OLSNES, S. & WESCHE, J. 2005. Different 
intracellular trafficking of FGF1 endocytosed by the four homologous FGF receptors. J 
Cell Sci, 118, 3869-81. 
HAUGSTEN, E. M., ZAKRZEWSKA, M., BRECH, A., PUST, S., OLSNES, S., SANDVIG, K. & 
WESCHE, J. 2011. Clathrin- and dynamin-independent endocytosis of FGFR3--
implications for signalling. PLoS One, 6, e21708. 
HAYASHI, Y., OKINO, N., KAKUTA, Y., SHIKANAI, T., TANI, M., NARIMATSU, H. & ITO, M. 
2007. Klotho-related protein is a novel cytosolic neutral beta-glycosylceramidase. J Biol 
Chem, 282, 30889-900. 
HECHT, R., LI, Y. S., SUN, J., BELOUSKI, E., HALL, M., HAGER, T., YIE, J., WANG, W., 
WINTERS, D., SMITH, S., SPAHR, C., TAM, L. T., SHEN, Z., STANISLAUS, S., 
CHINOOKOSWONG, N., LAU, Y., SICKMIER, A., MICHAELS, M. L., BOONE, T., 
VENIANT, M. M. & XU, J. 2012. Rationale-Based Engineering of a Potent Long-Acting 
FGF21 Analog for the Treatment of Type 2 Diabetes. PLoS One, 7, e49345. 
HEINRICH, M. C., CORLESS, C. L., DUENSING, A., MCGREEVEY, L., CHEN, C. J., JOSEPH, 
N., SINGER, S., GRIFFITH, D. J., HALEY, A., TOWN, A., DEMETRI, G. D., 
FLETCHER, C. D. & FLETCHER, J. A. 2003. PDGFRA activating mutations in 
gastrointestinal stromal tumors. Science, 299, 708-10. 
HELSTEN, T., ELKIN, S., ARTHUR, E., TOMSON, B. N., CARTER, J. & KURZROCK, R. 2016. 
The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation 
Sequencing. Clin Cancer Res, 22, 259-67. 
HELSTEN, T., SCHWAEDERLE, M. & KURZROCK, R. 2015. Fibroblast growth factor receptor 
signaling in hereditary and neoplastic disease: biologic and clinical implications. Cancer 
Metastasis Rev, 34, 479-96. 
HENRISSAT, B. & BAIROCH, A. 1993. New families in the classification of glycosyl hydrolases 
based on amino acid sequence similarities. Biochem J, 293 ( Pt 3), 781-8. 
HERBERT, C., LASSALLE, G., ALCOUFFE, C. & BONO, F. 2014. Approaches targeting the 
FGF-FGFR system: a review of the recent patent literature and associated advanced 
therapeutic agents. Pharm Pat Anal, 3, 585-612. 
HERRERA-ABREU, M. T., PEARSON, A., CAMPBELL, J., SHNYDER, S. D., KNOWLES, M. 
A., ASHWORTH, A. & TURNER, N. C. 2013. Parallel RNA interference screens identify 
EGFR activation as an escape mechanism in FGFR3-mutant cancer. Cancer Discov, 3, 
1058-71. 
HOLDMAN, X. B., WELTE, T., RAJAPAKSHE, K., POND, A., COARFA, C., MO, Q., HUANG, 
S., HILSENBECK, S. G., EDWARDS, D. P., ZHANG, X. & ROSEN, J. M. 2015. 
Upregulation of EGFR signaling is correlated with tumor stroma remodeling and tumor 
recurrence in FGFR1-driven breast cancer. Breast Cancer Res, 17, 141. 
HU, L. & CONG, L. 2015. Fibroblast growth factor 19 is correlated with an unfavorable 
prognosis and promotes progression by activating fibroblast growth factor receptor 4 in 
advanced-stage serous ovarian cancer. Oncol Rep, 34, 2683-91. 
HU, M. C., KURO-O, M. & MOE, O. W. 2012. Secreted klotho and chronic kidney disease. Adv 
Exp Med Biol, 728, 126-57. 
HU, M. C., KURO-O, M. & MOE, O. W. 2013. Klotho and chronic kidney disease. Contrib 
Nephrol, 180, 47-63. 
HU, M. C. & MOE, O. W. 2012. Klotho as a potential biomarker and therapy for acute kidney 
injury. Nat Rev Nephrol, 8, 423-9. 
HU, M. C., SHI, M., ZHANG, J., PASTOR, J., NAKATANI, T., LANSKE, B., RAZZAQUE, M. S., 
ROSENBLATT, K. P., BAUM, M. G., KURO-O, M. & MOE, O. W. 2010. Klotho: a novel 
phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. 
FASEB J, 24, 3438-50. 
HUANG, J., ISHINO, T., CHEN, G., ROLZIN, P., OSOTHPRAROP, T. F., RETTING, K., LI, L., 
JIN, P., MATIN, M. J., HUYGHE, B., TALUKDAR, S., BRADSHAW, C. W., PALANKI, 
M., VIOLAND, B. N., WOODNUTT, G., LAPPE, R. W., OGILVIE, K. & LEVIN, N. 2013a. 
Development of a novel long-acting antidiabetic FGF21 mimetic by targeted conjugation 
to a scaffold antibody. J Pharmacol Exp Ther, 346, 270-80. 
209 
 
HUANG, Z., CHEN, H., BLAIS, S., NEUBERT, T. A., LI, X. & MOHAMMADI, M. 2013b. 
Structural mimicry of a-loop tyrosine phosphorylation by a pathogenic FGF receptor 3 
mutation. Structure, 21, 1889-96. 
HUANG, Z., TAN, L., WANG, H., LIU, Y., BLAIS, S., DENG, J., NEUBERT, T. A., GRAY, N. S., 
LI, X. & MOHAMMADI, M. 2015. DFG-out mode of inhibition by an irreversible type-1 
inhibitor capable of overcoming gate-keeper mutations in FGF receptors. ACS Chem 
Biol, 10, 299-309. 
HUANG, Z., WANG, H., LU, M., SUN, C., WU, X., TAN, Y., YE, C., ZHU, G., WANG, X., CAI, L. 
& LI, X. 2011. A better anti-diabetic recombinant human fibroblast growth factor 21 
(rhFGF21) modified with polyethylene glycol. PLoS One, 6, e20669. 
HUBBARD, S. R. 1999. Structural analysis of receptor tyrosine kinases. Prog Biophys Mol Biol, 
71, 343-58. 
IBRAHIMI, O. A., ZHANG, F., ELISEENKOVA, A. V., LINHARDT, R. J. & MOHAMMADI, M. 
2004. Proline to arginine mutations in FGF receptors 1 and 3 result in Pfeiffer and 
Muenke craniosynostosis syndromes through enhancement of FGF binding affinity. 
Hum Mol Genet, 13, 69-78. 
IMURA, A., IWANO, A., TOHYAMA, O., TSUJI, Y., NOZAKI, K., HASHIMOTO, N., FUJIMORI, 
T. & NABESHIMA, Y. 2004. Secreted Klotho protein in sera and CSF: implication for 
post-translational cleavage in release of Klotho protein from cell membrane. FEBS Lett, 
565, 143-7. 
INAGAKI, T., CHOI, M., MOSCHETTA, A., PENG, L., CUMMINS, C. L., MCDONALD, J. G., 
LUO, G., JONES, S. A., GOODWIN, B., RICHARDSON, J. A., GERARD, R. D., REPA, 
J. J., MANGELSDORF, D. J. & KLIEWER, S. A. 2005. Fibroblast growth factor 15 
functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab, 2, 
217-25. 
INAGAKI, T., DUTCHAK, P., ZHAO, G., DING, X., GAUTRON, L., PARAMESWARA, V., LI, Y., 
GOETZ, R., MOHAMMADI, M., ESSER, V., ELMQUIST, J. K., GERARD, R. D., 
BURGESS, S. C., HAMMER, R. E., MANGELSDORF, D. J. & KLIEWER, S. A. 2007. 
Endocrine regulation of the fasting response by PPARalpha-mediated induction of 
fibroblast growth factor 21. Cell Metab, 5, 415-25. 
INTERNATIONAL CANCER GENOME, C., HUDSON, T. J., ANDERSON, W., ARTEZ, A., 
BARKER, A. D., BELL, C., BERNABE, R. R., BHAN, M. K., CALVO, F., EEROLA, I., 
GERHARD, D. S., GUTTMACHER, A., GUYER, M., HEMSLEY, F. M., JENNINGS, J. 
L., KERR, D., KLATT, P., KOLAR, P., KUSADA, J., LANE, D. P., LAPLACE, F., 
YOUYONG, L., NETTEKOVEN, G., OZENBERGER, B., PETERSON, J., RAO, T. S., 
REMACLE, J., SCHAFER, A. J., SHIBATA, T., STRATTON, M. R., VOCKLEY, J. G., 
WATANABE, K., YANG, H., YUEN, M. M., KNOPPERS, B. M., BOBROW, M., 
CAMBON-THOMSEN, A., DRESSLER, L. G., DYKE, S. O., JOLY, Y., KATO, K., 
KENNEDY, K. L., NICOLAS, P., PARKER, M. J., RIAL-SEBBAG, E., ROMEO-
CASABONA, C. M., SHAW, K. M., WALLACE, S., WIESNER, G. L., ZEPS, N., 
LICHTER, P., BIANKIN, A. V., CHABANNON, C., CHIN, L., CLEMENT, B., DE ALAVA, 
E., DEGOS, F., FERGUSON, M. L., GEARY, P., HAYES, D. N., HUDSON, T. J., 
JOHNS, A. L., KASPRZYK, A., NAKAGAWA, H., PENNY, R., PIRIS, M. A., SARIN, R., 
SCARPA, A., SHIBATA, T., VAN DE VIJVER, M., FUTREAL, P. A., ABURATANI, H., 
BAYES, M., BOTWELL, D. D., CAMPBELL, P. J., ESTIVILL, X., GERHARD, D. S., 
GRIMMOND, S. M., GUT, I., HIRST, M., LOPEZ-OTIN, C., MAJUMDER, P., MARRA, 
M., MCPHERSON, J. D., NAKAGAWA, H., NING, Z., PUENTE, X. S., RUAN, Y., 
SHIBATA, T., STRATTON, M. R., STUNNENBERG, H. G., SWERDLOW, H., 
VELCULESCU, V. E., WILSON, R. K., XUE, H. H., YANG, L., SPELLMAN, P. T., 
BADER, G. D., BOUTROS, P. C., CAMPBELL, P. J., et al. 2010. International network 
of cancer genome projects. Nature, 464, 993-8. 
ITO, S., FUJIMORI, T., HAYASHIZAKI, Y. & NABESHIMA, Y. 2002. Identification of a novel 
mouse membrane-bound family 1 glycosidase-like protein, which carries an atypical 
active site structure. Biochim Biophys Acta, 1576, 341-5. 
ITO, S., KINOSHITA, S., SHIRAISHI, N., NAKAGAWA, S., SEKINE, S., FUJIMORI, T. & 
NABESHIMA, Y. I. 2000. Molecular cloning and expression analyses of mouse 
betaklotho, which encodes a novel Klotho family protein. Mech Dev, 98, 115-9. 
ITOH, N., OHTA, H. & KONISHI, M. 2015. Endocrine FGFs: Evolution, Physiology, 
Pathophysiology, and Pharmacotherapy. Front Endocrinol (Lausanne), 6, 154. 




ITOH, N. & ORNITZ, D. M. 2008. Functional evolutionary history of the mouse Fgf gene family. 
Dev Dyn, 237, 18-27. 
ITOH, N. & ORNITZ, D. M. 2011. Fibroblast growth factors: from molecular evolution to roles in 
development, metabolism and disease. J Biochem, 149, 121-30. 
JABS, E. W., LI, X., SCOTT, A. F., MEYERS, G., CHEN, W., ECCLES, M., MAO, J. I., 
CHARNAS, L. R., JACKSON, C. E. & JAYE, M. 1994. Jackson-Weiss and Crouzon 
syndromes are allelic with mutations in fibroblast growth factor receptor 2. Nat Genet, 8, 
275-9. 
JOHNSON, D. E., LEE, P. L., LU, J. & WILLIAMS, L. T. 1990. Diverse forms of a receptor for 
acidic and basic fibroblast growth factors. Mol Cell Biol, 10, 4728-36. 
JURA, N., ENDRES, N. F., ENGEL, K., DEINDL, S., DAS, R., LAMERS, M. H., WEMMER, D. 
E., ZHANG, X. & KURIYAN, J. 2009. Mechanism for activation of the EGF receptor 
catalytic domain by the juxtamembrane segment. Cell, 137, 1293-307. 
KAIBORI, M., SAKAI, K., ISHIZAKI, M., MATSUSHIMA, H., DE VELASCO, M. A., MATSUI, K., 
IIDA, H., KITADE, H., KWON, A. H., NAGANO, H., WADA, H., HAJI, S., TSUKAMOTO, 
T., KANAZAWA, A., TAKEDA, Y., TAKEMURA, S., KUBO, S. & NISHIO, K. 2016. 
Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with 
a complete response after sorafenib treatment. Oncotarget, 7, 49091-49098. 
KALININA, J., BYRON, S. A., MAKARENKOVA, H. P., OLSEN, S. K., ELISEENKOVA, A. V., 
LAROCHELLE, W. J., DHANABAL, M., BLAIS, S., ORNITZ, D. M., DAY, L. A., 
NEUBERT, T. A., POLLOCK, P. M. & MOHAMMADI, M. 2009. Homodimerization 
controls the fibroblast growth factor 9 subfamily's receptor binding and heparan sulfate-
dependent diffusion in the extracellular matrix. Mol Cell Biol, 29, 4663-78. 
KALININA, J., DUTTA, K., ILGHARI, D., BEENKEN, A., GOETZ, R., ELISEENKOVA, A. V., 
COWBURN, D. & MOHAMMADI, M. 2012. The alternatively spliced acid box region 
plays a key role in FGF receptor autoinhibition. Structure, 20, 77-88. 
KANG, S., ELF, S., DONG, S., HITOSUGI, T., LYTHGOE, K., GUO, A., RUAN, H., LONIAL, S., 
KHOURY, H. J., WILLIAMS, I. R., LEE, B. H., ROESEL, J. L., KARSENTY, G., 
HANAUER, A., TAUNTON, J., BOGGON, T. J., GU, T. L. & CHEN, J. 2009. Fibroblast 
growth factor receptor 3 associates with and tyrosine phosphorylates p90 RSK2, 
leading to RSK2 activation that mediates hematopoietic transformation. Mol Cell Biol, 
29, 2105-17. 
KHARITONENKOV, A., BEALS, J. M., MICANOVIC, R., STRIFLER, B. A., RATHNACHALAM, 
R., WROBLEWSKI, V. J., LI, S., KOESTER, A., FORD, A. M., COSKUN, T., DUNBAR, 
J. D., CHENG, C. C., FRYE, C. C., BUMOL, T. F. & MOLLER, D. E. 2013. Rational 
design of a fibroblast growth factor 21-based clinical candidate, LY2405319. PLoS One, 
8, e58575. 
KHARITONENKOV, A., DUNBAR, J. D., BINA, H. A., BRIGHT, S., MOYERS, J. S., ZHANG, C., 
DING, L., MICANOVIC, R., MEHRBOD, S. F., KNIERMAN, M. D., HALE, J. E., 
COSKUN, T. & SHANAFELT, A. B. 2008. FGF-21/FGF-21 receptor interaction and 
activation is determined by beta Klotho. Journal of Cellular Physiology, 215, 1-7. 
KHARITONENKOV, A., SHIYANOVA, T. L., KOESTER, A., FORD, A. M., MICANOVIC, R., 
GALBREATH, E. J., SANDUSKY, G. E., HAMMOND, L. J., MOYERS, J. S., OWENS, 
R. A., GROMADA, J., BROZINICK, J. T., HAWKINS, E. D., WROBLEWSKI, V. J., LI, D. 
S., MEHRBOD, F., JASKUNAS, S. R. & SHANAFELT, A. B. 2005. FGF-21 as a novel 
metabolic regulator. J Clin Invest, 115, 1627-35. 
KILKENNY, D. M. & ROCHELEAU, J. V. 2016. The FGF21 Receptor Signaling Complex: 
Klothobeta, FGFR1c, and Other Regulatory Interactions. Vitam Horm, 101, 17-58. 
KIM, B., WANG, S., LEE, J. M., JEONG, Y., AHN, T., SON, D. S., PARK, H. W., YOO, H. S., 
SONG, Y. J., LEE, E., OH, Y. M., LEE, S. B., CHOI, J., MURRAY, J. C., ZHOU, Y., 
SONG, P. H., KIM, K. A. & WEINER, L. M. 2015. Synthetic lethal screening reveals 
FGFR as one of the combinatorial targets to overcome resistance to Met-targeted 
therapy. Oncogene, 34, 1083-93. 
KIM, S. M., KIM, H., YUN, M. R., KANG, H. N., PYO, K. H., PARK, H. J., LEE, J. M., CHOI, H. 
M., ELLINGHAUS, P., OCKER, M., PAIK, S., KIM, H. R. & CHO, B. C. 2016. Activation 
of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer 
therapy. Oncogenesis, 5, e241. 
KIMURA, T., SUZUKI, H., OHASHI, T., ASANO, K., KIYOTA, H. & ETO, Y. 2001. The incidence 
of thanatophoric dysplasia mutations in FGFR3 gene is higher in low-grade or 
superficial bladder carcinomas. Cancer, 92, 2555-61. 
KIR, S., KLIEWER, S. A. & MANGELSDORF, D. J. 2011. Roles of FGF19 in liver metabolism. 
Cold Spring Harb Symp Quant Biol, 76, 139-44. 
211 
 
KITAYAMA, H., KANAKURA, Y., FURITSU, T., TSUJIMURA, T., ORITANI, K., IKEDA, H., 
SUGAHARA, H., MITSUI, H., KANAYAMA, Y., KITAMURA, Y. & ET AL. 1995. 
Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-
independent growth and tumorigenicity of factor-dependent hematopoietic cell lines. 
Blood, 85, 790-8. 
KOBASHIGAWA, Y., AMANO, S., YOKOGAWA, M., KUMETA, H., MORIOKA, H., INOUYE, M., 
SCHLESSINGER, J. & INAGAKI, F. 2015. Structural analysis of the mechanism of 
phosphorylation of a critical autoregulatory tyrosine residue in FGFR1 kinase domain. 
Genes Cells, 20, 860-70. 
KOBAYASHI, S., BOGGON, T. J., DAYARAM, T., JANNE, P. A., KOCHER, O., MEYERSON, 
M., JOHNSON, B. E., ECK, M. J., TENEN, D. G. & HALMOS, B. 2005. EGFR mutation 
and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med, 352, 786-92. 
KOLUMAM, G., CHEN, M. Z., TONG, R., ZAVALA-SOLORIO, J., KATES, L., VAN BRUGGEN, 
N., ROSS, J., WYATT, S. K., GANDHAM, V. D., CARANO, R. A., DUNSHEE, D. R., 
WU, A. L., HALEY, B., ANDERSON, K., WARMING, S., RAIRDAN, X. Y., LEWIN-KOH, 
N., ZHANG, Y., GUTIERREZ, J., BARUCH, A., GELZLEICHTER, T. R., STEVENS, D., 
RAJAN, S., BAINBRIDGE, T. W., VERNES, J. M., MENG, Y. G., ZIAI, J., SORIANO, R. 
H., BRAUER, M. J., CHEN, Y., STAWICKI, S., KIM, H. S., COMPS-AGRAR, L., LUIS, 
E., SPIESS, C., WU, Y., ERNST, J. A., MCGUINNESS, O. P., PETERSON, A. S. & 
SONODA, J. 2015. Sustained Brown Fat Stimulation and Insulin Sensitization by a 
Humanized Bispecific Antibody Agonist for Fibroblast Growth Factor Receptor 
1/betaKlotho Complex. EBioMedicine, 2, 730-43. 
KONG, B., HUANG, J., ZHU, Y., LI, G., WILLIAMS, J., SHEN, S., ALEKSUNES, L. M., 
RICHARDSON, J. R., APTE, U., RUDNICK, D. A. & GUO, G. L. 2014. Fibroblast growth 
factor 15 deficiency impairs liver regeneration in mice. Am J Physiol Gastrointest Liver 
Physiol, 306, G893-902. 
KONG, M., WANG, C. S. & DONOGHUE, D. J. 2002. Interaction of fibroblast growth factor 
receptor 3 and the adapter protein SH2-B. A role in STAT5 activation. J Biol Chem, 277, 
15962-70. 
KORNEV, A. P., HASTE, N. M., TAYLOR, S. S. & EYCK, L. F. 2006. Surface comparison of 
active and inactive protein kinases identifies a conserved activation mechanism. Proc 
Natl Acad Sci U S A, 103, 17783-8. 
KORNEV, A. P., TAYLOR, S. S. & TEN EYCK, L. F. 2008. A helix scaffold for the assembly of 
active protein kinases. Proc Natl Acad Sci U S A, 105, 14377-82. 
KOUHARA, H., HADARI, Y. R., SPIVAK-KROIZMAN, T., SCHILLING, J., BAR-SAGI, D., LAX, I. 
& SCHLESSINGER, J. 1997. A lipid-anchored Grb2-binding protein that links FGF-
receptor activation to the Ras/MAPK signaling pathway. Cell, 89, 693-702. 
KOVESDY, C. P. & QUARLES, L. D. 2016. FGF23 from bench to bedside. Am J Physiol Renal 
Physiol, 310, F1168-74. 
KRAUSE, D. S. & VAN ETTEN, R. A. 2005. Tyrosine kinases as targets for cancer therapy. N 
Engl J Med, 353, 172-87. 
KREJCI, P., SALAZAR, L., KASHIWADA, T. A., CHLEBOVA, K., SALASOVA, A., THOMPSON, 
L. M., BRYJA, V., KOZUBIK, A. & WILCOX, W. R. 2008. Analysis of STAT1 activation 
by six FGFR3 mutants associated with skeletal dysplasia undermines dominant role of 
STAT1 in FGFR3 signaling in cartilage. PLoS One, 3, e3961. 
KROGH, A., LARSSON, B., VON HEIJNE, G. & SONNHAMMER, E. L. 2001. Predicting 
transmembrane protein topology with a hidden Markov model: application to complete 
genomes. J Mol Biol, 305, 567-80. 
KURO-O, M., MATSUMURA, Y., AIZAWA, H., KAWAGUCHI, H., SUGA, T., UTSUGI, T., 
OHYAMA, Y., KURABAYASHI, M., KANAME, T., KUME, E., IWASAKI, H., IIDA, A., 
SHIRAKI-IIDA, T., NISHIKAWA, S., NAGAI, R. & NABESHIMA, Y. I. 1997. Mutation of 
the mouse klotho gene leads to a syndrome resembling ageing. Nature, 390, 45-51. 
KUROSU, H., CHOI, M., OGAWA, Y., DICKSON, A. S., GOETZ, R., ELISEENKOVA, A. V., 
MOHAMMADI, M., ROSENBLATT, K. P., KLIEWER, S. A. & KURO-O, M. 2007. 
Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor 
isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem, 282, 26687-
95. 
KUROSU, H. & KURO, O. M. 2009. The Klotho gene family as a regulator of endocrine 
fibroblast growth factors. Mol Cell Endocrinol, 299, 72-8. 
KUROSU, H., OGAWA, Y., MIYOSHI, M., YAMAMOTO, M., NANDI, A., ROSENBLATT, K. P., 
BAUM, M. G., SCHIAVI, S., HU, M. C., MOE, O. W. & KURO-O, M. 2006. Regulation of 
fibroblast growth factor-23 signaling by klotho. J Biol Chem, 281, 6120-3. 
212 
 
KUROSU, H., YAMAMOTO, M., CLARK, J. D., PASTOR, J. V., NANDI, A., GURNANI, P., 
MCGUINNESS, O. P., CHIKUDA, H., YAMAGUCHI, M., KAWAGUCHI, H., 
SHIMOMURA, I., TAKAYAMA, Y., HERZ, J., KAHN, C. R., ROSENBLATT, K. P. & 
KURO-O, M. 2005. Suppression of aging in mice by the hormone Klotho. Science, 309, 
1829-33. 
KWAK, Y., CHO, H., HUR, W. & SIM, T. 2015. Antitumor Effects and Mechanisms of AZD4547 
on FGFR2-Deregulated Endometrial Cancer Cells. Mol Cancer Ther, 14, 2292-302. 
LAEDERICH, M. B., DEGNIN, C. R., LUNSTRUM, G. P., HOLDEN, P. & HORTON, W. A. 2011. 
Fibroblast growth factor receptor 3 (FGFR3) is a strong heat shock protein 90 (Hsp90) 
client: implications for therapeutic manipulation. J Biol Chem, 286, 19597-604. 
LEE, J., JEONG, D. J., KIM, J., LEE, S., PARK, J. H., CHANG, B., JUNG, S. I., YI, L., HAN, Y., 
YANG, Y., KIM, K. I., LIM, J. S., YANG, I., JEON, S., BAE, D. H., KIM, C. J. & LEE, M. 
S. 2010. The anti-aging gene KLOTHO is a novel target for epigenetic silencing in 
human cervical carcinoma. Mol Cancer, 9, 109. 
LEE, J. H., GIANNIKOPOULOS, P., DUNCAN, S. A., WANG, J., JOHANSEN, C. T., BROWN, 
J. D., PLUTZKY, J., HEGELE, R. A., GLIMCHER, L. H. & LEE, A. H. 2011. The 
transcription factor cyclic AMP-responsive element-binding protein H regulates 
triglyceride metabolism. Nat Med, 17, 812-5. 
LEES, J. G., MILES, A. J., WIEN, F. & WALLACE, B. A. 2006. A reference database for circular 
dichroism spectroscopy covering fold and secondary structure space. Bioinformatics, 
22, 1955-62. 
LEES, J. G., SMITH, B. R., WIEN, F., MILES, A. J. & WALLACE, B. A. 2004. CDtool-an 
integrated software package for circular dichroism spectroscopic data processing, 
analysis, and archiving. Anal Biochem, 332, 285-9. 
LEMMON, M. A. & SCHLESSINGER, J. 2010. Cell signaling by receptor tyrosine kinases. Cell, 
141, 1117-34. 
LEW, E. D., FURDUI, C. M., ANDERSON, K. S. & SCHLESSINGER, J. 2009. The precise 
sequence of FGF receptor autophosphorylation is kinetically driven and is disrupted by 
oncogenic mutations. Sci Signal, 2, ra6. 
LIAO, R. G., JUNG, J., TCHAICHA, J., WILKERSON, M. D., SIVACHENKO, A., BEAUCHAMP, 
E. M., LIU, Q., PUGH, T. J., PEDAMALLU, C. S., HAYES, D. N., GRAY, N. S., GETZ, 
G., WONG, K. K., HADDAD, R. I., MEYERSON, M. & HAMMERMAN, P. S. 2013. 
Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. 
Cancer Res, 73, 5195-205. 
LIEVENS, P. M. & LIBOI, E. 2003. The thanatophoric dysplasia type II mutation hampers 
complete maturation of fibroblast growth factor receptor 3 (FGFR3), which activates 
signal transducer and activator of transcription 1 (STAT1) from the endoplasmic 
reticulum. J Biol Chem, 278, 17344-9. 
LIM, K., GROEN, A., MOLOSTVOV, G., LU, T., LILLEY, K. S., SNEAD, D., JAMES, S., 
WILKINSON, I. B., TING, S., HSIAO, L. L., HIEMSTRA, T. F. & ZEHNDER, D. 2015. 
alpha-Klotho Expression in Human Tissues. J Clin Endocrinol Metab, 100, E1308-18. 
LIN, B. C., WANG, M., BLACKMORE, C. & DESNOYERS, L. R. 2007. Liver-specific activities of 
FGF19 require Klotho beta. J Biol Chem, 282, 27277-84. 
LIN, C. C., MELO, F. A., GHOSH, R., SUEN, K. M., STAGG, L. J., KIRKPATRICK, J., AROLD, 
S. T., AHMED, Z. & LADBURY, J. E. 2012. Inhibition of basal FGF receptor signaling by 
dimeric Grb2. Cell, 149, 1514-24. 
LIU, S., GUO, R., SIMPSON, L. G., XIAO, Z. S., BURNHAM, C. E. & QUARLES, L. D. 2003. 
Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J 
Biol Chem, 278, 37419-26. 
LIU, Y., MA, J., BEENKEN, A., SRINIVASAN, L., ELISEENKOVA, A. V. & MOHAMMADI, M. 
2017. Regulation of Receptor Binding Specificity of FGF9 by an Autoinhibitory 
Homodimerization. Structure. 
LOBB, R. R. & FETT, J. W. 1984. Purification of two distinct growth factors from bovine neural 
tissue by heparin affinity chromatography. Biochemistry, 23, 6295-9. 
LUNDASEN, T., HUNT, M. C., NILSSON, L. M., SANYAL, S., ANGELIN, B., ALEXSON, S. E. & 
RUDLING, M. 2007. PPARalpha is a key regulator of hepatic FGF21. Biochem Biophys 
Res Commun, 360, 437-40. 
LUO, Y., YANG, C., LU, W., XIE, R., JIN, C., HUANG, P., WANG, F. & MCKEEHAN, W. L. 
2010. Metabolic regulator betaKlotho interacts with fibroblast growth factor receptor 4 




MAKARENKOVA, H. P., HOFFMAN, M. P., BEENKEN, A., ELISEENKOVA, A. V., MEECH, R., 
TSAU, C., PATEL, V. N., LANG, R. A. & MOHAMMADI, M. 2009. Differential 
interactions of FGFs with heparan sulfate control gradient formation and branching 
morphogenesis. Sci Signal, 2, ra55. 
MANAVALAN, P. & JOHNSON, W. C., JR. 1987. Variable selection method improves the 
prediction of protein secondary structure from circular dichroism spectra. Anal Biochem, 
167, 76-85. 
MANNING, G., WHYTE, D. B., MARTINEZ, R., HUNTER, T. & SUDARSANAM, S. 2002. The 
protein kinase complement of the human genome. Science, 298, 1912-34. 
MAO, D., WACHTER, E. & WALLACE, B. A. 1982. Folding of the mitochondrial proton 
adenosinetriphosphatase proteolipid channel in phospholipid vesicles. Biochemistry, 21, 
4960-8. 
MARKAN, K. R., NABER, M. C., AMEKA, M. K., ANDEREGG, M. D., MANGELSDORF, D. J., 
KLIEWER, S. A., MOHAMMADI, M. & POTTHOFF, M. J. 2014. Circulating FGF21 is 
liver derived and enhances glucose uptake during refeeding and overfeeding. Diabetes, 
63, 4057-63. 
MATSUMURA, Y., AIZAWA, H., SHIRAKI-IIDA, T., NAGAI, R., KURO-O, M. & NABESHIMA, Y. 
1998. Identification of the human klotho gene and its two transcripts encoding 
membrane and secreted klotho protein. Biochem Biophys Res Commun, 242, 626-30. 
MCDONELL, L. M., KERNOHAN, K. D., BOYCOTT, K. M. & SAWYER, S. L. 2015. Receptor 
tyrosine kinase mutations in developmental syndromes and cancer: two sides of the 
same coin. Hum Mol Genet, 24, R60-6. 
MCSKIMMING, D. I., DASTGHEIB, S., TALEVICH, E., NARAYANAN, A., KATIYAR, S., 
TAYLOR, S. S., KOCHUT, K. & KANNAN, N. 2015. ProKinO: a unified resource for 
mining the cancer kinome. Hum Mutat, 36, 175-86. 
MCWHIRTER, J. R., GOULDING, M., WEINER, J. A., CHUN, J. & MURRE, C. 1997. A novel 
fibroblast growth factor gene expressed in the developing nervous system is a 
downstream target of the chimeric homeodomain oncoprotein E2A-Pbx1. Development, 
124, 3221-32. 
MEHARENA, H. S., CHANG, P., KESHWANI, M. M., ORUGANTY, K., NENE, A. K., KANNAN, 
N., TAYLOR, S. S. & KORNEV, A. P. 2013. Deciphering the structural basis of 
eukaryotic protein kinase regulation. PLoS Biol, 11, e1001680. 
MELLOR, H. R. 2014. Targeted inhibition of the FGF19-FGFR4 pathway in hepatocellular 
carcinoma; translational safety considerations. Liver Int, 34, e1-9. 
MENCKE, R., OLAUSON, H. & HILLEBRANDS, J. L. 2017. Effects of Klotho on fibrosis and 
cancer: A renal focus on mechanisms and therapeutic strategies. Adv Drug Deliv Rev. 
MICANOVIC, R., RACHES, D. W., DUNBAR, J. D., DRIVER, D. A., BINA, H. A., DICKINSON, 
C. D. & KHARITONENKOV, A. 2009. Different roles of N- and C- termini in the 
functional activity of FGF21. J Cell Physiol, 219, 227-34. 
MICSONAI, A., WIEN, F., KERNYA, L., LEE, Y. H., GOTO, Y., REFREGIERS, M. & KARDOS, 
J. 2015. Accurate secondary structure prediction and fold recognition for circular 
dichroism spectroscopy. Proc Natl Acad Sci U S A, 112, E3095-103. 
MIKI, T., BOTTARO, D. P., FLEMING, T. P., SMITH, C. L., BURGESS, W. H., CHAN, A. M. & 
AARONSON, S. A. 1992. Determination of ligand-binding specificity by alternative 
splicing: two distinct growth factor receptors encoded by a single gene. Proc Natl Acad 
Sci U S A, 89, 246-50. 
MILBURN, D., LASKOWSKI, R. A. & THORNTON, J. M. 1998. Sequences annotated by 
structure: a tool to facilitate the use of structural information in sequence analysis. 
Protein Eng, 11, 855-9. 
MING, A. Y., YOO, E., VORONTSOV, E. N., ALTAMENTOVA, S. M., KILKENNY, D. M. & 
ROCHELEAU, J. V. 2012. Dynamics and Distribution of Klothobeta (KLB) and fibroblast 
growth factor receptor-1 (FGFR1) in living cells reveal the fibroblast growth factor-21 
(FGF21)-induced receptor complex. J Biol Chem, 287, 19997-20006. 
MIYAKE, M., ISHII, M., KOYAMA, N., KAWASHIMA, K., KODAMA, T., ANAI, S., FUJIMOTO, 
K., HIRAO, Y. & SUGANO, K. 2010. 1-tert-butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-
diethylamino-butylamino)-pyrido[2,3 -d]pyrimidin-7-yl]-urea (PD173074), a selective 
tyrosine kinase inhibitor of fibroblast growth factor receptor-3 (FGFR3), inhibits cell 
proliferation of bladder cancer carrying the FGFR3 gene mutation along with up-
regulation of p27/Kip1 and G1/G0 arrest. J Pharmacol Exp Ther, 332, 795-802. 
MIZUNO, I., TAKAHASHI, Y., OKIMURA, Y., KAJI, H. & CHIHARA, K. 2001. Upregulation of the 
klotho gene expression by thyroid hormone and during adipose differentiation in 3T3-L1 
adipocytes. Life Sci, 68, 2917-23. 
214 
 
MOHAMMADI, M., DIKIC, I., SOROKIN, A., BURGESS, W. H., JAYE, M. & SCHLESSINGER, 
J. 1996a. Identification of six novel autophosphorylation sites on fibroblast growth factor 
receptor 1 and elucidation of their importance in receptor activation and signal 
transduction. Mol Cell Biol, 16, 977-89. 
MOHAMMADI, M., HONEGGER, A. M., ROTIN, D., FISCHER, R., BELLOT, F., LI, W., 
DIONNE, C. A., JAYE, M., RUBINSTEIN, M. & SCHLESSINGER, J. 1991. A tyrosine-
phosphorylated carboxy-terminal peptide of the fibroblast growth factor receptor (Flg) is 
a binding site for the SH2 domain of phospholipase C-gamma 1. Mol Cell Biol, 11, 
5068-78. 
MOHAMMADI, M., OLSEN, S. K. & GOETZ, R. 2005a. A protein canyon in the FGF-FGF 
receptor dimer selects from an a la carte menu of heparan sulfate motifs. Curr Opin 
Struct Biol, 15, 506-16. 
MOHAMMADI, M., OLSEN, S. K. & IBRAHIMI, O. A. 2005b. Structural basis for fibroblast 
growth factor receptor activation. Cytokine Growth Factor Rev, 16, 107-37. 
MOHAMMADI, M., SCHLESSINGER, J. & HUBBARD, S. R. 1996b. Structure of the FGF 
receptor tyrosine kinase domain reveals a novel autoinhibitory mechanism. Cell, 86, 
577-87. 
MU, J., PINKSTAFF, J., LI, Z., SKIDMORE, L., LI, N., MYLER, H., DALLAS-YANG, Q., 
PUTNAM, A. M., YAO, J., BUSSELL, S., WU, M., NORMAN, T. C., RODRIGUEZ, C. 
G., KIMMEL, B., METZGER, J. M., MANIBUSAN, A., LEE, D., ZALLER, D. M., ZHANG, 
B. B., DIMARCHI, R. D., BERGER, J. P. & AXELROD, D. W. 2012. FGF21 analogs of 
sustained action enabled by orthogonal biosynthesis demonstrate enhanced 
antidiabetic pharmacology in rodents. Diabetes, 61, 505-12. 
MUENKE, M., SCHELL, U., HEHR, A., ROBIN, N. H., LOSKEN, H. W., SCHINZEL, A., 
PULLEYN, L. J., RUTLAND, P., REARDON, W., MALCOLM, S. & ET AL. 1994. A 
common mutation in the fibroblast growth factor receptor 1 gene in Pfeiffer syndrome. 
Nat Genet, 8, 269-74. 
NAGATA, H., WOROBEC, A. S., OH, C. K., CHOWDHURY, B. A., TANNENBAUM, S., 
SUZUKI, Y. & METCALFE, D. D. 1995. Identification of a point mutation in the catalytic 
domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients 
who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U 
S A, 92, 10560-4. 
NAKANISHI, Y., AKIYAMA, N., TSUKAGUCHI, T., FUJII, T., SAKATA, K., SASE, H., ISOBE, T., 
MORIKAMI, K., SHINDOH, H., MIO, T., EBIIKE, H., TAKA, N., AOKI, Y. & ISHII, N. 
2014. The fibroblast growth factor receptor genetic status as a potential predictor of the 
sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor. Mol Cancer 
Ther, 13, 2547-58. 
NASKI, M. C., WANG, Q., XU, J. & ORNITZ, D. M. 1996. Graded activation of fibroblast growth 
factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nat 
Genet, 13, 233-7. 
NICHOLES, K., GUILLET, S., TOMLINSON, E., HILLAN, K., WRIGHT, B., FRANTZ, G. D., 
PHAM, T. A., DILLARD-TELM, L., TSAI, S. P., STEPHAN, J. P., STINSON, J., 
STEWART, T. & FRENCH, D. M. 2002. A mouse model of hepatocellular carcinoma: 
ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. 
Am J Pathol, 160, 2295-307. 
NISHIMURA, T., NAKATAKE, Y., KONISHI, M. & ITOH, N. 2000. Identification of a novel FGF, 
FGF-21, preferentially expressed in the liver. Biochim Biophys Acta, 1492, 203-6. 
NISHIMURA, T., UTSUNOMIYA, Y., HOSHIKAWA, M., OHUCHI, H. & ITOH, N. 1999. Structure 
and expression of a novel human FGF, FGF-19, expressed in the fetal brain. Biochim 
Biophys Acta, 1444, 148-51. 
NOGOVA, L., SEQUIST, L. V., PEREZ GARCIA, J. M., ANDRE, F., DELORD, J. P., HIDALGO, 
M., SCHELLENS, J. H., CASSIER, P. A., CAMIDGE, D. R., SCHULER, M., 
VAISHAMPAYAN, U., BURRIS, H., TIAN, G. G., CAMPONE, M., WAINBERG, Z. A., 
LIM, W. T., LORUSSO, P., SHAPIRO, G. I., PARKER, K., CHEN, X., CHOUDHURY, 
S., RINGEISEN, F., GRAUS-PORTA, D., PORTER, D., ISAACS, R., BUETTNER, R. & 
WOLF, J. 2017. Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase 
Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in 
Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and 
Dose-Expansion Study. J Clin Oncol, 35, 157-165. 
OGAWA, Y., KUROSU, H., YAMAMOTO, M., NANDI, A., ROSENBLATT, K. P., GOETZ, R., 
ELISEENKOVA, A. V., MOHAMMADI, M. & KURO-O, M. 2007. BetaKlotho is required 
215 
 
for metabolic activity of fibroblast growth factor 21. Proc Natl Acad Sci U S A, 104, 
7432-7. 
OLAUSON, H., MENCKE, R., HILLEBRANDS, J. L. & LARSSON, T. E. 2017. Tissue 
expression and source of circulating alphaKlotho. Bone, 100, 19-35. 
OLSEN, S. K., GARBI, M., ZAMPIERI, N., ELISEENKOVA, A. V., ORNITZ, D. M., GOLDFARB, 
M. & MOHAMMADI, M. 2003. Fibroblast growth factor (FGF) homologous factors share 
structural but not functional homology with FGFs. J Biol Chem, 278, 34226-36. 
OLSEN, S. K., IBRAHIMI, O. A., RAUCCI, A., ZHANG, F., ELISEENKOVA, A. V., YAYON, A., 
BASILICO, C., LINHARDT, R. J., SCHLESSINGER, J. & MOHAMMADI, M. 2004. 
Insights into the molecular basis for fibroblast growth factor receptor autoinhibition and 
ligand-binding promiscuity. Proc Natl Acad Sci U S A, 101, 935-40. 
OLSEN, S. K., LI, J. Y., BROMLEIGH, C., ELISEENKOVA, A. V., IBRAHIMI, O. A., LAO, Z., 
ZHANG, F., LINHARDT, R. J., JOYNER, A. L. & MOHAMMADI, M. 2006. Structural 
basis by which alternative splicing modulates the organizer activity of FGF8 in the brain. 
Genes Dev, 20, 185-98. 
ONG, S. H., GUY, G. R., HADARI, Y. R., LAKS, S., GOTOH, N., SCHLESSINGER, J. & LAX, I. 
2000. FRS2 proteins recruit intracellular signaling pathways by binding to diverse 
targets on fibroblast growth factor and nerve growth factor receptors. Mol Cell Biol, 20, 
979-89. 
OPALINSKI, L., SOKOLOWSKA-WEDZINA, A., SZCZEPARA, M., ZAKRZEWSKA, M. & 
OTLEWSKI, J. 2017. Antibody-induced dimerization of FGFR1 promotes receptor 
endocytosis independently of its kinase activity. Sci Rep, 7, 7121. 
ORNITZ, D. M. & ITOH, N. 2015. The Fibroblast Growth Factor signaling pathway. Wiley 
Interdiscip Rev Dev Biol, 4, 215-66. 
ORNITZ, D. M. & LEDER, P. 1992. Ligand specificity and heparin dependence of fibroblast 
growth factor receptors 1 and 3. J Biol Chem, 267, 16305-11. 
ORNITZ, D. M., XU, J., COLVIN, J. S., MCEWEN, D. G., MACARTHUR, C. A., COULIER, F., 
GAO, G. & GOLDFARB, M. 1996. Receptor specificity of the fibroblast growth factor 
family. J Biol Chem, 271, 15292-7. 
ORNITZ, D. M., YAYON, A., FLANAGAN, J. G., SVAHN, C. M., LEVI, E. & LEDER, P. 1992. 
Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble 
receptor and for mitogenesis in whole cells. Mol Cell Biol, 12, 240-7. 
ORR-URTREGER, A., BEDFORD, M. T., BURAKOVA, T., ARMAN, E., ZIMMER, Y., YAYON, 
A., GIVOL, D. & LONAI, P. 1993. Developmental localization of the splicing alternatives 
of fibroblast growth factor receptor-2 (FGFR2). Dev Biol, 158, 475-86. 
OSTROVSKY, O., BERMAN, B., GALLAGHER, J., MULLOY, B., FERNIG, D. G., DELEHEDDE, 
M. & RON, D. 2002. Differential effects of heparin saccharides on the formation of 
specific fibroblast growth factor (FGF) and FGF receptor complexes. J Biol Chem, 277, 
2444-53. 
OWEN, B. M., MANGELSDORF, D. J. & KLIEWER, S. A. 2015. Tissue-specific actions of the 
metabolic hormones FGF15/19 and FGF21. Trends Endocrinol Metab, 26, 22-9. 
PANNIER, S., MARTINOVIC, J., HEUERTZ, S., DELEZOIDE, A. L., MUNNICH, A., SCHIBLER, 
L., SERRE, V. & LEGEAI-MALLET, L. 2009. Thanatophoric dysplasia caused by double 
missense FGFR3 mutations. Am J Med Genet A, 149A, 1296-301. 
PAO, W., MILLER, V. A., POLITI, K. A., RIELY, G. J., SOMWAR, R., ZAKOWSKI, M. F., KRIS, 
M. G. & VARMUS, H. 2005. Acquired resistance of lung adenocarcinomas to gefitinib or 
erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med, 
2, e73. 
PATANI, H., BUNNEY, T. D., THIYAGARAJAN, N., NORMAN, R. A., OGG, D., BREED, J., 
ASHFORD, P., POTTERTON, A., EDWARDS, M., WILLIAMS, S. V., THOMSON, G. S., 
PANG, C. S., KNOWLES, M. A., BREEZE, A. L., ORENGO, C., PHILLIPS, C. & 
KATAN, M. 2016. Landscape of activating cancer mutations in FGFR kinases and their 
differential responses to inhibitors in clinical use. Oncotarget, 7, 24252-68. 
PELLEGRINI, L., BURKE, D. F., VON DELFT, F., MULLOY, B. & BLUNDELL, T. L. 2000. 
Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and 
heparin. Nature, 407, 1029-34. 
PENG, W. C., LIN, X. & TORRES, J. 2009. The strong dimerization of the transmembrane 
domain of the fibroblast growth factor receptor (FGFR) is modulated by C-terminal 
juxtamembrane residues. Protein Sci, 18, 450-9. 
PETERSEN, T. N., BRUNAK, S., VON HEIJNE, G. & NIELSEN, H. 2011. SignalP 4.0: 
discriminating signal peptides from transmembrane regions. Nat Methods, 8, 785-6. 
216 
 
PIETRAS, K., PAHLER, J., BERGERS, G. & HANAHAN, D. 2008. Functions of paracrine PDGF 
signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. 
PLoS Med, 5, e19. 
PILLAY, V., ALLAF, L., WILDING, A. L., DONOGHUE, J. F., COURT, N. W., GREENALL, S. A., 
SCOTT, A. M. & JOHNS, T. G. 2009. The plasticity of oncogene addiction: implications 
for targeted therapies directed to receptor tyrosine kinases. Neoplasia, 11, 448-58, 2 p 
following 458. 
PLOTNIKOV, A. N., ELISEENKOVA, A. V., IBRAHIMI, O. A., SHRIVER, Z., SASISEKHARAN, 
R., LEMMON, M. A. & MOHAMMADI, M. 2001. Crystal structure of fibroblast growth 
factor 9 reveals regions implicated in dimerization and autoinhibition. J Biol Chem, 276, 
4322-9. 
PLOTNIKOV, A. N., SCHLESSINGER, J., HUBBARD, S. R. & MOHAMMADI, M. 1999. 
Structural basis for FGF receptor dimerization and activation. Cell, 98, 641-50. 
POTTHOFF, M. J., KLIEWER, S. A. & MANGELSDORF, D. J. 2012. Endocrine fibroblast 
growth factors 15/19 and 21: from feast to famine. Genes Dev, 26, 312-24. 
POWELL, M. A., SILL, M. W., GOODFELLOW, P. J., BENBROOK, D. M., LANKES, H. A., 
LESLIE, K. K., JESKE, Y., MANNEL, R. S., SPILLMAN, M. A., LEE, P. S., HOFFMAN, 
J. S., MCMEEKIN, D. S. & POLLOCK, P. M. 2014. A phase II trial of brivanib in 
recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology 
Group Study. Gynecol Oncol, 135, 38-43. 
POWNALL, M. E. & ISAACS, H. V. 2010. FGF Signalling in Vertebrate Development. San 
Rafael (CA). 
QING, J., DU, X., CHEN, Y., CHAN, P., LI, H., WU, P., MARSTERS, S., STAWICKI, S., TIEN, 
J., TOTPAL, K., ROSS, S., STINSON, S., DORNAN, D., FRENCH, D., WANG, Q. R., 
STEPHAN, J. P., WU, Y., WIESMANN, C. & ASHKENAZI, A. 2009. Antibody-based 
targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. 
J Clin Invest, 119, 1216-29. 
QU, X., CARBE, C., TAO, C., POWERS, A., LAWRENCE, R., VAN KUPPEVELT, T. H., 
CARDOSO, W. V., GROBE, K., ESKO, J. D. & ZHANG, X. 2011. Lacrimal gland 
development and Fgf10-Fgfr2b signaling are controlled by 2-O- and 6-O-sulfated 
heparan sulfate. J Biol Chem, 286, 14435-44. 
QU, X., PAN, Y., CARBE, C., POWERS, A., GROBE, K. & ZHANG, X. 2012. 
Glycosaminoglycan-dependent restriction of FGF diffusion is necessary for lacrimal 
gland development. Development, 139, 2730-9. 
RAPRAEGER, A. C., KRUFKA, A. & OLWIN, B. B. 1991. Requirement of heparan sulfate for 
bFGF-mediated fibroblast growth and myoblast differentiation. Science, 252, 1705-8. 
REARDON, W., WINTER, R. M., RUTLAND, P., PULLEYN, L. J., JONES, B. M. & MALCOLM, 
S. 1994. Mutations in the fibroblast growth factor receptor 2 gene cause Crouzon 
syndrome. Nat Genet, 8, 98-103. 
RED BREWER, M., CHOI, S. H., ALVARADO, D., MORAVCEVIC, K., POZZI, A., LEMMON, M. 
A. & CARPENTER, G. 2009. The juxtamembrane region of the EGF receptor functions 
as an activation domain. Mol Cell, 34, 641-51. 
ROBERTSON, S. C., TYNAN, J. & DONOGHUE, D. J. 2000. RTK mutations and human 
syndromes: when good receptors turn bad. Trends Genet, 16, 368. 
ROGHANI, M. & MOSCATELLI, D. 2007. Prostate cells express two isoforms of fibroblast 
growth factor receptor 1 with different affinities for fibroblast growth factor-2. Prostate, 
67, 115-24. 
RONCHETTI, D., GRECO, A., COMPASSO, S., COLOMBO, G., DELL'ERA, P., OTSUKI, T., 
LOMBARDI, L. & NERI, A. 2001. Deregulated FGFR3 mutants in multiple myeloma cell 
lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D 
mutations. Oncogene, 20, 3553-62. 
ROSTY, C., AUBRIOT, M. H., CAPPELLEN, D., BOURDIN, J., CARTIER, I., THIERY, J. P., 
SASTRE-GARAU, X. & RADVANYI, F. 2005. Clinical and biological characteristics of 
cervical neoplasias with FGFR3 mutation. Mol Cancer, 4, 15. 
ROUSSEAU, F., BONAVENTURE, J., LEGEAI-MALLET, L., PELET, A., ROZET, J. M., 
MAROTEAUX, P., LE MERRER, M. & MUNNICH, A. 1994. Mutations in the gene 
encoding fibroblast growth factor receptor-3 in achondroplasia. Nature, 371, 252-4. 
RYU, E. K., CHO, K. J., KIM, J. K., HARMER, N. J., BLUNDELL, T. L. & KIM, K. H. 2006. 
Expression and purification of recombinant human fibroblast growth factor receptor in 
Escherichia coli. Protein Expr Purif, 49, 15-22. 
SAKAMOTO, K., KAWATA, Y., MASUDA, Y., UMEMOTO, T., ITO, T., ASAMI, T., TAKEKAWA, 
S., OHTAKI, T. & INOOKA, H. 2016. Discovery of an artificial peptide agonist to the 
217 
 
fibroblast growth factor receptor 1c/betaKlotho complex from random peptide T7 phage 
display. Biochem Biophys Res Commun, 480, 55-60. 
SAKSELA, O., MOSCATELLI, D., SOMMER, A. & RIFKIN, D. B. 1988. Endothelial cell-derived 
heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic 
degradation. J Cell Biol, 107, 743-51. 
SANDILANDS, E., AKBARZADEH, S., VECCHIONE, A., MCEWAN, D. G., FRAME, M. C. & 
HEATH, J. K. 2007. Src kinase modulates the activation, transport and signalling 
dynamics of fibroblast growth factor receptors. EMBO Rep, 8, 1162-9. 
SANTOS-OCAMPO, S., COLVIN, J. S., CHELLAIAH, A. & ORNITZ, D. M. 1996. Expression 
and biological activity of mouse fibroblast growth factor-9. J Biol Chem, 271, 1726-31. 
SARABIPOUR, S. 2017. Parallels and Distinctions in FGFR, VEGFR, and EGFR Mechanisms 
of Transmembrane Signaling. Biochemistry, 56, 3159-3173. 
SARABIPOUR, S. & HRISTOVA, K. 2015. FGFR3 unliganded dimer stabilization by the 
juxtamembrane domain. J Mol Biol, 427, 1705-14. 
SARABIPOUR, S. & HRISTOVA, K. 2016. Mechanism of FGF receptor dimerization and 
activation. Nat Commun, 7, 10262. 
SAWEY, E. T., CHANRION, M., CAI, C., WU, G., ZHANG, J., ZENDER, L., ZHAO, A., 
BUSUTTIL, R. W., YEE, H., STEIN, L., FRENCH, D. M., FINN, R. S., LOWE, S. W. & 
POWERS, S. 2011. Identification of a therapeutic strategy targeting amplified FGF19 in 
liver cancer by Oncogenomic screening. Cancer Cell, 19, 347-58. 
SCHLESSINGER, J., PLOTNIKOV, A. N., IBRAHIMI, O. A., ELISEENKOVA, A. V., YEH, B. K., 
YAYON, A., LINHARDT, R. J. & MOHAMMADI, M. 2000. Crystal structure of a ternary 
FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and 
dimerization. Mol Cell, 6, 743-50. 
SCHLESSINGER, J., SHECHTER, Y., CUATRECASAS, P., WILLINGHAM, M. C. & PASTAN, I. 
1978. Quantitative determination of the lateral diffusion coefficients of the hormone-
receptor complexes of insulin and epidermal growth factor on the plasma membrane of 
cultured fibroblasts. Proc Natl Acad Sci U S A, 75, 5353-7. 
SCHMID, C., NEIDERT, M. C., TSCHOPP, O., SZE, L. & BERNAYS, R. L. 2013. Growth 
hormone and Klotho. J Endocrinol, 219, R37-57. 
SESHAGIRI, S., STAWISKI, E. W., DURINCK, S., MODRUSAN, Z., STORM, E. E., CONBOY, 
C. B., CHAUDHURI, S., GUAN, Y., JANAKIRAMAN, V., JAISWAL, B. S., GUILLORY, 
J., HA, C., DIJKGRAAF, G. J., STINSON, J., GNAD, F., HUNTLEY, M. A., 
DEGENHARDT, J. D., HAVERTY, P. M., BOURGON, R., WANG, W., KOEPPEN, H., 
GENTLEMAN, R., STARR, T. K., ZHANG, Z., LARGAESPADA, D. A., WU, T. D. & DE 
SAUVAGE, F. J. 2012. Recurrent R-spondin fusions in colon cancer. Nature, 488, 660-
4. 
SHAH, D. R., SHAH, R. R. & MORGANROTH, J. 2013a. Tyrosine kinase inhibitors: their on-
target toxicities as potential indicators of efficacy. Drug Saf, 36, 413-26. 
SHAH, N. P., NICOLL, J. M., NAGAR, B., GORRE, M. E., PAQUETTE, R. L., KURIYAN, J. & 
SAWYERS, C. L. 2002. Multiple BCR-ABL kinase domain mutations confer polyclonal 
resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast 
crisis chronic myeloid leukemia. Cancer Cell, 2, 117-25. 
SHAH, R. R., MORGANROTH, J. & SHAH, D. R. 2013b. Cardiovascular safety of tyrosine 
kinase inhibitors: with a special focus on cardiac repolarisation (QT interval). Drug Saf, 
36, 295-316. 
SHIANG, C. Y., QI, Y., WANG, B., LAZAR, V., WANG, J., FRASER SYMMANS, W., 
HORTOBAGYI, G. N., ANDRE, F. & PUSZTAI, L. 2010. Amplification of fibroblast 
growth factor receptor-1 in breast cancer and the effects of brivanib alaninate. Breast 
Cancer Res Treat, 123, 747-55. 
SHIANG, R., THOMPSON, L. M., ZHU, Y. Z., CHURCH, D. M., FIELDER, T. J., BOCIAN, M., 
WINOKUR, S. T. & WASMUTH, J. J. 1994. Mutations in the transmembrane domain of 
FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell, 78, 
335-42. 
SHIMADA, T., HASEGAWA, H., YAMAZAKI, Y., MUTO, T., HINO, R., TAKEUCHI, Y., FUJITA, 
T., NAKAHARA, K., FUKUMOTO, S. & YAMASHITA, T. 2004. FGF-23 is a potent 
regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res, 19, 
429-35. 
SHIMADA, T., MIZUTANI, S., MUTO, T., YONEYA, T., HINO, R., TAKEDA, S., TAKEUCHI, Y., 
FUJITA, T., FUKUMOTO, S. & YAMASHITA, T. 2001. Cloning and characterization of 




SHIMADA, T., MUTO, T., URAKAWA, I., YONEYA, T., YAMAZAKI, Y., OKAWA, K., 
TAKEUCHI, Y., FUJITA, T., FUKUMOTO, S. & YAMASHITA, T. 2002. Mutant FGF-23 
responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic 
cleavage and causes hypophosphatemia in vivo. Endocrinology, 143, 3179-82. 
SHIMIZU, A., TADA, K., SHUKUNAMI, C., HIRAKI, Y., KUROKAWA, T., MAGANE, N. & 
KUROKAWA-SEO, M. 2001. A novel alternatively spliced fibroblast growth factor 
receptor 3 isoform lacking the acid box domain is expressed during chondrogenic 
differentiation of ATDC5 cells. J Biol Chem, 276, 11031-40. 
SHING, Y., FOLKMAN, J., SULLIVAN, R., BUTTERFIELD, C., MURRAY, J. & KLAGSBRUN, 
M. 1984. Heparin affinity: purification of a tumor-derived capillary endothelial cell growth 
factor. Science, 223, 1296-9. 
SHIRAKI-IIDA, T., AIZAWA, H., MATSUMURA, Y., SEKINE, S., IIDA, A., ANAZAWA, H., 
NAGAI, R., KURO-O, M. & NABESHIMA, Y. 1998. Structure of the mouse klotho gene 
and its two transcripts encoding membrane and secreted protein. FEBS Lett, 424, 6-10. 
SIEVERS, F., WILM, A., DINEEN, D., GIBSON, T. J., KARPLUS, K., LI, W., LOPEZ, R., 
MCWILLIAM, H., REMMERT, M., SODING, J., THOMPSON, J. D. & HIGGINS, D. G. 
2011. Fast, scalable generation of high-quality protein multiple sequence alignments 
using Clustal Omega. Mol Syst Biol, 7, 539. 
SINGH, D., CHAN, J. M., ZOPPOLI, P., NIOLA, F., SULLIVAN, R., CASTANO, A., LIU, E. M., 
REICHEL, J., PORRATI, P., PELLEGATTA, S., QIU, K., GAO, Z., CECCARELLI, M., 
RICCARDI, R., BRAT, D. J., GUHA, A., ALDAPE, K., GOLFINOS, J. G., ZAGZAG, D., 
MIKKELSEN, T., FINOCCHIARO, G., LASORELLA, A., RABADAN, R. & IAVARONE, 
A. 2012. Transforming fusions of FGFR and TACC genes in human glioblastoma. 
Science, 337, 1231-5. 
SINGLETON, K. R., KIM, J., HINZ, T. K., MAREK, L. A., CASAS-SELVES, M., HATHEWAY, C., 
TAN, A. C., DEGREGORI, J. & HEASLEY, L. E. 2013. A receptor tyrosine kinase 
network composed of fibroblast growth factor receptors, epidermal growth factor 
receptor, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, and hepatocyte 
growth factor receptor drives growth and survival of head and neck squamous 
carcinoma cell lines. Mol Pharmacol, 83, 882-93. 
SLEEMAN, M., FRASER, J., MCDONALD, M., YUAN, S., WHITE, D., GRANDISON, P., 
KUMBLE, K., WATSON, J. D. & MURISON, J. G. 2001. Identification of a new fibroblast 
growth factor receptor, FGFR5. Gene, 271, 171-82. 
SMITH, R., DUGUAY, A., BAKKER, A., LI, P., WEISZMANN, J., THOMAS, M. R., ALBA, B. M., 
WU, X., GUPTE, J., YANG, L., STEVENS, J., HAMBURGER, A., SMITH, S., CHEN, J., 
KOMOROWSKI, R., MOORE, K. W., VENIANT, M. M. & LI, Y. 2013a. FGF21 can be 
mimicked in vitro and in vivo by a novel anti-FGFR1c/beta-Klotho bispecific protein. 
PLoS One, 8, e61432. 
SMITH, R., DUGUAY, A., WEISZMANN, J., STANISLAUS, S., BELOUSKI, E., CAI, L., YIE, J., 
XU, J., GUPTE, J., WU, X. & LI, Y. 2013b. A novel approach to improve the function of 
FGF21. BioDrugs, 27, 159-66. 
SOHL, C. D., RYAN, M. R., LUO, B., FREY, K. M. & ANDERSON, K. S. 2015. Illuminating the 
molecular mechanisms of tyrosine kinase inhibitor resistance for the FGFR1 gatekeeper 
mutation: the Achilles' heel of targeted therapy. ACS Chem Biol, 10, 1319-29. 
SONG, Y., DING, J., JIN, R., JUNG, J., LI, S., YANG, J., WANG, A. & LI, Z. 2016. Expression 
and purification of FGF21 in Pichia pastoris and its effect on fibroblast-cell migration. 
Mol Med Rep, 13, 3619-26. 
SORIA, J. C., DEBRAUD, F., BAHLEDA, R., ADAMO, B., ANDRE, F., DIENSTMANN, R., 
DELMONTE, A., CEREDA, R., ISAACSON, J., LITTEN, J., ALLEN, A., DUBOIS, F., 
SABA, C., ROBERT, R., D'INCALCI, M., ZUCCHETTI, M., CAMBONI, M. G. & 
TABERNERO, J. 2014. Phase I/IIa study evaluating the safety, efficacy, 
pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors. Ann 
Oncol, 25, 2244-51. 
SORKIN, A. & VON ZASTROW, M. 2009. Endocytosis and signalling: intertwining molecular 
networks. Nat Rev Mol Cell Biol, 10, 609-22. 
SPIELBERGER, R., STIFF, P., BENSINGER, W., GENTILE, T., WEISDORF, D., 
KEWALRAMANI, T., SHEA, T., YANOVICH, S., HANSEN, K., NOGA, S., MCCARTY, 
J., LEMAISTRE, C. F., SUNG, E. C., BLAZAR, B. R., ELHARDT, D., CHEN, M. G. & 
EMMANOUILIDES, C. 2004. Palifermin for oral mucositis after intensive therapy for 
hematologic cancers. N Engl J Med, 351, 2590-8. 
STAUBER, D. J., DIGABRIELE, A. D. & HENDRICKSON, W. A. 2000. Structural interactions of 
fibroblast growth factor receptor with its ligands. Proc Natl Acad Sci U S A, 97, 49-54. 
219 
 
STOMMEL, J. M., KIMMELMAN, A. C., YING, H., NABIOULLIN, R., PONUGOTI, A. H., 
WIEDEMEYER, R., STEGH, A. H., BRADNER, J. E., LIGON, K. L., BRENNAN, C., 
CHIN, L. & DEPINHO, R. A. 2007. Coactivation of receptor tyrosine kinases affects the 
response of tumor cells to targeted therapies. Science, 318, 287-90. 
STUHLMILLER, T. J., MILLER, S. M., ZAWISTOWSKI, J. S., NAKAMURA, K., BELTRAN, A. 
S., DUNCAN, J. S., ANGUS, S. P., COLLINS, K. A., GRANGER, D. A., REUTHER, R. 
A., GRAVES, L. M., GOMEZ, S. M., KUAN, P. F., PARKER, J. S., CHEN, X., SCIAKY, 
N., CAREY, L. A., EARP, H. S., JIN, J. & JOHNSON, G. L. 2015. Inhibition of Lapatinib-
Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET 
Family Bromodomains. Cell Rep, 11, 390-404. 
SUZUKI, M., UEHARA, Y., MOTOMURA-MATSUZAKA, K., OKI, J., KOYAMA, Y., KIMURA, M., 
ASADA, M., KOMI-KURAMOCHI, A., OKA, S. & IMAMURA, T. 2008. betaKlotho is 
required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 
1c and FGFR3c. Mol Endocrinol, 22, 1006-14. 
TAMBORINI, E., BONADIMAN, L., GRECO, A., ALBERTINI, V., NEGRI, T., GRONCHI, A., 
BERTULLI, R., COLECCHIA, M., CASALI, P. G., PIEROTTI, M. A. & PILOTTI, S. 2004. 
A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a 
gastrointestinal stromal tumor patient. Gastroenterology, 127, 294-9. 
TAN, L., WANG, J., TANIZAKI, J., HUANG, Z., AREF, A. R., RUSAN, M., ZHU, S. J., ZHANG, 
Y., ERCAN, D., LIAO, R. G., CAPELLETTI, M., ZHOU, W., HUR, W., KIM, N., SIM, T., 
GAUDET, S., BARBIE, D. A., YEH, J. R., YUN, C. H., HAMMERMAN, P. S., 
MOHAMMADI, M., JANNE, P. A. & GRAY, N. S. 2014. Development of covalent 
inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors. Proc 
Natl Acad Sci U S A, 111, E4869-77. 
TANNER, Y. & GROSE, R. P. 2016. Dysregulated FGF signalling in neoplastic disorders. Semin 
Cell Dev Biol, 53, 126-35. 
TAVORMINA, P. L., BELLUS, G. A., WEBSTER, M. K., BAMSHAD, M. J., FRALEY, A. E., 
MCINTOSH, I., SZABO, J., JIANG, W., JABS, E. W., WILCOX, W. R., WASMUTH, J. 
J., DONOGHUE, D. J., THOMPSON, L. M. & FRANCOMANO, C. A. 1999. A novel 
skeletal dysplasia with developmental delay and acanthosis nigricans is caused by a 
Lys650Met mutation in the fibroblast growth factor receptor 3 gene. Am J Hum Genet, 
64, 722-31. 
TAVORMINA, P. L., SHIANG, R., THOMPSON, L. M., ZHU, Y. Z., WILKIN, D. J., LACHMAN, R. 
S., WILCOX, W. R., RIMOIN, D. L., COHN, D. H. & WASMUTH, J. J. 1995. 
Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast 
growth factor receptor 3. Nat Genet, 9, 321-8. 
TAYLOR, S. S. & KORNEV, A. P. 2011. Protein kinases: evolution of dynamic regulatory 
proteins. Trends Biochem Sci, 36, 65-77. 
TERAI, H., SOEJIMA, K., YASUDA, H., NAKAYAMA, S., HAMAMOTO, J., ARAI, D., ISHIOKA, 
K., OHGINO, K., IKEMURA, S., SATO, T., YODA, S., SATOMI, R., NAOKI, K. & 
BETSUYAKU, T. 2013. Activation of the FGF2-FGFR1 autocrine pathway: a novel 
mechanism of acquired resistance to gefitinib in NSCLC. Mol Cancer Res, 11, 759-67. 
THE UNIPROT, C. 2017. UniProt: the universal protein knowledgebase. Nucleic Acids Res, 45, 
D158-D169. 
THORNTON, S. C., MUELLER, S. N. & LEVINE, E. M. 1983. Human endothelial cells: use of 
heparin in cloning and long-term serial cultivation. Science, 222, 623-5. 
TOHYAMA, O., IMURA, A., IWANO, A., FREUND, J. N., HENRISSAT, B., FUJIMORI, T. & 
NABESHIMA, Y. 2004. Klotho is a novel beta-glucuronidase capable of hydrolyzing 
steroid beta-glucuronides. J Biol Chem, 279, 9777-84. 
TOMLINSON, D. C., BALDO, O., HARNDEN, P. & KNOWLES, M. A. 2007a. FGFR3 protein 
expression and its relationship to mutation status and prognostic variables in bladder 
cancer. J Pathol, 213, 91-8. 
TOMLINSON, D. C., HURST, C. D. & KNOWLES, M. A. 2007b. Knockdown by shRNA identifies 
S249C mutant FGFR3 as a potential therapeutic target in bladder cancer. Oncogene, 
26, 5889-99. 
TOMLINSON, D. C., L'HOTE, C. G., KENNEDY, W., PITT, E. & KNOWLES, M. A. 2005. 
Alternative splicing of fibroblast growth factor receptor 3 produces a secreted isoform 
that inhibits fibroblast growth factor-induced proliferation and is repressed in urothelial 
carcinoma cell lines. Cancer Res, 65, 10441-9. 
TOMLINSON, E., FU, L., JOHN, L., HULTGREN, B., HUANG, X., RENZ, M., STEPHAN, J. P., 
TSAI, S. P., POWELL-BRAXTON, L., FRENCH, D. & STEWART, T. A. 2002. 
220 
 
Transgenic mice expressing human fibroblast growth factor-19 display increased 
metabolic rate and decreased adiposity. Endocrinology, 143, 1741-7. 
TOUAT, M., ILEANA, E., POSTEL-VINAY, S., ANDRE, F. & SORIA, J. C. 2015. Targeting 
FGFR Signaling in Cancer. Clin Cancer Res, 21, 2684-94. 
TRUDEL, S., ELY, S., FAROOQI, Y., AFFER, M., ROBBIANI, D. F., CHESI, M. & 
BERGSAGEL, P. L. 2004. Inhibition of fibroblast growth factor receptor 3 induces 
differentiation and apoptosis in t(4;14) myeloma. Blood, 103, 3521-8. 
TRUEB, B. 2011. Biology of FGFRL1, the fifth fibroblast growth factor receptor. Cell Mol Life 
Sci, 68, 951-64. 
TRUEB, B., ZHUANG, L., TAESCHLER, S. & WIEDEMANN, M. 2003. Characterization of 
FGFRL1, a novel fibroblast growth factor (FGF) receptor preferentially expressed in 
skeletal tissues. J Biol Chem, 278, 33857-65. 
TURNER, N. & GROSE, R. 2010. Fibroblast growth factor signalling: from development to 
cancer. Nat Rev Cancer, 10, 116-29. 
UEMATSU, F., JANG, J. H., KAN, M., WANG, F., LUO, Y. & MCKEEHAN, W. L. 2001. 
Evidence that the intracellular domain of FGF receptor 2IIIb affects contact of the 
ectodomain with two FGF7 ligands. Biochem Biophys Res Commun, 283, 791-7. 
URAKAWA, I., YAMAZAKI, Y., SHIMADA, T., IIJIMA, K., HASEGAWA, H., OKAWA, K., 
FUJITA, T., FUKUMOTO, S. & YAMASHITA, T. 2006. Klotho converts canonical FGF 
receptor into a specific receptor for FGF23. Nature, 444, 770-4. 
URIARTE, I., FERNANDEZ-BARRENA, M. G., MONTE, M. J., LATASA, M. U., CHANG, H. C., 
CAROTTI, S., VESPASIANI-GENTILUCCI, U., MORINI, S., VICENTE, E., 
CONCEPCION, A. R., MEDINA, J. F., MARIN, J. J., BERASAIN, C., PRIETO, J. & 
AVILA, M. A. 2013. Identification of fibroblast growth factor 15 as a novel mediator of 
liver regeneration and its application in the prevention of post-resection liver failure in 
mice. Gut, 62, 899-910. 
URIARTE, I., LATASA, M. U., CAROTTI, S., FERNANDEZ-BARRENA, M. G., GARCIA-
IRIGOYEN, O., ELIZALDE, M., URTASUN, R., VESPASIANI-GENTILUCCI, U., 
MORINI, S., DE MINGO, A., MARI, M., CORRALES, F. J., PRIETO, J., BERASAIN, C. 
& AVILA, M. A. 2015. Ileal FGF15 contributes to fibrosis-associated hepatocellular 
carcinoma development. Int J Cancer, 136, 2469-75. 
VALIEV, M., KAWAI, R., ADAMS, J. A. & WEARE, J. H. 2003. The role of the putative catalytic 
base in the phosphoryl transfer reaction in a protein kinase: first-principles calculations. 
J Am Chem Soc, 125, 9926-7. 
VAN RHIJN, B. W., LURKIN, I., RADVANYI, F., KIRKELS, W. J., VAN DER KWAST, T. H. & 
ZWARTHOFF, E. C. 2001. The fibroblast growth factor receptor 3 (FGFR3) mutation is 
a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res, 
61, 1265-8. 
WANG, F., KAN, M., YAN, G., XU, J. & MCKEEHAN, W. L. 1995. Alternately spliced NH2-
terminal immunoglobulin-like Loop I in the ectodomain of the fibroblast growth factor 
(FGF) receptor 1 lowers affinity for both heparin and FGF-1. J Biol Chem, 270, 10231-5. 
WARE, K. E., MARSHALL, M. E., HEASLEY, L. R., MAREK, L., HINZ, T. K., HERCULE, P., 
HELFRICH, B. A., DOEBELE, R. C. & HEASLEY, L. E. 2010. Rapidly acquired 
resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression 
of FGFR2 and FGFR3 expression. PLoS One, 5, e14117. 
WEBSTER, M. K., D'AVIS, P. Y., ROBERTSON, S. C. & DONOGHUE, D. J. 1996. Profound 
ligand-independent kinase activation of fibroblast growth factor receptor 3 by the 
activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric 
dysplasia type II. Mol Cell Biol, 16, 4081-7. 
WEISS, J., SOS, M. L., SEIDEL, D., PEIFER, M., ZANDER, T., HEUCKMANN, J. M., ULLRICH, 
R. T., MENON, R., MAIER, S., SOLTERMANN, A., MOCH, H., WAGENER, P., 
FISCHER, F., HEYNCK, S., KOKER, M., SCHOTTLE, J., LEENDERS, F., GABLER, F., 
DABOW, I., QUERINGS, S., HEUKAMP, L. C., BALKE-WANT, H., ANSEN, S., RAUH, 
D., BAESSMANN, I., ALTMULLER, J., WAINER, Z., CONRON, M., WRIGHT, G., 
RUSSELL, P., SOLOMON, B., BRAMBILLA, E., BRAMBILLA, C., LORIMIER, P., 
SOLLBERG, S., BRUSTUGUN, O. T., ENGEL-RIEDEL, W., LUDWIG, C., PETERSEN, 
I., SANGER, J., CLEMENT, J., GROEN, H., TIMENS, W., SIETSMA, H., 
THUNNISSEN, E., SMIT, E., HEIDEMAN, D., CAPPUZZO, F., LIGORIO, C., DAMIANI, 
S., HALLEK, M., BEROUKHIM, R., PAO, W., KLEBL, B., BAUMANN, M., BUETTNER, 
R., ERNESTUS, K., STOELBEN, E., WOLF, J., NURNBERG, P., PERNER, S. & 
THOMAS, R. K. 2010. Frequent and focal FGFR1 amplification associates with 
221 
 
therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl 
Med, 2, 62ra93. 
WERNER, S., DUAN, D. S., DE VRIES, C., PETERS, K. G., JOHNSON, D. E. & WILLIAMS, L. 
T. 1992. Differential splicing in the extracellular region of fibroblast growth factor 
receptor 1 generates receptor variants with different ligand-binding specificities. Mol 
Cell Biol, 12, 82-8. 
WHITE, K. E., CARN, G., LORENZ-DEPIEREUX, B., BENET-PAGES, A., STROM, T. M. & 
ECONS, M. J. 2001. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations 
stabilize FGF-23. Kidney Int, 60, 2079-86. 
WIEDEMANN, M. & TRUEB, B. 2000. Characterization of a novel protein (FGFRL1) from 
human cartilage related to FGF receptors. Genomics, 69, 275-9. 
WILKIE, A. O. 2005. Bad bones, absent smell, selfish testes: the pleiotropic consequences of 
human FGF receptor mutations. Cytokine Growth Factor Rev, 16, 187-203. 
WILLIAMS, S. V., HURST, C. D. & KNOWLES, M. A. 2013. Oncogenic FGFR3 gene fusions in 
bladder cancer. Hum Mol Genet, 22, 795-803. 
WILSON, T. R., FRIDLYAND, J., YAN, Y., PENUEL, E., BURTON, L., CHAN, E., PENG, J., 
LIN, E., WANG, Y., SOSMAN, J., RIBAS, A., LI, J., MOFFAT, J., SUTHERLIN, D. P., 
KOEPPEN, H., MERCHANT, M., NEVE, R. & SETTLEMAN, J. 2012. Widespread 
potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature, 487, 
505-9. 
WOHRLE, S., HENNINGER, C., BONNY, O., THUERY, A., BELUCH, N., HYNES, N. E., 
GUAGNANO, V., SELLERS, W. R., HOFMANN, F., KNEISSEL, M. & GRAUS PORTA, 
D. 2013. Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling 
ameliorates FGF23-mediated hypophosphatemic rickets. J Bone Miner Res, 28, 899-
911. 
WOLF, I., LEVANON-COHEN, S., BOSE, S., LIGUMSKY, H., SREDNI, B., KANETY, H., 
KURO-O, M., KARLAN, B., KAUFMAN, B., KOEFFLER, H. P. & RUBINEK, T. 2008. 
Klotho: a tumor suppressor and a modulator of the IGF-1 and FGF pathways in human 
breast cancer. Oncogene, 27, 7094-105. 
WONG, A., LAMOTHE, B., LEE, A., SCHLESSINGER, J. & LAX, I. 2002. FRS2 alpha 
attenuates FGF receptor signaling by Grb2-mediated recruitment of the ubiquitin ligase 
Cbl. Proc Natl Acad Sci U S A, 99, 6684-9. 
WONG, J. P., TODD, J. R., FINETTI, M. A., MCCARTHY, F., BRONCEL, M., VYSE, S., 
LUCZYNSKI, M. T., CROSIER, S., RYALL, K. A., HOLMES, K., PAYNE, L. S., DALEY, 
F., WAI, P., JENKS, A., TANOS, B., TAN, A. C., NATRAJAN, R. C., WILLIAMSON, D. 
& HUANG, P. H. 2016. Dual Targeting of PDGFRalpha and FGFR1 Displays 
Synergistic Efficacy in Malignant Rhabdoid Tumors. Cell Rep, 17, 1265-1275. 
WRIGHT, J. D., AN, S. W., XIE, J., YOON, J., NISCHAN, N., KOHLER, J. J., OLIVER, N., LIM, 
C. & HUANG, C. L. 2017. Modeled structural basis for the recognition of alpha2-3-
sialyllactose by soluble Klotho. FASEB J. 
WU, A. L., COULTER, S., LIDDLE, C., WONG, A., EASTHAM-ANDERSON, J., FRENCH, D. 
M., PETERSON, A. S. & SONODA, J. 2011. FGF19 regulates cell proliferation, glucose 
and bile acid metabolism via FGFR4-dependent and independent pathways. PLoS One, 
6, e17868. 
WU, X., GE, H., GUPTE, J., WEISZMANN, J., SHIMAMOTO, G., STEVENS, J., HAWKINS, N., 
LEMON, B., SHEN, W., XU, J., VENIANT, M. M., LI, Y. S., LINDBERG, R., CHEN, J. L., 
TIAN, H. & LI, Y. 2007. Co-receptor requirements for fibroblast growth factor-19 
signaling. J Biol Chem, 282, 29069-72. 
WU, X., GE, H., LEMON, B., VONDERFECHT, S., WEISZMANN, J., HECHT, R., GUPTE, J., 
HAGER, T., WANG, Z., LINDBERG, R. & LI, Y. 2010. FGF19-induced hepatocyte 
proliferation is mediated through FGFR4 activation. J Biol Chem, 285, 5165-70. 
WU, X., LEMON, B., LI, X., GUPTE, J., WEISZMANN, J., STEVENS, J., HAWKINS, N., SHEN, 
W., LINDBERG, R., CHEN, J. L., TIAN, H. & LI, Y. 2008. C-terminal tail of FGF19 
determines its specificity toward Klotho co-receptors. J Biol Chem, 283, 33304-9. 
WU, Y. M., SU, F., KALYANA-SUNDARAM, S., KHAZANOV, N., ATEEQ, B., CAO, X., 
LONIGRO, R. J., VATS, P., WANG, R., LIN, S. F., CHENG, A. J., KUNJU, L. P., 
SIDDIQUI, J., TOMLINS, S. A., WYNGAARD, P., SADIS, S., ROYCHOWDHURY, S., 
HUSSAIN, M. H., FENG, F. Y., ZALUPSKI, M. M., TALPAZ, M., PIENTA, K. J., 
RHODES, D. R., ROBINSON, D. R. & CHINNAIYAN, A. M. 2013. Identification of 
targetable FGFR gene fusions in diverse cancers. Cancer Discov, 3, 636-47. 
XIE, B., CHEN, J., LIU, B. & ZHAN, J. 2013. Klotho acts as a tumor suppressor in cancers. 
Pathol Oncol Res, 19, 611-7. 
222 
 
XIE, M. H., HOLCOMB, I., DEUEL, B., DOWD, P., HUANG, A., VAGTS, A., FOSTER, J., 
LIANG, J., BRUSH, J., GU, Q., HILLAN, K., GODDARD, A. & GURNEY, A. L. 1999. 
FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4. Cytokine, 
11, 729-35. 
XIN, X., ABRAMS, T. J., HOLLENBACH, P. W., RENDAHL, K. G., TANG, Y., OEI, Y. A., 
EMBRY, M. G., SWINARSKI, D. E., GARRETT, E. N., PRYER, N. K., TRUDEL, S., 
JALLAL, B., MENDEL, D. B. & HEISE, C. C. 2006. CHIR-258 is efficacious in a newly 
developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma 
model in mice. Clin Cancer Res, 12, 4908-15. 
XU, A. M. & HUANG, P. H. 2010. Receptor tyrosine kinase coactivation networks in cancer. 
Cancer Res, 70, 3857-60. 
XU, H., LEE, K. W. & GOLDFARB, M. 1998a. Novel recognition motif on fibroblast growth factor 
receptor mediates direct association and activation of SNT adapter proteins. J Biol 
Chem, 273, 17987-90. 
XU, J., BUSSIERE, J., YIE, J., SICKMIER, A., AN, P., BELOUSKI, E., STANISLAUS, S. & 
WALKER, K. W. 2013. Polyethylene glycol modified FGF21 engineered to maximize 
potency and minimize vacuole formation. Bioconjug Chem, 24, 915-25. 
XU, J., LLOYD, D. J., HALE, C., STANISLAUS, S., CHEN, M., SIVITS, G., VONDERFECHT, S., 
HECHT, R., LI, Y. S., LINDBERG, R. A., CHEN, J. L., JUNG, D. Y., ZHANG, Z., KO, H. 
J., KIM, J. K. & VENIANT, M. M. 2009. Fibroblast growth factor 21 reverses hepatic 
steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced 
obese mice. Diabetes, 58, 250-9. 
XU, R., ORI, A., RUDD, T. R., UNIEWICZ, K. A., AHMED, Y. A., GUIMOND, S. E., SKIDMORE, 
M. A., SILIGARDI, G., YATES, E. A. & FERNIG, D. G. 2012. Diversification of the 
structural determinants of fibroblast growth factor-heparin interactions: implications for 
binding specificity. J Biol Chem, 287, 40061-73. 
XU, X., WEINSTEIN, M., LI, C., NASKI, M., COHEN, R. I., ORNITZ, D. M., LEDER, P. & DENG, 
C. 1998b. Fibroblast growth factor receptor 2 (FGFR2)-mediated reciprocal regulation 
loop between FGF8 and FGF10 is essential for limb induction. Development, 125, 753-
65. 
YAMASHITA, T., YOSHIOKA, M. & ITOH, N. 2000. Identification of a novel fibroblast growth 
factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the 
brain. Biochem Biophys Res Commun, 277, 494-8. 
YAMAZAKI, Y., IMURA, A., URAKAWA, I., SHIMADA, T., MURAKAMI, J., AONO, Y., 
HASEGAWA, H., YAMASHITA, T., NAKATANI, K., SAITO, Y., OKAMOTO, N., 
KURUMATANI, N., NAMBA, N., KITAOKA, T., OZONO, K., SAKAI, T., HATAYA, H., 
ICHIKAWA, S., IMEL, E. A., ECONS, M. J. & NABESHIMA, Y. 2010. Establishment of 
sandwich ELISA for soluble alpha-Klotho measurement: Age-dependent change of 
soluble alpha-Klotho levels in healthy subjects. Biochem Biophys Res Commun, 398, 
513-8. 
YAMAZAKI, Y., TAMADA, T., KASAI, N., URAKAWA, I., AONO, Y., HASEGAWA, H., FUJITA, 
T., KUROKI, R., YAMASHITA, T., FUKUMOTO, S. & SHIMADA, T. 2008. Anti-FGF23 
neutralizing antibodies show the physiological role and structural features of FGF23. J 
Bone Miner Res, 23, 1509-18. 
YANG, C., JIN, C., LI, X., WANG, F., MCKEEHAN, W. L. & LUO, Y. 2012. Differential specificity 
of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB. PLoS 
One, 7, e33870. 
YAYON, A., KLAGSBRUN, M., ESKO, J. D., LEDER, P. & ORNITZ, D. M. 1991. Cell surface, 
heparin-like molecules are required for binding of basic fibroblast growth factor to its 
high affinity receptor. Cell, 64, 841-8. 
YEH, B. K., IGARASHI, M., ELISEENKOVA, A. V., PLOTNIKOV, A. N., SHER, I., RON, D., 
AARONSON, S. A. & MOHAMMADI, M. 2003. Structural basis by which alternative 
splicing confers specificity in fibroblast growth factor receptors. Proc Natl Acad Sci U S 
A, 100, 2266-71. 
YIE, J., HECHT, R., PATEL, J., STEVENS, J., WANG, W., HAWKINS, N., STEAVENSON, S., 
SMITH, S., WINTERS, D., FISHER, S., CAI, L., BELOUSKI, E., CHEN, C., MICHAELS, 
M. L., LI, Y. S., LINDBERG, R., WANG, M., VENIANT, M. & XU, J. 2009. FGF21 N- and 
C-termini play different roles in receptor interaction and activation. FEBS Lett, 583, 19-
24. 
YIE, J., WANG, W., DENG, L., TAM, L. T., STEVENS, J., CHEN, M. M., LI, Y., XU, J., 
LINDBERG, R., HECHT, R., VENIANT, M., CHEN, C. & WANG, M. 2012. 
Understanding the physical interactions in the FGF21/FGFR/beta-Klotho complex: 
223 
 
structural requirements and implications in FGF21 signaling. Chem Biol Drug Des, 79, 
398-410. 
YLI-KAUHALUOMA, J. & TUOMINEN, R. K. 2011. Protein kinases as drug targets. Curr Top 
Med Chem, 11, 1304. 
YU, X., IBRAHIMI, O. A., GOETZ, R., ZHANG, F., DAVIS, S. I., GARRINGER, H. J., 
LINHARDT, R. J., ORNITZ, D. M., MOHAMMADI, M. & WHITE, K. E. 2005. Analysis of 
the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. 
Endocrinology, 146, 4647-56. 
ZEBISCH, K., VOIGT, V., WABITSCH, M. & BRANDSCH, M. 2012. Protocol for effective 
differentiation of 3T3-L1 cells to adipocytes. Anal Biochem, 425, 88-90. 
ZHANG, J., GUPTE, J., GONG, Y., WEISZMANN, J., ZHANG, Y., LEE, K. J., RICHARDS, W. 
G. & LI, Y. 2017a. Chronic Over-expression of Fibroblast Growth Factor 21 Increases 
Bile Acid Biosynthesis by Opposing FGF15/19 Action. EBioMedicine, 15, 173-183. 
ZHANG, X., GUREASKO, J., SHEN, K., COLE, P. A. & KURIYAN, J. 2006a. An allosteric 
mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell, 
125, 1137-49. 
ZHANG, X., IBRAHIMI, O. A., OLSEN, S. K., UMEMORI, H., MOHAMMADI, M. & ORNITZ, D. 
M. 2006b. Receptor specificity of the fibroblast growth factor family. The complete 
mammalian FGF family. J Biol Chem, 281, 15694-700. 
ZHANG, X., STAPPENBECK, T. S., WHITE, A. C., LAVINE, K. J., GORDON, J. I. & ORNITZ, 
D. M. 2006c. Reciprocal epithelial-mesenchymal FGF signaling is required for cecal 
development. Development, 133, 173-80. 
ZHANG, Y., HIRAISHI, Y., WANG, H., SUMI, K. S., HAYASHIDO, Y., TORATANI, S., KAN, M., 
SATO, J. D. & OKAMOTO, T. 2005. Constitutive activating mutation of the FGFR3b in 
oral squamous cell carcinomas. Int J Cancer, 117, 166-8. 
ZHANG, Y., WANG, L., WU, Z., YU, X., DU, X. & LI, X. 2017b. The Expressions of Klotho 
Family Genes in Human Ocular Tissues and in Anterior Lens Capsules of Age-Related 
Cataract. Curr Eye Res, 42, 871-875. 
ZHOU, H., HE, F., MENDELSOHN, C. L., TANG, M. S., HUANG, C. & WU, X. R. 2016. 
FGFR3b Extracellular Loop Mutation Lacks Tumorigenicity In Vivo but Collaborates with 
p53/pRB Deficiency to Induce High-grade Papillary Urothelial Carcinoma. Sci Rep, 6, 
25596. 
ZHOU, X. & WANG, X. 2015. Klotho: a novel biomarker for cancer. J Cancer Res Clin Oncol, 
141, 961-9. 
ZOU, X. & BLANK, M. 2017. Targeting p38 MAP kinase signaling in cancer through post-
translational modifications. Cancer Lett, 384, 19-26. 
 
 
